<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">This document is a summary of the European Public Library report (EPAR) in which explains how the Committee for Humanarztend (CHMP) has assessed carried out in order to make recommendations concerning the application of the drug.</seg>
<seg id="2">"if you need more information about your ailment or treatment, please read the pack included (also part of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="3">"if you want more information about the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as 5 mg, 10 mg, 15 mg and 30 mg tablets, than 10 mg, 15 mg and 30 mg of melting tablets (tablets, which can trigger in the mouth (1 mg / ml) and as injection solution (7,5 mg / ml)."</seg>
<seg id="5">B. wirres thinking and Speech, hallucinations (hearing or vision of things that are not present), distrust and madness; • Bipolar disorder; • Bipolar disorder (periods) alternately with periods of normal mood (periods) alternately with periods of normal mood. "</seg>
<seg id="6">Abilify is used for the treatment of medium-heavy episodes and prevention of manic episodes with patients who have addressed the medicine in the past.</seg>
<seg id="7">The injection solution is applied to the fast control of increased unrest or behavioural disorders if the orale intake of the drug is not possible.</seg>
<seg id="8">"in both diseases, the solution to take or the melting tablets are used in patients to prepare the swallowing of tablets difficulties."</seg>
<seg id="9">"in case of patients who are simultaneously taking other medicines, which are just as lovingly designed, the dose of anbilify should be adapted."</seg>
<seg id="10">"this affects the transmission of the transmission between brain cells by" neurotransmitters ", i.e. chemical substances which allow the communication of nerve cells each other."</seg>
<seg id="11">Aripiorzol presumably appears mainly as a "partite Agonist" for the receptors for the neurotransmitters Dopamine and 5-hydroxytryptamin (also called serotonin).</seg>
<seg id="12">"this means that Aripiorzol like 5-hydroxytryptamin and Dopamine, but in the lower dimensions as the neurotransmitter acts to activate the receptors."</seg>
<seg id="13">"da Dopamine and 5-hydroxytryptamine with schizophrenia and bipolar disorder play a role, contributes Aripiping to normalize the activity of the brain, causing psychotic or manic symptoms and their reoccur will be prevented."</seg>
<seg id="14">"the effectiveness of bilify, to prevent the reoccur of symptoms, was examined in three studies up to one year."</seg>
<seg id="15">"the effectiveness of the injection solution was compared in two studies at 805 patients with schizophrenia or similar diseases, which compared to increased unrest, compared to a period of two hours with a placebo."</seg>
<seg id="16">"in another study Agrofy about twelve weeks to 347 patients with Haloperidol, in another study the effectiveness of anbilify and placebo to prevent reoccur in 160 patients where the manic symptoms were already stabilized with Abilify, compared to."</seg>
<seg id="17">"the effectiveness of aromafy injections was compared in a study to 301 patients with bipolar disorder, which compared to increased unrest, with which by Lorazepam (another antipsychotic medication) and placebo over a period of two hours."</seg>
<seg id="18">"in all studies, the change in the symptoms of patients by a standard skala for bipolar disorder or the number of patients that were examined on treatment."</seg>
<seg id="19">"the company also led studies in order to investigate, as the body melting the melting tablets and the solution to invitations."</seg>
<seg id="20">"in the two studies with the injection solution, patients, Abilify in doses of 5,25 mg, 75 mg or 15 mg have received a significant reduction in symptoms of increased unrest than the patients who received a placebo."</seg>
<seg id="21">In the application to treat bipolar disorder decreased aromanfy in four of the five short term studies manic symptoms more effective than placebo.</seg>
<seg id="22">Abilify they also prevented up to 74 weeks of more effective than placebo the reoccur of manic episodes with previously treated patients and if it was in addition to an existing treatment has been administered.</seg>
<seg id="23">Herbal injections in 10- or 15-mg doses decreased also more effective than placebo the symptoms of increased unrest and were similarly effective as Lorazepam.</seg>
<seg id="24">"the most common side effects of Abilify for one (observed at 1 to 10 of 100 patients), heathisy (continuous movement), headaches (constipation), fluids, nausea (increased memory), fatigue and exhaustion, restlessness, insomnia, insomnia (singular) and anxiety."</seg>
<seg id="25">The committee for human medicines (CHMP) came to the conclusion that the advantages of Abilify in the treatment of schizophrenia and the prevention of a new manic episode in patients who had predominantly manic episodes and in which the manic episodes on the treatment with Aripiorzol Anlanguages to overseize the risks.</seg>
<seg id="26">"in addition, the committee came to the result that the benefits of injections in patients with schizophrenia or in patients with manzophrenia or in patients with manic episodes with Bipolar-I-disorder if a orial therapy is not suitable to prevail over the risks."</seg>
<seg id="27">June 2004 the European Commission dedicated to the company Otsuka Pharmaceutical Europe Ltd. a permit for launching Abilify in the entire European Union.</seg>
<seg id="28">ABILIFY is for the treatment of moderate to heavy manic episodes of the bipolar bial disorder and for the prevention of a new manic episode in patients indicated mainly manic episodes and their manic episodes on treatment with Aripiorzol Anlanguages (see Section 5.1).</seg>
<seg id="29">The recommended starting dose for ABILIFY is 10 or 15 mg / day at a posture dose of 15 mg / day once daily independent of meals.</seg>
<seg id="30">Increased effectiveness in dosages over a daily dose of 15 mg was not proven though individual patients can benefit from a higher dose.</seg>
<seg id="31">The recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see Section 5.1). "</seg>
<seg id="32">The effectiveness of ABILIFY in the treatment of schizophrenia and bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">With regard to the greater sensitivity of this patient group should be considered a lower initiate dose when clinical factors justify this (see Section 4.4).</seg>
<seg id="34">If the CYP3A4 inductor is set out of the combination therapy should be reduced the Aripid dose to the recommended dose (see Section 4.5).</seg>
<seg id="35">The appearance of suicide behavior belongs to psychotic diseases and affective disorders and was reported in some cases after the beginning or after a change of antipsychotic therapy (see section 4.8).</seg>
<seg id="36">"the results of an epidemiological study showed that in patients with bipolar disorder, no increased suicism risk with Aripiorzol compared to other antipsychotics."</seg>
<seg id="37">"Aripizzol should be treated with caution in patients with well-known cardiovascular diseases (Myocardiac diseases), cerebrovasculation (dehydration), hypovolaemia (dehydrated drugs) or hypertension (including akzelerated and Maligne form)."</seg>
<seg id="38">"3 Spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="39">If at one with ABILIFY patients treated signs and symptoms of a spätdyskinesia should be considered to reduce the dose or to break the treatment.</seg>
<seg id="40">"when a patient indication and symptoms developed to a mns, or unclear high fever without an additional clinical manifestation of mns, all antipsychotics must be set, including ABILIFY."</seg>
<seg id="41">"therefore Aripiorzol should be used in patients with cranes in the anamnese or at states that are applied with sampouling in connection with caution."</seg>
<seg id="42">"56 - 99 years) with Aripiorzol treated in patients with psychosis who were treated with Alzheimer's disease, patients who were treated with Aripiorzov, a increased sterberisiko compared to placebo."</seg>
<seg id="43">"however, there was in one of these studies, a study involving fixed dosage, a significant relationship between the dosage and the contact for unwanted cerebrovasculular events treated with Aripiorzol patients."</seg>
<seg id="44">"hyperglycaemia, in some cases extremely and associated with Ketoaziial box or hyperosmolarem Koma or death, was reported in patients with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="45">There are no precise risk estimates for hyperglycaemia-related events with ABILIFY and other atypical antipsychotic agents treated patients who allow direct comparisons.</seg>
<seg id="46">"Polydipsy, polyurie, polyphagy and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucose values."</seg>
<seg id="47">"a weight can be found in general for schizophragm patients and patients with bipolar Manage, using antipsychotics, the application of antipsychotics, the use of antipsychotics, or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="48">"due to the primary effect of Aripiorzol on the central nervous system, caution is advisable when Aripiorzol is taken in combination with alcohol or other central effective medicines such as Sedation (see section 4.8)."</seg>
<seg id="49">"the H2-antagonist Famotidine, a gastric acid blocker, reduces the resorption rate of Aripivzol, whereby this effect is not relevant as clinically."</seg>
<seg id="50">In a clinical study with healthy probabilities a highly effective CYP2D6-Inhibitor (Chinidine) the AUC of Aripiorzol by 107% while the Cmax remained unchanged.</seg>
<seg id="51">"it is expected that other highly effective inhibitors of CYP2D6, such as fluoxetine and paroxetine, similar effects have and therefore ought to be done similar dosisions."</seg>
<seg id="52">At CYP2D6 'bad' (= "poor") Metabolisierers can result the joint application with highly effective Inhibitors of CYP3A4 in higher plasma-concentration of Aripiorzol - compared to CYP2D6 extensively sizing metabolic disorders.</seg>
<seg id="53">If one draws the common gift of Ketoconazol or other highly effective CYP3A4-inhibitors with ABILIFY, the potential benefits should seize the potential risks for the patient. "</seg>
<seg id="54">"other highly effective inhibitors of CYP3A4, such as Itraconazol and HIV-Proteins, are likely to have similar effects and therefore ought to be done similar dosisions."</seg>
<seg id="55">After finishing the CYP2D6- or 3A4-inhibitors should be the dosage of ABILIFY to be raised to the dosage-level before the start of the accompanying therapy.</seg>
<seg id="56">Diltiazem or Escitalopram) or CYP2D6 will be administered with ABILIFY can be calculated with an moderate increase in the Aripizol- concentrations.</seg>
<seg id="57">In clinical studies showed cans of 10-30 mg of the substrates of CYP2D6 (Dextromethmorphed / 3-methodology of CYP2D6 (Dextromethmorphan / 3-methodology (Warfarin), 2C19 (Omeprazol) and 3A4 (Dextromethorphan). "</seg>
<seg id="58">Patients should be advised to notify their physician when they get pregnant or pregnancy during the treatment with Aripivzol.</seg>
<seg id="59">"due to the insufficient data base for the safety of people and due to the reproductive studies in pregnant women, this medicine may not be applied to pregnancy, unless the potential health benefits are clearly the potential risk for the fetus."</seg>
<seg id="60">"however, even with other antipsychotics, patients should be warned of, dangerous machines, including strength vehicles, until they are sure that Aripiorzol has no negative influence."</seg>
<seg id="61">The following side effects are more common (≥ 1 / 100) on than under placebo or were classified as possible medical-effects (*):</seg>
<seg id="62">"the incidence of the side-effects listed below is defined according to the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"schizophrenia - In a controlled long-term study has been treated with patients who were treated with Aripiorzol, a total of lower incidence (25,8%) from EPS including parinsonism, acathisie, acystony and Dyskinesia, compared to patients who were treated with Haloperidol (57,3%)."</seg>
<seg id="64">In a placebo-controlled long-term student over 26 weeks the incidence of EPS 19% in patients under Aripiorzol-treatment and 13.5% in patients under placebo.</seg>
<seg id="65">"in another controlled long-term student study about 26 weeks, the incidence of EPS 14.8% in patients who were treated with Aripiorzol, and 15.1% in patients under Olanzapper therapy."</seg>
<seg id="66">Manic episodes with Bipolar-I-disorder - In a controlled study about 12 weeks the incidence of EPS 23.5% in patients under Aripiorzol- treatment and 53.3% in patients under Haloperidol-treatment.</seg>
<seg id="67">In another study more than 12 weeks the incidence of EPS 26.6% in patients under Aripiorzol-treatment and 17.6% for those under lithium treatment.</seg>
<seg id="68">In the long-time detection phase over 26 weeks at a placebo-controlled study the incidence of EPS 18.2% for patients under Aripiorzol- treatment and 15.7% for patients treated patients.</seg>
<seg id="69">"a comparison between the patients groups under Aripiorzol and placebo, in which potentially clinically significant changes in routine-controlled laboratory parameters appeared, yielded not medically significant differences."</seg>
<seg id="70">"CPK (Kreatin-Phosphokinase), generally temporarily and asymptomatic, were observed at 3,5% of patients with Aripiorzol patients compared to 2.7% of the patients treated with placebo."</seg>
<seg id="71">"the side effects that may occur in connection with an anti-psychotic therapy, the Maligne neuroleptic syndrome, spätdyskinesthesia and increased mortality rates, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="72">In clinical trials and since the launch were unintentional or intentional overdose with Aripiorzol alone in adult patients with estimated doses of up to 1260 mg and without death succession.</seg>
<seg id="73">"although no information on the effectiveness of a hemoralysis during the treatment of an overdosage with Aripiorzol; however, it is unlikely that hermodialysis in the treatment of a metering of benefits, since Aripiorzov has a high plastic attack."</seg>
<seg id="74">It is assumed that the effectiveness of Aripiophrenia at schizophrenia and bipolar-I disturbance on the combination of a participally agonistic effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">"Aripiorzol showed a high affinity to Dopamine D2- and D3 receptors and 5HT2a receptors, as well as an excessive affinity to Dopamine D4-, for the serotonin 5HT2c- and 5HT2a, for alpha-1 hrad and for histamine-H1Recipe."</seg>
<seg id="76">"at Gabe of Aripid zol in dosages from 0,5 to 30 mg once daily about 2 weeks in healthy food-tomography, a dosis@-@ dependent reduction in the bond of 11C-Racloprid, a D2 / D3 receptor Liganden, at Nucleus caudatus and on Putamen."</seg>
<seg id="77">In three placebo-controlled short-time studies (4 to 6 weeks) to 1.228 schizophragm patients with positive or negative symptoms showed Aripiorzol compared to placebo a statistically significant improvement of psychotic symptoms.</seg>
<seg id="78">"in a Haloperidol-controlled study was in week 52 the share of the Responses patients who held an approach to study media, in both groups (Aripiorzol 77% and Haloperidol 73%)."</seg>
<seg id="79">"current values from Messenger, defined as secondary study potentials, including PANSS and the Montgomery Asberg- depressed scale, showed a significant stronger improvement than at Haloperidol."</seg>
<seg id="80">In a placebo-controlled study on 26 weeks due to stabilized patients with chronic schizophrenia showed itself a significant higher reduction in the back rate that was at 34% in the Aripiorzol group and at 57% below placebo.</seg>
<seg id="81">"in an Olanzapin-controlled, multinational double-blind study at schizophrenia at 26 weeks, the 314 patients were converted to a weight increase of at least 7% compared to the starting value (i.e. an increase of at least 5,6 kg in an average weight of ca."</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with an manic or mixed episode of the Bipolar-I-disorder showed Aripiorzol a compared to placebo over 3 weeks.</seg>
<seg id="83">In a placebo-controlled monotherapy study more than 3 weeks with fixed dosage with patients with an manic or mixed episode of the Bipolar-I-disorder showed Aripiorzol towards placebo no extra effectiveness.</seg>
<seg id="84">"in two placeboarding and active-controlled monotherapy studies about 12 weeks in patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristic, that comparable was comparable to that of Lithium or Haloperidol in week 12."</seg>
<seg id="85">"moreover, Aripiorzol dismissed a comparable proportion of patients with symptomatic remission of the manie on such as lithium or Haloperidol."</seg>
<seg id="86">"in a placebo-controlled study on 6 weeks with patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristics that are partly over 2 weeks not to Lithium- or Valproat-Monotherapy in therapeutic psychotherapy, compared to Monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo controlled study about 26 weeks followed by a long-term expansion phase over 74 weeks for manic phase, who had achieved a remission during a stabilisation phase prior to placebo superior in terms of prevention of a bipolar reimbursement with regard to prevention of a refund."</seg>
<seg id="88">"based on in vitro studies, the enzymes CYP3A4 and CYP2D6 is responsible for the Dehydrip and hydroxymodelling of Aripiorzol, the N-Dealkyution is catalyzed by CYP3A4."</seg>
<seg id="89">"the average Eliminational period is approximate at almost 75 hours for Aripiorzol on CYP2D6 and at almost 146 hours at 'bad' (=" poor ") Metabolisierers via CYP2D6."</seg>
<seg id="90">"at Aripivzol, there are no differences in Pharmakokinetics between male and female healthy proportions, as well as in a pharmacoinetic examination of schizophrener patients showed no gender-dependent effects."</seg>
<seg id="91">A pope-specific evaluation of Pharmakokinetics revealed no indication of clinically significant differences in ethnic affiliation or the impact of the censer to the Pharmacoinetics of Aripiorzol.</seg>
<seg id="92">The pharynokinetic characteristics of Aripiorzol and dehydro-Aripiorzol were similar in patients with severe kidney failure compared to young healthy proportions.</seg>
<seg id="93">"a single dose study with proving radiators live-rainfants (Child-Pugh class A, B and C) showed no significant effect on the impairment of liver function to the pharyngeosis of Aripid-Aripiorzol, but the study only showed 3 patients with liver cirrhosis of class C, which is not sufficient to draw conclusions on their metabolic capacity."</seg>
<seg id="94">"based on conventional studies on safety spharmacology, toxicity in repetitive gifts, Reproductionist, Genotoxicity and for cancerous potential, the preclinical data had no special hazards for the people."</seg>
<seg id="95">Toxicologically significant effects were only observed in dosages or expositions which clearly exceeded the maximum dosage or exposure to humans so they have only limited or no meaning for the clinical use.</seg>
<seg id="96">The effects of fibre a dosisdependent adrenaline (Lipofuscine pigments and / or parenchyieldosis in humans) and an increase by tributaries of the middle Steady-State-Exposition (AUC) at low Steady-State-Exposition (AUC) at the recommended maximum-dose (AUC) at the recommended maximal dose of humans).</seg>
<seg id="97">"in addition, a cholelithiasis has been established as a result of the reduction of sulphate conjugates from Aripiorzol in the gums of 25 to 125 mg / kg / day (AUC) in recommended clinical dose or the 16- to 81in the recommended maximum number dose to people based on mg / m2)."</seg>
<seg id="98">"however, in human Galle found in the highest recommended day dose of 30 mg of concentrations of sulphate conjugates from Hydroxy- Aripiorzol not more than 6% of concentrations that were found in the study about 39 weeks in Galle by monkeys, and lie far below the limit values (6%) of the in vitro solubility."</seg>
<seg id="99">"in rabbits these effects were observed after dosages, which led to expositions of the 3 and 11increments of the mid Steady-State AUC in the recommended clinical value-dose."</seg>
<seg id="100">"perforated blister packs for handover made of aluminium in folding boxes with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 Spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="102">It is assumed that the effectiveness of Aripiophrenia at schizophrenia and bipolar-I disturbance on the combination of a participally agonistic effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">"22 In a placebo controlled study about 26 weeks followed by a long-term expansion phase over 74 weeks for manic phase, who had achieved a remission during a stabilisation phase prior to placebo."</seg>
<seg id="104">"27 Spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="105">It is assumed that the effectiveness of Aripiophrenia at schizophrenia and bipolar-I disturbance on the combination of a participally agonistic effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">"34 In a placebo controlled study about 26 weeks followed by a long-term expansion phase over 74 weeks for manic phase, who had achieved a remission during a stabilisation phase prior to placebo."</seg>
<seg id="107">"39 Spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="108">It is assumed that the effectiveness of Aripiophrenia at schizophrenia and bipolar-I disturbance on the combination of a participally agonistic effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">"46 In a placebo controlled study about 26 weeks followed by a long-term expansion phase over 74 weeks for manic phase, who had achieved a remission during a stabilisation phase prior to placebo superior in terms of prevention of a bipolar reimbursement in case of prevention."</seg>
<seg id="110">The recommended starting dose for Aripiorzol is 10 or 15 mg / day at a posture dose of 15 mg / day once daily independent of meals.</seg>
<seg id="111">"patients, the difficulties in tocks of ABILIFY tablets have, can take the melting tablets alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="112">"the occurrence of suicidal behavior belongs to psychotic diseases and affective disorders, reported in some cases after the beginning or after a change of anti-psychotic therapy, even in the treatment with Aripiorzol (see section 4.8)."</seg>
<seg id="113">"spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="114">"clinical manifestations of a mns are high fever, muscle rigidity, alternating consciousness and signs of autonomous instability (irregularity or blood pressure, tachykarate, sweating and cardiac arrhythmia)."</seg>
<seg id="115">"a weight increase is generally observed in schizophragm patients and patients with bipolar Manage, using antipsychotics, the application of antipsychotics, in which weight is well-known or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="116">Patients should be advised to notify their physician when they get pregnant or pregnant during treatment with Aripivzol</seg>
<seg id="117">The following side effects are more common (≥ 1 / 100) on than under placebo or were classified as possible medical-effects of the drug by means of (*):</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with an manic or mixed episode of the Bipolar-I-disorder showed Aripiorzol a compared to placebo over 3 weeks.</seg>
<seg id="119">"58 In a placebo-controlled study on 6 weeks with patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristics that are partly over 2 weeks not to Lithium- or Valproat-Monotherapy with therapeutic strategies, compared to Monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a placebo-controlled study about 26 weeks followed by a long-term expansion phase over 74 weeks for manic phase, who had achieved a remission during a stabilisation phase prior to placebo superior in terms of prevention of a bipolar reimbursement with regard to prevention of a reimbursement into the manie."</seg>
<seg id="121">In rabbits these effects were according to dosages which were recommended to expositions of the 3 and 11increments of the mid Steady-State AUC in recommended clinical studies</seg>
<seg id="122">"patients, the difficulties in tocks of ABILIFY tablets have, can take the melting tablets alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="123">"spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="124">"71 In a placebo controlled study on 6 weeks with patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristics that are partly over 2 weeks not to Lithium- or Valproat-Monotherapy with therapeutic strategies, compared to Monotherapy with lithium or Valproat."</seg>
<seg id="125">"patients, the difficulties in tocks of ABILIFY tablets have, can take the melting tablets alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="126">"spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="127">"84 In a placebo controlled study on 6 weeks with patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristics that are partly over 2 weeks not to Lithium- or Valproat-Monotherapy with therapeutic strategies, compared to Monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg fructose je ml 400 mg of methyl-4-hydroxybenzoat (E218) per ml 0.2 mg Propyl-4-hydroxybenzoat (E216) per ml.</seg>
<seg id="129">The recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see Section 5.1). "</seg>
<seg id="130">"to the prevention of reestablishment of manic episodes with patients, who have already received Aripiorzol, the therapy with the same dosage should be continued."</seg>
<seg id="131">"spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="132">"hyperglycaemia, in some cases extremely and associated with Ketoaziial box or hyperosmolarem Koma or death, was reported in patients with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="133">There are no precise risk estimates for hyperglycaemia-related events with ABILIFY and other atypical antipsychotic agents treated patients who allow direct comparisons.</seg>
<seg id="134">92 In a clinical trial with healthy proportions increased a highly effective CYP2D6-Inhibitor (Chinidin) the AUC of Aripiorzol by 107% while the Cmax remained unchanged.</seg>
<seg id="135">Diltiazem or Escitalopram) or CYP2D6 will be administered with ABILIFY can be calculated with an moderate increase in the Aripizol- concentrations.</seg>
<seg id="136">Manic episodes with Bipolar-I-disorder - In a controlled study about 12 weeks the incidence of EPS 23.5% in patients under Aripiorzol-</seg>
<seg id="137">It is assumed that the effectiveness of Aripiophrenia at schizophrenia and bipolar-I disturbance on the combination of a participally agonistic effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"in an Olanzapin-controlled, multinational double-blind study at schizophrenia at 26 weeks, the 314 patients were converted to a weight increase of at least 7% compared to the starting value (i.e. an increase of at least 5,6 kg in an average weight of ca."</seg>
<seg id="139">97 In a placebo-controlled monotherapy study more than 3 weeks with fixed dosage with patients with an manic or mixed episode of the Bipolar-I-disorder showed Aripiorzol towards placebo no extra effectiveness.</seg>
<seg id="140">"in a relative bioverspeed study, in which the Pharmakokinetics of 30 mg Aripiorzol was compared with healthy food items, the relationship between the geometric Cmax was compared to the solution and the value of tablets at 122% (N = 30)."</seg>
<seg id="141">99 outside was a cholelithiasis as a result of the reduction of sulphate conjugate between 25 to 125 mg / kg / day (AUC) at recommended clinical dosage or the 16- to 81in the recommended maximum number dose for people based on mg / m2).</seg>
<seg id="142">"in rabbits these effects were observed after dosages, which led to expositions of the 3 and 11increments of the mid Steady-State AUC in the recommended clinical value-dose."</seg>
<seg id="143">ABILIFY injection solution will be applied to fast control of Agichity and vertical disorders in patients with schizophrenia or in patients with manic episodes of the Bipolar I-disorder if an orale therapy is not appropriate.</seg>
<seg id="144">"once it is clinically appropriate, the treatment should be terminated with Aripid injections, and commence with the oral application of Aripiorzol."</seg>
<seg id="145">To increase the orption and minimize the variability is recommended an injection in the M. Deltoideus or deep into the Gluteus Maximus muscle among adipous regions.</seg>
<seg id="146">A lower dose of 5.25 mg (0.7 ml) may vary depending on the individual clinical status taking into account the medicines or acute therapy. (see Section 4.5).</seg>
<seg id="147">"if a further orale treatment with Aripiorzol is indexed, see the summary of the characteristics of the medication by means of ABILIFY tablets, ABILIFY melting or ABILIFY solution to inhalation."</seg>
<seg id="148">There are no investigations on the effectiveness of Aripivzol injections in patients with Agichessness and behavioural disorders that were different from schizophrenia and manic episodes of the Bipolar-I disorder.</seg>
<seg id="149">"if a parenteral therapy with gasoline addition to Aripian injection solution is considered necessary, patients should be observed with regard to extreme sepower or a blood pressure in case (see Section 4.5)."</seg>
<seg id="150">Studies on the safety and effectiveness of Aripivzol injections can be found for patients with alcohol or drugs (through prescribed or illegal drugs).</seg>
<seg id="151">"Aripizzol should be treated with caution in patients with well-known cardiovascular diseases (Myocardiac diseases), cerebrovasculation (dehydration), hypovolaemia (dehydrated drugs) or hypertension (including akzelerated and Maligne form)."</seg>
<seg id="152">"spätdyskinesia: in clinical trials, which have been a year or less digestible, there were occasional reports of during treatment with Aripiorzol ascending Dyskinesia."</seg>
<seg id="153">"clinical manifestations of a mns are high fever, muscle mass, alternating consciousness and signs of autonomous instability (irregularity or blood pressure, tachykarate, sweating and cardiac arrhythmia)."</seg>
<seg id="154">"Polydipsy, polyurie, polyphagy and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucose values."</seg>
<seg id="155">"a weight gain is generally observed in general for schizophragm patients and patients with bipolar virtues, using antipsychotics, the application of antipsychotics, in which weight is well-known or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="156">"nevertheless, the intensity of the Sedation was greater compared to the alleviation of Aripivzol, in a study, in common Probanden Aripivzol (15 mg dose) as single intra intramuscular (2 mg dose) intra uscular."</seg>
<seg id="157">"105 The H2 Antagonist Famotidine, a gastric acid blocker, reduces the resorption rate of Aripivzol, whereby this effect is not relevant as clinically."</seg>
<seg id="158">At CYP2D6 'bad' (= "poor") Metabolisierers can result in comparison to CYP2D6 extensively sizing the common application with highly effective inhibitors of CYP3A4 in higher plastic-centrations of Aripiorzol.</seg>
<seg id="159">"other highly effective inhibitors of CYP3A4, such as Itraconazol and HIV- Proteins, are likely to have similar effects and therefore ought to be done similar dosisions."</seg>
<seg id="160">After finishing the CYP2D6- or 3A4-inhibitors should be the dosage of ABILIFY to be raised to the dosage-level before the start of the accompanying therapy.</seg>
<seg id="161">106 Lorazepam (2 mg dose) intra uscult was greater compared to the intensity of the Sedation bigger compared to the some gift of Aripiorzol.</seg>
<seg id="162">The following side effects played in clinical studies with Aripian injection solution more common to (≥ 1 / 100) than under placebo or were classified as possible medical-effects (see Section 5.1):</seg>
<seg id="163">"the incidence of the side-effects listed below is defined according to the following criteria: commonly (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects are more common on (≥ 1 / 100) than under placebo or were classified as possible medical-effects (*) as possible medical-effects (see Section 5.1):</seg>
<seg id="165">In a placebo-controlled long-term student over 26 weeks the incidence of EPS 19% in patients under Aripiorzol- treatment and 13.5% in patients under placebo.</seg>
<seg id="166">"in another study about 12 weeks, the incidence of EPS 26.6% in patients under Aripiorzol- treatment and 17.6% for those under lithium treatment."</seg>
<seg id="167">In the long-time detection phase over 26 weeks at a placebo-controlled study the incidence of EPS 18.2% for patients under Aripiorzol treatment and 15.7% for patients treated patients.</seg>
<seg id="168">"a comparison between the patients groups under Aripiorzol and placebo, in which potentially clinically significant changes in routine-controlled laboratory parameters appeared, yielded not medically significant differences."</seg>
<seg id="169">"CPK (Kreatinphosphokinase), generally temporarily and asymptomatic, were observed at 3,5% of patients with Aripiorzol patients compared to 2.7% of the patients treated with placebo."</seg>
<seg id="170">"the side effects that may occur in connection with an anti-psychotic therapy, the Maligne neuroleptic syndrome, spätdyskinesthesia and increased mortality rates, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="171">110 and behavioural disorders had been the Aripian injection solution with statistically significant improvements of Agiedity / vertical disorders compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">"in a placebo-controlled short-time study (24 h) with 291 patients with bipolar disorder, as well as Agisity injection solution associated with a statistically significant improvement in relation to placebo and behavioural disorders compared to placebo and similar to Lorazepam- reference arm."</seg>
<seg id="173">The observed average recovery from the starting value on the PANSS Excitement Component score at the primary 2-hour end point was 5.5 for placebo 9.6 for Lorazepam and 8,7 for Aripiorzol.</seg>
<seg id="174">"in analyses of sub-groups in patients with mixed episodes or patients with severe Agisness, a similar effectiveness in relation to the overall population has been observed, but a Statistical Significity could be established due to the reduced patient's number."</seg>
<seg id="175">In three placebo-controlled short-time studies (4 to 6 weeks) to 1.228 schizophragm patients with positive or negative symptoms showed Aripiorzol (oral) compared to placebo a statistically significant improvement of psychotic symptoms.</seg>
<seg id="176">"in a Haloperidol-controlled study was in week 52 the share of the Responses patients who contributed a response to study media, in both groups (Aripiorzol 77% (oral) and Haloperidol 73%)."</seg>
<seg id="177">"current values from Messenger, defined as secondary study potentials, including PANSS and the Montgomery-Asberg scale, showed a significant stronger improvement than at Haloperidol."</seg>
<seg id="178">In a placebo controlled study on 26 weeks due to stabilized patients with chronic schizophrenia showed itself a significant higher reduction in the back rate that was at 34% in the Aripiorzol- (oral) group and at 57% below placebo.</seg>
<seg id="179">"in an Olanzapin-controlled, multinational double-blind study at schizophrenia over 26 weeks, the 314 patients were refused by at least 7% compared to the starting value (N = 18 or 13% of the most valuable patients (N = 18 or 13% of the most valuable patients (i.e. an increase of at least 5,6 kg in an average weight of approx. 1)."</seg>
<seg id="180">"111 In a placebo controlled study on 6 weeks with patients with an manic or mixed episode of a Bipolar-I-disorder, with or without psychotic characteristics that are partly over 2 weeks not to Lithium- or Valproat-Monotherapy with therapeutic strategies, compared to Monotherapy with lithium or Valproat."</seg>
<seg id="181">"in a placebo controlled study on 26 weeks followed by a 74-week curriculum in manic patients, who had achieved a remission during a stabilisation phase prior to placebo superior in terms of prevention of a bipolar reimbursement with regard to prevention of a reimbursement into the manie."</seg>
<seg id="182">The Aripiorzol AUC is in the first 2 hours following intramuscular injection 90% greater the AUC to Gabe of the same dose as tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">In two studies with healthy food items the average time until reaching the maximum plasma-piegels at 1 to 3 hours of application.</seg>
<seg id="184">The gift of Aripivzol injections was well tolerated by rats and monkeys in no direct toxicity of a target group after repetitive result in a systemic exposure (AUC) that 15- and 5 times over the maximum human therapeutic exposure of 30 mg intramuscular systems.</seg>
<seg id="185">"in studies on reproductive-toxicity according to intravenous application, there is no safety-relevant concerns about maternaler Exposure, the 15- (rats) and 29-times (rabbits) about the maximum human therapeutic exposure of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripiorzol (oral) for security spharmacology, toxicity in repetitive gifts, reproductive-toxicity, Genotoxicity and for cancerous potential let the preclinical data have no particular danger to man."</seg>
<seg id="187">Toxicologically significant effects were only observed in dosages or expositions which clearly exceeded the maximum dosage or exposure to human beings; they have only limited or no meaning for the clinical use.</seg>
<seg id="188">The effects of fibre a dosis@-@ dependent adrenaline (AUD) with rats after 104 weeks at 20 to 60 mg / kg / day (corresponds to the recommended maximum-state dose of male recks at 60 mg / kg / day (the 10-fold of the middle-state-exposure (AUC) at the recommended maximum-state dose of humans).</seg>
<seg id="189">"in addition, a cholelithiasis has been established as a result of the reduction of sulphate conjugates from Aripiorzol in the galle by monkeys after repetitive gifts from 25 to 125 mg / kg / day (the 1- to 3-fold of the recommended maximum number dose for people based on mg / m2)."</seg>
<seg id="190">"in rabbits these effects were observed after dosages, which led to expositions of the 3- and 11-fold of the medium-state AUC in the recommended clinical value-dose."</seg>
<seg id="191">"regulatory authorities must ensure that, before and during the product is marketed as the pharmaceutical vigilanzer system, as described in the version 1.0 of module 1.8.1. of authorisation is, established and functioning."</seg>
<seg id="192">According to the "CHMP guideline on Risk Management Systems for Medicinal products for human use" has to be submitted to the updated risk management plan at the same time with the next Periodic Safety Update Report (PSUR).</seg>
<seg id="193">"in addition, a updated risk management plan must be submitted if new information can be announced that the current security data, denpharmaceutical vigilance or the measures aimed at risk assessment within 60 days after an important milestone of Pharmakovigilance or the measures to risk management."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablet EU / 1 / 04 / 276 / 003 49 x 1 tablet EU / 1 / 04 / 276 / 005 98 x 1 tablet</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablet EU / 1 / 04 / 276 / 009 56 x 1 tablet EU / 1 / 04 / 276 / 010 98 x 1 tablet</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablet EU / 1 / 04 / 276 / 014 56 x 1 tablet EU / 1 / 04 / 276 / 015 98 x 1 tablet</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablet EU / 1 / 04 / 276 / 018 49 x 1 tablet EU / 1 / 04 / 276 / 020 98 x 1 tablet</seg>
<seg id="199">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="200">"it is used for the treatment of adults who suffer from disease, which is characterized by symptoms such as hearing, seeing or feeling of things that are not present, distrust, unconnected language, wires behavior and flawed mood."</seg>
<seg id="201">ABILIFY is used in adults to treat a condition with excessive stronghold to have much less sleep than usual, very fast speaking with fast changing ideas and sometimes strong stimbility. "</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugar disease) in the family beginnings unarbitrary, inregular muscle motions, especially in the face of heart or vascular disease in the family, stroke or temporary maneuvering of brain-Flemish attacke / TIA), abnormal blood pressure."</seg>
<seg id="203">"if you suffer as an older patient to dementia (loss of memory or other intellectual skills), you should or a pledges / a relative to your doctor if you had ever had a stroke or temporary detachment of the brain."</seg>
<seg id="204">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="205">Children and young people ABILIY is not easy to apply for children and adolescents as patients under 18 years of age were not examined.</seg>
<seg id="206">"intake of ABILIFY with other medicines, please inform your doctor or pharmacist if you have to take any other medicines / apply or applied recently, even if it is not prescription drugs."</seg>
<seg id="207">Medicines for the treatment of cardiac disorders antidepressants or herbal medicines that treat depression and anxiety disorders are applied for treating depression and anxiety disorders which are used to treat epilepsy infection</seg>
<seg id="208">"pregnancy and downtime you should not take ABILIFY if you are pregnant unless you have discussed this with your doctor."</seg>
<seg id="209">Transportation and storage of machines you should not drive car and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="210">"please take this medicine only after consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="211">Please talk to your doctor or a pharmacist if you have the impression that the effect of ABILIFY too strong or too weak.</seg>
<seg id="212">"even if you feel better, change or contact the daily dose of ABILIFY without asking your doctor previously."</seg>
<seg id="213">If you have taken a larger amount of ABILIFY when you should find that you have more ABILIFY tablets have been advised than by your doctor (or if anyone has taken any other hand some of your ABILIY tablets) just contact your doctor.</seg>
<seg id="214">"if you have forgotten the intake of ABILIFY If you have forgotten a dose, take the forgotten dose as soon as you think, do not take a day the double dose."</seg>
<seg id="215">"frequent Side Effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable, fatigue, nausea, troublity, sleeably, sleeplessness, tufty, lemon, lemon, bliss and blurry vision."</seg>
<seg id="216">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel narrow-windy, especially when they stand out of a underlying or seated position or they can determine an accelerated pulse."</seg>
<seg id="217">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="218">"how ABILIFY looks and contents of ABILIFY 5 mg tablets are rectangular and blue, with stamping of A-007 and 5 on one side."</seg>
<seg id="219">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="220">"even if you feel better, change or contact the daily dose of ABILIFY without asking your doctor previously."</seg>
<seg id="221">Just like ABILIFY looks and content of ABILIFY 10 mg tablets are rectangular and rojuicy, with stamping of A-008 and 10 on one side. "</seg>
<seg id="222">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="223">"even if you feel better, change or contact the daily dose of ABILIFY without asking your doctor previously."</seg>
<seg id="224">"how ABILIFY looks and contents of ABILIFY 15 mg tablets are round and yellow, with stamping of A-009 and 15 on one side."</seg>
<seg id="225">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="226">"even if you feel better, change or contact the daily dose of ABILIFY without asking your doctor previously."</seg>
<seg id="227">"how ABILIFY looks and contents of ABILIFY 30 mg tablets are round and rojuicy, with stamping of A-011 and 30 on one side."</seg>
<seg id="228">"171 If you suffer as an older patient of dementia (loss of memory or other intellectual skills), you should or a plaster / a relative to your doctor if you had ever had a stroke or temporary detachment of the brain."</seg>
<seg id="229">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="230">"important information about certain other components of ABILIFY patients who may take no phenylalanine to themselves, should note that ABILIFY melting aspartame aspartame as a source of phenylalanine."</seg>
<seg id="231">"take away immediately after opening the blister packs the tablet with dry hands, and place the melting zenge in the whole on the tongue."</seg>
<seg id="232">"even if you feel better, change or contact the daily dose of ABILIFY without asking your doctor previously."</seg>
<seg id="233">If you have taken a larger amount of ABILIFY when you should find that you have more ABILIFY melting tablets have been advised than by your doctor (or if anyone has taken some of your ABILIFY melting tray), contact your doctor as soon as possible. "</seg>
<seg id="234">"Calciumtrimetasilicat, Croscarmte-sodium, xciumol, acentric acid-potassium, Vanille- Aroma artificially (contains vanilla and ethic acid), wineic acid, iron (III) - oxide (E172)."</seg>
<seg id="235">"how ABILIFY looks and contents of the package Die ABILIFY 10 mg of melting tablets are round and rojuarben, with stamping of" A "on" 640 "on one side and" 10 "on the other."</seg>
<seg id="236">"177 If you suffer as an older patient to dementia (loss of memory or other intellectual skills), you should or a plver / a relative to your doctor if you had ever had a stroke or temporary detachment of the brain."</seg>
<seg id="237">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="238">"Calciumtrimetasilicat, Croscarmte-sodium, xciumol, acentric acid-calium, Vanille- Aroma (contains vanilla and ethic acid), wineic acid, iron (III) - hydroxide-oxide x H2O (E172)."</seg>
<seg id="239">"how ABILIFY looks and contents of the package Die ABILIFY 15 mg melt tablets are round and yellow, with stamping of" A "above" 641 "on one side and" 15 "on the other."</seg>
<seg id="240">"183 If you suffer as an older patient to dementia (loss of memory or other intellectual skills), you should or a plver / a relative to your doctor if you had ever had a stroke or temporary detachment of the brain."</seg>
<seg id="241">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="242">"how ABILIFY looks and contents of the package Die ABILIFY 30 mg of melting tablets are round and pink-jured, with stamping of" A "above" 643 "on one side and" 30 "on the other."</seg>
<seg id="243">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="244">Transportation and storage of machines you should not drive car and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="245">190 Important information on certain other components of ABILIFY Any ml ABILIFY solution for insertion contains 200 mg fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor has informed you that you suffer from a intolerance towards certain sugar, contact your doctor before you take this medicine."</seg>
<seg id="247">The dose of ABILIFY solution to inhaling must be measured with the submitted cery or the submitted 2 ml Tropfpipette which are included in the package.</seg>
<seg id="248">Please talk to your doctor or a pharmacist if you have the impression that the effect of ABILIFY too strong or too weak.</seg>
<seg id="249">If you have taken a larger amount of ABILIFY when you should find that you have more ABILIFY solution to take you than by your doctor (or if someone has taken any other ABILIFY solution for insertion), contact your doctor immediately. "</seg>
<seg id="250">"Dinatriumedetate, fructose, glycereic acid-hydroxybenzoat (E216), Propyl-hydroxybenzoat (E216), Natriumhydroxide, Sucrose, smoked water and natural Orangecream flavor with other natural flavours."</seg>
<seg id="251">How ABILIFY looks and content of ABILIFY 1 mg / ml solution to inhale is a clear, colorful liquid in bottles with a child-safe polypropylene valve and 50 ml, 150 ml or 480 ml</seg>
<seg id="252">"ABILIFY injection solution is applied to the rapid treatment of increased unrest and desperate behavior that may occur as symptoms of a disease which are not present, distrust, insulating language, wirelessly behaviour and flushing voice."</seg>
<seg id="253">"people with this disease can also be depressed to feel guilty, anxious or tense. exceeding excessive energy to have much less sleep than usual, very fast speaking with changing ideas and sometimes strong stimbility."</seg>
<seg id="254">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness, with high fever, sweating, changing state of mind or very fast or irregularity."</seg>
<seg id="255">"when using ABILIFY with other medicines, please inform your doctor or pharmacist if you have to take any other medicines / apply or applied recently, even if it is not prescription drugs."</seg>
<seg id="256">Medicines for the treatment of cardiac disorders antidepressants or herbal medicines that treat depression and anxiety disorders are applied to treat depression and anxiety disorders which are used to treat epilepsy infection.</seg>
<seg id="257">"196 pregnancy and downtime you should not apply ABILIFY if you are pregnant unless you have discussed this with your doctor."</seg>
<seg id="258">Transportation and storage of machines you should not drive car and use no tools or machines when you feel after the application of ABILIFY injections.</seg>
<seg id="259">"if you have any concerns, you will receive more ABILIFY injections to you as you think, please talk to your doctor or plers about it."</seg>
<seg id="260">"frequent Side Effects (with more than 1 of 100, less than 1 of 10 treated) by ABILIFY injection solution are fatigue, wedge, headaches, nausea and vomiting."</seg>
<seg id="261">"occasional side effects (with more than 1 of $1,000, less than 1 of 100-treated) Some persons can feel a changed blood pressure, particularly when set up from the songs or sitting, or a fast powder, have a dry self-esteem in the mouth or feel themselves depressed."</seg>
<seg id="262">"frequent Side Effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable, fatigue, nausea, sleeably, sleeably, sleeplessness, flessness, tremity, tremity and blurry vision."</seg>
<seg id="263">"if you need more information about your ailment or treatment, please read the packaging template (also part of the EPAR), or contact your doctor or a pharmacist."</seg>
<seg id="264">Abraxane should be applied only under the supervision of a qualified Oncologist based on the use of cytostatika (kills of cells) specialized departments.</seg>
<seg id="265">"in patients with certain side effects on the blood or the nervous system, the dose may be reduced or interrupted treatment."</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.</seg>
<seg id="267">The effectiveness of abraxane was examined in a main study which took part in the 460 women with metastatic breast cancer in which about three quarters used to be a anthracycline.</seg>
<seg id="268">The effect of abraxane (in a few gifts or as Monotherapy) was compared with the conventional paclitaxel drugs by means (given in combination with other medicines to reduce side effects).</seg>
<seg id="269">"in total, 72 (31%) of the 229 with abraxane treated patients on the treatment to 37 (16%) of the 225 patients, the conventional paclitaxel drugs."</seg>
<seg id="270">"considered only the patients who were treated for the first time in metastatic breast cancer, in relation to the deterioration of illness and survival such as time until the deterioration of disease and survival."</seg>
<seg id="271">"against it showed themselves with patients who had previously received other treatments of their metastatic breast cancer, with regard to these indicators, that abraxane was more effective than conventional paclitaxel drugs."</seg>
<seg id="272">"it must not be used in patients, breastfeeding or before the beginning of the treatment of low neutrophilis in the blood."</seg>
<seg id="273">"the committee for human medicines (CHMP) presented that abrasiane is incomparative with patients, more effective than conventional paclitaxel drugs, and that it must not be given in contrast to other Paclitaxel drugs that must not be used with other medicines to decrease side effects."</seg>
<seg id="274">January 2008 the European Commission adopted the company abraxis Bioscience Limited has a permit for the sale of abrasiane in the entire European Union.</seg>
<seg id="275">Abraxane-Monotherapy is indexed to the treatment of metastatic Mammacarcinoma in patients where the first-line treatment for metastatic anthracycline-enthrative therapy is not shown (see also section 4.4).</seg>
<seg id="276">In patients with severe neutropeners &lt; 0.50 x 109 / l over a period of a week or longer) or severe sensory Neuropathy during the abraxane therapy should be reduced the dose in the following series to 220 mg / m2.</seg>
<seg id="277">"in sensory Neuropathy degree 3 is the treatment to break down, until an improvement to degrees 1 or 2 will be achieved, and in all subsequent cycles must be reduced the dose."</seg>
<seg id="278">There are currently no adequate data for the recommendation of dosage adaptations in patients with mild to moderate impairment of liver function (see Section 4.4. and 5.2).</seg>
<seg id="279">There are no studies conducted with patients with compromised kidney function and there are currently no adequate data for the recommendation of dosage adaptations in patients with impairment of the kidney function (see section 5.2).</seg>
<seg id="280">Abraxane is not recommended for use in children under the age of 18 due to non-sufficient data for immortality and effectiveness.</seg>
<seg id="281">"abraxane is an album-built nanoparticular modelling of Paclitaxel, which could be essentially different pharyngeological characteristics as other formulations of Paclitaxel (see Section 5.1 and 5.2)."</seg>
<seg id="282">"if an allergic reaction occurs, the medicine should be deposed immediately and enforced a symptomatic treatment, and the patient must not be treated again with paclitaxel."</seg>
<seg id="283">In the patient there should be no renewed abraxane treatment cycles up to &gt; 1.5 x 109 / l ascended and the romatic cylinders back up to &gt; 100 x 109 / l.</seg>
<seg id="284">Patients with severe liver dysfunctions (Bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with abraxane.</seg>
<seg id="285">"while a ambiguous with abraxane is not proven in relation to the cardiotoxicity, cardiac incidents are not unusual in the indices anthracyclin treatment or underlying heart - or lunches."</seg>
<seg id="286">"if in case of patients following the gift of abraxane nausea, exiting and diarrhea, these can be treated with the usual antiemetika and conical means."</seg>
<seg id="287">"abraxane should not be applied with pregnant or women in childbearing age, which is no effective conception to practice, except the treatment of the mother with Paclitaxel is unavoidable."</seg>
<seg id="288">Women in childbearing age should be used during and up to 1 month after treatment with abraxane.</seg>
<seg id="289">"male patients who are treated with abraxane, is recommended, during and up to six months after treatment no child to bear witness."</seg>
<seg id="290">Male patients should be advised in the treatment of a locking conservation since the treatment with abraxane is the possibility of irreversible infertility.</seg>
<seg id="291">Abraxane can cause unwanted side effects such as tiredness (very common) and Schwinch (frequently) that can affect traffic noise and the ability to serve machines.</seg>
<seg id="292">"below are the most common and important occurrences of side-effects listed, which were treated at 229 patients with metastatic Mammacarcinoma study in the pivotal clinical phase III study once every three weeks with 260 mg / m2 abraxane."</seg>
<seg id="293">Neutropenie was the most noticeable important hematological toxicity (in 79% of the patients) and was quickly reversible and dosisdependent; leukopenie has been reported at 71% of the patients.</seg>
<seg id="294">Anemia (HB &lt; 10 g / dl) was observed at 46% of the patients treated with abraxane patients and was severe in three cases (HB &lt; 8 g / dl).</seg>
<seg id="295">In table 1 are the side effects listed in conjunction with the gift of abraxane as monotherapy in each dose and indications in studies (N = 789).</seg>
<seg id="296">"very common (≥ 1 / 10); often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 1,000); very rare (&lt; 1 / 10,000)."</seg>
<seg id="297">"occasionally: increased blood pressure, weight increase, increased lactose-hydrochlorine in the blood, increased blood sugar in the blood, increased blood sugar and increased potassium in the blood, reduced caliphate in the blood of hereditary diseases:"</seg>
<seg id="298">"Dycelagie, bubbles, tongue, dry gums, loose gums, evocative gums, pains in the mouth, orale pain, rectal bleeding diseases of the kidneys and urinary tract:"</seg>
<seg id="299">"pain in the breast-wall, weakness of the musculature, genickness, mussels, mussels, redness in the limbs, redness in the limbs, muscle weaker Very common:"</seg>
<seg id="300">Restlessness 1 The frequency of hypersensitivity actions will be calculated based on a definitive event in regard to a population of 789 patients</seg>
<seg id="301">"since these events were reported on a voluntary basis during the clinical practice, there are no estimates of the actual frequency possible and it was not established any failing related to these events."</seg>
<seg id="302">Paclitaxel is a anti-scrap ingredient that encourages the assembling of the Mikrotubuli and stabilized the microtubuli by inhibition of their landolymerization.</seg>
<seg id="303">"this stabilisation leads to a inhibition of the normal dynamic reorganization of the microrotary network, which is essential for the vital form phase and the exotic cell functions."</seg>
<seg id="304">It is known that Albuminto the Transzytose of Plasmakomponents put into the endothelous cells and in the frame of in-vitro studies has been proven that the present of Albums promotes the transport of paclitaxel by the Endothelous cells.</seg>
<seg id="305">It is believed that this improved transendothelial transport through the gp-60-Albuminrezeptor is conveys and due to the albuminescent Protacidic rich in cysteine) a paclitaxel accumulation in the area of tumor appearance.</seg>
<seg id="306">"the application of abraxane for metastatic Mammacarcinoma is treated with data of 106 patients in two singular unblinded studies and of 454 patients, which were treated in a randomized phase III comparative study."</seg>
<seg id="307">In a study 43 patients treated with metastatic Mammacarcinoma treated with abraxane which was given in form of infusion over 30 minutes with a dose of 175 mg / m2.</seg>
<seg id="308">The second study was used a dose of 300 mg / m2 as infusion over 30 minutes to 63 patients with metastatic Mammacarcinoma.</seg>
<seg id="309">This multicentric study was conducted in patients with metastatic Mammacaxel 175 mg / m2 than 3-hour infusion with prefabrication to reduce an allergic reaction (N = 225) or in the form of abraxane 260 mg / m2 as 30-minute infusion without limitation (N = 229).</seg>
<seg id="310">"in the trial in the study 64% of patients had a compromised general state (ECOG 1 or 2), 79% had viscerale Metastases and 76% had more than 3 metastasels."</seg>
<seg id="311">"14% of patients had not received any chemotherapy, 27% had only a adjuvant chemotherapy, 40% only because of Metastasification and 19% due to Metastasification and adjuvant treatment."</seg>
<seg id="312">"9 The results for the general contact rate and time until progression of disease as well as progressing free survival and survival for patients who receive &gt; First-line treatment, are shown below."</seg>
<seg id="313">"neurotoxicity compared to Paclitaxel has been improved by improving a degree of patients who lived at a time during therapy an peripheral Neuropathy degree 3."</seg>
<seg id="314">The natural course of peripheral Neuropathy for drawing on baseline due to the cumulative toxicity of abraxane to &gt; 6 treatment courses was not evaluated and continues to be unknown.</seg>
<seg id="315">The Pharmakokinetics of the total-Paclitaxel after 30- and 180-minute infusions of abraxane with a dose of 80 to 375 mg / m2 was obtained in clinical studies.</seg>
<seg id="316">The active ingredients (AUC) increased linear from 2653 to 16736 ng.h / ml analog to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 After intravenous Gabe of abraxane in patients with metastatic Mammacarcinoma in the recommended clinical dose of 260 mg / m2 took the Paclitaxel-Plasmakoncentration on multiphashic way.</seg>
<seg id="318">The medium size volume was 632 l / m2; the high volume of volume points to a far-reaching extravascular distribution and / or softpart of paclitaxel.</seg>
<seg id="319">In a study involving patients with advanced solid tumors the pharmacopoinetic characteristics were compared to intravenous 30-minute infusion of 260 mg / m2 abraxane with values after a 3-hour injection of 175 mg / m2 of solvent-based Paclitaxel.</seg>
<seg id="320">The clearance of Paclitaxel was higher after the abraxane-Gabe higher (43%) than after a solution-consuming paclitaxel injection, and also the distribution volume was higher in abraxane (53%). "</seg>
<seg id="321">In the published literature about in-vitro-studies of human liver microsome and tissue layers will be reported that Paclitaxel is primarily associated with 6α -Hydroxyypaclitaxel and 6α -3 "-p-dihydroxypaclitaxel) metabolized.</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 abrasion in patients with metastatic Mammacarcinoma was the mean value for cumulative urinary tract and 3 "-p-hydroxypaclitaxel, which indicates a far-reaching non-renal clearance."</seg>
<seg id="323">"however, over 75 years patients age are available only a few data since only 3 patients of these age group participated in pharmacopoeia analysis."</seg>
<seg id="324">The chemical and physical stability was proved at 2 ° C - 8 ° C in original cardboard and light-light light protected over 8 hours.</seg>
<seg id="325">Paclitaxel is a cytotoxic medication medicine and as well as with other potentially toxic substances should be treated in handling abraxane caution.</seg>
<seg id="326">Using a sterile sprayer slowly over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) Natriumchlorid-infusion solution in a abraxane bottle.</seg>
<seg id="327">"after complete traction, the solution should rest at least 5 minutes to ensure good use of the solids."</seg>
<seg id="328">"then, the bottle case should be slowly and careful for at least 2 minutes and / or inverted, until a complete restructuring of the pulvers is done."</seg>
<seg id="329">"if exchangers or sinkers are visible, the pouch has to be easily inverted to achieve a complete restructuring before the application."</seg>
<seg id="330">For the patient the exact dosisvolume of 5-mg / ml suspension is charged and the appropriate amount of the reconstitutional abraxane is injected into an empty, sterile PVC- or non-PVC infusion. "</seg>
<seg id="331">"Pharmakovigilanzsystem The owner of the permit has to make sure that Pharmakovigilanzsystem, as described in Version 2.0 and is set in module 1.8.1 of authorisation application, is and works before and while the drug is brought into traffic."</seg>
<seg id="332">"risk management plan The owner of the approval for the entry is obliged to perform, as described in Version 4 of the risk management plan (RMP), as well as all subsequent updates of the application procedure, which will be agreed with the CHMP."</seg>
<seg id="333">"according to the CHMP directive on risk management systems for drugs to use on human beings, the updated target will be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, a updated event will suffice • If new information will respond to the current security provider, the pharmaceutical vigilance or the risk assessment activities • within 60 days after reaching an important milestone (Pharmakovigilance or Risikominimmemorial) • On request of EMEA"</seg>
<seg id="335">"8 hours in the fridge in the bottle case, if it is stored in carton, to protect the content from light."</seg>
<seg id="336">"abraxane is used to treat Mammacarcinoma, if other therapies were tried, but not successful, and if you do not come for anthracycline-enthused therapies."</seg>
<seg id="337">Abraxane may not be used: • If you are excessive (allergic) against Paclitaxel or one of the other components of abraxane • If you are breastfeeding (initial values for neutrophysics) of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"special attention to the application of abraxane is required: • If you have a compromised inclination, tingling, prickness, touching the feeling, touching up or muscle problem - if you suffer under heavy liver problems • if you have heart problems."</seg>
<seg id="339">"for using abraxane with other medicines, please inform the doctor if you apply other medicines or even if it is not prescription drugs, as this might cause a interaction with abraxane."</seg>
<seg id="340">Women in childbearing age should be used during and up to 1 month after treatment with abraxane.</seg>
<seg id="341">"in addition, they should be advised in the treatment of a sperm conservation since the treatment of abrasive treatment is the possibility of a constant infertility."</seg>
<seg id="342">Transportation and the filling of machinery abraxane can cause side effects such as tiredness (very common) and windling-esteem (common) that affect traffic noise and the ability to serve machines.</seg>
<seg id="343">"if you also receive other medicines within the scope of your treatment, you should consult with regard to the driving or filling machines from your doctor."</seg>
<seg id="344">"22 • The impact on the peripheral nerves (pain and numbness) • pain in one or more joints • pain in one or more joints • pain in the muscles • nausea, diarrhea • perbreak • weakness and fatigue"</seg>
<seg id="345">"the frequent side-effects (at least 1 of 100 patients reported) are: • rash, itching, redness, fake, fake, fake, fake, faint or disinfection, waste prevention or difficulty in reading • change in the heart rate or in the heart rhythm, painless mouth or wounce tongue, mouthsoor • insomnia."</seg>
<seg id="346">"the rare side effects (at least 1 of 10,000 patients reported) are: • Pneuminfection • Hauling reaction to a different substance after radiotherapy • Bloodine"</seg>
<seg id="347">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="348">"if they are not immediately used, it can be stored in flow bottle up to 8 hours in the fridge (2 ° C - 8 ° C) if this is stored in carton to protect the content from light."</seg>
<seg id="349">Each diarrhod bottle contains 100 mg of paclitaxel. • After the reconstitution contains every ml of the Suspension 5 mg Paclitaxel. • The other part is an album release of people (includes sodium) sodium and N Acetyltryptophan (Ph.Eur.))</seg>
<seg id="350">Precautions for the preparation and application Paclitaxel is a cytotoxic medication medicine and as well as with other potentially toxic substances should be treated in handling abraxane caution.</seg>
<seg id="351">Using a sterile syringe should slow over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) Natriumchlorid-infusion solution in a abraxane bottle.</seg>
<seg id="352">Then the flow bottle for at least 2 minutes slowly and cautious and / or inverted until a complete restructuring of the pulvers is done.</seg>
<seg id="353">That for the patient the exact dosisvolume of the 5 mg / ml Suspension calculate and the corresponding amount of reconstitutional abraxane in an empty, sterile PVC-infusion bag type IV injizers. "</seg>
<seg id="354">Parenteral medicines should be subjected to possible particles and discolorations in front of the application of a view on possible particles and discolorations when the solution or refrigerant will allow this.</seg>
<seg id="355">"stability Ungeopened flow bottles with abraxane are stable until the date specified on the packaging specified when the flow-bottle is stored in carton, in order to protect the content from light."</seg>
<seg id="356">"stability of the inaugural Suspension at the passage of the suspension latch after the first reconstruction, the Suspension should immediately be filled into an infusion bag."</seg>
<seg id="357">"member states must ensure that the owner of the permit will provide medical professional staff in dialysis centres and retail centres, with the following information and materials:"</seg>
<seg id="358">• Training brochure • summary of the characteristics of the medication by means of specialized information), labelling and packaging material. • With a clear picture of the correct application of the product versed cooling boxes for transport through the patient.</seg>
<seg id="359">"this means that Abseamed a biological drug is similar to that already in the European Union (EU), and the same active ingredient may contain (also" "reference medicines" ")."</seg>
<seg id="360">"it is used in patients with normal blood types, in connection with blood transfusion complications occur in case before the procedure is not possible and in which a blood loss is not possible from 900 to 1 800 ml."</seg>
<seg id="361">The treatment with Abseamed must be initiated under the supervision of a doctor who owns experience in the treatment of patients with diseases for which the drug is shown.</seg>
<seg id="362">"in case of patients with kidney problems and for patients who want to make a peculiar blood, is Abseamed to a vene to injecting."</seg>
<seg id="363">Injection can also be made from the patient or his supervisor if they have appropriate instructions for this purpose.</seg>
<seg id="364">"in patients with chronic kidney failure or patients who receive an chemotherapy, the hemoglobinds are always in recommended area (between 10 and 12 grams per decilitres in adults or between 9,5 and 11 g / dl in children)."</seg>
<seg id="365">"the iron values of all patients have to control before the treatment, to ensure that no iron bracket is, and iron detents should be administered throughout the treatment."</seg>
<seg id="366">"in case of patients who receive an chemotherapy, or in patients with kidney problems can be caused by a erythropodesmangel or by means that the body does not speak sufficient to the physical erythropoietin."</seg>
<seg id="367">Erythropoietin is also applied against operations to increase the number of red blood cells and thus reduce the consequences of a blood loss.</seg>
<seg id="368">It is produced by a cell in which a gene (DNA) was brought to the formation of epoetin alfa.</seg>
<seg id="369">Abseamed was compared with administration as injection in a vene in the framework of a major study with 479 patients suffering caused by kidney-problems with the reference problems.</seg>
<seg id="370">All patients participating in this study was at least eight weeks of Eprex / Erypo were included in a vene or continued Eprex / Erypo were received.</seg>
<seg id="371">Major indicator for the effectiveness was the change of hemoglobinds between the beginning of the study and the participation period in the weeks 25 to 29.</seg>
<seg id="372">The company also laid out the results of a study in which the effects of under the skin was investigated with those from Eprex / Erypo at 114 cancer patients who received an chemotherapy.</seg>
<seg id="373">"in the study with patients suffering caused by kidney-problems, the hemoglobinaries of patients were created on sewage levels, in the same measure, as with the patients who continue to receive Eprex / Erypo."</seg>
<seg id="374">"compared to that the patients, which continued by Eprex / Erypo, a rise from 0,063 g / dl of the starting value of 12,0 g / dl."</seg>
<seg id="375">"the most common side effect of Abseamed is a rise in blood pressure, who occasionally lead to symptom of an encephalopathy (brain problems) as sudden, staging headaches and Turbness."</seg>
<seg id="376">Abseamed may not be used in patients who may possibly be vulnerable (allergic) against epoetin alfa or one of the other components.</seg>
<seg id="377">"Abseamed as injection among the skin is not recommended to treat kidney problems, as further studies are needed to ensure that this is caused by no allergic reactions."</seg>
<seg id="378">"the Committee for Humanarztend (CHMP) came to the conclusion that for Abseamed in accordance with the provisions of the European Union of proof, the drug has a comparable quality, safety and efficacy profile such as Eprex / Erypo."</seg>
<seg id="379">"the company, the Abseamed, is provided for medical professionals in all Member States information packages, including information about the safety of the drug."</seg>
<seg id="380">August 2007 European Commission distributed the European Commission of Medice drugs Pütter GmbH & Co KG approving the sales of Abseamed in the entire European Union.</seg>
<seg id="381">"treatment of anemia and reduction of the Transfusionistle in adults with solid tumours, malignant lymphoma or multiplem myelom that exist as chemotherapy and with which the risk of transfusion due to the general rule (for example, cardiovascular status, existing anemia at the beginning of chemotherapy)."</seg>
<seg id="382">"treatment should only be carried out in patients with moderate anemia (HB] 10 - 13 g / dl [6,2 - 8,1 mmol / l], if blood-saving measures are not available or inadequate, with planned greater operative inputs (4 or more units blood with women; 5 or more units blood in men)."</seg>
<seg id="383">"in the reduction of foreign blink, Abseamed can be used in front of a great electorthodontic intervention in adults without fermentation, in which a high risk of Transfusion applications can be expected."</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml are used not to participate in an autonomic blood-up programme.</seg>
<seg id="385">"the hemoglobin target is between 10 and 12 g / dl (6,2 - 7,5 mmol / l), except for paediatric patients where the hemoglobinocation between 9,5 and 11 g / dl (5.5 - 6,8 mmol / l) lie."</seg>
<seg id="386">"symptoms, symptoms and folds may vary depending on age, gender and general disease according to age, gender and general disease, therefore the assessment of individual clinical use and disease condition is required by the doctor."</seg>
<seg id="387">A rise in hemogglobins by more than 2 g / dl (1,25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">Due to the variability between patients may occasionally be observed in a patient individual hemoglobined values above or under the hemoglobined target concentration.</seg>
<seg id="389">"given this hemogging variability should be tried over a corresponding dosage management, the hemoglobin-target concentration of 10 g / dl (6,2 mmol / l) up to 12 g / dl (7.5 mmol / l)."</seg>
<seg id="390">If the hemoglobined by more than 2 g / dl (1,25 mmol / l) per month increases or if the permanent hemoglobined 12 g / dl (7.5 mmol / l) is stepping up to reduce the epoetin-alfa dose by 25%.</seg>
<seg id="391">"patients should be monitored narrow to make sure that epetin alfa in the lowest condition, which is required for controlling the anemia and the allegedly symptoms."</seg>
<seg id="392">"the present clinical results suggest that patients with initially very low HB value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may need higher profitability less heavy (HB &gt; 8 g / dl or &gt; 5 mmol / l)."</seg>
<seg id="393">"the present clinical results suggest that patients with initially very low HB value (&lt; 6,8 g / dl or &lt; 4,25 mmol / l) may need higher profitability (HB &gt; 6,8 g / dl or &gt; 4,25 mmol / l)."</seg>
<seg id="394">"initial dose 50 i.e. / kg three times a week by means intravenous application, if necessary with a dosage adjustment of 25 i.e. / kg (three times per week), until the desired target is achieved (this should be done in steps of at least 4 weeks)."</seg>
<seg id="395">"symptoms symptoms and - folds may vary depending on age, gender and general disease, therefore the assessment of individual clinical use and disease condition is required by the doctor."</seg>
<seg id="396">"given this hemogging variability should be tried over a corresponding dosage management, the hemoglobin-target concentration of 10 g / dl (6,2 mmol / l) up to 12 g / dl (7.5 mmol / l)."</seg>
<seg id="397">"patients should be monitored narrow, to make sure that epetin alfa in the lowest condition, which is required for controlling the alleged symptoms."</seg>
<seg id="398">If after four treatment weeks of Hämoglobinable by at least 1 g / dl (postmmol / l) or the reticular cylinders around ≥ 40.000 cells / µl compared to the initial value should the dose of 150 g / kg three times per week or 450 i.e. / kg once per week will be retained.</seg>
<seg id="399">If the hemoglobinds has risen &lt; 1 g / dl (&lt; ppmmol / l) and the reaction number &lt; 40.000 cells / µl compared to the output value the dose should be raised to 300 i.e. / kg three times a week.</seg>
<seg id="400">If after a further four treatment weeks with 300 i.e. / kg three times a week of hemoglobined by ≥ 1 g / dl (≥ 4mmol / l) or the reaction speed to ≥ 40.000 cells / µl) should be maintained the dose of 300 i.e. / kg three times a week.</seg>
<seg id="401">"in contrast, the hemoglobinine is worth &lt; 1 g / dl (&lt; ppmmol / l) or the reaction number to &lt; 40.000 cells / µl compared to the output value, an approach to the epoetin-alfa therapy is unlikely and the treatment should be abandoned."</seg>
<seg id="402">"patients with mild anemia (hematokrit 33 - 39%), in which the prefabrication of ≥ 4 blood contrasting is required, Abseamed in a dose of 600 that / kg body weight twice weekly for 3 weeks prior to operating procedure."</seg>
<seg id="403">"with the iron substitution, as early as possible - for example, a few weeks before the start of the autonomic blood-up programme - began to be at the beginning of the seamed therapy big iron reserves."</seg>
<seg id="404">"6 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="405">"in this case, epetin alfa-operates 300 i.e. / kg at 10 consecutive days before, on the day of the intervention, as well as 4 days immediately afterward."</seg>
<seg id="406">"alternatively, the injection at the end of the dialysis can be given over the hose of a fistelnadel, followed by 10 ml isotonic saline solution to ensure the hose to rinse and an adequate injection of the medication by means of the circulation."</seg>
<seg id="407">Patients suffering from the treatment with any erythropoetin at a Erythroblastopenie (Pure Red Cell Aplasia, PRCA) should not be Abseamed or another Erythropoetin (see Section 4.4 - Erythroblastopenie). "</seg>
<seg id="408">"heart attack or stroke within one month before the treatment, instabile Angina pectoris, elevated risk for deep Venous thrombosis (e.g. anadestisch-known Thromboembolien)."</seg>
<seg id="409">"in case of patients who are intended for a greater electorthodontic intervention, the application of epoxetine cardiac disease, peripheral disease of the cardiac disease, vascular disease of the carotides or cerebrovasculine disease; in patients with recently uncommon heart attack or cerebrovasculum event."</seg>
<seg id="410">Erythroblastopenie (PRCA) Very rare was reported on the appearance of an antikuperate PRCA to Monthly - for years of treatment with subcutaneous erythropoetin.</seg>
<seg id="411">"in case of patients with sudden activity loss, defines as a reduction in the hemogram values (1 - 2 g / dl per month) with increased demand of transfusions, should be examined, or the usual causes for a non-failure (iron, folklore, or inflammation, blood loss and combs)."</seg>
<seg id="412">"if the Retikulocytes, considering the anemia (i.e. the Retikulocytes," index "), which is lower (&lt; 20,000 / mm3 or &lt; 0.5%), which is not-erythropoetin antibodies and an investigation of bone marrow should be conducted for diagnosis of a PRCA."</seg>
<seg id="413">The data for immunity at subcutaneous application of Abseamed in patients with a risk for an antically induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">8 For patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="415">In clinical studies have been observed a raised mortal risk and risk of serious cardiovascular events when erythropoesis-stimulating agents (ESA) were given with a hemoglobined target centration of over 12 g / dl (7.5 mmol / l).</seg>
<seg id="416">Controlled clinical studies have no significant benefits that is attributable to the hub of epoxetine if the hemoglobinocation is increased by the concentration of bloomiting symptoms and the prevention of blood transfusions.</seg>
<seg id="417">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="418">In patients with chronic kidney failure and clinically evidently coronary disease-sufficiency should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="419">"after the time of this knowledge, by the treatment of anemia with epoxettin alfa in adults with kidney failure, which are not yet dialysis, the progression of kidney failure is not accelerated."</seg>
<seg id="420">In tumor patients under chemotherapy should be taken into account for the assessment of the therapeutic efficiency of epetin alfa a 2 - 3-week delay between epoetin-alfa-Gabe and the erythropoetin-answer (patients that may have to be transfigured).</seg>
<seg id="421">If the HB increase is greater than 2 g / dl (1,25 mmol / l) per month or a HB value of 13 g / dl (8,1 mmol / l) is required to minimize the risk for possible thrombosis anemia (see Section 4.2 treatment of patients with chemotherapyconditional anemia - Dosage customization between 10 g / dl and 12 g / dl).</seg>
<seg id="422">"the decision to use recombinant Erythropoetine should be based on a benefit risk involving the participation of the respective patient, which should also take into account the specific clinical context."</seg>
<seg id="423">"in case of patients who are intended for greater electorthodontic intervention, if possible, prior to the beginning of epoetin-alfa therapy the cause of anemia examined and treated accordingly."</seg>
<seg id="424">"patients suffering from an enlarged orthopedic procedure should get an adequate Thromboseprophylaxis because they have a increased risk of thrombotic and vascular diseases, particularly with a primary cardiovascular disease."</seg>
<seg id="425">Furthermore it may not be excluded that in treatment with epoxetine alfa for patients with an initial shotmoglobined by &gt; 13 g / dl a raised risk for postoperative thrombotic / vascular events.</seg>
<seg id="426">In several controlled studies were not proven for epoxetine that they diminish in tumour patients with symptomatic anaemia or reduce the risk of tumor progression.</seg>
<seg id="427">4 months in patients with metastatic breast cancer which were received an chemotherapy once a hemoglobin target range from 12 - 14 g / dl (7.5 - 8,7 mmol / l).</seg>
<seg id="428">"will be used as epetin alfa along with Ciclosporin, the blood levels of Ciclosporin is controlled and the Ciclosporindosis to be adapted to the rising hematry."</seg>
<seg id="429">"in-vitro-investigations on tumor tissues, there is no evidence of an interaction between epoxetine alfa and G-CSF or GM-CSF regarding domestic differentiation or proclamation."</seg>
<seg id="430">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, arterial Thrombosis, lung cancer treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="431">The most common side effect during the treatment with epoetin alfa is a dosisdependent increase in blood pressure or the deterioration of an existing hypertension.</seg>
<seg id="432">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="433">Independent of the erythropoetin treatment can be used in surgical patients with cardiovascular disease after repetitive blood-spelling to thrombal and vascular complications.</seg>
<seg id="434">"the Technological epoxetine alfa is glycosily and in terms of amino acids, and of the carbohydrate-part identical with the endogenous humanic erythropoetin, which was isolated from the Urine-Mixer patients."</seg>
<seg id="435">It could be shown with the help of cultures of human bone market that epetin alfa specific to the erythropoesis and not influence the leukopoese.</seg>
<seg id="436">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="437">"1895 patients with solid tumours (683 Mammakarcinoma, 260 bronchialkarcinoma, 174 gynecological tumors, 300 gastrointestinal tumors and 802 patients with hermoblastomless."</seg>
<seg id="438">Survival and tumor progression were examined in five large controlled studies with a total of 2833 patients; four of these studies were double blind placebokontrolfiled Studies and</seg>
<seg id="439">In the open study there was no difference in total survive between the patients with recombinant humanic erythropoetin treated patients and the checkers.</seg>
<seg id="440">"in these studies, the patients treated with recombinant Erythropoetin-treated patients with an anemia due to various common Malignome consistent an unresolved, statistically significant mortality than with the controls."</seg>
<seg id="441">The overall survival in the studies could not be explained by differences in the incidence of Thrombosis and related complications in with recombinant humanic erythropoetin treated patients and inspecter.</seg>
<seg id="442">"it is a raised risk for thrombocharitable events in tumours, which can be treated with recombinant humanic erythropoetin, and a negative impact on the overall survival can not be excluded."</seg>
<seg id="443">"it is not clear how far these results are treated to the application of recombinations humanic erythropoetin in tumours, which can be handled by chemotherapy, a hemoglobined under 13 g / dl, since too few patients with these characteristics were included in the checked data."</seg>
<seg id="444">Epoxetine-alfa provisions after repetitive intravenous application showed a half-time period of about 4 hours in healthy food and a slightly prolonged half-time period of about 5 hours in patients with kidney failure.</seg>
<seg id="445">"after subcutaneous injection, the serum levels of epetin alfa are much lower than the Serumber, which can be achieved after intravenous injecting."</seg>
<seg id="446">"there is no gulation: the Serumance will remain identical, regardless of whether she will be determined 24 hours after the first ticket or 24 hours after the last gift."</seg>
<seg id="447">(bone market fibrosis is a known complication of chronic kidney failure in humans and could be attributed to a secondary Hyperparathyreoidal or unknown factors.</seg>
<seg id="448">"in a study at hematalysis, the three years were treated with epoetin alfa, the incidence of bone market compared to the control group with dialysis cases, which were not treated with epetin alfa."</seg>
<seg id="449">"14 In animal studies with approximate the 20morals of the people recommended for the application with recommended weekly dose, epetin alfa to diminish body weight, to a delay in the oscillations and to an increase in fetal mortality."</seg>
<seg id="450">These reports are based on in vitro Befunde with cells of humanic tumor sprockets, which are intended for the clinical situation but by unsafe Significtifics. "</seg>
<seg id="451">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="452">The syringes are provided with graduating and the volume is indicated by a glued label so that if necessary, the dimensions of sub-quantities is possible. "</seg>
<seg id="453">The treatment with Abseamed must be initiated under the supervision of doctors that have experience in the treatment of patients with the above indications.</seg>
<seg id="454">"21 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="455">23 In patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="456">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="457">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, fragile Thrombosis and 26 bloodine sine treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="458">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="459">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="460">29 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="461">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="463">38 For patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="464">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="465">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, arterial Thrombosis and 41 hemrombosis in artisan treatment, as well as patients under epoxettin alfa."</seg>
<seg id="466">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="467">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="468">44 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="469">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage is 600 that / kg epoxetine alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="471">53 For patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration.</seg>
<seg id="472">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="473">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, arterial Thrombosis and 56 hemrombosis in artisan treatment, as well as patients under epoxettin alfa."</seg>
<seg id="474">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="475">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="476">59 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="477">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="478">"66 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="479">68 For patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration.</seg>
<seg id="480">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="481">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, fragile Thrombosis and 71 hemrombosis in artificial remembrance of patients under erythropoetin-treatment, so also patients under epetin alfa."</seg>
<seg id="482">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="483">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="484">74 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in fetal mortality. "</seg>
<seg id="485">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="487">83 For patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration.</seg>
<seg id="488">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="489">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis and 86 bloodine, arterosophisticated treatment, so also patients under epoxettin alfa."</seg>
<seg id="490">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="491">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="492">89 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="493">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="494">"96 The recommended dosage is 600 that / kg epetin alfa, which should once a week more than three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="495">98 In patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="496">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="497">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, arterial Thrombosis in artists.htm, as well as patients under epythropoetin treatment, so also patients under epetin alfa."</seg>
<seg id="498">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="499">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="500">104 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="501">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="502">"111 The recommended dosage is 600 that / kg epetin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and on the day of the operation (day 0) should be given."</seg>
<seg id="503">113 In patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration.</seg>
<seg id="504">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="505">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis, arterial Thrombosis in artists.htm, as well as patients under epythropoetin treatment, so also patients under epetin alfa."</seg>
<seg id="506">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="507">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="508">119 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="509">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="510">"126 The recommended dosage is 600 that / kg epetin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="511">128 In patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration should not be exceeded.</seg>
<seg id="512">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="513">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis of lung cancer treatment, as well as patients under epythropoetin treatment, so also patients under epetin alfa."</seg>
<seg id="514">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="515">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="516">134 In animal experimented studies with approximate the 20morals of the application with recommended weekly dose of epetin alfa to diminished body weight, to a delay in the oscillation and to an increase in the fetal mortality. "</seg>
<seg id="517">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="518">"141 The recommended dosage is 600 that / kg epoxettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the operation (day 0) should be given."</seg>
<seg id="519">143 In patients with chronic kidney failure should be passed under Section 4.2 The limit of the hemoglobin target concentration.</seg>
<seg id="520">The hemoglobinanrose should be about 1 g / dl (ohmmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month not to minimize the risk of an increase in hypertension.</seg>
<seg id="521">"via thrombotic, vascular events such as myocardiac arteries, fragile Thrombosis, fragile Thrombosis, fragile Thrombosis, arterial Thrombosis and 146 Bloodmbosis in artisan treatment, as well as patients under epoxettin alfa."</seg>
<seg id="522">An increased incidence of incidence diseases (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="523">"389 patients with spmoblosis (221 multiple Myelome, 144 non-Hodgcinoma, 64 gynecological tumors, 23 bronchialkarzinome, 22 prostate cancer, 21 gastrointestinal cardiac and 30 other)."</seg>
<seg id="524">149 In animal experimental studies with approximate the 20morals for the use of the people recommended weekly dose of epetin alfa to diminish body weight, to a delay in the oscillation and to an increase in fetal mortality. "</seg>
<seg id="525">"within the framework of the outpatient application, the patient can store Abseamed once for a period of a maximum of 3 days outside the cooler and not over 25 ° C."</seg>
<seg id="526">"the owner of the authorization of the permit has been launched before the launch and in accordance with the competent authorities of member states, medical professionals in the following information and materials: • Designation brochure • summary of the characteristics of the medication by means of the correct use of the product versed cooling boxes for the transport through the patient."</seg>
<seg id="527">"the holder of approval for the permit has to ensure that the Pharmacovigilance system has been set up and functioning in the module 1.8.1 of the authorisation application, and as long as it is applied into traffic-hand medicines."</seg>
<seg id="528">"the authorisation of the authorisation for the entry is obliged to conduct research and additional measures on Pharmakovigilance, as described in Version 5 of the application's Risk Management Plan (RMP), as well as in accordance with any subsequent update of the Risk Management Plan."</seg>
<seg id="529">"a updated RMP should be provided according to the" CHMP guideline on Risk Management Systems for Medicinal products for human use "at the same time with the next updated report on the imitability of the medication by means of (Periodic Safety Update Report, PSUR)."</seg>
<seg id="530">"in addition, a updated event should be submitted: • in obtaining a new information that could have an effect on current safety specifications (Safety Specification), the pharmaceutical vigilance or the measures to achieve an important one (the Pharmacovigilance or risk reduction) milder by the EMEA"</seg>
<seg id="531">• If you have suffered a heart attack within one month before your treatment - if you have suffered in instabiler Angina Pectoris (for the first time) the risk of a bloodstream education in the veins (deep Venous membrance) - if you have already occurred earlier one such bloodropy.</seg>
<seg id="532">"they are suffering heavy blood circulation of the heart (coronary artery disease), the arteries of the legs or arms (peripheral disease of the carotions), or the brain (cerebrovascular disease), you have recently suffered a heart attack or stroke."</seg>
<seg id="533">During the treatment with Abseamed it can come within the standardization it can come back to an easy dosisdependent increase of blood pressure number which is again back for further treatment.</seg>
<seg id="534">Your doctor will be able to conduct regular blood tests to regularly check the number of blood cells during the first 8 weeks of treatment.</seg>
<seg id="535">"iron-gel, resolution of the red blood cells (lambs), blood loss, vitamin B12- or folklore-gel, should be taken into account and be treated before the beginning of therapy with Abseamed."</seg>
<seg id="536">Very rare was reported on the appearance of an antikuperate Erythroblastopenie after monthunder up to years of treatment with subcutaneous (among the skin with subcutted) erythropoetin.</seg>
<seg id="537">"if you suffer from Erythroblastopenie, he will break your therapy with Abseamed and set how your anaemia is best treated."</seg>
<seg id="538">"therefore, Abseamed must be given by injection in a vene (intravenous) if you are treated because of an anemia due to a kidney disease."</seg>
<seg id="539">A high hemogram binds the risk of problems with the heart or blood vessels and the sterberisiko could be increased.</seg>
<seg id="540">"in an increased or increasing potassium, your doctor can consider any interruption of the treatment with Abseamed, until the calibration values are back in the standardization area."</seg>
<seg id="541">"if you suffer from chronic sodium and clinically obvious coronary disease, your doctor will ensure that your hemoglobinders will not exceed a certain value."</seg>
<seg id="542">"after the time of this knowledge, by treating the blood-mwood with sewage in adults with chronic kidney failure (kidney failure), which are not yet dialysis, the progression of kidney failure is not accelerated."</seg>
<seg id="543">A 2 - 3-week delay between epoetin-alfa-Gabe and the desired effect should be taken into account for the assessment of the effectiveness of Abseamed.</seg>
<seg id="544">200 Your doctor will regularly determine your values of the red blood cells (hemoglobin) and adjust your Abseamed dose to keep the risk of bleeding (thrombotic event) as low as possible.</seg>
<seg id="545">"this risk should have done across from the treatment with epoxettin alfa advantages very carefully, in particular if you have already occurred risk for thrombotic vascular events (e.g. a deep venerthrombosis or pulmonary)."</seg>
<seg id="546">"if you are a cancer patient, think that Abseamed can act like a growth factor for blood cells and under certain circumstances may affect the tumor negative."</seg>
<seg id="547">If you impending a larger orthopedic surgery should be investigated before treatment with Abseamed the cause of your anaemia and treated accordingly.</seg>
<seg id="548">"if your values of the red blood cells (hemoglobin) are too high, you should not get Abseamed, since a raised risk for bloodroses after surgery exists."</seg>
<seg id="549">"please inform your doctor or a pharmacist if you have to take any other medicines / apply, or have been adopted recently, even if it is not prescription drugs."</seg>
<seg id="550">"if you take Ciclosporin (means of repression of the immune system) during your treatment with Abseamed, your doctor will be able to arrange certain blood tests to measure the blood levels of Ciclosporin."</seg>
<seg id="551">Laboratories have no interaction between epetin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means to build the immune system, for example in cancers or HIV). "</seg>
<seg id="552">"depending on how your blood poverty (anemia) speaks to the treatment, the dose may be adjusted around every four weeks until your condition is under control."</seg>
<seg id="553">Your doctor will arrange in appropriate regular blood tests to verify the treatment results and make sure that the drug works properly and your hemoglobinations worth a certain value.</seg>
<seg id="554">"once you are well adjusted, you will receive regular cans of Abseamed between 25 and 50 i.e. / kg twice weekly, spread over two equal injections."</seg>
<seg id="555">Your doctor will arrange if necessary regular bladder tests to check the treatment results and make sure your hemoglobinations worth a certain value.</seg>
<seg id="556">"depending on how the anemia speaks to the treatment, the dose may be adjusted around every four weeks until the condition under control is."</seg>
<seg id="557">"to ensure this and ensure that the hemoglobinations worth a certain value is not exceeds, the doctor will perform regular blood tests."</seg>
<seg id="558">"if it is necessary to shorten the treatment times prior to the surgery, a dose of 300 i.e. / kg at 10 consecutive days before the surgery, on the day of the surgery and another 4 days after the surgery."</seg>
<seg id="559">"however, you can also learn if your doctor keeps this for appropriate, also learn how to splash yourself into the skin."</seg>
<seg id="560">"heart, heart blood, shaking bleeding, stroke blood circulation of the brain, deep venous Thrombosis, radial Thrombosis, radial Thrombosis in artificial kidneys were reported in patients under erythropoetin-treatment."</seg>
<seg id="561">"eyelid and the lips (quake odes) and shocked allergic reactions with symptoms such as tingling, redness, itch, heat and accelerated pulse were reported in rare cases."</seg>
<seg id="562">Erythroblastopenie means that no longer enough red blood cells in bone marrow can be formed (see section "Special beware of the application of Abseamed is required).</seg>
<seg id="563">After repetitive blood flow it can come - independently of the treatment with Abseamed - to a bleeding (thrombotic vascular events).</seg>
<seg id="564">The treatment with Abseamed may be associated with an increased risk for bloodshed after surgery (postoperative thrombotic events) when your starting-time glolobinhp is too high</seg>
<seg id="565">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably impaired, or if you notice side effects which are not specified in this usage information."</seg>
<seg id="566">"if a syringe from the fridge was taken and room temperature has reached (up to 25 ° C), it must be used either within 3 days or be rejected."</seg>
<seg id="567">Aclasta is applied to the treatment of the following diseases: • Osteoporosis (an ailment that makes the bones sprinkde) both in women after menopause and in men.</seg>
<seg id="568">"it is used in patients with a high Frakturrisiko (bone breaks), including patients who suffered a little traumatist hips like when they stumbled; • Morbus Paget of bone, a disease, which changed the normal course of bone growth."</seg>
<seg id="569">"in addition, patients with Morbus pet should take at least 500 mg calcium twice daily for at least 10 days after treatment; patients with hip freshness should be obtained from the first infusion of a large dose of vitamin D (50 000 to 125 000 IE) oral or by injection in a muscle."</seg>
<seg id="570">"administration of Paracetamol or Ibuprofen (means against inflammation) shortly after the application of Aclasta may be reduced in the three days following the infusion of infusion, such as fever, muscle aches, grippeals and headaches."</seg>
<seg id="571">"for the treatment of the Morbus Paget, Aclasta may only be prescribed by doctors, who have experience in treating this disease."</seg>
<seg id="572">"since the active ingredient in Aclasta is the same as in Zometa, a part of the data material for Zometa was attracted to the evaluation of Aclasta."</seg>
<seg id="573">"during the first study nearly 8 000 older women were involved with osteoporosis, and the number of spine has been studied over a period of three years."</seg>
<seg id="574">"the second study deals with 2 127 men and women with osteoporosis over 50 years, which had recently suffered a hip refracture; it was examined the number of fractures over a period of up to five years."</seg>
<seg id="575">"at Morbus Paget, Aclasta has been tested in two studies on a total of 357 patients and compared to six months with Risedronat (another Bisphosphonate)."</seg>
<seg id="576">"the main indicator of the efficacy was whether the salary of alkaline phosphate are in the Serum (a enzyme, the bone substance demolishing) in the blood back to normalized or at least 75% compared to the starting value."</seg>
<seg id="577">In the study with older women the risk of whirlpools were reduced in patients under Aclasta (without other osteoporosis) over a period of three years compared to the patients under placebo by 70%.</seg>
<seg id="578">In comparison of all patients under Aclasta (with or without other osteoporosis) with those under placebo the risk of hips was reduced by 41%.</seg>
<seg id="579">"in the study involving males and women with hip, 9% of patients under Aclasta towel (92 of 1 065) compared to 13% of patients under placebo (139 of 1 062)."</seg>
<seg id="580">Most side effects of Aclasta occur within the first three days of infusion and are less common in repetitive infusions.</seg>
<seg id="581">Aclasta may not be used in patients who may possibly be vulnerable (allergic) against Zoledronic acid or other Bisphosphor or one of the other components.</seg>
<seg id="582">"as with all bisphosphates, patients are subject to patients at Aclasta the risk of kidney disease, reactions to the infusion station and Osteonekrose (dying of bone fabric) in the pine."</seg>
<seg id="583">"the manufacturer of Aclasta provides educational material for doctors, the Aclasta for the treatment of osteoporosis, the indications contains how the drug applies, as well as similar material for patients in which the side effects of the drug are discussed and pointed out when they should contact the doctor."</seg>
<seg id="584">April 2005 the European Commission published the Novartis Europharm Limited approval for the transport of Aclasta throughout the European Union.</seg>
<seg id="585">"conditions ODER restrictions with regard to DER safe AND effective application of ZU, DIE by DIE member states ZU implement SIND • Conditions ODER restrictions with regard to THE safe AND effective application of DES SARE by DIE member states ZU, SIND"</seg>
<seg id="586">"treatment of osteoporosis in postmenopausal women and men with an increased risk of fractures, including patients with a recent suffered low-traumatist hips."</seg>
<seg id="587">"the patient information package is intended to be provided and the following core message includes: • The packing machine • contraindication in pregnancy and with breastfeeding women • Required physical activity, the non-smoothing and symptoms for serious side effects • Wann on medical or nursing help."</seg>
<seg id="588">"treatment of osteoporosis • in case of postmenopausal women • in men with an increased risk of fractures, including patients with a recent suffered low-traumatist hips."</seg>
<seg id="589">For the treatment of postmenopausal osteoporosis and the osteoporosis in men will be recommended as intravenous infusion of 5 mg of Aclasta once a year.</seg>
<seg id="590">"in case of patients with low-traumatic hip, the administration of infusion of Aclasta is recommended two or more weeks after the operative care of the hips (see section 5.1)."</seg>
<seg id="591">"for the treatment of the Morbus Paget, Aclasta should be used only by doctors, the experience in the treatment of the Morbus Paget."</seg>
<seg id="592">"after a treatment of the Morbus Paget with Aclasta, a long revocation period was observed in patients who have addressed to therapy (see section 5.1)."</seg>
<seg id="593">"in addition, it is very advisable when patients with Morbus Paget an adequate supply of calcium, corresponding to twice a day at least 500 mg cap, for at least 10 days after the gift of Aclasta (see Section 4.4)."</seg>
<seg id="594">"in patients with a recent learned low-traumatic hip, a initialddose from 50.000 to 125.000 i.e. orally or intramuscular vitamin D especially recommended in front of the first Aclasta infusion."</seg>
<seg id="595">"the frequency of symptoms, which occur within the first three days of administration of Aclasta may be reduced by Gabe of Paracetamol or Ibuprofen shortly after the application of Aclasta."</seg>
<seg id="596">Patients with kidney dysfunctions (see Section 4.4) In case of patients with a creatinin-Clearance &lt; 35 ml / min Aclasta is not recommended as limited clinical experience for these patients.</seg>
<seg id="597">"older patients (≥ 65 years) A dosage adjustment is not necessary, since the bioavailability, distribution and elimination of older patients are similar to younger."</seg>
<seg id="598">"children and adolescents Aclasta will not be recommended for the use in children and young people under the age of 18, as data for immortality and effectiveness are missing."</seg>
<seg id="599">Aclasta is not recommended in patients with severe kidney failure (Creatinin-Clearance &lt; 35 ml / min) as for these patient population only limited clinical experiences.</seg>
<seg id="600">An advanced Hypokalzemia is before the beginning of the therapy with Aclasta due to sufficient intake of calcium and vitamin D (see Section 4.3).</seg>
<seg id="601">"due to the rapid introduction of the effect of Zoledronic acid on the bone construction, a temporary, withdrawn in symptomatic hypokalzemia is able to develop their maximum usually within the first 10 days of the infusion of Aclasta (see section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable when patients with Morbus Paget an adequate supply of calcium, corresponding to twice a day at least 500 mg cap, for at least 10 days after the gift of Aclasta (see Section 4.2)."</seg>
<seg id="603">"cancer disease, chemotherapy, treatment with corticosteroids, poor oral hygiene) should be used before an application of bisphosphor for a dental treatment with adequate preventive tooth treatment."</seg>
<seg id="604">"for patients, the dental handles, are no data available whether the interruption of treatment with bisphosphates are the risk for osteoporosis in the orthodontics."</seg>
<seg id="605">Clinical evaluation by the treatmenting doctor should be the basis for the treatment plan of each patient and based on an individual benefit risk assessment.</seg>
<seg id="606">"the frequency of symptoms, which occur within the first three days of administration of Aclasta may be reduced by Gabe of Paracetamol or Ibuprofen shortly after the application of Aclasta (see Section 4.2)."</seg>
<seg id="607">"the frequency of as serious side-effect cases of pre-hoped disorders was increased in patients who received Aclasta (1,3%) (51 of 3,862) compared to patients who received placebo (0,6%) (22 of 3,852)."</seg>
<seg id="608">In the osteoporosis Studies (PFT) HORIZON - Recurrent Fracture Trial [RFT]) was the total amount of prehoped between Aclasta (2.8%) and placebo (2.3%).</seg>
<seg id="609">"very frequent (≥ 1 / 10), frequent (≥ 1 / 100, &lt; 1 / 10), rare (≥ 1 / 10,000, &lt; 1 / 1,000) unwanted drug effects are listed in table 1."</seg>
<seg id="610">"kidney-Function Zoledronic acid was associated with kidney dysfunctions, which incurred as acceptance of the kidney function (i.e. an increase in the Serum Creatinins) and in rare cases as an acute of kidney failure."</seg>
<seg id="611">The change of the Kreatinin-Clearance (yearly before administration) and the appearance of kidney failure and a restricted Nierenfunction were comparable to osteoporosis for three years compared to the Aclasta- and the placebo group.</seg>
<seg id="612">A temporary increase of the Serum Kreatinins within 10 days after Gabe was observed at 1.8% of patients with Aclasta-treated patients compared to 0.7% of the patients treated with placebo.</seg>
<seg id="613">"based on evaluating the laboratories, the temporary asymptomatic calzium values, which apply below the normal sponge range (less than untreated mmol / l), at 2.3% of patients with Aclasta in a great clinical study treated patients compared to 21% of the patients treated with Aclasta in the morbus pagoet studies."</seg>
<seg id="614">"all patients received supplementary amounts of vitamin D and calcium in the study to postmenopausal osteoporosis, in the study for avoiding clinical fractures after a hips and in the Morbus Paget-studies (see Section 4.2)."</seg>
<seg id="615">"in the study to prevent clinical fractures after a recent learn hip, the majority of patients were not syndically measured, however, the majority of patients received a initialdosis vitamin D before administration of Aclasta (see Section 4.2)."</seg>
<seg id="616">"local reactions according to administration of Zoledronic acid in a great clinical study was reported about local reactions to the infusion point such as redness, swelling and / or pain, reported (0.7%)."</seg>
<seg id="617">"Osteonekrosen in the orthodontic was occasionally especially at cancer patients, above Osteonekrosen (primorr in the orthodontics) reported that were treated with bisphosphates, including Zoledronic acid."</seg>
<seg id="618">"many of these patients had signs for local infections, including osteomyelitis, and the majority of reports refer to cancer patients on cancer extracts or other dental."</seg>
<seg id="619">7 study with 7.736 patients joined Osteonekrose in the orthodontics at one with Aclasta and with a placebo treated patients.</seg>
<seg id="620">"in case of overdosage, which leads to a clinically relevant hypokalzemia, can be reached by hub of oral calcium and / or an intravenous infusion of calcium gluing."</seg>
<seg id="621">Clinical effectiveness in the treatment of postmenopausal osteoporosis (PFT) The effectiveness and safety of Aclasta 5 mg once a year for 3 consecutive years (7.736 women aged between 65 and 89 years) with either an Knox-T-score for the shaft holder or a BMT-T-score for the shaft holder as ≤ -2.5 with or without signs of an existing spine.</seg>
<seg id="622">Effects on morphometric fluids Aclasta sensed significantly over a period of three years as well as after a year the frequency of one or more new whirlpools (see table 2).</seg>
<seg id="623">Aclasta-treated patients aged 75 years and older had a reduced amount of 60% reduced risk for vertebrefractures compared to placebo-patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on hips Aclasta proved a equitable effect over three years in one around 41% (95% CI, 17% up to 58%) reduced risk of hips. "</seg>
<seg id="625">Effect on the bone density (BMD) Aclasta increased the bone density on the lumbar range compared to the placebo treatment significantly compared to the placebo treatment (6, 12, 24 and 36 months). "</seg>
<seg id="626">"9 increase the bone density of the lumber column by 6,7%, the entire strokes by 6,0%, of the lower than 5.1% and the distal radius by 3.2%."</seg>
<seg id="627">Bone histology For 152 postmenopausal osteopathic patient who were treated with Aclasta (N = 82) or placebo (N = 70) were taken one year after the third annual dose of Knochenbiopsies of the pelvic.</seg>
<seg id="628">A microcomputer analysis (µCT) -analysis showed with Aclasta-treated patients compared to placebo an increase in the traocular bone-volume and the preservation of traocular bone architecture.</seg>
<seg id="629">Knochenumber marker The knochenspecific alkald phosphatase (B1NP) in the Serum and the beta-C-Telopeptid (b-CTX) in Serum were determined in subgroups of 517 to 1.246 patients in periodical intervals during the duration of study.</seg>
<seg id="630">The treatment with an annual 5-mg dose Aclasta reduced by SAP under 12 months decreased by 30% compared to the starting value and was held at 28% below the starting value up to 36 months.</seg>
<seg id="631">P1NP was significantly reduced by 61% below the starting value after 12 months and has been kept under 52% below the starting value of up to 36 months.</seg>
<seg id="632">B-CTX has been significantly reduced by 61% below the starting point after 12 months and was held at 55% below the starting value to 36 months.</seg>
<seg id="633">"the vitamin D mirror were not measured not lined, but the majority of patients received a initial ssrosis vitamin D (50,000 to 125.000 i.e., oral or intra uscular) 2 weeks before the infusion."</seg>
<seg id="634">"the overall mortal was 10% (101 patients) in the group with Aclasta-treated group, compared to 13% (141 patients) in the placebo group."</seg>
<seg id="635">Effect on the bone mineral density (BMD) In the HORIZON-RFT study increased the Aclasta treatment compared to placebo treatment the BMD at all times of time.</seg>
<seg id="636">The Aclasta treatment led over 24 months compared to placebo treatment to increase the BMD by 5.5% at the overall level and around 4.3% at the Schenkelhals.</seg>
<seg id="637">Clinical effectiveness in men In the HORIZON-RFT study were randomized 508 men and in 185 patients the BMD was assessed after 24 months.</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in males; the frequency of clinical fractures was 7.5% at Aclasta-treated men compared to 8,7% in placebo.</seg>
<seg id="639">In another study in men (study CZOL446M2308) was the once annual administration of Aclasta compared to the once weekly transformation of the Lenmebel BMD after 24 months compared to the starting value.</seg>
<seg id="640">"clinical effectiveness of the treatment at Morbus Paget of the femur Aclasta became examined in patients and patients aged over 30 years with radiologically confirmed, especially light to moderate-mirror of alkaline phosphatase according to 2.6triple-specific upper normal (in the study)."</seg>
<seg id="641">11 The effectiveness of an infusion of 5 mg Zoledronic acid compared to intake of 30 mg Risedronat once daily during 2 months has been proven in two six months case studies.</seg>
<seg id="642">With the combined results after 6 months a similar acceptance of pain pressure and painless influenced compared to the starting value for Aclasta and Risedronat.</seg>
<seg id="643">"patients, which were classified as a Responsibilities before the end of the sixth month (in therapy), were included in a follow-up phase."</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with Risedronat treatment patients, the therapeutic approach to 141 of using Aclasta, compared to 71 of using Risedronat treatment treated patients, maintained in a mid-term duration of the follow-up phase of 18 months after application."</seg>
<seg id="645">"unique and multiples 5 and 15 minutes continuous infusions of 2, 4, 8 and 16 mg Zoledronic acid at 64 patients takes the following pharmacogenic data that proved to be dosisindependent."</seg>
<seg id="646">"after that, the plasmasbar took up rapidly from &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 h, followed by a long lasting phase very low concentration, no more than 0.1% of the maximum value."</seg>
<seg id="647">"hot biphashic disappearance of the large cycle with half times t ½ α 0,24 and t ½ -24 hours, followed by a long elimination of elimination with a temporal elimination of ½ g 146 hours."</seg>
<seg id="648">"the early distribution phases (α and β, with the above ½ -values) represent probably the rapid resorption into the bones and the excretion of the kidneys."</seg>
<seg id="649">"in the first 24 h 39 ± 16% of the dose dose in urine, while the rest is mainly tied to bone fabric."</seg>
<seg id="650">"the entire body-Clearance is independent of the dose 5.04 ± 2.5 l / h, and remains uninfluenced by gender, age, race or body weight."</seg>
<seg id="651">An extension of infusion time of 5 to 15 minutes led to the withdrawal of the Zoledronym - concentration by 30% at the end of infusion but had no effect on the surface under the curve (Plasmakoncentration against time).</seg>
<seg id="652">"a diminished Clearance by Cytochrom-P450-Enzymsystems metabolized substances is unlikely, because Zoledronic acid is not yet metabolized by humans and because they are a watchful or not direct and / or irreversible, material-dependent Inhibitor of the P450-"</seg>
<seg id="653">"special patient groups (see Section 4.2) The renal Clearance of the Zoledronic acid correlated with the Kreatinin-Clearance, namely 75 ± 33% of the Kreatinin-Clearance, and was among the 64 examined patients in the average 84 ± 29 ml / min (range 22 to 143 ml / min)."</seg>
<seg id="654">This makes a light (Clone = 50- 80 ml / min) and an excessive amount of incline disrupting up to 35 ml / min no dosage adjustment of the zoledronic acid requires.</seg>
<seg id="655">"because of serious kidney function (Kreatinin- Clearance &lt; 30 ml / min), only restricted data are possible for these Population."</seg>
<seg id="656">Acute toxicity The highest not letal intravenous single dosis was at mice 10 mg / kg body weight and with rats 0,6 mg / kg body weight. "</seg>
<seg id="657">"for studies in dogs were retailer of 1,0 mg / kg (based on the AUC the 6n of recommended human therapeutic exposure), administered over a period of 15 minutes, good and without a renal attack."</seg>
<seg id="658">"chronic and chronic toxicity In studies with intravenous application, the renal compatibility of Zoledronic acid was obtained at the AUC, a total of 6-minute infusion to 3-day intervals ranging from 2- 3 weeks (a cumulative dose which corresponds to the case of the human therapeutic exposure to the AUC, corresponds to the AUC."</seg>
<seg id="659">"in long-term studies with repetitive application in cumulated expositions, which had sufficiently exceeded the maximum of intended human exposure to other organs, including the gastrointestinal tract and the liver, as well as the intravenous injections."</seg>
<seg id="660">"the most common claims for studies with repetitive application was a multi-stage Spongiosa in the metaphhyse of long bones in the growth phase with virtually all dosages, a demonstration, which reflects the pharmacological, anti-resortive effects of substance."</seg>
<seg id="661">"at rats, one observed a teratogenicity in doses from 0,2 mg / kg as an outer and inner (visceral) abnormalities and such of the skeleton."</seg>
<seg id="662">In rabbits no teratogenic effects or embryo may be observed although the maternal toxicity at 0.1 mg / kg as a result of reduced serum calcium levels.</seg>
<seg id="663">"if the drug is not directly used, the user is responsible for the warehousing and conditions before the application; normally 24 h at 2 ° C to 8 ° C are not exceeded."</seg>
<seg id="664">Aclasta is provided as a package with a bottle of packaging unit or as a bundle packer consisting of 5 packages which each have a bottle.</seg>
<seg id="665">"treatment of osteoporosis in postmenopausal women and men with an increased risk of fractures, including patients with a recent suffered low-traumatist hips."</seg>
<seg id="666">"the patient information package is intended to be provided and the following core message includes: • The packing machine • contraindication in pregnancy and with breastfeeding women • Required physical activity, the non-smoking and symptoms for serious side effects • Wann on medical or nursing help."</seg>
<seg id="667">"July 2007, amended on 29 September 2006, published on 29 September 2006, in the module 1.8.1 of the application for Pharmacovigilance system and is working before and marketed during the product."</seg>
<seg id="668">Risk-management plan The owner of the approval for authorisation is obliged to perform the studies and additional activities on Pharmakovigilance plan (RMP) in module 1.8.2 of authorisation application and all the following versions approved by the CHMP approved versions of the RMP.</seg>
<seg id="669">"according to the CHMP directive for risk management systems for human medicines, the revised RMP should be submitted together with the next" Periodic Safety Update Report (PSUR). "</seg>
<seg id="670">"a reworking process should be submitted • If new information will be announced, which could affect the current statements about security, the pharmaceutical vigilance plan or activities for minimization of the risk. • within 60 days when an important milestone (to Pharmakovigilance or Risikominimination). • On request of EMEA."</seg>
<seg id="671">"Zoledronic acid is a representative of a subclass-class that is called Bisphosphations, and is used to treat the osteoporosis in postmenopausal women, the osteoporosis in men and the morbus Paget of the femur."</seg>
<seg id="672">"absorbing blood levels of sex hormones, especially estrogen, which are made from androgen, play a role in rather gradual loss of bone mass, which is observed in men."</seg>
<seg id="673">"by the Pagbus Paget takes place the bone construction too fast, and new bone material is unarranged which the bone material is weaker than normal."</seg>
<seg id="674">"Aclasta works by adding the bone-construction, a normal bone-formation, and thus gives the bones to strength again."</seg>
<seg id="675">"if you are suffering in dental treatment or need to undergo any dental surgery, please inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"using Aclasta with other medicines, please inform your doctor, pharmacists or toiletries, if you have to take other medicines / apply or applied recently, even if it is not prescription drugs."</seg>
<seg id="677">"for your doctor, it is particularly important to know if you take drugs, of which is known that they compensate the kidneys."</seg>
<seg id="678">"when using Aclasta together with food and drinks, you are worried that you have to take enough liquid according to the instructions of your physician to take enough liquid before and after treatment with Aclasta."</seg>
<seg id="679">Osteoporosis The usual dosage is 5 mg once per year that will allow you to be administered by your doctor or the patient as an infusion into a vene.</seg>
<seg id="680">"if you have recently broken down the hips, is recommended to make appointments by Aclasta 2 or more weeks after the operative care of the hips."</seg>
<seg id="681">Morbus Paget The usual dosage is 5 mg that will allow you to be administered by your doctor or the patient as an infusion into a vene.</seg>
<seg id="682">"since Aclasta works for a long time, you will possibly need a further dose after a year or longer."</seg>
<seg id="683">"it is important to follow these instructions exactly, so that the calcium mirror in your blood is not too low in time after the infusion."</seg>
<seg id="684">"by Morbus Paget, Aclasta can work for more than one year, and your doctor will inform you if you need a renewed treatment."</seg>
<seg id="685">"if the administration of Aclasta suits your doctor or hospital, please contact your doctor or hospital to arrange a new date."</seg>
<seg id="686">"prior to the termination of therapy with Aclasta If you are considering the cending of the treatment with Aclasta, please take your next doctor's name and discuss it with your doctor."</seg>
<seg id="687">"side effects in connection with the first infusion are often very common to (if more than 30% of patients), are still less common after the subsequent infusions."</seg>
<seg id="688">Fever and shakes and shakes and headaches and headaches occur within the first three days of the administration of Aclasta.</seg>
<seg id="689">"currently, it is unclear whether Aclasta causes this irregular heart attack, but you should report it to your doctor if you notice such symptoms after you've received Aclasta."</seg>
<seg id="690">"physical signs due to low calcium concentration in the blood, such as muscle crasms or critical feeling, especially in the area around the mouth."</seg>
<seg id="691">"flu, sleeplessness, fatigue, redness, diarrhoea, diarrhea, fragmentation, redness, redness, redness, reddish, redness, reddish, reddish, redness, redness of the Serum Creatinins, tissue decancers and thirst."</seg>
<seg id="692">Persistent pains and / or not healing wounds in the mouth or on the jaws were mainly reported to patients who were treated with bisphosphates because of other diseases.</seg>
<seg id="693">"allergic reactions, including rare cases of breathing difficulties, kidney failure and angioöver (such as swelling in the face, the tongue, or in the throat), was reported."</seg>
<seg id="694">"please inform your doctor, pharmacist or nursing staff, if any of the above-effects you have significantly impaired or you may notice the side effects that are not listed in this usage information."</seg>
<seg id="695">"if the drug is not directly used, the user is responsible for the storage period and conditions until the application; normally 24 h at 2 ° C to 8 ° C are not exceeded."</seg>
<seg id="696">"in patients with a recently suffered low-traumatic girdment, is recommended to make infusion of Aclasta two or more weeks after the operational supply of hip refracture."</seg>
<seg id="697">"before and after administration of Aclasta, patients must be sufficiently supplied with fluid; this is particularly important in patients who receive a diuretic therapy."</seg>
<seg id="698">"due to the rapid introduction of the effect of Zoledronic acid on the bone-construction, a temporary, sometimes symptomatic branched, hypokalzemia is able to develop their maximum usually within the first 10 days after the infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable when patients with Morbus Paget an adequate supply of calcium, according to at least twice a day, 500 mg of calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently suffered low-traumatic hip, a initial dose of 50,000 to 125.000 i.e. orally or intra uscular vitamin D before the infusion of Aclasta recommended."</seg>
<seg id="701">"if you need more information about your ailment or treatment, please read the pack included (also part of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="702">"ACOMPLIA will be applied in addition to a diet and movement for the treatment of adult patients, in addition to obesity (body mass index - BMI) of 30 kg / m ² or above (BMI of 27 kg / m ² or above) and beyond one or more"</seg>
<seg id="703">"moreover, four studies conducted at more than 7 000 patients in which ACOMPLIA was used as a supportive means of setting the censer."</seg>
<seg id="704">"zu The studies on the setting of the censer showed no single results, so that the effect of ACOMPLIA was difficult to assess this application area."</seg>
<seg id="705">Which risk is related to ACOMPLIA? he found the most common side effects of ACOMPLIA which were observed during the studies (observed during more than 1 of 10 patients) were the full listing of the associated associated with ACOMPLIA.</seg>
<seg id="706">"it may also be used in patients suffering from severe depression or treated with antidepressants, as it can reinforce the risk of depression and among others among a small minority of patients sufficile."</seg>
<seg id="707">Caution is advisable to use ACOMPLIA with medicines such as Ketoconazol or Itraconazol (medicine against fungal infections), Ritonavir (a means of use with HIV- infection), Telithromycin or Clarithromycin (antibiotics). LN</seg>
<seg id="708">The committee for human medicines (CHMP) came to the conclusion that the effectiveness of ACOMPLIA in regard to the weight reduction in patients with obesity or overweight</seg>
<seg id="709">Medicines used in patients who need it from health and not for cosmetic reasons (by providing a clarifications for patients and doctors) and around the Arz</seg>
<seg id="710">He Additional to diet and movement for treatment of obesity (BMI ≥ 30 kg / m ²) or overweight patients (BMI &gt; 27 kg / m ²) which also have one or more risk factors such as type-2-diabetes or other lipidemia (see Section 5.1).</seg>
<seg id="711">ACOMPLIA is not recommended for the use in children and young people under the age of 18 on the basis of misery of data for effectiveness and inconsistency.</seg>
<seg id="712">"La depressant disorders or singular changes with depressant symptoms were given at up to 10%, suiciled for up to 1% of patients who were Rims, reported (see section 4.8)."</seg>
<seg id="713">"and with depressive disorders may not be used for Rimonshore, unless the benefit of treatment in the individual case weighs the risk (see section 4.3 and 4.8)."</seg>
<seg id="714">"he also Also in patients, who is in addition to obesity, not recognizable risks, can occur depressive reactions."</seg>
<seg id="715">Related or other right people) are to point out that it is necessary to monitor the reoccur of such symptoms and get immediate medical advice if these symptoms arise.</seg>
<seg id="716">• Elder patients The effectiveness and immortality of Rims in the treatment of patients over 75 years were not sufficiently demonstrated.</seg>
<seg id="717">Patients with a cardiovascular event (myocardinary or stroke etc.) just less than 6 months ago by studies with RimonBrabant. ln</seg>
<seg id="718">"Rifampicin, phenytoin, phenobarbital, Carbamazepin, Johanniskraut) were not examined that the simultaneous Gabe CYP3A4-Induktores the Plasmakoncentration of RimonBrabant."</seg>
<seg id="719">SSE overweight patients and patients with obesity are examined and beyond 3800 patients in other indications.</seg>
<seg id="720">"the following table (table 1) shows the necessary unwanted effects in placebokontrolfiled studies in patients, which were treated to weight reduction and due to accompanying metabolic disorders."</seg>
<seg id="721">When the incidence of statistically significant was significantly higher than the corresponding placeborate (for unwanted effects ≥ 1%) or if they were clinically relevant (for unwanted effects &lt; 1%). ng At the evaluation of side effects are basically laid down:</seg>
<seg id="722">"very frequent (≥ 10%); often (≥ 1, &lt; 10%); occasionally (≥ 0.1, &lt; 1%); rarely (≥ 0,01, &lt; 0.1%); very t lä"</seg>
<seg id="723">"in a familial study, in which a limited number of individuals were administered by up to 300 mg were observed, only light symptoms were observed."</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and one at the same time existing hypertension and / or sellipidemia.</seg>
<seg id="725">"N Weight reduction after a year was for ACOMPLIA 20 mg 6,5 kg, related to the output value, compared to 1,6 kg for the placebo group (difference -4.3 kg CI95% -5,3; -4,4, p &lt; 0.001)."</seg>
<seg id="726">Patients who were treated with ACOMPLIA 20 mg and 1.2 kg in the placebo group (difference -3.3 kg; CI95% -4.4% -3; p &lt; 0.001).</seg>
<seg id="727">"after 2 years the difference in the whole weight reduction between ACOMPLIA and placebo -4.4 kg (CI95% -5,0%; -3,4, p &lt; 0.001)."</seg>
<seg id="728">9 weight reduction and further risk factors in the studies of patients without diabetes in which a mixed population of patients with</seg>
<seg id="729">Under RimonBrabant 20 mg was seen an average waste of triglyceride by 6.9% (starting point triglyceride 82 mmol / l) compared to a rise of 5.4%</seg>
<seg id="730">"in a second study in patients with a obesity and with so far unnegotiating type-2- diabetes (serenade), the absolute change in the HbA1c-value (with an output value of 7,9% for both groups) after 6 months -0.8 for Rimonaires 20 mg and 0.3 under placebo"</seg>
<seg id="731">"the percentage of patients who reached a hbA1c- value of &lt; 7%, was 51% in the Rimline group and 35% in the placebo group."</seg>
<seg id="732">The difference between the medium weight change between the 20 mg- and the placebo group lay at 3.8 kg (CI95% -5.0% -2.6 p &lt; 0.001). LN</seg>
<seg id="733">"improving HbA1c-value in patients, the RimOct. 20 mg have been taken about 50% due to direct effects of Rims and about 50% by the weight reduction. n eim Arz"</seg>
<seg id="734">2 hours reached the Steady-State plasmasks were reached after 13 days (Cmax = 196 ± 28,1 ng / ml; Ctrough = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"influence of food: he got the reasons for Rimonaires either in the blood-condition or after a fat meal, but in case of food intake a around 67% increased Cmax or by 48% increased ng AUC."</seg>
<seg id="736">Patients with black skin colour can reduce up to 31% lower Cmax and one around 43% lower AUC as patients of other ethnic populations.</seg>
<seg id="737">N populist spharmacinetic analyses (age spectrum 18- 81 years) is estimated that a 75- year-old patient is estimated at 21% higher Cmax and one around 27% higher AUC as a 40-year-year-old</seg>
<seg id="738">"5.3 preclinical data for safety he relentment unwanted effects which were not observed in clinical studies, which were used in clinical studies according to exposure in human therapeutic field, were regarded as possibly relevant for the clinical use:"</seg>
<seg id="739">"in some, however, not in all cases the beginning of the convulsions seems to be related to procedural stress such as dealing with animals."</seg>
<seg id="740">"for any longer period prior to the pairing (9 weeks) was given that a recovery from the initials effects of Rimonaires, so have no unwanted effects on the fertilisation or cycleus disruptions."</seg>
<seg id="741">The influence of Riminters on the pre- and postnatal development was examined at the rat in dosages of up to 10 mg / kg / day.</seg>
<seg id="742">"in a study on rats to the imitation and postnatal development caused an exposition with Rims in utero, and by means of lacked no changes in learning or memory."</seg>
<seg id="743">Detailed information on these medicines are available on the website of the European Drug Agency (EMEA) http: / / www.emea.europa.eu / availability-cuts</seg>
<seg id="744">"La On the carrier of the medication by means of name and address of the manufacturer, who are responsible for the release of the responsible charge."</seg>
<seg id="745">"26 severity of psychiatric events such as depression or vocal changes were given in patients, the ACOMPLIA, reports (see paragraph" which side effects "</seg>
<seg id="746">"SSE If with you symptoms of a depression (see below) during the treatment with ACOMPLIA, please contact your doctor and break the treatment."</seg>
<seg id="747">"unwind-feeling, diarrhea, anxiety, itch, redness, low-fatigue and inflammation (rendemic), back pain (diminishing or uncommon burning or tingling) in hands and feet, Hitzewallus, petal, gripping collectionery. germs"</seg>
<seg id="748">"please note your doctor or a pharmacist if any of the above-effects side effects you have significantly impaired, or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="749">Abstract of the EPAR for the public The present document is a summary of the European Public Library report (EPAR) in which explains how the Committee for Humanarztend (CHMP) has been evaluated in order to make recommendations concerning the application of the drug.</seg>
<seg id="750">Actos is applied to the treatment of type-2 diabetes (also known as non-insulin-dependent diabetes). • It can be applied solely (Monotherapy) in patients (especially overweight patients) in which metformin (a diabetesdrug medicine) can be applied together with another diabetesdrug medicine (dual therapy).</seg>
<seg id="751">"it can be applied in addition to metformin patients (especially overweight patients), which can not be satisfactory with metformin alone in the highest tolerable dose."</seg>
<seg id="752">In combination with a sulphylharnstoff or insulin can be maintained the present dose of Sulphylharnate or insulin with the beginning of the Accorglycaemia (low blood sugar); here the dose of the Sulphylharnatives or insulin can be reduced.</seg>
<seg id="753">"this means that the body's physical insulin can be better utilized and the blood sugar levels, thus reducing type-2-diabetes."</seg>
<seg id="754">"for more than 1 400 patients the effectiveness of Actos in TripleTherapy has been studied; the patients received a combination of metformin with a sulphylharnstoff, in addition they received either actos or placebo."</seg>
<seg id="755">"in the studies, the concentration of a substance in the blood was measured (glycosylized Hemmoglobin, HbA1c) which shows how well the blood sugar is adjusted."</seg>
<seg id="756">"Actos led to a lowering of the HbA1c value, which suggests that the blood sugar have been lowered by using the doses of 15 mg, 30 mg and 45 mg."</seg>
<seg id="757">"at the end of the triplea study, the effect of the additional gift of accounts for existing treatment performed with metformin and a sulphylharnstoff in a reduction in hbA1c values at 50%, while the additional Gabe of placebo led to a reduction of 0.35%."</seg>
<seg id="758">"in a small study, in which the combination of accounts and insulin for 289 patients were examined, the patients, the accounts in addition to insulin, compared with 0,14% in patients compared with 0,14% in patients who were in addition placebo."</seg>
<seg id="759">"the most common side effects in connection with acettos were tendous disorders, infections of the upper airways (colds), weight increase and hypoesthesia (diminished sensitivity to irritating)."</seg>
<seg id="760">Accounts may not be used in patients who may possibly be vulnerable (allergic) compared to Pioglitazon or one of the other components, even in patients with liver problems, heart failure or diabetic Ketoaziial - in the blood). "</seg>
<seg id="761">"it has been decided that Actos within the framework of a monopolotherapy (in some use) as an alternative to the standard treatment with metformin patients serve, where Metformin is not shown."</seg>
<seg id="762">October 2000 the European Commission published the European Commission Takeda Europe R & D Centre Limited permit a permit for the transport of accounts within the European Union.</seg>
<seg id="763">"tablets are white until white, round, domed and carry on one side the markings" 15 "and on the other side the wording" ACTOS. "</seg>
<seg id="764">Pioglitazon is also shown to combine with insulin in patients with type 2 diabetes mellitus whose blood sugar has been inadequate and in which metformin due to contraindications or intolerance is inappropriate (see Section 4.4).</seg>
<seg id="765">"for use by Pioglitazon in patients under 18 years of age, no data is available, therefore the application in this age group is not recommended."</seg>
<seg id="766">"in patients who are at risk with the presence at least one risk factor (such as former coronary heart disease), a decomposition of heart failure, should begin medical treatment with the lowest possible dose and increase the dose."</seg>
<seg id="767">"patients should be observed on signs and symptoms of a heart failure, gaining weight or oil-sufficiency, especially those with reduced karst reserve."</seg>
<seg id="768">"patients should be observed on signs and symptoms of a heart failure, gaining weight and odeme when Pioglitazon is applied in combination with insulin."</seg>
<seg id="769">A cardiovascular outcome study with Pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-existing advanced macrovascular disease was carried out.</seg>
<seg id="770">"this study showed an increase in reports of heart failure, which however did not lead to an increase in mortality in the study."</seg>
<seg id="771">Patients with increased output hepatitis (ALT &gt; 2.5 x upper limit of the standard area) or with other signs of liver disease may not be used by Pioglitazon.</seg>
<seg id="772">"if the ALT-mirror up to 3-fold the upper limit of the standard are increased, the liver values are as soon as possible to control again."</seg>
<seg id="773">"if a patient's symptoms developed to refer to a hepatic dysfunction, such as unresolved nausea, vomiting, fatigue, appetite loss and / or darker harn, are the liver values to check."</seg>
<seg id="774">The decision whether the treatment of the patient should be continued with Pioglitazon should be led to the forefront of the laboratory parameters from the clinical assessment.</seg>
<seg id="775">"in clinical studies with Pioglitazon, a dosis@-@ dependent weight can be found, which can be glorified by liposing and in some cases associated with a hydration retention."</seg>
<seg id="776">As a result of a hemortion occurred under therapy with Pioglitazon a lower reduction in the mean hemoglobinvalues (relative reduction by 4%) and of the hematocrits (relative reduction by 4.3%).</seg>
<seg id="777">Similar changes have been observed in comparative controlled studies with Pioglitazon at patients under Metformin (relative reduction of hemogram by 3.3%) and at a lower level also in patients under Sulfonylharnstoff and insulin (relative reduction of the hemogram by 1-2%) and of the hematocrits around 1-3.3%).</seg>
<seg id="778">"as a result of increased insulin sensitive, with patients, Pioglitazon as orale branch therapy or as a two-combination therapy with insulin delivery, the risk of dosisdependent hypoglycaemia."</seg>
<seg id="779">"after the launch was reported in the treatment with thiazolidIndians, including Pioglitazon, above an appearance or deterioration of a diabetic Makuledems, with a reduction in the visual acuity."</seg>
<seg id="780">"it is unclear whether there is a direct connection between the intake of Pioglitazon and the occurrence of Makulaöes, but negotiating doctors should be aware of the possibility of a Makulaös, if patients report on disorders of visual sharpops; a suitable ophthalmologic evaluation should be considered."</seg>
<seg id="781">"in a summary analysis of notifictional events regarding bone brakes out of randomized, controlled, double-based clinical trials over a period of up to 3.5 years with more than 8,100 patients who were treated with Pioglitazon."</seg>
<seg id="782">"the reckoning fracture was 1,9 Fraktures per 100 patients with the Pioglitazon-treated women and 1,1 Fraktures per 100 patient-years in women, who were treated with a comparative medicine."</seg>
<seg id="783">"in the proactive study, a study on 3.5 years for the investigation of cardiovascular events, Fraktures appeared in 44 / 870 (5.2%; 1.0 fractures per 100 patient-years) with patients who were treated with a comparative medicine."</seg>
<seg id="784">"the patients should be aware of the possibility of pregnancy, and if a patient wants a pregnancy or enter this, is the treatment (see Section 4.6)."</seg>
<seg id="785">Studies on the study of interactions have shown that Pioglitazon has no relevant effects on the Pharmacoinetics or Pharmakodynamics of Digoxin, Warfarin, phenprocoumon and metformin. "</seg>
<seg id="786">"interactions with medicines that are metabolized by these enzymes metabolized, e.g. orale contrabtiva, cyclosporin, calcium-blocker and HMGCoA reduction are not to be expected."</seg>
<seg id="787">The simultaneous application of Pioglitazon with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) results in an increase in the AUC by Pioglitazon around the 3-fold.</seg>
<seg id="788">The simultaneous application of Pioglitazon with Rifampicin (a cytochrom P450 2C8-Indup) results in a reduction in AUC by Pioglitazon by 54%.</seg>
<seg id="789">This is attributable that under treatment with Pioglitazon which decreased hyperinsulin resistance and increased insulin resistance of the womens and thus reduces the availability of the metabolic substrates for the fetal growth.</seg>
<seg id="790">"very common &gt; 1 / 10; often &gt; 1 / 100, &lt; 1 / 10; occasionally &gt; 1 / 1000, &lt; 1 / 1000; very rare &lt; 1 / 10000, single cases: unknown (from present data not estimated)."</seg>
<seg id="791">These lead to a temporary change of the turmoors and the billing indexes of the lens as well as with other hypoglycaemic agents.</seg>
<seg id="792">"in clinical studies with Pioglitazon, ALT-goat on the three-fold the upper limit of the normals also appeared frequently on how to placebo, however more rare than in comparative groups under Metformin or Sulfonylharnstoff."</seg>
<seg id="793">"in an outcome study in patients with pre-existing advanced macrovascular disease was the frequency of a severe heart sufficiency under Pioglitazon by 1,6% higher than under placebo, if Pioglitazon bzw."</seg>
<seg id="794">"since the launch has rarely been reported about heart sufficiency in Pioglitazon, however, when Pioglitazon was used in combination with insulin or in patients with heart failure in the Anamnese."</seg>
<seg id="795">"it became a summary analysis of reports of undesirable incidents, controlled, double-based clinical trials over a period of up to 3,5 years with more than 8,100 patients in the groups of Pioglitazon-treated groups and over 7,400 patients associated with comparative medicine."</seg>
<seg id="796">"over a period of 3.5 years of ongoing proactive study, Fraktures appeared at 44 / 870 (5.1%) who treated with Pioglitazon-treated patients, compared to 23 / 905 (2.5%) in patients who were treated with a comparative medicine."</seg>
<seg id="797">"taking the reported peak dose of 120 mg / day over four days, then 180 mg / day over seven days there are no symptoms."</seg>
<seg id="798">"Pioglitazon seems to have a activation of specific core receptors (Peroxisome proliferator Activated Receptor-g (PPAR-g)), which results in the animal model to an increased incidence of liver, fat and skeleton muscle cells."</seg>
<seg id="799">It could be shown that Pioglitazon the glcoseproduction is reduced in the liver and increases the peripheral glcosity in the case of insulin resistance.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclazid as monotherapy was initiated over two years to investigate the time until the post of therapeutic effects (defined as HbA1c ≥ 8,0% after the first 6 treatments).</seg>
<seg id="801">"at the time after two years after the beginning of the therapy, a blood sugar control was defined as HbA1c &lt; 8.0%) by Pioglitazon at 69% of patients (compared to 50% of patients under Gliclazide)."</seg>
<seg id="802">"in a placebokontrolfiled study on 12 months, patients whose blood sugar was insufficient despite three imonatiger optimization phase with insulin delivery was randomized to pioglitazon or placebo."</seg>
<seg id="803">"in patients under Pioglitazon reduced the middle HbA1c - value around 0,45%, compared to the patients who continued only insulin; a reduction in the insulin-treated group was observed."</seg>
<seg id="804">"in clinical trials over one year, under Pioglitazon showed statistically significant acceptance of the album / Kreatinin-merotiencies in comparison to the output values."</seg>
<seg id="805">The effect of Pioglitazon (Monotherapy with 45 mg versus placebo) was tested in a small, on 18 weeks investigation into type-2 diabetics. "</seg>
<seg id="806">"in most clinical trials, compared to placebo a reduction in the total plasma triglyceride and the free fatty acids and an increase of HDL- cholesterol levels as well as low-style, however clinically not significant increased LDL- cholesterol levels."</seg>
<seg id="807">"in clinical trials over a period of up to two years reduced pioglitazon in comparison to placebo, metformin or gliclazide the total plasma-matrixide and the free fatty acids, and increased the HDL cholesterol levels."</seg>
<seg id="808">"compared to placebo, under Pioglitazon was not statistically significant increase in the LDL cholesterol levels, while under metformin and gliclazide decreased values were observed."</seg>
<seg id="809">"in a study about 20 weeks reduced pioglitazon not only the sober triglyceride, but also improved the postprandial elevated triglycery levels, this is both an effect on the triglycerid absorption and the hepatic triglycerid synthesis."</seg>
<seg id="810">"in the proactive study, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing advanced macrovasculosis disease in groups were randomized over a period of up to 3.5 years in addition to existing antidiabetic and cardiovascular therapy."</seg>
<seg id="811">"after an application of Pioglitazon, Pioglitazon is fast resorted, with the peak concentration on unchanging Pioglitazon in plasma is usually reached 2 hours of application."</seg>
<seg id="812">"based on M-IV, the contribution of M-IV is equivalent to the effectiveness of Pioglitazon, while the relative effectiveness of M-II is minimal."</seg>
<seg id="813">"Interaction studies could be proven that Pioglitazon could not affect the relevant effect on Pharmakokinetics or Pharmakodynamics of Digoxin, Warfarin, phenprocoumon and metformin."</seg>
<seg id="814">The simultaneous application of Pioglitazon with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) or with Rifampicin (a cytochrom P450 2C8-Indup) increased or lowers the plasma concentration by Pioglitazon (see Section 4.5).</seg>
<seg id="815">"according to oral application of radioactive marked Pioglitazon at the human being the marker was mainly found in the wood (55%), and to a lower extent in the harn (45%)."</seg>
<seg id="816">The mean plasma-EliminationPeriod of unchanging Pioglitazon amounts to people 5-6 hours and that of the entire active metabolic rate lies at 16 - 23 hours.</seg>
<seg id="817">"the plasma concentration of Pioglitazon and its metabolic disorders are lower compared to patients with reduced kidney function, whereas the edges of the oral clearance of the native substance is similar."</seg>
<seg id="818">"in toxicological studies occurred at mice, rats, dogs and monkeys convoting after repetitive administration of Plasmaths, anemia and reversible cardiopic heart hypertropic."</seg>
<seg id="819">This is attributable that under treatment with Pioglitazon which is diminished in the formation of hyperinsulin resistance and increased insulin resistance of the uterine substrates and reduces the availability of the metabolic substrates for the fetal growth.</seg>
<seg id="820">In long-term studies (up to 2 years) were taken at the rat increased incidence of hyperplasies (with male and female rats) and tumors (with male rechat) of the urinary bladder induces.</seg>
<seg id="821">In a animal model of the familiarity omatous polyposis (FAP) carried the treatment with two other thiazolidindians to an increased frequency of colonization.</seg>
<seg id="822">"tablets are white to white, round, flat and wear on one side the markings" 30 "and on the other side the wording" ACTOS. "</seg>
<seg id="823">"the reckoning fracture was 1,9 Fraktures per 100 patients with the Pioglitazon-treated women and 1,1 Fraktures per 100 patient-years in women, who were treated with a comparative medicine."</seg>
<seg id="824">"in the proactive study, a study on 3.5 years for the investigation of cardiovascular events, Fraktures appeared in 44 / 870 (5.2%; 1.0 fractures per 100 patient-years) with patients who were treated with a comparative medicine."</seg>
<seg id="825">In another study more than two years the effects of a combination therapy of metformin each with Pioglitazon or Gliclazid were examined.</seg>
<seg id="826">"in clinical trials over 1 year, under Pioglitazon showed statistically significant acceptance of the album / Kreatinin-merotiencies in comparison to the output values."</seg>
<seg id="827">In a study more than 20 weeks reduced pioglitazon not only the sober triglyceride but also improved the postprandial elevated triglyceride levels that can be used both via a effect on the tryglycerid absorption as well as the hepatic Tryglioid synthesis.</seg>
<seg id="828">"although the study was mised in terms of its primary end point, who presented a combination of overall mortal disease, non-deadly coronary coronary coronary coronarians, coronary revasculzation and revascularization of leg arteries, creating the results close that with intake of Pioglitazon are not associated with the intake of Pioglitazon."</seg>
<seg id="829">"tablets are white to white, round, flat and wear on one side the markings" 45 "and on the other side the wording" ACTOS. "</seg>
<seg id="830">"in a summary analysis of reports of reports from randomized, controlled, double-blind studies have been treated over a period of up to 3.5 years with more than 8,100 patients who were treated with Pioglitazon, became an increased incidence of bone brakes in women."</seg>
<seg id="831">"in the proactive study, a study on 3.5 years for the investigation of cardiovascular events, Fraktures appeared in 44 / 870 (5.2%; 1.0 fractures per 100 patient-years) with patients who were treated with a comparative medicine."</seg>
<seg id="832">"in a study about 20 weeks reduced pioglitazon not only the sober triglyceride, but also improved the postprandial elevated triglycery levels, this is both an effect on the triglycerid absorption and the hepatic triglycerid synthesis."</seg>
<seg id="833">"the packaging module of the drug must be given name and address of the manufacturer, which is responsible for the release of the responsible charge."</seg>
<seg id="834">"the pharmaceutical companies will submit an additional 6 month Periodic Safety Update Report (PSUR) and then submit an annual PSURs, up to a different loud decision of CHMP."</seg>
<seg id="835">It has to be set up a updated risk management plan according to the CHMP-guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">If you are interested in type 2-diabetes support Actos 15 mg tablets to control your blood sugar by bringing a better utilisation of the body insulin.</seg>
<seg id="837">"if you know is known that you suffer from a sugar intolerance, please contact your doctor before taking Actos 15mg tablets your doctor."</seg>
<seg id="838">"please inform your doctor or a pharmacist if you have any further medicine or have been taken up until recently, even if it is not prescription drugs."</seg>
<seg id="839">"if you take Actos 15 mg tablets in combination with other medicines to treat diabetes (such as insulin, gliclacid, Gliclazid, Tolclazid, Tolclash), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="840">"in some patients with long-term type 2 diabetes mellitus and heart disease or earlier stroke, which were treated with acettos and insulin, developed a heart failure."</seg>
<seg id="841">"in clinical trials, in which Pioglitazon compared with other oral antidiabetic or placebo (real free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone china."</seg>
<seg id="842">"if you have taken to many tablets, or if any other or a child has taken your medicine, you will get in touch with a doctor or a pharmacist."</seg>
<seg id="843">"how actos looks and content of the package Actos 15 mg tablets are white to white, round, domed tablets with markings" 15 "on one side and the wording" ACTOS "on the other."</seg>
<seg id="844">If you are interested in type 2-diabetes support Actos 30 mg tablets to control your blood sugar by bringing a better utilisation of the body insulin.</seg>
<seg id="845">"if you know is known that you suffer from a sugar intolerance, please contact your doctor before taking Actos 30mg tablets your doctor."</seg>
<seg id="846">"if you take Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, gliclacid, Gliclazid, Tolclazid, Tolclazid, Tolclash), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="847">61 Informing as soon as possible your doctor if you find signs of a heart sufficiency in yourself such as unusual short shortage or rapid weight increase or local swelling (Ödeme).</seg>
<seg id="848">"in clinical trials, in which Pioglitazon compared with other oral antidiabetic or placebo (real free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone china."</seg>
<seg id="849">"how actos looks and content of the package Actos 30 mg tablets are white to white, round, flat tablets with markings" 30 "on one side and the wording" "ACTOS" "on the other."</seg>
<seg id="850">If you are interested in type 2-diabetes support Actos 45 mg tablets to control your blood sugar by bringing a better utilisation of the body insulin.</seg>
<seg id="851">"if you know is known that you suffer from a sugar intolerance, please contact your doctor before taking Actos 45mg tablets your doctor."</seg>
<seg id="852">"if you take Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, gliclacid, Gliclazid, Tolclazid, Tolclash), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="853">"66 When some patients with long-term type 2 diabetes mellitus and heart disease, which were treated with Actos and insulin, developed a heart failure."</seg>
<seg id="854">Find out as soon as possible your doctor if you find signs of a heart sufficiency in yourself such as unusual short shortage or rapid weight increase or local swelling (Ödeme).</seg>
<seg id="855">"in clinical trials, in which Pioglitazon compared with other oral antidiabetic or placebo (real free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone china."</seg>
<seg id="856">"67 If any of the above-side effects you impaired considerably, or you may notice the side effects which are not specified in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="857">"how actos looks and content of the package Actos 45 mg tablets are white to white, round, flat tablets with markings" 45 "on one side and the wording" ACTOS "on the other."</seg>
<seg id="858">"this document is a summary of the European Public Proverbs report (EPAR) in which explains how the Committee for Humanarztend (CHMP), carried out in order to make recommendations concerning the application of the drug."</seg>
<seg id="859">"if you need more information about your medical condition or treatment of your disease, please read the packing machine (which is also part of the EPAR) or contact a doctor or a pharmacist."</seg>
<seg id="860">"if you want more information about the recommendations of CHMP, please read the scientific discussion (which is also part of the EPAR)."</seg>
<seg id="861">Actraphane 10: soluble insulin 20% and isophan-insulin 30% Actraphane 40% Actraphane 40% Actraphane 40% Actraphane 50% Actraphane 50% Actraphane 50% actraphane 50% and isophan-insulin 50%</seg>
<seg id="862">Actraphane is usually applied once or twice a day when a fast initials effect will be desired along with a longer lasting effect.</seg>
<seg id="863">"(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http:</seg>
<seg id="864">"Actraphane has been producing a total of 294 patients with type-1 diabetes, in which the pancreas can not produce insulin, and type-2 diabetes in which the body is unable to use the insulin effective."</seg>
<seg id="865">In the study after 12 weeks the concentration of a substance (glycosylized hemoglobin) which shows how well the blood sugar is adjusted.</seg>
<seg id="866">Actraphane led to a decrease of the HbA1c mirrors that hindered that the blood sugar lowered as strong as with any other human insulin lowered.</seg>
<seg id="867">Actraphane should not be used in patients who may possibly be vulnerable (allergic) to human insulin (rinsulin) or one of the other components.</seg>
<seg id="868">"furthermore, the doses of Actraphanmay need to be customized if it is administered together with a number of other medicines that can affect blood sugar (the full list is the package section)."</seg>
<seg id="869">The committee for human cells (CHMP) came to the conclusion that the benefits of Actraphanous has overseize the benefits of diabetes in comparison to the risks.</seg>
<seg id="870">October 2002 the European Commission gave the Company Novo Nordisk A / S a permit for the sale of Actraphane throughout the European Union.</seg>
<seg id="871">Pre-mixed insulin products are usually applied once or twice a day when a fast initials effect will be desired along with a longer lasting effect.</seg>
<seg id="872">The injections for at least 6 seconds must be taken under the skin to make sure that the whole dosage was injected.</seg>
<seg id="873">"patients whose blood sugar has significantly improved, for example, by a intensified insulin therapy, the Hypoglycaemia management may be altered and should be advised accordingly."</seg>
<seg id="874">"every change in terms of strength, brand (manufacturer), insulin type (fast-effective, biological insulin, insulin insulin or insulin pump) can lead to insulin DNS compared to insulin origin), that a change in dosage is required."</seg>
<seg id="875">"if there is a dosage adjustment to the patient, this can be necessary with the first dosage or during the first few weeks or months after the conversion."</seg>
<seg id="876">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="877">"traveling over several times of time, the patient should be advised to bring the advice of his physician since such trips can lead to other times and to be taken at other times."</seg>
<seg id="878">The doctor must therefore take account of possible interactions in the therapy and take care of their patients from the drugs used by them.</seg>
<seg id="879">"4 Both Hypoglycaemia as well as hyperglycaemia, which can occur in a non-sufficient control therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="880">Heavy hypoglycaemic can lead to consciousness and / or crampouling and with temporary or permanent disturbances of the brain function and even death.</seg>
<seg id="881">Disorders of the nervous system occasionally - peripheral Neuropathy a rapid improvement of blood sugar control can be associated with complaints that are considered as acute painful neuropathy and usually reversible.</seg>
<seg id="882">5 A intensification of the insulin therapy with an abrupting improvement in blood sugar can however be connected with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="883">Diseases of the skin and sub-manipellebes occasionally - Lipodystrophy On the injection point may arise a Lipodystrophy if failed to switch the insertion within the injecting range.</seg>
<seg id="884">General conditions and complaints on appointments occasionally - Local oversensitivity to the injection point of the Insulintherapy can occur local hypersensitivity actions (redness, swelling, itch, pains and hematom at the injection point). "</seg>
<seg id="885">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="886">But a hypoglycaemia is able to develop gradually: • Easy hypoglycaemic can be treated by the orale feed of glucose or sugar foods.</seg>
<seg id="887">"diabetics should therefore always have grape pieces, candy, biscuits or sugar fruit juice to have been treated with intra-muscular or subcutaneous injecting from Glucagon (0,5 to 1,0 mg) by a fixed support person or by glucose who will be intravenous by the doctor."</seg>
<seg id="888">"the effect begins within half an hour, the active ingredients is achieved within 2 to 8 hours and the entire duration of the operation is up to 24 hours."</seg>
<seg id="889">Resorption Profile is justified in it that the product is a mixture of insulin products with fast or restrained resorption.</seg>
<seg id="890">A number of cleavements (hydrolyse-) places on the humanistic molecule were considered; none of the metabolic pathites were active.</seg>
<seg id="891">"based on conventional studies on safety spharmacology, toxicity in repeatable gift, genotoxicity, for carcinogenic potential and for reproductive-toxicity, the preclinical data can not recognise any special hazards for the people."</seg>
<seg id="892">"it is recommended - after the Actraphanbottle has been removed from the fridge - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="893">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="894">The doctor must therefore take account of possible interactions in the therapy and take care of their patients from the drugs used by them.</seg>
<seg id="895">"12 Both Hypoglycaemia as well as hyperglycaemia, which can occur in a non-sufficient control therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="896">13 A intensification of the insulin therapy with an abrupting improvement in blood sugar can however be connected with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="897">The terminale half-time (t ½) is therefore more of a measure of the orption as a measure of the elimination per se of the Insulus from the plasma (insulin cycle in blood circulation one t of only a few minutes).</seg>
<seg id="898">"it is recommended - after the Actraphanbottle has been removed from the fridge - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="899">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="900">"20 Both Hypoglycaemia as well as hyperglycaemia, which can occur in a non-sufficiently controlled conductor therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="901">21 A intensification of the insulin therapy with an abrupting improvement in blood sugar can however be connected with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="902">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="903">Cartridges may only be used together with products which are compatible with them and ensure safe and effective function of the cartridge.</seg>
<seg id="904">"it is recommended - after actraphane Penfill out from the fridge was removed - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="905">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="906">"28 Both Hypoglycaemia as well as hyperglycaemia, which can occur in a non-sufficient control therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="907">29 A intensification of the insulin therapy with an abruptive improvement in blood adjustment can however be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="908">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="909">"36 Both Hypoglycaemia as well as hyperglycaemia, which can occur in a non-sufficient control therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="910">37 A intensification of the insulin therapy with an abruptive improvement in blood adjustment can however be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="911">44 Both Hypoglycaemia as well as hyperglycaemia which occur in a non-sufficiently controlled conductor therapy can increase the risk of abnormalities and fruity in utero.</seg>
<seg id="912">45 A intensification of the insulin therapy with an abruptive improvement in blood adjustment can however be connected with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="913">"some patients suffering from hypoglycaemic reactions after a change of animal on human insulin, reported that the early warnings symptom of a hypoglycaemia were less pronounced or different from their previous insulin."</seg>
<seg id="914">"52" "Hypoglycaemia as well as hyperglycaemia which can occur in a non-sufficiently controlled conductor therapy, increase the risk of abnormalities and fruity in utero."</seg>
<seg id="915">53 A intensification of the insulin therapy with an abruptive improvement in blood sugar. however, it can be connected with a temporary deterioration of the diabetic retinopathy. "</seg>
<seg id="916">The injection devices must be prepared prior to injection that the dosisregler has to be traced to zero and a slemulsion at the top of the injection needle reappears.</seg>
<seg id="917">59 patients whose blood sugar has significantly improved by a intensified insulin therapy can be seen by hypoglycaemia's symptom symptoms and should be advised accordingly.</seg>
<seg id="918">"both hypoglycaemia and hyperglycaemia, which can occur in a non-sufficient control therapy, increase the risk of abnormalities and frutod in utero."</seg>
<seg id="919">"however, an intensification of the insulin therapy with an abruptive improvement in blood sugar, however, can be connected with a temporary deterioration of the diabetic retinopathy."</seg>
<seg id="920">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="921">These prefabricated may only be used together with products which are compatible with them and ensure a safe and effective function of prefabrication.</seg>
<seg id="922">"it is recommended - after Actraphane NovoLet removed from the fridge - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="923">"67 patients whose blood sugar has significantly improved, for example, by a intensified insulin therapy, the hypoglycaemia management may be altered and should be advised accordingly."</seg>
<seg id="924">"75 patients whose blood sugar has significantly improved, for example, by a intensified insulin therapy, the Hypoglycaemia management may be altered and should be advised accordingly."</seg>
<seg id="925">"83 patients whose blood sugar has significantly improved, for example, by a intensified insulin therapy, the Hypoglycaemia management may be altered and should be advised accordingly."</seg>
<seg id="926">91 patients whose blood sugar has significantly improved the hypoglycaemia management symptom symptoms and should be advised and should be advised accordingly.</seg>
<seg id="927">"99 patients whose blood sugar has significantly improved, for example, by a intensified insulin therapy, the Hypoglycaemia management may be altered and should be advised accordingly."</seg>
<seg id="928">"every change in terms of strength, brand (manufacturer), insulin type (fast-effective, biological insulin, insulin insulin or insulin pump) can lead to insulin DNS compared to insulin origin), that a change in dosage is required."</seg>
<seg id="929">"it is recommended - after acetaphanous Innolet from the fridge was removed - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="930">"it is recommended - after actraphanous FlexPen from the fridge was removed - the temperature of the insulin at room temperature (not over 25 ° C), before it is used according to the manual for the first use."</seg>
<seg id="931">"the packaging module of the drug must be given name and address of the manufacturer, which is responsible for the release of the responsible charge."</seg>
<seg id="932">To store in the fridge (2 ° C - 8 ° C) Not infreeze The flow bottle can be stored in carton to protect the content from light: not in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous application and fill cartridges are intended for use with insulin delivery devices from Novo Nordisk intended to be used as prestrapane 10 Pencil may only be used by one person</seg>
<seg id="934">In the fridge store (2 ° C - 8 ° C) Not unfreeze The cartridge in carton can be kept in order to protect the content from light by quarry: not in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous application and fill cartridges are intended for use with insulin delivery devices from Novo Nordisk intended to be used as prestrapane 20 Pencil may only be used by one person</seg>
<seg id="936">Subcutaneous application and fill cartridges are intended for use with insulin delivery devices from Novo Nordisk intended to be used as prestrapane 30 Pencil may only be used by one person</seg>
<seg id="937">Subcutaneous application and fill cartridges are intended for use with insulin delivery devices from Novo Nordisk intended to be used as prestrapane 40 Pencil may only be used by one person</seg>
<seg id="938">Subcutaneous application and fill cartridges are intended for use with insulin delivery devices from Novo Nordisk intended to be used as prestrapane 50 pepper may only be used by one person</seg>
<seg id="939">Subcutaneous application to use with Actraphane 10 NovoLet there are NovoFine injection packets envisaged by the manual resuspenal packet. Actraphane 10 NovoLet may only be used by one person</seg>
<seg id="940">To store in the fridge (2 ° C - 8 ° C) Not to freeze the light after quarry: not in the fridge or over 30 ° C</seg>
<seg id="941">Subcutaneous application to use with Actraphane 20 NovoLet there are NovoFine injection packets foresaw the manual resuspenal packet. Actraphane 20 NovoLet may only be used by one person</seg>
<seg id="942">Subcutaneous application to use with Actraphane 30 NovoLet there are NovoFine injection packets envisaged by the manual resuspenal packet. Actraphane 30 NovoLet may only be used by one person</seg>
<seg id="943">Subcutaneous application to use with Actraphane 40 NovoLet there are NovoFine injection packets envisaged by the manual resuspenal packet. Actraphane 40 NovoLet may only be used by one person</seg>
<seg id="944">Subcutaneous application to use with Actraphane 50 NovoLet there are NovoFine injection packets envisaged by the manual resuspenal packet. Actraphane 50 NovoLet may only be used by one person</seg>
<seg id="945">Subcutaneous application to use with Actraphane 30 Innolet are provided NovoFine S injections blissors of the manual resuspenal Packagaphane 30 Innolet may only be used by one person</seg>
<seg id="946">That means that about half an hour after you have applied it to sink your blood sugar and that the effect will hold about 24 hours.</seg>
<seg id="947">"► if you allergic (hypersensitive) to this insulin product, Metacresol or one of the other ingredients (see Section 7 more information)."</seg>
<seg id="948">Pay attention to the under 5 World Side Effects are possible? described symptoms of an allergy) if you feel first signs of Hypoglycaemia (symptoms of a subsistence).</seg>
<seg id="949">"if your doctor has prompted a change from an insulin or brand to another, possibly the dose must be adjusted by your doctor."</seg>
<seg id="950">► Check the basis of the label whether it is concerned about the correct insulin type and disinfect the rubber compound with a medical cloth.</seg>
<seg id="951">"if this is not completely unmistaken, if you return the flow-bottle to your pharmacy (see 6 How is Actraphane to preserve?) ► if it is not correct or frozen."</seg>
<seg id="952">"use the injection technology that you have recommended your doctor or your Diabetesberaterin ► Lassen the injections for at least 6 seconds under your skin, to make sure that the complete dosage was injected."</seg>
<seg id="953">"the warps of a subsisting can suddenly occur and may be: cold sweat, cold blacks, nausea, great hunger, redness, redness, nervousness, nervousness, nervousness, nervousness, anxiety or citations, anxiety, confusion, concentration."</seg>
<seg id="954">"tell your relatives, friends and tight workplaces that they will bring you in the case of a consciousness to a stable side and instantly desire a doctor."</seg>
<seg id="955">"you may not have to eat or drink nothing to eat or drink because you could provoke it. ► If a heavy undercarriage may not be treated, can lead to (temporary or permanent) of harm or even to death, if you had a subsistence with consciessness or even if you encounter downwards, search your doctor."</seg>
<seg id="956">"you can regain the consciousness faster, when you get the hormone glucagon of a person who is familiar with its gift, is injected."</seg>
<seg id="957">"this may happen: • If you too much insulin, when you eat too little or meal, if you do more than anything else physically."</seg>
<seg id="958">"intensified urinary, Durst, appetite, nausea or vomiting, lightheadedness or fatigue, rounded skin, mouth dry and fruity (according to acetone) riechender breath."</seg>
<seg id="959">• You have forgotten an insulin delivery • repetitive injecting of less insulin as you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="960">If you often give yourself an injection in the same place can be shrink at this point the substrate tissues shrinking (Lievrophy) or increase (Lipohypertrophia).</seg>
<seg id="961">"if you see depressions or thicknesses of your skin at the injection point, because these reactions can be welded or the inclusion of your insulin if you are in such a position."</seg>
<seg id="962">"if you are immediately looking for a doctor when the symptoms of an allergy to other parts of the body, or • if you suddenly feel uncomfortable and you will have welvouts, nausea, harvesters have you to be windy or you have the impression to become unconscious."</seg>
<seg id="963">They may have a very rare heavy allergic reaction to Actraphane or one of its components (a so-called systemic allergic reaction).</seg>
<seg id="964">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="965">What Actraphane 30 contains - the active ingredient is characterized by recombinant DNS-technology. insulin inulin (30% as soluble insulin and 70% as isophan insulin).</seg>
<seg id="966">"how Actraphane looks and content of the package Ininjections, is used as trush, white, aqueous suspension latches in packs of 1 or 5 slippers each with 5 ml or a bundle packaged 10 ml each 10 ml."</seg>
<seg id="967">"use the injection technology that you have recommended your doctor or your Diabetesberaterin ► Lassen the injections for at least 6 seconds under your skin, to make sure that the complete dosage was injected."</seg>
<seg id="968">"it is recommended - after having been removed from the refrigerator - to increase the temperature of penetration to room temperature, before the insulin must be resins according to the manual for the first use."</seg>
<seg id="969">"how Actraphane looks and content of the package Ininjections, is used as trush, white, aqueous suspension latches in packs of 1 or 5 slippers each with 5 ml or a bundle packaged 10 ml each 10 ml."</seg>
<seg id="970">► Check the basis of the label whether it is concerned by the correct insulin type and always check the penis-fill cartridge including the rubber tip (stoves).</seg>
<seg id="971">Use them not when any damage to see is visible or a gap between the blanket and the white band of the labet is visible.</seg>
<seg id="972">"for more information, please refer to the manual of your insulin delivery system. ► Linfy the rubber compound with a medical cloth. ► Bendering always for any injection a new injections to avoid a contamination."</seg>
<seg id="973">"► in Insulininfusion pumps, if the penis-fill or the device that includes the penis fill, the danger of discontinued by insulin if it was not correct or frozen (see 6 How is Actraphane to preserve?) ► if it is not correct or frozen."</seg>
<seg id="974">"if you are treated with Actraphane 10 Penile and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="975">"before you use the cartridge in the insulin delivery system, you move at least 20 times between positions a and b and from (see picture) so that the glars from one end of the cartridge for the other moves."</seg>
<seg id="976">"use the injection technology that you have described your doctor or your diet system, ► Lassen is described in your skin for at least 6 seconds long under your skin to make sure that the complete dose is injected at least 6 seconds after every injection the injections to be removed and worry-down injecting injection needle."</seg>
<seg id="977">"183 Are you put your family, friends and tight workplaces that they bring you in the case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="978">• You have forgotten an insulin delivery • repetitive injecting of less insulin as you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="979">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="980">"it is recommended - after having been removed from the fridge - the temperature of the clean cartridge to increase temperature, before the insulin under the manual for the first use is resins."</seg>
<seg id="981">185 Preserve the cartridges always in carton if you do not use them to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - The active ingredient is characterized by recombinant DNS-technology. insulin inulin (10% as soluble insulin and 90% as isophan insulin).</seg>
<seg id="983">"how Actraphane looks and content of the package Ininjections, is supplied as trush, white, aqueous suspension of suspension in packs of 1, 5 or 10 cartridges each 3 ml each."</seg>
<seg id="984">"for more information, please refer to the manual of your insulin delivery system. ► Linfy the rubber compound with a medical cloth. ► Bendering always for any injection a new injections to avoid a contamination."</seg>
<seg id="985">"if you are treated with Actraphane 20 Penile and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="986">"189 Are you put your family, friends and tight workplaces that they will bring you in case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="987">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="988">191 keeper you keep the cartridges always in carton if you do not use it to protect them from light.</seg>
<seg id="989">What Actraphane 20 contains - The active ingredient is characterized by recombinant DNS-technology. insulin inulin (20% as soluble insulin and 80% as isophan insulin).</seg>
<seg id="990">"how Actraphane looks and content of the package Ininjections, is supplied as trush, white, aqueous suspension of suspension in packs of 1, 5 or 10 cartridges each 3 ml each."</seg>
<seg id="991">"for more information, please refer to the manual of your insulin delivery system. ► Linfy the rubber compound with a medical cloth. ► Bendering always for any injection a new injections to avoid a contamination."</seg>
<seg id="992">"if you are treated with Actraphane 30 Penile and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="993">"195 Are you put your family, friends and tight workplaces that they bring you in the case of a consciousness to the stable side and immediately create a doctor."</seg>
<seg id="994">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="995">197 Move the cartridges always in carton if you do not use it to protect them from light.</seg>
<seg id="996">Manufacturer The manufacturer may be printed by the chargers of carton and printed on the label:</seg>
<seg id="997">"if at the second and third place of the load-combination W5, S6, P5, K7 or ZF is released, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark"</seg>
<seg id="998">"if at the second and third place of the Charge designation, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Oréans, F-28002 Chartres, France."</seg>
<seg id="999">"for more information, please refer to the manual of your Insul ininjection system. ► Desinfy the rubber compound with a medical Tupper. ► Bendering always for any injection a new injections to avoid a contamination."</seg>
<seg id="1000">"if you are treated with Actraphane 40 Penile and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="1001">"201 Searing your family, friends and tight workplaces that they will bring you in the case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="1002">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1003">203 Move the cartridges always in carton if you do not use it to protect them from light.</seg>
<seg id="1004">What Actraphane 40 contains - The active ingredient is characterized by recombinant DNS-technology. insulin inulin (40% as soluble insulin and 60% as isophan-insulin).</seg>
<seg id="1005">"for more information, please refer to the manual of your Insul ininjection system. ► Desinfy the rubber compound with a medical Tupper. ► Bendering always for any injection a new injections to avoid a contamination."</seg>
<seg id="1006">"if you are treated with Actraphane 50 Penile and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="1007">"before you use the poultry cartridge into the insulin delivery system, you move at least 20 times between positions a and b and from (see picture) so that the glues from one end of the cartridge for the other moves."</seg>
<seg id="1008">"207 Searing your family, friends and tight workplaces that they will bring you in case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="1009">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1010">209 keeper you keep the cartridges always in carton if you do not use to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - The active ingredient is characterized by recombinant DNS-technology. insulin inulin (50% as soluble insulin and 50% as isophan insulin).</seg>
<seg id="1012">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1013">► Check the basis of the label whether it is the right Insul intyp ► Bendering you always for any injection a new injections to avoid a contamination.</seg>
<seg id="1014">"► in Insulininfusion lump when the NovoLet's dropped was damaged, damaged or zercled, the danger of discontinued by insulin if it was not correct or frozen (see 6 How is Actraphane to preserve?) ► if it is not synced after the resignant."</seg>
<seg id="1015">"the warps of a subsisting can suddenly occur and may be: cold sweat, cold blacks, nausea, great hunger, redness, redness, nervousness, nervousness, nervousness, nervousness, anxiety or citations, anxiety, confusion, concentration."</seg>
<seg id="1016">"214 If any of the above-side effects you impaired significantly or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1017">"in use of the NovoLet's finishing and such that are used shortly, or be kept as a substitute, are not to be kept in the fridge."</seg>
<seg id="1018">"it is recommended - after having been removed from the fridge - the temperature of the NovoLet's finishing on room temperature, before the insulin under the manual for the first use is resins."</seg>
<seg id="1019">Let the slender of your NovoLet's finish always set if NovoLet's not in use is to protect the insulin before light.</seg>
<seg id="1020">"how Actraphane looks and content of the package Ininjections, is delivered as trush, white, aqueous suspension of Suspension in packs of 5 or 10 ready-to each 3 ml each."</seg>
<seg id="1021">"prior to every injection, check whether or at least 12 units insulin in the cartridge are still ensured, thus ensuring a homogeneous mix."</seg>
<seg id="1022">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actraphane 10 NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1023">"if air bubbles are present, this way in the cartridge are still collecting Actraphane 10 NovoLet continue to keep up with the injection needle to top, push the button again in the direction of the arrow."</seg>
<seg id="1024">"• Setting the sluggle back so on the finished pen, that the number 0 is in front of the dosing brand (Figure E) • Control, whether the button pressed over."</seg>
<seg id="1025">"if not, rotate the slender, until the press knob is very hindered, • Keep your Actraphane 10 NovoLet's horizontal."</seg>
<seg id="1026">"if the button-button can not move freely to the outside, insulin out of injection-nadel suppressed • The scale on the slender cap shows 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1027">"the push-button moves to the outside, while you spin the slap cap • The scale below shows 20, 40 and 60 units."</seg>
<seg id="1028">"check the number on the slender cap directly next to the dosing stamp • If you have the highest number, you have to receive a false dose when you have a wrong dose when you have a false dose just forward or backwards until you have set the correct number of units."</seg>
<seg id="1029">"otherwise insulin are insulin out of the injection needle, and the dosage will not be accurate • If you set wrong one dose of more than 78 units, take the following steps by:"</seg>
<seg id="1030">Then take the sluggappe from and put them back on that the 0 of the dosing brand lies.</seg>
<seg id="1031">"pay attention to only during the injection button on the press button. • Keep the pressure button down into the injection, until the injection needle was pulled out of the skin."</seg>
<seg id="1032">"if not, rotate the slender, until the press knobs very quickly and then proceed as described in the use of use • Possibly you can listen to the drag of the button."</seg>
<seg id="1033">"it may possibly unaccurate • You can no dose which is higher than the number of remaining in the cartridge units, you can use the residual scale as much insulin still remains."</seg>
<seg id="1034">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1035">"224 If any of the above-side effects you impaired significantly or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1036">"226 on every injection, check whether or at least 12 units insulin in the cartridge are thus ensuring a homogeneous mix."</seg>
<seg id="1037">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actraphane 20 NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1038">"if air bubbles are present, this way in the cartridge are still collecting Actraphane 20 NovoLet continue to keep up with the injection needle to top, push the button again into direction of the arrow."</seg>
<seg id="1039">"if not, rotate the slender, until the press knob is very hindered, • Keep your Actraphane 20 NovoLet's horizontal."</seg>
<seg id="1040">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1041">"234 If any of the above-side effects you impaired significantly or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1042">"236 on every injection, check whether or at least 12 units insulin in the cartridge are thus ensuring a homogeneous mix."</seg>
<seg id="1043">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actraphane 30 NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1044">"if air bubbles are present, this way in the cartridge are still collecting Actraphane 30 NovoLet continue to keep up with the injection needle to top, push the button again in direction of the arrow."</seg>
<seg id="1045">"if not, rotate the slender, until the press knob is very hindered, • Keep your Actraphane 30 NovoLet's horizontal."</seg>
<seg id="1046">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1047">"244 If any of the above-side effects you impaired considerably, or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1048">"246 In every injection, check if still at least 12 units insulin in the cartridge are left, thus ensuring an even mixture."</seg>
<seg id="1049">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actraphane 40 NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1050">"if air bubbles are present, this way in the cartridge are still collecting Actraphane 40 NovoLet continue to keep up with the injection needle to top, push the button again into the direction of the arrow."</seg>
<seg id="1051">"if not, rotate the slender, until the press knob is very hindered, • Keep your Actraphane 40 NovoLet's horizontal."</seg>
<seg id="1052">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1053">"254 If any of the above-side effects you impaired significantly or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1054">"it is recommended - after having been removed from the fridge - the temperature of the NovoLet's finishing on room temperature, before the insulin under the manual for the first use is resins."</seg>
<seg id="1055">"256 In every injection, check whether or at least 12 units insulin in the cartridge left, so that an even mixture is ensured."</seg>
<seg id="1056">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actraphane 50 NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1057">"if air bubbles are present, this way in the cartridge are still collecting Actraphane 50 NovoLet continue to keep up with the injection needle to top, push the button again in the direction of the arrow."</seg>
<seg id="1058">"if not, rotate the slender, until the press knob is very hindered, • Keep your Actraphane 50 NovoLet's horizontal."</seg>
<seg id="1059">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1060">"► in Insulininfusion lump when the Innolet has been dropped, damaged or zersed, the danger of discontinued by insulin if it was not correct or frozen (see 6 How is Actraphane to preserve?) ► if it is not synced after the resignant."</seg>
<seg id="1061">"the warps of a subsisting can suddenly occur and may be: cold sweat, cold blacks, nausea, great hunger, redness, redness, nervousness, nervousness, nervousness, nervousness, anxiety or citations, anxiety, confusion, concentration."</seg>
<seg id="1062">"264 If any of the above-side effects you impaired significantly or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1063">"in use, InnoLet's finishing and such that will be used shortly or managed as a substitute, are not to be kept in the fridge."</seg>
<seg id="1064">"it is recommended - after having removed from the refrigerator - to rise to the temperature of the InnoLet's finishing on room temperature, before the insulin must be resins according to the manual for the first use."</seg>
<seg id="1065">"let the slender of your innolet finishing always set, if Innolet is not in use to protect the insulin before light."</seg>
<seg id="1066">"how Actraphane looks and content of the package Ininjections, is regarded as trübe, white, aqueous suspension of suspension in packs of 1, 5 or 10 finishing in packs of 3 ml each."</seg>
<seg id="1067">"the movement must be repeated, until the fluid looks like white and trübe • After the restraint, you perform all the steps of the injection without delay."</seg>
<seg id="1068">• Descfy the rubber compound with a medical Tupper • Use always for any injecting a new injecting needle to avoid a contamination that are straight and fixed at Actraphane 30 Innolet (figure 1B) • Pull the big outer injection cap and the inner injecting valve.</seg>
<seg id="1069">• Control always check if the button pressed down completely and the Dosisregler on zero represents • Make the number of units you have to injecting the dosage trippers in the clockwise (figure 2).</seg>
<seg id="1070">Do not use the residual scale to measure your insulindosis • You hear each one individually included unit a clickdevice.</seg>
<seg id="1071">"perform the injection technology, which has shown your doctor • Provide the dose by pressing the press knob. (figure 3)."</seg>
<seg id="1072">"the Dosisreaker puts itself down to zero and you listen to the injection packers for at least 6 seconds in order to make sure you press the Dosisregler on zero, as you click on the injection button • Remove the injecting needle to zero, depending on the injection button."</seg>
<seg id="1073">"medical staff, family members, as well as other supervisors must notice general precautions to removal and disposal of injections to avoid unintentional stitches with the injection needle."</seg>
<seg id="1074">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1075">"► in Insulinfinfusion pumps, if the FlexPen was dropped, damaged or zersed, is the risk of discontinued by insulin if it was not correct or frozen (see 6 How is Actraphane to preserve?) ► if it is not synced after the resignant."</seg>
<seg id="1076">"if you see depressions or thicknesses of your skin at the injection point, because these reactions can be welded or the inclusion of your insulin if you are in such a position."</seg>
<seg id="1077">"274 If any of the above-side effects you impaired considerably, or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1078">"in use of semi-flextive manufacturing and such that are used shortly, or be kept as a substitute, are not to be kept in the fridge."</seg>
<seg id="1079">"it is recommended - after having removed from the refrigerator - to increase temperature of the Flexpen on room temperature, before the insulin under the manual for the first use is resins."</seg>
<seg id="1080">Let the slender of your FlexPen finish always set if FlexPen is not in use to protect the insulin before light.</seg>
<seg id="1081">"how Actraphane looks and content of the package Ininjections, is regarded as trübe, white, aqueous suspension of suspension in packs of 1, 5 or 10 finishing in packs of 3 ml each."</seg>
<seg id="1082">Manufacturer The manufacturer may be printed by the chargers of carton and printed on the label:</seg>
<seg id="1083">"275 • If in the second and third place of the Charge designation, the manufacturer Novo Nordisk A / S, Novo Allé, Denmark • Falls at the second and third place of the chargers, is the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Oréans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B Move to the pen between positions 1 and 2 twenty times, so that the glars from one end of the cartridge for the other moves."</seg>
<seg id="1085">"move the prepen at least 10 times between positions 1 and 2 and down, until the fluid is uniform and traded."</seg>
<seg id="1086">• To reduce the risk of accidental coniferous coniferous you will never put the inner cover back on the injection needle refine after you have taken them once.</seg>
<seg id="1087">279 G Keep the Flexpen with the injection needle to the top and knocking a few times with the finger easily against the cartridge so that existing air bubbles in the cartridge have to collect.</seg>
<seg id="1088">The dose can be corrected either as well as downwards by turning the dosage button in the appropriate direction until the correct dose compared to the placement of the display.</seg>
<seg id="1089">This document is a summary of the European Public Library report (EPAR) in which explains how the Committee for Humanarztend (CHMP) has assessed carried out in order to make recommendations concerning the application of the drug.</seg>
<seg id="1090">"the arztend effective component in Actrapid, insulin human (rDNA), is manufactured with the method of the so-called" recombinant technology ":"</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.</seg>
<seg id="1092">Actrapid may not be used in patients who may possibly be sensitive to insulin human rights (rDNA) or one of the other components.</seg>
<seg id="1093">"furthermore, the doses of Actrapid may be adjusted when it is administered with a number of other medicines that will affect blood sugar."</seg>
<seg id="1094">October 2002 the European Commission published the Novo Nordisk A / S accepts a permit for the sale of Actrapid throughout the European Union.</seg>
<seg id="1095">"if two types of insulin pusurers must first be raised the quantity of the insulin insulus, then the quantity of the long insulin insulin."</seg>
<seg id="1096">"3 If the switch to Actrapid is required when patients need a dosage adjustment, this can be necessary with the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1097">"traveling over several times of time, the patient should be advised to bring the advice of his physician since such trips can lead to other times and to be taken at other times."</seg>
<seg id="1098">"5 General diseases and complaints at the end of occasionally - Local oversensitivity to the injection point of the Insulintherapy can occur local hypersensitivity actions (redness, swelling, itch, pains and hematom at the injection point)."</seg>
<seg id="1099">"diabetics should therefore always have grape pieces, candy, biscuits or sugar fruit juice to have been treated with intra-muscular or subcutaneous injecting from Glucagon (0,5 to 1,0 mg) by a fixed support person or by glucose who will be intravenous by the doctor."</seg>
<seg id="1100">A clinical trial in an intensive care for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabeous patients who decreased by intravenous Actrapid inemia (blood sugar 4.4 - 6.1 mmol / l) the mortality reduced by 42% (8% compared to 4.8%).</seg>
<seg id="1101">"the effect begins within half an hour, the active ingredients is achieved within 1.5 to 3.5 hours and the entire duration of the operation is about 7 to 8 hours."</seg>
<seg id="1102">Children and young adults The pharmacopoinetic profile of Actrapid was examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents (aged between 13 and 17 years).</seg>
<seg id="1103">"the data is limited, however, however, the acceptance is close to that pharmacopoinetic profile in children and adolescents are similar."</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0.05 i.e. / ml - 1,0 g / ml insulin in infusion with 40 mmol / l Caliphchlorid are stable when using infusion exploitation of polypropylene available at room temperature 24 hours long.</seg>
<seg id="1105">"11 If the switch to Actrapid is required when patients need a dosage adjustment, this can be necessary with the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1106">"traveling over several times of time, the patient should be advised to bring the advice of his physician since such trips can lead to other times and to be taken at other times."</seg>
<seg id="1107">"13 General diseases and complaints on the appointment of occasionally - Local oversensitivity to the injections of the Insulintherapy can occur local hypersensitivity actions (redness, swelling, itch, pains and hematom at the injection point)."</seg>
<seg id="1108">"diabetics should therefore always have grape pieces, candy, biscuits or sugar fruit juice to have been treated with intra-muscular or subcutaneous injecting from Glucagon (0,5 to 1,0 mg) by a fixed support person or by glucose who will be intravenous by the doctor."</seg>
<seg id="1109">Children and young adults The pharmacopoinetic profile of Actrapid was examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents (aged between 13 and 17 years).</seg>
<seg id="1110">The intravenous application of Actrapid from finished or cartridges should be an exception and only occur in situations where no diarrhea are available.</seg>
<seg id="1111">"if the change to Actrapid is required when you need a dosage adjustment, this can be necessary with the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1112">"21 diseases of the skin and sub-haust, occasionally - Lipodystrophy In the injecting place may arise a Lipodystrophy, if failed to switch the insertion within the injecting range."</seg>
<seg id="1113">Children and young adults The pharmacopoinetic profile of Actrapid was examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents (aged between 13 and 17 years).</seg>
<seg id="1114">29 diseases of the skin and the substrates occasionally - Lipodystrophy to the injection point may arise a Lipodystrophy if failed to switch the insertion within the injecting range.</seg>
<seg id="1115">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="1116">Children and young adults The pharmacopoinetic profile of Actrapid was examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents (aged between 13 and 17 years).</seg>
<seg id="1117">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="1118">38 A clinical trial in an intensive care for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabeous patients who decreased by intravenous Actrapid inemia (blood sugar 4.4 - 6.1 mmol / l) the mortality reduced by 42% (8% compared to 4.8%).</seg>
<seg id="1119">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, sweating, sweating, redness, carpineapple, low blood pressure, low blood pressure and impotence / consciousness."</seg>
<seg id="1120">46 A clinical trial in an intensive care for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabeous patients who decreased by intravenous Actrapid inemia (blood sugar 4.4 - 6.1 mmol / l) the mortality reduced by 42% (8% compared to 4.8%).</seg>
<seg id="1121">To store in the fridge (2 ° C - 8 ° C) Not infreeze The flow bottle can be stored in carton to protect the content from light: not in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application and fill cartridges are intended for use with Novo Nordisk Insulinines.Actrapid Penfill may only be used by one person</seg>
<seg id="1123">To store in the fridge (2 ° C - 8 ° C) Not unfreeze The cartridge in carton can be kept in order to protect the content from light by quarry: not in the fridge or over 30 ° C</seg>
<seg id="1124">Subcutaneous application to use with Actrapid NovoLet's NovoFine injection packets required for Actrapid NovoLet may only be used by one person</seg>
<seg id="1125">To store in the fridge (2 ° C - 8 ° C) Not infreeze on light protection: do not keep in the fridge or over 30 ° C</seg>
<seg id="1126">Subcutaneous application to use with Actrapid Innolet are provided NovoFine S injections envisaged by a person Actrapid Innolet may only be used by one person</seg>
<seg id="1127">That means that about half an hour after you have applied it to sink your blood sugar and that the effect will stop about 8 hours.</seg>
<seg id="1128">► Check the basis of the label whether it is concerned by the correct insulin type. ► Desinfy the rubber compound with a medical cloth.</seg>
<seg id="1129">"if this is not completely unfinished, if you get the flow-bottle back to your pharmacy, if it was not correct or frozen (see 6 How is Actrapid to preserve?) ► if it does not look clear such as water and colourless."</seg>
<seg id="1130">"use the injection technology that you have recommended your doctor or your Diabetesberaterin ► Lassen the injections for at least 6 seconds under your skin, to make sure that the complete dosage was injected."</seg>
<seg id="1131">"83 Are you put your family, friends and tight workplaces that they will bring you in case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="1132">You possibly have a very rare heavy allergic reaction to Actrapid or one of its components (a so-called systemic allergic reaction).</seg>
<seg id="1133">"the injection solution is made as clear, color-color solution in packs of 1 or 5 msnail bottles each 10 ml or a bundle packaged with 5 ml each."</seg>
<seg id="1134">"89 Are you put your family, friends and tight labor, that they will bring you in case of a consciousness to a stable side and immediately create a doctor."</seg>
<seg id="1135">► Check the basis of the label whether it is concerned by the correct insulin type and always check the cartridge including the rubber mikolbens (stoves).</seg>
<seg id="1136">"► in Insulininfusion lump, if the penis fill or the device, which contains the penis fill, damaged, damaged or broken it was (see 6 How is Actrapid to preserve?) ► if it does not look clear such as water and colourless."</seg>
<seg id="1137">"if you are treated with Actrapid Penfill and another insulin in Penile cartridges, you should use two insulin delivery systems, each one for each insulinart."</seg>
<seg id="1138">"use the injection technology that you have described your doctor or your diet system, ► Lassen is described under your skin, to make sure that the complete dose is injected at least 6 seconds long under your skin, to remove the injecting injection needle, and keep an abrupt injecting needle."</seg>
<seg id="1139">"• Falls at the second and third place of the load-combination W5, S6, P5, K7 or ZF is released, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark"</seg>
<seg id="1140">"• If in the second and third place of the Charge designation, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1142">► Check the basis of the label whether it is concerned about the correct insulin type. ► Bendering always for any injection a new injections to avoid a contamination.</seg>
<seg id="1143">"► in Insulininfusion pumps, if the NovoLet's dropped was damaged, damaged or broken; it is the risk of discontinued by insulin when it was not correct or frozen (see 6 How is Actrapid to preserve?) ► if it does not look clear such as water and colourless."</seg>
<seg id="1144">"this can happen: • If you too much insulin, when you eat too little or meal, if you do more than otherwise physically anstrict"</seg>
<seg id="1145">Let the slender of your NovoLet's finish always set if he is not in use to protect it from light.</seg>
<seg id="1146">"take the slender cap. • Despair the rubber embraces with a medical Tupper • If you always use the injections of a NovoFine injecting needle, • screws, you have the injections of the injections and the inner cap of the injection needle reap."</seg>
<seg id="1147">Go as to avoid the injection of air and to ensure a correct dosage: • Keep Actrapid NovoLet with the injection needle to the top • clocking a few times with the finger easily against the cartridge.</seg>
<seg id="1148">"if air bubbles are present, this way in the cartridge continue, while the cartridge continue to keep up in direction of the arrow (figure B) • During the injection needle, continue in (figure C) • now you must stream from the tip of the injection needle, a drop of insulin pending."</seg>
<seg id="1149">"• Setting the sluggle back so on the finished pen, that the number 0 is in front of the dosing brand (Figure D) • Control, whether the button pressed over."</seg>
<seg id="1150">"if the button-button is not able to move freely, insulin out of injection-nadel suppressed • The scale on the slender cap shows 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1151">"the push-button moves to the outside, while you spin the sluggle cap • The scale below the pressure button (Druckknopfskala) shows 20, 40 and 60 units."</seg>
<seg id="1152">"107 • noting the highest number you can see on the pressure knopfskala, • add the two numbers to have the prescribed dose as if you have a false dose just forward or backwards until you have set the correct number of units."</seg>
<seg id="1153">"turn it down, until the press knob down below is and you can sense a resistance, then take the sluggappe from and put them back on that the 0 of the dosing brand lies."</seg>
<seg id="1154">"pay attention to only during the injection button, • Keep the pressure button down into the injection, until the injection needle was pulled out of the skin."</seg>
<seg id="1155">"it may possibly unaccurate • You can not set any dose which is higher than the number of remaining in the cartridge units, you can use the residual scale, but you can not use it to stop your dose or choose."</seg>
<seg id="1156">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1157">"► in Insulininfusion pumps, if the Innolet fall dropped, damaged or zersed; it is the risk of discontinued by insulin when it was not correct or frozen (see 6 How is Actrapid to preserve?) ► if it does not look clear such as water and colourless."</seg>
<seg id="1158">Let the slender of your innolet finishing always set if he is not in use to protect it from light.</seg>
<seg id="1159">• Descfy the rubber compound with a medical Tupper • Use always for any injecting a new injecting needle to avoid a contamination that are straight and fixed at Actrapid Innolet (picture 1A) • Praise the big outer cap of the injection needle and the inner cap of the injection needle reap.</seg>
<seg id="1160">"the Dosisreaker puts itself down to zero and you listen to the injection packers for at least 6 seconds under the skin, to make sure you press the Dosisregler on zero, as you click on the injection button • Remove the injection needle instead of any injection."</seg>
<seg id="1161">"oral Antidiabetic (for entry), monoaminoxides (MAO-Hemmer), angiotensin- converting steroids, thyroid, thyroid hormones, thyroid hormones, thyroid hormones, Danazotid, Octreotid or Lanre otid."</seg>
<seg id="1162">"121 ► if it was not adequately kept correctly or frozen (see 6 How is Actrapid to preserve?) ► if it looks not clear like water and colourless."</seg>
<seg id="1163">"if any of the above-effects you have significantly impaired or you may notice the side effects which are not specified in this usage information, please inform your doctor, your diabetine or your pharmacist."</seg>
<seg id="1164">Let the slender of your FlexPen finish always set if he is not in use to protect it from light.</seg>
<seg id="1165">F Keep the Flexpen with the injections to the top and knockout a few times with the finger easily against the cartridge so that available air bubbles above in the cartridge.</seg>
<seg id="1166">The dose can be corrected either as well as downwards by turning the dosage button in the appropriate direction until the correct dose compared to the marker of the dosage display.</seg>
<seg id="1167">"Adenuric is used for patients who already have signs of crystalluations, including arthritis (pains and inflammation in the joints) or laminate (" stones ", i.e. greater Uratcrystalline, which can lead to gels and bone compensations)."</seg>
<seg id="1168">"if the urinary tract can still be increased over 6 mg for up to four weeks, the dose can be increased once daily 120 mg once a day."</seg>
<seg id="1169">"during the first treatment series, the patients can still occur and therefore, advised that patients take at least during the first six months under treatment with Adenuric even further medicines for prevention of fork waste."</seg>
<seg id="1170">The drug is not recommended in children and for patients who had an organic transplant since these groups were not examined.</seg>
<seg id="1171">"in the first study, on the 1 072 patients, the efficacy of various adenuric dosages (once daily 80, 120 and 240 mg) with that of a placebo (projections) and of Allopurinol (other medicines to treat hyperuricide)."</seg>
<seg id="1172">"in the second study two doses were compared by Adenuric (once daily 80 and 120 mg) one year long at 762 patients each with Allopurinol."</seg>
<seg id="1173">In both studies Allopurinol was used in a dose of once daily 300 mg; patients with kidney problems were only 100 mg per day.</seg>
<seg id="1174">"the main indicator of the efficacy was the number of patients, their urinary tract in the blood of the last three measurements under 6 mg / dl."</seg>
<seg id="1175">"in the first study 48% (126 of 262) of patients, Adenauer in a dose of once daily 80 mg, and 65% (175 of 269) of patients, which took once daily 120 mg in the blood of under 6 mg / dl."</seg>
<seg id="1176">"compared to this, this was at 22% (60 of 268) patients under Allopurinol and in no of 134 patients under placebo."</seg>
<seg id="1177">"the most common side effects of Adenuric (observed at 1 to 10 of 100 patients) are headaches, diarrhea, nausea and abnormal liver values."</seg>
<seg id="1178">"in particular, in patients with cardiac disease, perhaps a increased risk of certain side effects that affect the heart and blood vessels."</seg>
<seg id="1179">"the committee for human cells (CHMP) came to the conclusion that Adenuric was more effective in the reduction of urinary tract, but also a higher risk of side effects associated with the heart and blood vessels."</seg>
<seg id="1180">"treatment of chronic hyperuronic disease in disorders that have already led to Uratablelations (including one from the hypothetical, or current present gene, and / or a gichtarrant)."</seg>
<seg id="1181">If the Serumharnsaws after 2-4 weeks still &gt; 6 mg / dl (357 µmol / l) can be considered a dosage increase to ADENURIC 120 mg 1 x daily.</seg>
<seg id="1182">In patients with severe kidney diseases the effectiveness and safety have not been fully examined (Kreatinin- Clearance &lt; 30 ml / min. see Section 5.2).</seg>
<seg id="1183">"children and adolescents are not recommended in children and young people, the application of Febuxostat is not recommended in this patient group."</seg>
<seg id="1184">Organtransplants since it has been transplants with organtransplants not recommended experience the application of Febuxostat in this patient group is not recommended (see Section 5.1).</seg>
<seg id="1185">Cardiovascular diseases in patients with ischaedic heart disease or decompensated heart failure is not recommended in the treatment with Febuxostat (see section 4.8).</seg>
<seg id="1186">"as with other harnsoy drugs, it may occur during the treatment of treatment to an acute loss, because by lowering the serumharnsäurespiegels first of the urinary tract can be mobilized in the tissues."</seg>
<seg id="1187">B. for malignant diseases and their treatment, Lesch- Nyhan syndrome) the absolute concentration of Xanthin in the urine in rare cases so far rise that it comes to aggrazing in the urinary tract. "</seg>
<seg id="1188">Liver diseases During the clinical trials of phase 3 have been observing slight realities of the liver limbs at with Febuxostat treatment (3.5%).</seg>
<seg id="1189">It is therefore recommended to perform before the beginning of the Febuxostattreatment and in the further course depending on the clinical trial (see Section 5.1).</seg>
<seg id="1190">Theophyllin Zwas were not carried out exchange studies to Febuxostat but it is known that the XO-shirt lead to an increase in theophyllinism (a inhibition of the metabolic rate of Theophylls also has been reported for other XO-shirts.</seg>
<seg id="1191">With Probanden was the simultaneous gripping of Febuxostat and Naprox250 mg 2 x daily with a rise in Febuxostatexposition (Cmax 28%, AUC 41% and t1 / 2 26%). "</seg>
<seg id="1192">In clinical studies the application of bowl or other NSAR / Cox-2 shirts are not associated with a clinically significant increase of unwanted events.</seg>
<seg id="1193">Colours in / Indometacin / hydrochlorthiazid / Warfarin Febuxostat can be used together with Coline in or Indometacin, without a dosage adjustment for Febuxostat or at the same time used other active ingredient. "</seg>
<seg id="1194">"in a study with Probanden 120 mg ADENURIC 1 x daily a medium 22% increase in AUC by Desipramine, a CYP2D6 substrate, which indicates a possible weak inhibital effect of Febuxostat on the CYP2D6-enzyme in vivo."</seg>
<seg id="1195">"Antazida It could be shown that the simultaneous intake of an antacid, the magnesium-hydroxid and aluminium hydroxid contains, the absorption of Febuxostat (around 1 hour) delays and a decrease in the Cmax by 32%, however no significant change in AUC."</seg>
<seg id="1196">Pregnancy data on a very limited number of exponated pregnancy do not let the side effects of Febuxostat on the pregnancy or the health of Fetus / newborns.</seg>
<seg id="1197">Animal studies do not leave a direct or indirect impact on pregnancy, embryonic / fetal development or birth (see Section 5.3). "</seg>
<seg id="1198">Patients should be careful when controlling a vehicle and serve machines or in the exercise of hazardous activities until they may be certain that ADENURIC can not be influenced their performance.</seg>
<seg id="1199">A numerically increased incidence of cardiovascular events reported in the overall form of cardiovascular events compared to the Allopurinol group in the pivotal study group (1.4 versus 0.3 events per 100 patient-years) and in long-term extension (1.4 versus 0.7 events per 100 patients) were observed and no verbal connection with Febuxostat.</seg>
<seg id="1200">The risk factors used in these patients were a arterial clauses disease and / or a myocardinary or a decomposition of heart failure in the ambulance.</seg>
<seg id="1201">"frequent (≥ 1 / 100 to &lt; 1 / 10), occasional (≥ 1 / 1,000 to &lt; 1 / 100) and rare (≥ 1 / 1,000 to &lt; 1 / 100) side effects, which were reported in the treatment units with 80 mg / 120 mg, uxostat treatment groups in a total of more than once, are listed below."</seg>
<seg id="1202">"diarrhea, nausea and vomiting are more common in patients who are simultaneously treated with colonnine. * * In clinical trials were no severe skin-hits or serious hypersensitivity actions."</seg>
<seg id="1203">"7 Open long-time extension studies In the open long-time extension studies were treated as 906 patients up to 1 year, 322 patients up to 2 years, 57 patients up to 3 years and 53 patients aged up to 4 years with Febuxostat 80 mg / 120 mg respectively."</seg>
<seg id="1204">"the events related to long-term studies were similar, which were reported in the studies of phase 3 (see table 1)."</seg>
<seg id="1205">"the following treatment events were reported in all Febuxostat- treatment groups altogether more than once and stood with patients, the Febuxostat 80 mg / 120 mg in long-time extension studies (up to 4 years with an exposure time of &gt; 1,900 patient-years), according to the statements occasionally."</seg>
<seg id="1206">The following treatment-related events were either reported at the pivotal studies of phase 3 for these doses either at all or with a lower frequency:</seg>
<seg id="1207">"diabetes, hypertension, sleeplessness, nasty, shorts, shorthonation, burying, burying, burying, burns, burial concentration in the blood, decline of tendhocytes, decrease in the number of white blood cells."</seg>
<seg id="1208">"" "collectivism" "is at the human being the end product of Purinmetism and arises in the framework of the reactioneaskade Hypoxanthin → Xanthin → uric acid."</seg>
<seg id="1209">"Febuxostat is a powerful, not Purin-selective Inhibitor of the XO (NP-SIXO) with a Ki-value for which in vitro-shirt, which is below the nanomolean area."</seg>
<seg id="1210">Clinical study results The effectiveness of ADENURIC was described in two pivotal studies of phase 3 (APEX study and fact study as described below) that have been carried out with 1.832 patients with hypertension and toxins.</seg>
<seg id="1211">The primary efficacy point was in every study of the proportion of patients where the last three month of serumharnsaurinary tract &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1212">"placebo (n = 134), ADENURIC 100 mg 1 x daily (n = 134), ADENURIC 240 mg 1 x daily (n = 134) for patients with a serverincremental inworth to study beginning of &gt; 1.5 mg / dl and ≤ 2,0 mg / dl."</seg>
<seg id="1213">The APEX-study showed in terms of lowering the Serumharnsaurinary tract (see table 2 and picture 1) the statistically significant superiority both of the treatment with ADENURIC 120 mg 1 x daily compared to treatment with conventional used doses Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The fact-study showed in regard to the durable reduction of serumharnsaurels under 6 mg / dl (357 µmol / l) the statistically significant superiority both of the treatment with ADENURIC 120 mg 1 x daily with the traditional used dose of Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serotomininvalues &gt; 1.5 and ≤ 2,0 mg / dl) or 300 mg 1 x daily (n = 509) were summarised for the analyses. * p &lt; 0.001 versus Allopurinol. # p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">Lowering of the Serumharnsaurels on &lt; 6.0 mg / dl (357 µmol / l) was observed in a range 2 and kept permanently over the entire treatment.</seg>
<seg id="1217">509 patients received Allopurinol 300 mg 1 x daily; 10 patients with serorbitininvalues &gt; 1.5 and &lt; 2,0 mg / dl received 100 mg 1 x daily. "</seg>
<seg id="1218">Primary Endpoint in the subgroup of patients with kidney functioning The APEX-study rated the effectiveness in 40 patients with kidney function (d. h).</seg>
<seg id="1219">"with ADENURIC, the primary efficiencies of 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients achieved."</seg>
<seg id="1220">There was no clinically significant differences regarding the process of serrenal regation of serumharnsore-centations with probation of their kidney function (58% in the group with normal kidney function and 55% in group with severe kidney functioning).</seg>
<seg id="1221">Primary end in the subgroup of patients with serumharnslications ≥ 10 mg / dl Etwa 40% of patients (Baseline) had a serumharnslaughter of ≥ 10 mg / dl.</seg>
<seg id="1222">The data collected in two years of an open extension study phase 3 showed that the longterm reduction of serumharnsai wns on &lt; 6 mg / dl (&lt; 357 µmol / l) a decrease in incidence of incidence required (i.e. more than 97% of patients required any treatment against a barrier).</seg>
<seg id="1223">"this was associated with a reduction in the sealing size, which at 54% of patients had a complete disappearance of inclding up to month 24 for a row."</seg>
<seg id="1224">Increased TSH- Values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostat (5.0%) and also in patients who received Allopurinol (see Section 4.4).</seg>
<seg id="1225">In healthy trials increased the maximum plasma concentration (Cmax) and the area under the plasma centric time curve (AUC) from Febuxostat after administration easier and multi-plet doses from 10 mg to 120 mg dosisproportionate.</seg>
<seg id="1226">For cans of 120 mg and 300 mg for Febuxostat is observed an increase in AUC the greater than the dosisdisproportionate increase.</seg>
<seg id="1227">After taking simple or multi-plorical doses from 80 and 120 mg 1 x daily the Cmax is about 2.7-3.3 µg / ml and 5.0-5.6 µg / ml.</seg>
<seg id="1228">However no clinically significant change in the percentage decrease in serumharnsapcentration observed if this was tested (multiple doses of 80 mg).</seg>
<seg id="1229">Distribution The seeming steady-state volume (Vpp / F) of Febuxostat lies in the range from 29 to 75 l after intake of 10-300 mg.</seg>
<seg id="1230">"the Plastika rotation of Febuxostat amounts to about 99,2% (primary bond to Albumin) and is reached via the concentration of concentration, which is achieved with doses from 80 and 120 mg."</seg>
<seg id="1231">"in vitro-studies at human liver microceren showed that these oxidative metabolic disorders demonstrated mainly by CYP1A1, CYP1A2, CYP2C9, and that Febuxostatglucuronid mainly created by UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">After taking a 80 mg dose of 14C-marked Febuxostat found approximately 49% of the dose in urine than untreated Febuxostat (3%), Acylgluelonid of the active ingredients (30%), whose known oxidative metabolic rate and their Conjugate (13%) as well as other non-known metabolic rate (3%). "</seg>
<seg id="1233">"in addition to the expulsion across the urine were also about 45% of the dose in the stool as an unchangeable way uxostat (12%), Acylgluelonid of the active ingredients (1%), whose well-known metabolic chemicals and their conjugates (25%), as well as other non-known metabolic rate (7%)."</seg>
<seg id="1234">"special patients suffering from insufficiency may vary from 80 mg ADENURIC in patients with mild, moderate or severe kidney failure, the Cmax of Febuxostat does not change in relation to proaches with normal kidney function."</seg>
<seg id="1235">The mean total-AUC of Febuxostat took around the 1.8-fold of 7.5 μ g ⋅ h / ml in the group with normal kidney function to 13,2 μ g ⋅ h / ml in the group with severe kidney function.</seg>
<seg id="1236">12 Living functional cells after taking multiplet doses from 80 mg ADENURIC in patients with mild (child-Pugh classification A) or medium-heavy (Child-Pugh classification A) or medium-heavy (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or the metabolic rate changed not significant compared to proving with normal liver function.</seg>
<seg id="1237">Age There were no significant changes in regard to the AUC of Febuxostat or its metabolic rate after taking multiploric doses from ADENURIC in older patients compared to younger people.</seg>
<seg id="1238">"carcinogenesis, nuts, impairment of the fertilisation For male saws has been a statistically significant increase of urinary bladder and carcinoma) only in connection with Xanthin-stones in the high-state-treated group, at about 11-fold the exposure to man."</seg>
<seg id="1239">These findings are seen as a result of a specific Purchmetallization and urine and for the clinical use as not relevant.</seg>
<seg id="1240">It was established that Febuxostat in oral doses of up to 48 mg / kg / day no effect on the fertilisation and reproduction performance of male and female rats.</seg>
<seg id="1241">"with high doses, which were about 4,3- the humanistic exposition, entered maternal toxicity, which entered into with a reduction in performance and a development delay in the descendants of rats."</seg>
<seg id="1242">"teratological studies in supporting rats with expositions, which are about 4,3-fold and in the tragic rabbit with expositions which are about the 13-fold of humanistic exposition, there are no teratogenic effects."</seg>
<seg id="1243">Colours in / Indometacin / hydrochlorthiazid / Warfarin Febuxostat can be used together with Coline in or Indometacin, without a dosage adjustment for Febuxostat or at the same time used other active ingredient. "</seg>
<seg id="1244">"diarrhea, nausea and vomiting are more common in patients who are simultaneously treated with colonnine. * * In clinical trials were no severe skin-hits or serious hypersensitivity actions."</seg>
<seg id="1245">"21 Open long-time extension Studies In the open long-time extension studies, 906 patients were treated up to 1 year long, 322 patients up to 2 years, 57 patients up to 3 years and 53 patients aged up to 4 years with Febuxostat 80 mg / 120 mg respectively."</seg>
<seg id="1246">The primary efficacy point was in every study of the proportion of patients where the last three month of serumharnsaurinary tract &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1247">The data collected in two years of an open extension study phase 3 showed that the longterm reduction of serumharnsai wns on &lt; 6 mg / dl (&lt; 357 µmol / l) a decrease in incidence of incidence required (i.e. more than 97% of patients required any treatment against a barrier).</seg>
<seg id="1248">26 as unchangeable Febuxostat (3%); Acylgluelonid of the active ingredients (30%) whose well-known oxidative metabolic and their conjugates (13%) as well as other non-known metabolic rate (3%).</seg>
<seg id="1249">Liver dysfunctions After intake multiplet doses from 80 mg ADENURIC in patients with mild (Child-Pugh classification A) or medium-heavy (Child-Pugh classification A) or medium-heavy (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh classification A) or medium-severe (Child-Pugh-classification A) or the metabolic rate changed not significant compared to proaches with normal liver function.</seg>
<seg id="1250">"carcinogenesis, nuts, impairment of the fertilisation For male saws has been a statistically significant increase of urinary bladder and carcinoma) only in connection with Xanthin-stones in the high-state-treated group, at about 11-fold the exposure to man."</seg>
<seg id="1251">"the holder of approval for the permit has to ensure that an Pharmacovigilance system as described in Version 2.0 module 1.8.1 of authorisation is available, and so long is available how the drug is brought into traffic."</seg>
<seg id="1252">A updated RMP is set to present in accordance with the CHMP guideline to risk management systems for human cells with the next Periodic Safety Update Report (PSUR).</seg>
<seg id="1253">"in addition, an update of the RMP will be required when new information is required, the pharmaceutical vigilance plan or activities for risk prevention, • within 60 days of reaching important milestones (Pharmacovigilance or risk assessment) • On request of EMEA"</seg>
<seg id="1254">"in some people the uric acid is in the blood, and can achieve concentrations that are so high that uric acid is insoluble."</seg>
<seg id="1255">If you hold the urinary concentration by the 1 x daily intake of ADENURIC is prevented the crystal-speciation and in this way a minimizing of complaints can be achieved.</seg>
<seg id="1256">"ADENURIC must not be taken, • if you are excessive (allergic) against the ingredient, uxostat or one of the other components of ADENURIC."</seg>
<seg id="1257">"inform your doctor before you begin taking this medication by using this medication, if you have a heart disease or had a heart disease (a rare congenital disease, where you can be treated much uric acid in the blood)."</seg>
<seg id="1258">"if you have a change in the moment (sudden appearance of serious pain, pressure-sensitive, redness, heat expeeling and money-swelling), wait until the coating process, before you begin with the treatment with ADENURIC."</seg>
<seg id="1259">"this does not have to be so, but also with you, especially during the first treatment weeks or - months, occur if you are using ADENURIC."</seg>
<seg id="1260">Your doctor will treat you with need for other medicines to prevent a loss or to treat the associated symptoms (such as pains and money-swelling).</seg>
<seg id="1261">"please inform your doctor or a pharmacist if you have to take any other medicines / apply, or have been adopted recently, even if it is not prescription drugs."</seg>
<seg id="1262">It is particularly important that you may take your doctor or pharmacist if you may take medications and apply one of the listed substances since interaction with ADENURIC (for the treatment of asthma) • Warmiioprin (for the treatment of asthma) • Warfares (for the treatment of asthma) •</seg>
<seg id="1263">There were no studies on the effects of ADENURIC and the ability to serve machines.</seg>
<seg id="1264">"please enter ADENURIC therefore only after consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="1265">On the back of the blister packs are printed the individual weekdays are printed so that you may have taken a tablet every day. • The tablets need to be swallowed and can be taken with or without food.</seg>
<seg id="1266">"if you have taken down an overdose, please contact your doctor or to the nearest hospital house."</seg>
<seg id="1267">"if you have forgotten the intake of ADENURIC, take it as soon as possible unless the next intake is just before."</seg>
<seg id="1268">"if you break the intake of ADENURIC, your urinary tract can rise again, and your complaints can be wasted because new Uratcrystals can form in your lover and kidneys, as well as their environment."</seg>
<seg id="1269">"frequent Side Effects (more than 1 of 100 patients treated, but less than 1 of 10 treated): • eye-catching liver • diarrhea • rash •"</seg>
<seg id="1270">"rare side effects (more than 1 of 10,000 patients treated but less than 1 of 1,000 treated): • weakness • nervousness • During-feeling • carpity"</seg>
<seg id="1271">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="1272">ADENURIC is available in 2 blister packs of 14 tablets (packaged with 28 tablets) or in 6 blister packs with 14 tablets (package with 84 tablets).</seg>
<seg id="1273">Бълиария Grenzsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">"Danmark, Norge, Suomi / Finland, Sverige, Ínland Institute produced Synthèse (IPSEN) AB Kista Sverige / Ruotsi / Svími / Sími / Sími / Sími / Sími: + 46 8 588 370 70</seg>
<seg id="1275">"ADROVANCE is used for the treatment of osteoporosis (one disease, in which the bones, are used in women after menopause when a risk for a low vitamin D mirror consists."</seg>
<seg id="1276">"the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or lease of other medicines (including Antazida, Calcium and Vitaminsupplementary items)."</seg>
<seg id="1277">"to avoid a irritation of the esophagus, the patient may take up until after the first food intake of the day, the earliest 30 minutes after taking the tablet should not lie."</seg>
<seg id="1278">"since Alendronat and vitamin D3 are already separated from each other in drugs that are approved in the European Union, the company laid data from earlier studies and published literature."</seg>
<seg id="1279">The company also led a study with 35 men and 682 postmenopausal women with osteoporosis to prove the effectiveness of ADROVANCE in relation to increasing the vitamin D mirror.</seg>
<seg id="1280">"after a 15-week treatment, the proportion of patients with low vitamin D mirror in patients who were treated with ADROVANCE (11%) than those who took only Alendronat (32%)."</seg>
<seg id="1281">"the company also laid data before, which daring that in ADROVANCE's dose-dose exactly the dose which is required for the prevention of a bone loss."</seg>
<seg id="1282">"the most common side effects (observed at 1 to 10 of 100 patients) are headaches, pain, or joints) and symptoms of digestive apparatus such as abstaining, dysheepy (diarrhea), ulceration (diarrhoea), ulceration (dialysis), ulcereal abdomen (branded belly) as well as saures breaking."</seg>
<seg id="1283">"in case of patients with possible oversensitivity (allergy) against aging, vitamin D3 or any of the other components may not be applied ADROVANCE."</seg>
<seg id="1284">"it may not be applied in diseases of the esophagus, in patients with Hypocalcemia (low calcium levels) or in patients who can not stand up or sit for at least 30 minutes."</seg>
<seg id="1285">"January2007, the European Commission announced the European Commission of Merck Sharp & Dohmen Ltd. a permit for the discharge of ADROVANCE, throughout the European Union."</seg>
<seg id="1286">"T-shaped, white to broken white tablets, marked with an outline of a bone on one side and" "710" "on the other side."</seg>
<seg id="1287">"ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first meal, beverage or taking of medicines (including Antazida, calcium, and Showcases supplement) for the day."</seg>
<seg id="1288">Following hints are exactly to be followed in order to decrease the risk of misophageal irritation and associated side effects (see Section 4.4):</seg>
<seg id="1289">"• ADROVANCE is supposed to be slured after the day of the day only with a full glass of water (at least 200 ml), as a risk to oropharyngeale Ulzera. • The patients should not take place before the first food intake of the day, the earliest 30 minutes after taking the tablet becomes."</seg>
<seg id="1290">B. peptic Ultimo, active gastrointestinal blocking or surgical procedures in the upper Gastrointestinal tract except Pyloroplasty, only under particular attention (see Section 4.3). "</seg>
<seg id="1291">"ectual responses, like Ösophagitis, ösophageale Ulzera and ösophageal erosions, were reported in patients under the intake of Alendronat (partly these severe and required a pathogenic instruction)."</seg>
<seg id="1292">"the doctor should therefore pay attention to all signs and symptoms which may indicate to possible hinocular reactions like Dycelagie, pains when pressing or retrosterous pain or a new or limmerging of Sodging the medicines and get medical advice (see section 4.8)."</seg>
<seg id="1293">"3 The risk of serious dophageal side effects seems to be increased in patients, which may not take the medicine correctly and / or it is after the appearance of symptoms resulting in an induce irritation."</seg>
<seg id="1294">It is very important that all dosing transactions are passed on to the patient and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"while in large covered clinical studies with Alendronat no elevated risk was established, rare (after market launch) Mag- and Duodenalulzera, including some severe and with complications, reported (see Section 4.8)."</seg>
<seg id="1296">"Osteonekrose of the pinewood, usually associated with a tooth extraction and / or a local infection (including Osteomyelitis), was reported in cancer patients whose therapist ime intravenously administered Bisphosphors."</seg>
<seg id="1297">"there are no data available, giving notice whether the suspending of a bisphosphonate treatment in patients who require a kale surgical procedure, reduces the risk of an Osteonekrose of the pinewood."</seg>
<seg id="1298">The clinical assessment by the treatmenting doctor is binding for the therapy planning with each patient based on an individual benefit risk assessment.</seg>
<seg id="1299">Patients should be dependent on taking care of the intake of taking a dose of ADROVANCE the tablet in the next morning after they have noticed their failure.</seg>
<seg id="1300">"you should not take two tablets per day, but taking one tablet per week as originally planned on the weekday."</seg>
<seg id="1301">"other diseases that affect the mineral change (such as vitamin D deficiency and hypoparathyreoidal), should be treated before the beginning of therapy with ADROVANCE."</seg>
<seg id="1302">"aging food and drinks (including mineral water), calcium supplements, antacid and some orale medicines may impair the resorption of alendronat when they are at the same time."</seg>
<seg id="1303">"therefore, patients must wait after taking the Alendronat at least 30 minutes before they take other medicines (see sections 4.2 and 5.2)."</seg>
<seg id="1304">"although specific Interaction studies were not carried out, Alendronat was taken in clinical trials together with a variety of usually prescribed medicines, without having clinically relevant interactions."</seg>
<seg id="1305">ADROVANCE is intended only for use in postmenopausal women and is therefore neither applicable during pregnancy nor by missive women.</seg>
<seg id="1306">Animal studies with alendronat leave no indication of direct damaging effects in terms of pregnancy, the embryonic / fetal or postnatal development. "</seg>
<seg id="1307">Osteonekrose of the pinewood was reported in patients under Bisphosphates; most of the reports come from cancer patients but also has been reported in osteoporosis.</seg>
<seg id="1308">"however, Abum-Calcium up to &lt; 8.0 mg / dl (2,0 mmol / l) and the Serum- phosphate up to ≤ 2,0 mg / dl (l mmol / l) in both treatment groups with similar frequency."</seg>
<seg id="1309">"Alendronym as a result of an oral overdose, hypocalcemia, hypophosphatemia and side effects in the upper Gastrointestinal tract, like Magenversal, Sodburn, Ösophagitis, Gastritis or Ulzera occur."</seg>
<seg id="1310">Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV light over the transformation of 7-Dehydrocholesterol to vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-Dihydroxyreis D3 is the increase of the intestinal resorption of calcium and phosphate, as well as the regulation of Serum calcium calcium, the renal equations of calcium and bone-resorption."</seg>
<seg id="1312">"in severe cases, a lack of secondary Hyperparathyreoiesis, hypophosphatemia, weakness of the proximal muscle and Osteomalazie, and thus lead to an increased risk for storms and knock-outs at osteoporosis in more osteoporosis."</seg>
<seg id="1313">"Bone mineral Density) on vertebral column or hip, the 2.5 standoffspring is located under the midvalue for a normal, young population or regardless of the bone density as this pathological fracture."</seg>
<seg id="1314">Patients received ADROVANCE (70 mg / 2.800 i.e.) (n = 350) or FOSAMAX (Alendronat) 70 mg once weekly (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15-week treatment the middle servumber has been significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800 g) (56 ng / ml]) than in the group under alendronat alone (46 nmol / l [18,2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 g) sensed significantly after 15 weeks the share of patients with vitamin D insufficiency (serum of 25-hydroxyreis D &lt; 37,5 nmol / l]) by 62.5% compared to Alendronat alone (12% vs.</seg>
<seg id="1317">Studies with Alendronat The therapeutic paramity of alendronat once weekly 70 mg (n = 519) and Alendronat 10 mg daily (n = 370) was demonstrated in a A-year multi-multicolenter study on postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronym on bone mass and fractional women were examined in two phase III studies of identical design (n = 944) as well as in the fracture study (FIT: N = 6.459).</seg>
<seg id="1319">In phase III studies the middle ascents of the BMD with Alendronyat 10 mg / day in relation to placebo after 3 years 8.5% on the spine, 5.9% of the Femurhals and 7,8% at the Trochanter. "</seg>
<seg id="1320">"compared to the placebo group, compared to the placebo group a reduction around 48% (Alendronat 3,2% compared to placebo 6.2%) with the share of patients who suffered one or several whirlpools."</seg>
<seg id="1321">"in the two-year extension of these studies, the ascents of the BMD of vertebral column and comfort continues to be maintained; also the BMD of the Femurhalses and the entire body was sustained."</seg>
<seg id="1322">Fit consisted of two plazebokontrolded studies where alendronym was taken daily (5 mg daily over 2 years and subsequently 10 mg daily to be taken over 1 or 2 years):</seg>
<seg id="1323">In this study the daily gift of alendronat the appearance of at least a new spine decreased by 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1324">Resorption based on an intravenous reference dose was the medium orale bioveravailability of alendronyat women 59% for doses between 5 and 70 mg after overnights fasting and two hours before recording a standardised breakfast.</seg>
<seg id="1325">"the bioavailability took place in accordance with the earnings per cent of the transaction, if alendronym was taken one or half an hour before a standardised breakfast."</seg>
<seg id="1326">"in osteoporosis, Alendronym was effective if it was taken at least 30 minutes before the first meal or drinking of the day."</seg>
<seg id="1327">"in healthy trials, the Gabe of orical Prednisone (20 mg three times a day on five days) to no clinically significant change in the bioavailability of alendronat (increase in the average of 20% to 44%)."</seg>
<seg id="1328">"9 distribution studies to rats have found that Alendronym will spread itself after intravensible Gabe of 1 mg / kg temporarily into soft parts, but then swiftly rapidly into the bones, or be retired with the urine."</seg>
<seg id="1329">Retirement After intravenous gift of a single dose of 14C-Alendronat were found approximately 50% of radioactive substance within 72 hours with the urine and little or no radioactivity was found in the wood.</seg>
<seg id="1330">After intravenous gift of a single dose of 10 mg the renal Clearance of Alendronat 71 ml / min and the systemic clearance is not 200 ml / min.</seg>
<seg id="1331">"alendronym will not be avoided by rats not about the suckre or basic transport system of the kidneys, and therefore it is not assumed that people influence the retirement of other medicines by these transportation systems."</seg>
<seg id="1332">Resorption For healthy adult men (women and men) was after the gift of ADROVANCE after night-concentration-time curve (AUC0-120 h) for vitamin D3 296,4 ng • h / ml (without taking endogenous vitamin D3 mirror). "</seg>
<seg id="1333">The medium maximum concentration in serum (Cmax) of Vitamin D3 was 5.5 ng / ml and the medium to achieve maximum serrate concentration (Tmax) 12 hours.</seg>
<seg id="1334">"biotransformations vitamin D3 is rapidly adjusted in the liver rapidly to 25-hydroxyreis D3 hydroxyites D3, the bioactive form, metabolized."</seg>
<seg id="1335">"in case of radioactive distinctive vitamin D3 in healthy food items in the urine was the average balance of radioactivity in the urine after 48 hours 2,4%, in the case after 4 days 4,9%."</seg>
<seg id="1336">"characteristika of patients preclinical studies have shown that the proportion of alendronat, which is not distracted in the bones, quickly via the urine."</seg>
<seg id="1337">"although there is no clinical data on this, yet to reckon that the renal elimination of Alendronat as in the animal also try to be reduced in patients with reduced kidney function."</seg>
<seg id="1338">Therefore in patients with reduced Nierenfunction a somewhat increased culation of alendronyate in the bones (see Section 4.2).</seg>
<seg id="1339">"alendronat non-clinical data on the basis of conventional studies on security spharmacology, for chronic toxicity, to the genotoxicity and for cancerous potential leave no particular danger to man."</seg>
<seg id="1340">Studies on rats showed that the gift from alendronym was generated with the appearance of Dystokie with the presence of Dystokie in the maternity which was due to a hypocalcemia.</seg>
<seg id="1341">Micro-crystalline cellulose medium-quettes Croscarsulphatine Croscarmuth-sodium polycarbonate-condenum (ph.Eur.) (E 321) strength, modified (corn) aluminium natriumsilicat (E 554) "</seg>
<seg id="1342">"Etui with sealing aluminium / aluminium blister packs in cartons to 2 (1 Etui with 2 tablets), 4 (3 cases with 4 tablets), 12 (3 cases with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablet EU / 1 / 06 / 364 / 003 - 6 tablets EU / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"rectangular, white to broken white tablets, marked with an outline of a bone on one side and" 270 "on the other side."</seg>
<seg id="1345">13 • The patients should not lie after intake of ADROVANCE at least 30 minutes. • ADROVANCE should not be taken before bedtime or before the first advent of the day.</seg>
<seg id="1346">"the risk of severe turophageal side effects seems to be increased in patients that may not take the medicine correctly and / or it comes after the appearance of symptoms, which may take on a ösophageal irritation."</seg>
<seg id="1347">"while in large covered clinical studies with Alendronat no elevated risk was established, rare (after market launch) Mag- and Duodenalulzera, including some severe and with complications, reported (see Section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) vitamin D3 is produced in the skin by UV light over the conversion from 7-Dehydrocholesterol to vitamin D3.</seg>
<seg id="1349">Patients received ADROVANCE (70 mg / 2.800 i.e.) (n = 350) or FOSAMAX (Alendronat) 70 mg once weekly (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly was shown in a 24-week extension student with 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24-week treatment the middle servumance of 25-Hydroxyreis D significantly higher in the 5.600-I.E.-vitamin D group (69 nmol / l]) than in the 2.800-I.E.-vitamin D group (64 nmol / l [25.5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups during the share of patients with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">3.1% on the entire hips in the group with 70 mg once weekly or in charge of 10 mg daily.</seg>
<seg id="1354">In this study the daily gift of alendronat the appearance of at least a new spine decreased by 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1355">"the bioavailability took place in accordance with the earnings per cent and earnings per hour, if alendronat one or half an hour before a standardised breakfast"</seg>
<seg id="1356">"distribution studies at rats have found that Alendronym will be spread only after intravensible Gabe of 1 mg / kg temporarily into soft parts, but then swiftly rapidly into the bones, or be retired with the urine."</seg>
<seg id="1357">Resorption For healthy adult men (women and men) was according to the gift of ADROVANCE (70 mg / 5.600) after crossing a meal the middle area under the Serum concentration period (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without taking endogenous vitamin D3 mirror).</seg>
<seg id="1358">The medium maximum concentration in serum (Cmax) of Vitamin D3 was 12.2 ng / ml and the medium to achieve maximum serrate (Tmax) 10.8 hours.</seg>
<seg id="1359">Smaller quantities are spread in obesity and muscle tissue and are stored there as vitamin D3 to be released later in the cycle.</seg>
<seg id="1360">"21 vitamin D3 is rapidly adjusted in the liver rapidly to 25-hydroxyreis D3 hydroxyine and then in the kidneys to 1,25-Dihydroxyreis D3, the bioactive form, metabolized."</seg>
<seg id="1361">There were no evidence on a saturation of the recording of bone for long-term dosage of cumulative cans of up to 35 mg / kg at animals.</seg>
<seg id="1362">"Etui with sealing aluminium / aluminium blister packs in cartons to 2 (1 Etui with 2 tablets), 4 (1 Etui with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1363">"Pharmakovigilance System The owner of the permit has been described for sure that an Pharmacovigilance system is described in version 2 module 1.8.1 of the authorization systems, and as long as it is available as marketed drugs used in the market."</seg>
<seg id="1364">Risk management plan The owner of the approval for authorisation is obliged to conduct studies and additional pharmaceutical vigilance plan which are described in the risk-management plan (RMP) and its corresponding updates in accordance with Version 1 module 1.8.2 of the authorization systems.</seg>
<seg id="1365">A updated RMP is set to present in accordance with the CHMP guideline to risk management systems for human cells with the next Periodic Saftey Update Report (PSUR).</seg>
<seg id="1366">"in addition, an update of the RMP - if new information is necessary, which have an effect on safety data, pharmaceutical vigilanzplan or activities on risk assessment (Pharmacovigilance or risk assessment) − on request of EMEA"</seg>
<seg id="1367">Take a ADROVANCE tablet after getting up and before the first meal and drink and before taking any other medications by swallow the tablet with a full glass of water (not with mineral water) (not distrust and not lutschen).</seg>
<seg id="1368">Perhaps you would like to read this later. • If you have any further questions please contact your doctor or a pharmacist. • This medicine was personally prescribed for you.</seg>
<seg id="1369">"in the menopause the ovaries produce no female hormones, oestrogen, more, which help the skeleton of women healthy."</seg>
<seg id="1370">"fry usually arise at the hips, the spine or the wrist and can not only pain, but also causing considerable problems like gearing attitude (" Witwenbuckel ") and a loss of motility."</seg>
<seg id="1371">"ADROVANCE does not only prevent loss of bone mass, but also contributes to the level of bone and hips to diminish the risk of whirlpools."</seg>
<seg id="1372">"constriction of the esophagus or swallowing (3) if it is not possible to sit or stand up at least 30 minutes, (4) if your doctor has established that your calcium content is lower in the blood."</seg>
<seg id="1373">"40 • If you have trouble when tocks or with digestion, • If your calcium can be lower in the blood, • if you have cancer, • if you have an chemotherapy or radiation treatment, • if you don't use steroids (cortisonals), • if you don't have routine prevention."</seg>
<seg id="1374">"these complaints can occur in particular, if patients do not take the ADROVANCE tablet with a full glass of water and / or lie ahead of 30 minutes after taking."</seg>
<seg id="1375">"at intake of ADROVANCE with other medicines of calcium, Antazida and some other medicines, can take the effectiveness of ADROVANCE at same time intake."</seg>
<seg id="1376">"certain medicines or food supplements allow the inclusion of vitamin D contained in ADROVANCE, including artificial fetterwear, minerals, orlistat and the cholesterinsenkenden medicines cholestyramine and colestipol."</seg>
<seg id="1377">"please inform your doctor or a pharmacist if you have to take any other medicines / apply, or have been adopted recently, even if it is not prescription pharmaceuticals."</seg>
<seg id="1378">"please take this medicine only after consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="1379">"please be sure to follow the indications 2), 3), 4) and 5) to facilitate the transport of ADROVANCE tablet into the stomach and to diminish possible irritation of the esophagus (Ösophagus; the tube that connects your mouth with the stomach)."</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first impression and before taking any other medicine only with a full glass (at least 200 ml) water (not with mineral water). • Not with mineral water or tea. • Not with juice or milk.</seg>
<seg id="1381">(3) Legen you not - stay erect (in the sitting or walking) - at least 30 minutes long after taking the tablet.</seg>
<seg id="1382">"(5) If with you difficulties or pain in the slain, pain behind the chest, reigning or dehydration of the sodging, put you ADROVANCE and look for your doctor."</seg>
<seg id="1383">"(6) Warten you after the swallowing of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (magnitrobined medicines), calcium or Vitaminated parate to that day."</seg>
<seg id="1384">"should you have taken too many tablets at once, drink a full glass of milk and contact your doctor immediately."</seg>
<seg id="1385">"if you have dreamed of taking a tablet, take only one tablet the next morning after you noticed your reconciliation."</seg>
<seg id="1386">"frequently: • saures uplift; sores of the esophagus; slaughter of the esophagus, chatting, muscle, and / or infectious diseases, • bone pain; diarrhea; diarrhea; diarrhea; diarrhea, headaches, • headaches."</seg>
<seg id="1387">"occasionally: • nausea; vomiting, • irritation and inflammation of the esophagus (Ösophagus, the tube, which connects your mouth with your stomach) or the stomach mucosa, • rash; Juckreiz; rounded skin."</seg>
<seg id="1388">"after launching the following side effects (frequency is not known): • (turning) shrubs, • fatigue, • severe problems (osteoporosis) in connection with hesitant wound and infections, often after the dragging of teeth, • swelling on hands or legs."</seg>
<seg id="1389">43 Daat is it helpful when you noting what complaints you had when they began and how long they stopped.</seg>
<seg id="1390">"other components are microcrystalline cellulose (E 460), Lactose, crocodiles, crocodiles, polished-disodium, buttonhydroxyumoluene (Ph.Eur.) (E 321), strength, modified (corn), and aluminium natriumsilicat (E 554)."</seg>
<seg id="1391">The tablets are available in Etuis with sealing aluminium / aluminium blister packs) • 4 tablets (1 Etui with 4 tablets in an aluminium blister packs) • 12 tablets (3 etuis with 4 tablets in aluminium blister packs) • 40 tablets (10 Etuis with 4 tablets in aluminium blister packs).</seg>
<seg id="1392">"in the menopause the ovaries produce no female hormones, oestrogen, more, which help the skeleton of women healthy."</seg>
<seg id="1393">"48 • If you have allergies, • If you have trouble when tocks or with digestion, • If you have trouble when you have cancer, • if you have cancer or radiation treatment, • if you don't have steroids (cortisonals), • if you don't have routine prevention."</seg>
<seg id="1394">"at intake of ADROVANCE with other medicines of calcium, Antazida and some other medicines, can take the effectiveness of ADROVANCE at same time intake."</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first impression and before taking any other medicine only with a full glass (at least 200 ml) water (not with mineral water). • Not with mineral water or tea. • Not with juice or milk.</seg>
<seg id="1396">3) Load yourself - stay entirely erect (in the sitting or walking) - at least 30 minutes long after taking the tablet.</seg>
<seg id="1397">"5) If with you difficulties or pain in the slain, pain behind the chest, reigning or dehydration of the sodging, put you ADROVANCE and look for your doctor."</seg>
<seg id="1398">"6) Waiting after the swallowing of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (magnitrobined medicines), calcium or Vitaminated parate to that day."</seg>
<seg id="1399">"• (turning) shrubs, • fatigue, • fatigue, • severe problems (Osteonekrose) in connection with hesitant wound and infections, often after the dragging of teeth, • swelling on hands or legs."</seg>
<seg id="1400">"tablets are available as rectangular, white to broken white tablets, marked with an outline of a bone on one side and" 270 "on the other side."</seg>
<seg id="1401">"Advance, adult patients will be administered to transports a kidney or liver to prevent a repulsion of the transplants by the immune system."</seg>
<seg id="1402">"since tactic and prograf / progre have already been used in the EU, the company has submitted the results from previously carried out studies with Prograf / Prograft as well as data from published literature."</seg>
<seg id="1403">"furthermore, the results of a clinical study was submitted to 668 patients with kidney transplantation, whereby the application of Advance was compared with Prograf / Prograft or Ciclosporin."</seg>
<seg id="1404">"the main indicator of the effectiveness was the number of patients in which the transplant after a treatment of a year was stopped by one year (by example, how often a renewed organic transplant or a revival of the dialysis was required)."</seg>
<seg id="1405">"in addition, temporary further studies on 119 patients were carried out with liver transplant and 129 patients with liver transplant and studied, as an advocacy compared to prograf / prograting from the body."</seg>
<seg id="1406">"Treble (lemon), headaches, nausea / vomiting, diarrhoea, higher blood sugar levels, higher blood sugar levels (hypertension), hypertension (hypertension) as well as sleeplessness (insomnever)."</seg>
<seg id="1407">"in case of patients with possible oversensitivity (allergy) against Tacrolim, macro-antibiotics (such as erythromycin) or one of the other components may not be applied."</seg>
<seg id="1408">Patients and doctors have to be careful when others (especially some herbal) drugs will be taken simultaneously with an Advance as the Advance dosage or the dose of at the same time should be adjusted accordingly.</seg>
<seg id="1409">"tungsten cemented, retarded yellow-orange yellow, printed in red ink on the lightening capsule with" 0.5 mg "and on the orangen capsule with" "647"; they contain white powder. "</seg>
<seg id="1410">Only doctors that are familiar with immunosuppressive therapy and the treatment of transplant patients should arrange this medicine or make changes in immunosuppressive therapy.</seg>
<seg id="1411">"due to clinically relevant differences of the systemic exposure of Tacrolim, this can lead to transplants or to an increased incidence of side effects, including under- or overimmunosuppression."</seg>
<seg id="1412">Patients should always keep the same Tactic formulation and the corresponding daily dosage; surveys of the formulation or the regime should only be made under the narrow contractor of experienced physician (see sections 4.4 and 4.8).</seg>
<seg id="1413">"in consequence of a changeover to an alternative formulation, a therapeutic monitoring and corresponding dosage adaptations must be performed to ensure that the systemic exposure of Tacrolimus remains."</seg>
<seg id="1414">The dosage of Advance should be primarily based on the clinical evaluation of repulsion and tolerability in the individual case and on blood levels. (see below) recommendations</seg>
<seg id="1415">"after conversion from Prograf on Advance, the Tactic level should be controlled before conversion and over two weeks after conversion."</seg>
<seg id="1416">"day 4 was the systemic exposure, measured as Talmirror, with both formulations with both kidney and living-transplanted patients comparable."</seg>
<seg id="1417">Careful and repeated controls of Tacrolimus levels are recommended during the first two weeks after transplantation under Advance. to ensure proper substance exposure to immediate post-transplants.</seg>
<seg id="1418">"since tactic is a substance with low Clearance, a adaptation of the Advance-Dosishalas can take several days until the Steady State is reached."</seg>
<seg id="1419">If the condition of patients in the first postoperative phase no orale intake of drugs may be intravenous (Prograf 5 mg / ml of concentrates for the production of an infusion solution).</seg>
<seg id="1420">The duration of application to suppression of transplants must be sustained its immunosupposes; in consequence, therefore a maximum duration of oral therapy can not be specified. "</seg>
<seg id="1421">Dosage recommendations - Nierentrants of prophylaxis of transplantation The orale Advance therapy should begin with 0,20 - Extra mg / kg / day as once daily gift in the morning. "</seg>
<seg id="1422">Further dosage adaptations may be required later as the Pharmacoinetics of Tacrolimus can change after the transplantation of the patient after the transplantation.</seg>
<seg id="1423">Dosage recommendations - liver transplantation of the transplantation of transplantation The orale Advance therapy should begin with 0.10 - 0.20 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1424">"dosage intake - changeover from Prograf to Advagraf's must be converted to a transplants of prograf capsules on a once daily intake of Advance, so this changeover in relation 1: 1 (mg: mg) related to the entire daily dose."</seg>
<seg id="1425">Nier- and liver transplant After an switching from other immunosuppresistiva on Advance once daily needs to start treatment with each in kidney and liver transplantation for the prophylaxis of transplantation.</seg>
<seg id="1426">Heart transplants In adult patients who will be converted to an Advance is an orale initialdosis of 0.15 mg / kg / day every day in the morning.</seg>
<seg id="1427">"other transplants - probably there is no clinical experience with an advocacy of lung cancer, pancreatic and darmtransplants patients in a oral initialdosis of 0,2 mg / kg / day and at intestinal unemployed dose of 0,3 mg / kg / day to use."</seg>
<seg id="1428">Dosage adaptations in special patients groups with reduced liver function to maintain blood circulation in the target range can be required in patients with severe liver dysfunctions a floating of dose.</seg>
<seg id="1429">Patients with reduced kidney function As the kidney function has no effect on the Pharmacoinetics of Tacrolimus can be assumed that a dosage adjustment is not required.</seg>
<seg id="1430">"due to the neo-liberal Potentials of Tacrolimus, however, a careful monitoring of the kidney function (including a regular determination of serpineequinlevels, a calculation of the creatinincline and an monitoring of the urinary volume)."</seg>
<seg id="1431">Switching of Ciclosporin at Advagraf in the conversion of a Ciclosporin- based on a tactic-based therapy is caution (see sections 4.4 and 4.5).</seg>
<seg id="1432">Recommendations on the Talvermirror in full blage The dose should be based primarily on the clinical evaluation of absorbing and compatibility with a state-taking of full-ut Tactic tactic controls.</seg>
<seg id="1433">"it is recommended to perform frequent controls of the Tactic Talrum level during the first two weeks after transplantation, followed by periodical controls during the conservation therapy."</seg>
<seg id="1434">"blood level of Tacrolim should also increase the conversion of prograf on Advance, dosisance, changes of immunosuppressive therapy or with simultaneous application of substances which could be controlled Tacrolimus concentric bleeding (see Section 4.5)."</seg>
<seg id="1435">"since advocates a medicine with a low clearance, adjustments of the dose may need several days until the steady state has entered."</seg>
<seg id="1436">"the statements made in clinical studies make it possible that a successful treatment is possible in most cases, if the talents can not exceed the blood 20 ng / ml."</seg>
<seg id="1437">In clinical practice the talents of Tacrolimus in the first time after liver transplant usually in the range of 5 - 20 ng / ml and with impregnated patients at 10 - 20 ng / ml.</seg>
<seg id="1438">During the following initial treatment of liver and heart transplants were generally used blood-concentration in the range from 5 to 15 ng / ml.</seg>
<seg id="1439">"this has led to serious unwanted events, including transplantation or other side effects which can occur in a result of tacrolimus under- or overexposure."</seg>
<seg id="1440">Patients should always keep the same Tactic formulation and the corresponding daily dosage; surveys of the formulation or the regime should only be made under the narrow contractor of experienced physician (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 For the treatment of adult patients with transplants, who proved to be therapist from other immunosuppresistiansas therapy, are not yet no clinical data for the retarded formulation Advance."</seg>
<seg id="1442">For the prophylaxis of transplants in adult heart transplants and transplants in the child age there are no clinical data for the retarded formulation Advance.</seg>
<seg id="1443">"because of possible interactions that can lead to a lowering of the Tacrolimb level in the blood and a weakening of the clinical effect of Tactic (hypericum perforatum), or other plant remedies during treatment with Advance. (see Section 4.5)."</seg>
<seg id="1444">"in patients with Diarrhö is a particularly careful monitoring of the Tacrolimus- concentrations in the blood, since the tactics can be subject to considerable fluctuations under such circumstances."</seg>
<seg id="1445">"in rare cases, under Prograf was referred to as Kardiomyopathy chamber or Septumhypertropy, which can therefore also occur at an advocacy."</seg>
<seg id="1446">"further factors that increase the risk of such clinical disorders are an already existing heart, a treatment with corticosteroids, hypertension, kidney or liver dysfunctions, infections, liquid-pollution and oils."</seg>
<seg id="1447">"as with other immunosuppressiva, the effect of sunlight or UV light should be restricted due to the possible risk of malignation caused by suitable clothing or using a solar protection with a high protection factor."</seg>
<seg id="1448">"if patients taking the Tacrolimus, symptoms for pRES such as headaches, changed consciousness-condition, crushing and visual dysfunctions, should be a radiological examination (e.g."</seg>
<seg id="1449">"since advocacy tungsten cemented, retarded, tactose, is provided in patients with the rare hereditary Galactose-intolerance, Lactase-shortage or glucose-painting."</seg>
<seg id="1450">The simultaneous application of medicines or herbal remedies that are known as inhibitors or induction of CYP3A4 can increase the metabolism of Tacrolimus and thus reduce blood levels of tactics.</seg>
<seg id="1451">It therefore recommends that tacrolimus- blood levels with simultaneous gripping of substances that can change the CYP3A metabolism and which to adjust the Tactic concentrations according to maintaining evenly concentrations (see sections 4.2 and 4.4).</seg>
<seg id="1452">"a strong interaction with Antimycotics such as Ketoconazol, Fluconazol, Itraconazol and Voriconazol, as well as with the Macrolid Erythromycin and HIV-Protocular numbers (z)."</seg>
<seg id="1453">"Pharmakokinetic studies, that the increase in the blood levels mainly from the increased bioavailability of Tacrolim, caused by the inhibition of gastrointestinal convergence."</seg>
<seg id="1454">High-dossized prednisolon or methylprednisolon how it is used in acute waste actions can increase the concentration of tactic drugs in the blood or lower.</seg>
<seg id="1455">Effect of Tacrolimus on the metabolism of other medicines Tacrolimus is known as CYP3A4 Hemmer; hence the simultaneous application of Tacrolimus can be metabolized by CYP3A4 metabolized by CYP3A4 metabolism.</seg>
<seg id="1456">"since tacticlim the clearance of steroid-contrabtiva can produce and thus increase the hormone exposure, is particularly careful when making decisions about receptive measures."</seg>
<seg id="1457">The results of animal trying to have shown that tacticlimus potentially potentially potentially reduce the clearance of Pentobarbital and phenazon and extend their half-value.</seg>
<seg id="1458">The results of a low number of investigations on transplant patients provide no indication that under tacticlimus compared to other immunosuppressiva a raised risk for unwanted events relating to the course and the outcome of pregnancy.</seg>
<seg id="1459">In the utero Exposition the monitoring of the newborn on possible detrimental effects of Tacrolimus (in particular with regard to its effect on the kidneys).</seg>
<seg id="1460">"there is the risk of an early birth (&lt; week 37) and a hyperclaliaemia of the newborns (incidence 8 of 111 newborns, i.e.,"</seg>
<seg id="1461">The side-effective profile of immunosuppressants often can not determine because of the atrocities of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"following, the side effects will be performed in descending order: very often (≥ 1 / 10, ≤ 1 / 10), occasionally (≥ 1 / 1,000, ≤ 1 / 1,000), very rare (≤ 1 / 1,000, ≤ 1 / 1.000), very rare (frequency on the basis of available data non-estimated)."</seg>
<seg id="1463">"ischaemic disorders of the cardiac vessels, sachykarameliinopathy, exogenic arrhythms, Palaeentricular arrhythms, Palestratio, abnormalities in the ECG, abnorme heart and pulse frequency."</seg>
<seg id="1464">"diarrhea, nausea and inforation, blood-intestinal fluid and perforation, asomatitis and ulceration, Aszites, fatigue, pains and symptoms, casual chair, symbols and symptoms in the stomach intestinal - area"</seg>
<seg id="1465">"infections and parasitic diseases As well-known for other highly effective immunosuppressiva is treated with patients who are treated with tacticism, vulnerability for infections (viral, bacterial, giootic, ans zoale) frequently."</seg>
<seg id="1466">Cases of BK-Virus-Associated Nephropathy and JC-virus-Association (PML) were reported in patients amongst immunosuppresists including therapy with an advocacy.</seg>
<seg id="1467">It was reported on benign or malignant Neoplasmen including EBV- Associated lymphoid diseases and skin-tumors in conjunction with the treatment with tacrolimus.</seg>
<seg id="1468">"due to its high molecular weighted, its low water-soluble and the high bond of erythrocytes and Plasmaprotone can be accepted that tacticlim is not dialyzed."</seg>
<seg id="1469">"associated mechanism and pharmacodynamic effects on molecular level are likely to be conveyed by its ties to a cytosolish protein (FKBP12), which is responsible for enriching the connection in the cellular cell."</seg>
<seg id="1470">This leads to a calciumdependent inhibition of Signaltransduction because of the T-cell and thereby prevents the transcription of a certain set of lymphokin genes.</seg>
<seg id="1471">Tacticlimus suppressed the activation of the T-cells and the formation of the T-Helferous Proliferation of the B-cells (like interrokin-2, interrokin-3 and g -Interferon) as well as the expression of the Interlightkin-2 receptors. "</seg>
<seg id="1472">12 Confirmed lamination was within the first 24 weeks in the Advance Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%. "</seg>
<seg id="1473">"patients-survival rates after 12 months were at 89,2% for Advance and 90.8% for prograf; in an Advance-arm 24 (14 women, 11 men) and in the Prograf-arm 24 (5 females, 19 men) deaths."</seg>
<seg id="1474">"Nierentransplantation, the effectiveness and safety of Advance and Prograf was compared in combination with Mycophenolatmofetil (MMF) and cortiosteroids, in 667 de Novo Nierentranism."</seg>
<seg id="1475">"patients-survival rates after 12 months are at 96.5% for Advance and 97,5% for prograf; in an Advance-arm came 10 (3 women, 7 men) and in the Prograf-arm 8 (3 women, 5 men) deaths."</seg>
<seg id="1476">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibodies, MMF and Cortikosteroids, at 638 de Novo Nierentranism."</seg>
<seg id="1477">The incidence of therapy for 12 months (defined as death; Transplantatloss) was 14.0% in the Advance Group (N = 214), 15.1% in the Prograf group (N = 212) and 17.0% in the Ciclosporin group (N = 212). "</seg>
<seg id="1478">The treatment difference was -3.0% (Advagraf- Ciclosporin) (95.2% Konfidenzinterval [-8.9%, 5.2%]) for Prograf vs Ciclosporin. "</seg>
<seg id="1479">"in an Advocraf's arm occurred 3 (men), in Prograf-arm 10 (3 women, 7 men) and in the Ciclosporin-arm 6 (3 women, 3 men) deaths."</seg>
<seg id="1480">Published results of primary immunosuppression with Tacrolimus in the form of twice a daily basis of prograf capsules after other primary organ transplants according to Pancreas-, pulmonary and intestinal transplants. "</seg>
<seg id="1481">175 lunchtransplanted patients with 475 patients who had undergone a pancreatic transplant and in 630 cases after a intestinal transplant as a primate immunosuppressive.</seg>
<seg id="1482">"in total, the safety profile of orderly prograf in these published studies reveal the observations in the great studies in which Prograf was applied in liver, kidney and heart transplants to primary immunosupposes."</seg>
<seg id="1483">"lung transplant In an intermediate analysis over a recently enguided, multicentric study with orical prograf was reported about 110 patients being reported in part of a 1: 1-Randomisation either tactic or Ciclosporin."</seg>
<seg id="1484">"also a chronic Transplaytis, the bronchiolitis obliterans- syndrome, was less frequent to observe in the first year after the transplantation less common (2.86% versus 8,57%)."</seg>
<seg id="1485">"the survival rate after a year was 80.8% in the Tacrolimus- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)."</seg>
<seg id="1486">In the patients treated with Tactic patients in 21.7% of the cases of the emergence of a bronchiolitis obliterans compared to 38,0% under Ciclosporin (p = 0,025). "</seg>
<seg id="1487">"the number of cases where Ciclosporin Tactic had to be turned (n = 13), was significant greater (p = 0,02) as the number of patients who were mutinees on Ciclosporin (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases where there came to no acute Transplayment was after 6 months (57,7% versus 45,8%) and after 1 year (50% versus 33,3%) in the lunchtransplanted patient of the Tacrolimus Group bigger (Treede et al., J Heart Lung Transplant 2001; 20: 511)."</seg>
<seg id="1489">In one study the frequency of the emergence of a bronchiolitis obliterans- Syndroms were significantly lower in patients with tactic patients.</seg>
<seg id="1490">"Pancreatic transplantation A multicentralized study with orical prograf was performed at 205 patients, which at the same time out a pancreatic and kidney transplantation, who received after a randomized trial Tacrolimus (n = 103) or Ciclosporin (n = 102)."</seg>
<seg id="1491">The orale initialdosis (per protocol) of Tacrolimus was 0.2 mg / kg / day and was afterwards to achieve the increased level of level 8 to 15 ng / ml of 5.</seg>
<seg id="1492">Intestinal transplant The published clinical results of a monocentric study with orical provisional results showed at 155 patients (65 only Darm, 75 Leber and the intestine and 25 multivated transition rate) under Tacrolim and Prednison a updated transition rate of 75% after 1 year, 5% after 5 years and 42% after 10 years. "</seg>
<seg id="1493">"methods for the early detection of Epstein-Barr (EBV) - and CMV-infections, bone market, additional gift of the Interlightkin-2-antagonists Daclizumab, that lead to the talents between 10 and 15 ng / ml (Abu-Elmagd et al., Ann Surg 2001; 234: 404)."</seg>
<seg id="1494">"factors such as a low hermatory value and low protein concentrations, which lead to an increase in the unfound group of tactic disease, or caused by treatment with corticosteroids, or to be responsible for the transplantation observed after the transplantation observed."</seg>
<seg id="1495">"this lets close that tactic is almost completely metabolized before the expel, whereby the excretion mainly takes place over the Galle."</seg>
<seg id="1496">"in stable patients suffering from Prograf (once daily) on Advance (once daily) in relation 1: 1 (mg: mg) related to the total average daily dose, the systemic exposure of Tacrolim (AUC0-24) under Advance was approximate 10% lower than under prograf."</seg>
<seg id="1497">"it is recommended to perform frequent controls of the Tactic Talrum level during the first two weeks after transplantation, followed by periodical controls during the conservation therapy."</seg>
<seg id="1498">"21 For the treatment of adult patients with transplants, who proved to be therapist from other immunosuppresistiansas therapy, are not yet no clinical data for the retarded formulation Advance."</seg>
<seg id="1499">"further factors that increase the risk of such clinical disorders are an already existing heart, a treatment with corticosteroids, hypertension, kidney or liver dysfunctions, infections, liquid-pollution and oils."</seg>
<seg id="1500">28 confirmed accomplices was within the first 24 weeks in the Advance Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%. "</seg>
<seg id="1501">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibodies, MMF and Cortikosteroids, at 638 de Novo Nierentranism."</seg>
<seg id="1502">"tungsten cemeteries, retarded grease-orange yellow, printed in red ink on the gray capsule part with" 5 mg "and the orange capslower with" "687", "they contain white powder."</seg>
<seg id="1503">"it is recommended to perform frequent controls of the Tactic Talrum level during the first two weeks after transplantation, followed by periodical controls during the conservation therapy."</seg>
<seg id="1504">37 For the treatment of adult patients with transplants that proved to be therapist on other immunosuppressants as a therapy did not yet have a clinical data for the retarded formulation Advance.</seg>
<seg id="1505">"further factors that increase the risk of such clinical disorders are an already existing heart, a treatment with corticosteroids, hypertension, kidney or liver dysfunctions, infections, liquid-pollution and oils."</seg>
<seg id="1506">44 Confirmed lamination was within the first 24 weeks in the Advance Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%. "</seg>
<seg id="1507">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibodies, MMF and Cortikosteroids, at 638 de Novo Nierentranism."</seg>
<seg id="1508">"in total, 34 patients were converted by Ciclosporin to Tacrolimus, while only 6 Tactic patients required a different therapy (Bechstein et al., transplantation 2004; 77: 1221)."</seg>
<seg id="1509">Intestinal transplant The published clinical results of a monocentric study with orical provisional results showed at 155 patients (65 only Darm, 75 Leber and the intestine and 25 multivated transition rate) under Tacrolim and Prednison a updated transition rate of 75% after 1 year, 5% after 5 years and 42% after 10 years. "</seg>
<seg id="1510">"this lets close that tactic is almost completely metabolized before the expel, whereby the excretion mainly takes place over the Galle."</seg>
<seg id="1511">"management plan The owner of the authorisation of the permit is obliged to perform the studies and additional pharmaceutical vigilance Plan (RMP), as well as all other updates of the application contract, as well as any other updates to the application that are approved by CHMP."</seg>
<seg id="1512">"according to the CHMP guideline to the risk management systems for drugs to use on people, the updated project has to be submitted at the same time with the next periodic security report (Periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">"perhaps you will also get Advance on the treatment of a repulsion of your liver, kidney or heart transplants or because the immunity of your body could not be controlled by a preceding treatment."</seg>
<seg id="1514">"taking Advance with other medicines, please inform your doctor or a pharmacist if you have taken other medicines or have recently taken away, even if it is not prescription drugs or remedies of herbal origin."</seg>
<seg id="1515">"Amilorid, Triamteren, or Spironolacton (so-called nonsteroidal antiphlogistika such as Ibuprofen), anti-agulants or drugs to take care of diabetes mellitus."</seg>
<seg id="1516">"pregnant and breastfeeding when pregnant is planned or already exists, ask before taking all drugs to your doctor or a pharmacist to advice."</seg>
<seg id="1517">Transportation and storage of machines you are not allowed to use the wheel of a vehicle or use tools or machines when you feel after taking Advance or sleepy or blurry.</seg>
<seg id="1518">"important information about certain other components of Advance request please make Advance directly after consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="1519">Make sure you always obtain the same Tactic drugs if you dissolve your prescription unless your specialist doctor has expressly agreed to a change in Tacrolimus Supplement.</seg>
<seg id="1520">"if you get a drug whose appearance changes from the habitual or the dosage instructions, please talk to your treatmenting doctor or pharmacist to get you to get the right medicine."</seg>
<seg id="1521">"so that your doctor can determine the proper dose and time to adjust from time to time, he must subsequently perform periodictions."</seg>
<seg id="1522">If you have taken a larger amount of Advance as you should have taken a larger amount of Advance when you are immediately looking for your doctor or the emergency department of the nearest hospital house.</seg>
<seg id="1523">"if you forget the intake of Advance, If you have forgotten the capsules take, please take this at the same day at the earliest possible time."</seg>
<seg id="1524">If you cancel the intake of Advance when termination of treatment with Advance is able to increase the risk of a repairing of your transplant.</seg>
<seg id="1525">"Advance 0.5 mg Hartkaples, retarded, their lightning bes" "with" 0.5 mg "and their oranges subpart with" "647" "each red of red and which are filled with white powder."</seg>
<seg id="1526">"Advance 1 mg cemic keys, retarded, their white upper part with" 1 mg "and their oranges subpart with" "677" "each red of red and which are filled with white powder."</seg>
<seg id="1527">"Advance 5 mg cemic ths, retarded, tungsten carbide rotary upper part with" "5 mg" "and their oranges subpart with" "687" "each red of red are filled with" "687" "and which are filled with white powder."</seg>
<seg id="1528">România Astellas Pharma Internaţ visional Detalii de contact pentru Românaua Bucureş ti-Ploieş by Clă dire 1, Parter, 013696-Bucureş ti: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská Republika Astellas Pharma s.r.o., organizač ná zlož ka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advocates will be used for the treatment and prevention of bloodations in patients with Hashophilia A (one by the lack of factor VIII related blood-disorder).</seg>
<seg id="1531">The dosage and frequency of application depends on whether an advocates for the treatment of bloodor or prevention of bloodations in surgical procedures is applied.</seg>
<seg id="1532">"patients with Hashophilia A suffer from a factor VIII, which causes blood problems like bleeding in joints, muscles or internal organs."</seg>
<seg id="1533">"Octocog alfa is not extracted from human plasma, but after a method that is called" recombinant DNA technology ":"</seg>
<seg id="1534">It is produced by a cell in which a gene (DNA) was brought to the formation of the human scent factor VIII.</seg>
<seg id="1535">"advocates is another in the European Union approved medicines called Recombinate, but similarly, but the drug does not contain proteins of human or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with severe to moderate hammophilia A, including a study with 53 children under six years, the application of the medication was examined by means of prevention of bloodor as well as for surgical procedures."</seg>
<seg id="1537">"in the main study, the effectiveness of Advates has been awarded in the prevention of bloodings in 86% of the 510 new blood sepsis with" "excellent" "or" "good." "</seg>
<seg id="1538">The most common side effects of Advate (observed during 1 to 10 of 100 patients) are Schwindel, headaches, Pyrexy (fever) and the formation of antibodies to factor VIII. "</seg>
<seg id="1539">"Advance may not be used in patients who may possibly be vulnerable (allergic) against the human scent factor VIII, mouse or hamstery or one of the other components."</seg>
<seg id="1540">March 2004 the European Commission adopted the Baxter AG accepts a permit for the sale of Advance in the entire European Union.</seg>
<seg id="1541">Dosage The dosage and duration of substitution therapy are directed after the severity of the factor VIII deficiency in accordance with the place and the extent of blood circulation and the clinical state of patient.</seg>
<seg id="1542">At the following hematrhagic events the factor VIII activity in the corresponding period does not apply to the given Plastimpiegel (in% of the standard or in i.e. / dl).</seg>
<seg id="1543">Injection every 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeat until the pains and the acute impairment are removed.</seg>
<seg id="1544">Injection every 8-24 hours (6-12 hours in patients under 6 years) repeat until the danger to the patient is prematurely.</seg>
<seg id="1545">"during treatment process, the control of the injurial dose and incidence of injections is an adequate determination of the factor VIII."</seg>
<seg id="1546">Individual patients can distinguish themselves in their reaction to factor VIII to reach various in vivo recovery and have different half times.</seg>
<seg id="1547">3 prophylaxis leprophylaxis of blood prophylaxis in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1548">"if the expected factor VIII is not reached or if the blood circulation is not controlled with a reasonable dose, a test must be carried out to prove a inhibitor."</seg>
<seg id="1549">"in patients with high inflation values, it is possible that the factor VIII therapy is not effective, so other therapeutic measures need to be weighed."</seg>
<seg id="1550">"the return speed should be directed after the conqueror of the patient, whereby a maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutral antibodies against factor VIII is a known complication in the treatment of patients with hammophilia A.</seg>
<seg id="1552">These inhibitors are always against the prokoagulatory activity of factor VIII into IgG immunoglobulins which are in Bethesda units (B.E.) per ml Plasma via modified Bethesda Assay quantified.</seg>
<seg id="1553">"the risk to develop inhibitors, correlation with the extent of exposure to the factor VIII, whereby the risk within the first 20 exposition is the largest and dependent on genetic and other factors."</seg>
<seg id="1554">"in case-treated patients (PTPs) with more than 100 exposition and anamnesty known inhibitordevelopment, after switching from a recombinant factor VIII product to another, the re-occur of (lowest) inhibitors."</seg>
<seg id="1555">"due to the rare transgressing of the hammophilia A on women lie over the use of factor VIII during pregnancy and lactation, no experiences."</seg>
<seg id="1556">"those in the largest number of patients arise in inhibitors against factor VIII (5 patients), which appeared in previously untreated patients that are a higher risk for the formation of inhibitors, headaches and shrubs (5 patients), Fieber and Schwindel (each 3 patients)."</seg>
<seg id="1557">"very common (≥ 1 / 10), often (≥ 1 / 100 to &lt; 1 / 10), occasionally (≥ 1 / 10,000 to &lt; 1 / 1,000), very rare &lt; 1 / 10,000), not known (frequency on the basis of available data non-estimated)."</seg>
<seg id="1558">A) The percentage of the patients was calculated by the sum of the individual patients (234). the unexpected waste of blood pressure factor is postoperatively (10 - 14 postoperatively day) during a patient under continuous ADVATE infusion.</seg>
<seg id="1559">The blood pressure was maintained throughout the period and both the VIII- mirror in the plasma as well as the Clearance rate showed sufficient values on the 15th of post.</seg>
<seg id="1560">In clinical studies with ADVATE with ADVATE at 145 children and adults 2 with diagnosed with effect of VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda's approach).</seg>
<seg id="1561">In addition not the 53 pediatric patients with an age of under 6 years and diagnosed with an age of severe hammophilia A (FVIII ≤ 2%) after previous exposure to factor VIII- concentrates (≥ 50 days) a FVIII Inhibitor.</seg>
<seg id="1562">"in case of previously not treated patients with a ongoing clinical study, 5 of 25 (20%) with ADVATE treated patients inhibitors against factor VIII."</seg>
<seg id="1563">"the immune response of patients on traces of contaminated proteins was analyzed through the investigation of antibodies against these proteins, laboratory parameters and gems side effects."</seg>
<seg id="1564">"a patient showed both a statistically significant upscale as well as a continuing peak of antibodies against anti-Cho cell, otherwise, however, does not occur any signs or symptoms which reported on an allergic reaction or hypersensitivity."</seg>
<seg id="1565">"in four patients the appearance of Urtikaria, Pruritus, rash and increased number of eosinophiler granulators in several repetitive production positions in the framework of the study reported."</seg>
<seg id="1566">"7 As with other intravenous products was reported in ADVATE over oversensitivity, including anaphylactic / anaphylac.ider reactions (frequency not known)."</seg>
<seg id="1567">The activated factor VIII works as a counter factor for the activated factor IX and accelerates the formation of activated factor X from factor X.</seg>
<seg id="1568">All pharmaceutical studies with ADVATE were conducted in patients treated with severe or moderate hammophilia A (base value of the factor VIII activity ≤ 2%).</seg>
<seg id="1569">"the pharmacoinetic parameters originates from a cross-Over study, with ADVATE in 100 previously treated patients, or &gt; 10 years and are listed in the table below 3."</seg>
<seg id="1570">Table 3 summary of Pharmakoinetic parameters of ADVATE with more than 100 patients with heavy to moderate hardness A (factor VIII &lt; 2%) PK-Parameter (Pharmakokinetics)</seg>
<seg id="1571">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1572">"each individual packaging consists of a pouch with powder, a flow bottle with 5 ml solvents (both glass type I with chloroutyl-rubber-mistress) and one device to reprostitution (BAXJECT II)."</seg>
<seg id="1573">"when the product is still stored in the refrigerator, both diameters are cut with ADVATE powder and solvents from the fridge and be up to room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A significant increase in the pulse frequency may be extended by slowing or temporarily injecting the injection usually immediately reduced (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 prophylaxis for long-term prophylaxis of bloody in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1576">"due to the rare transgressing of the hammophilia A on women lie over the use of factor VIII during pregnancy and lactation, no experiences."</seg>
<seg id="1577">"3 newborn (at the age of 0-1 month), infants (at the age of 2-12 years), children (aged 12-16 years), adults (over 16 years)"</seg>
<seg id="1578">In clinical studies with ADVATE with ADVATE with 145 children and adults 4 with diagnostic heavy until moderate hammation (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda-approach).</seg>
<seg id="1579">"18 As with other intravenous products was reported in ADVATE over oversensitivity, including anaphylactic / anaphylac.ider reactions (frequency not known)."</seg>
<seg id="1580">Table 3 summary of Pharmakoinetic parameters of ADVATE with more than 100 patients with heavy to moderate hardness A (factor VIII &lt; 2%) PK-Parameter (Pharmakokinetics)</seg>
<seg id="1581">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1582">25 prophylaxis for long-term prophylaxis of bloody in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1583">"5 newborn (at the age of 0-1 month), infants (at the age of 2-12 years), children (aged 12-16 years), adults (over 16 years)"</seg>
<seg id="1584">In clinical studies with ADVATE with ADVATE with 145 children and adults 6 with diagnosed harder to moderate hammation (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda-approach).</seg>
<seg id="1585">"29 As with other intravenous products was reported in ADVATE over oversensitivity, including anaphylactic / anaphylac.ider reactions (frequency not known)."</seg>
<seg id="1586">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1587">36 prophylaxis for long-term prophylaxis of bloody in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1588">"7 newborn (at the age of 0-1 month), infants (at the age of 2-12 years), children (aged 12-16 years), adults (over 16 years)"</seg>
<seg id="1589">In clinical studies with ADVATE with ADVATE at 145 children and adults 8 with diagnosed with effect of VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda-approach).</seg>
<seg id="1590">"40 As with other intravenous products was reported in ADVATE over oversensitivity, including anaphylactic / anaphylac.ider reactions (frequency not known)."</seg>
<seg id="1591">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1592">47 prophylaxis for long-term prophylaxis of blood circulation in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1593">"9 newborn (at the age of 0-1 month), infants (at the age of 2-12 years), children (aged 12-16 years), adults (over 16 years)"</seg>
<seg id="1594">In clinical studies with ADVATE with ADVATE with 145 children and adults 10 with diagnostic heavy until moderate hammation (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda-approach).</seg>
<seg id="1595">51 How with other intravenous products was reported in ADVATE via hypersensitivity actions of the allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known). "</seg>
<seg id="1596">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1597">58 prophylaxis for long-term prophylaxis of bloody in patients with severe harshilia A should be given doses between 20 and 40 that is given by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1598">"11 newborn (at the age of 0-1 month), infants (at the age of 2-12 years), children (aged 12-16 years), adults (over 16 years)"</seg>
<seg id="1599">In clinical studies with ADVATE with ADVATE with 145 children and adults 12 with diagnostic heavy until moderate hammation (≥ 150 days) showed only a patient after 26 exposition with ADVATE showed a low inhibitortiter (2.4 B.E. at the modified Bethesda-approach).</seg>
<seg id="1600">62 How with other intravenous products was reported in ADVATE via hypersensitivity actions of the allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known). "</seg>
<seg id="1601">"clinical data, based on the studies on security spharmacology, to akening, repetitive and local toxicity and to genotoxicity, show no special risk to the human being."</seg>
<seg id="1602">"Pharmacovigilance system The regulatory authorities must ensure that an Pharmacovigilance system, as described in paragraph 1.1 of the chapter 1.8.1 of the drug, which is in which the product is on the market in which it remains in force."</seg>
<seg id="1603">"as in the CHMP directive on the risk-managment plan for human medicines, these updates are to be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• if new information can be found, the pharmaceutical vigilance plan or measures to reduce risk minimization, • within 60 days after an important event (with regard to the pharmaceutical vigilance) or with regard to a measure for the risk minimization)"</seg>
<seg id="1605">1 bucket bottle with ADVATE 500 I.E Octocog alfa, 1 penetration with 5 ml flated water for injection purposes, 1 BAXJECT II-medical product. "</seg>
<seg id="1606">1 bucket bottle with ADVATE 1000 I.E Octocog alfa, 1 penetration with 5 ml flated water for injection purposes, 1 BAXJECT II-medical product "</seg>
<seg id="1607">"special attention to the application of ADVATE is required, you should inform your doctor if you have recently been treated with factor VIII products, especially when you have inhibitors."</seg>
<seg id="1608">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1609">"taking with other medicines, please inform your doctor if you have no other medicines or have recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="1610">"your doctor will charge your dose ADVATE (in international units or that), depending on your physical activity and body weight, and whether it is used to prevent or treat bleeding."</seg>
<seg id="1611">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1612">"in conjunction with operations catheterinfuses, lower number of red blood cells, swelling of limbs and joints, prolonged blood pressure after the removal of a drain, reduced factor-VIII and postoperative hematoms."</seg>
<seg id="1613">Rare Side Effects Since the introduction of the medication by means of the market has been obstructed over heavy and potentially life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1614">"inform your doctor, if any of the above side effects you have considerably impaired, or if you notice side effects which are not listed in this package."</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"hints for the production of the solution • Do not use the holder for holding the solution • Do not use the holder for holding casters. • The BAXJECT II may not use, when his sterile barrier is damaged, its packaging is damaged or signs of a manipulation, as in the symbol"</seg>
<seg id="1617">Important note: • Not to be administered before you have received the specific training from your doctor or your nurse. • Please check the product on a webcams or discolouration.</seg>
<seg id="1618">"the solution should slowly be accessed by an induction speed, which is able to use the patient and 10 ml per minute will not be administered, administered."</seg>
<seg id="1619">106 In the case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1620">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1621">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1622">"occasional side effects Juckreiz, reincareless flavours, uncommon flavours, confusion, exiting, irritation, breaking neck, inflammation of lymph vessels, flammation, inflammation, extremes, extremes, extremes"</seg>
<seg id="1623">116 In case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1624">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1625">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1626">126 In the case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1627">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1628">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1629">136 In case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1630">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1631">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1632">146 In the case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1633">"these symptoms can represent early signs of an anaphylactic shock, which can also include the following symptoms: extreme vertigo, consciousness loss and extreme breaths."</seg>
<seg id="1634">"patients, the factor of VIII Inhibitors are developed by the anticipated FACA mirror in your plasma, with ADVATE cannot be controlled or which may not be ruled in the development of factor VIII-"</seg>
<seg id="1635">"occasional side effects Juckreiz, reincareless flavours, uncommon flavours, confusion, exiting, irritation, breaking neck, inflammation of lymph vessels, flammation, inflammation, extremes, extremes, extremes"</seg>
<seg id="1636">Rare Side Effects Since the introduction of the medication by means of the market has been obstructed over heavy and potentially life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1637">156 In the case of blood circulation should be the factor VIII mirror within the appropriate period not under the given plasma activism (in% or in i.e. / ml).</seg>
<seg id="1638">"based on the data processing of the data processing, the CHMP has been rated as positive as positive, but considering that the safety profile must be closely monitored for the following reasons:"</seg>
<seg id="1639">"therefore, the CHMP is based on the basis of the security profile of ADVATE, which makes a filing of PSURs every 6 months, decided that the regulatory authorities should apply for another renewal procedure in 5 years."</seg>
<seg id="1640">December 2008 Gendux Molecular Limited Edition of the Committee for Humanarztend (CHMP) officially approved that the company can withdraw its application for approval of Li-Fraumeni cancer.</seg>
<seg id="1641">"however, the chest, the brain, the bones, or the softparts (tissues, the other structures in the body combines, surrounds and base) of it."</seg>
<seg id="1642">"this is a kind of virus that genetically modified, that it can carry a gene into the cells of the body."</seg>
<seg id="1643">"at the virus in Advance, it is a" "Adenovirus", "which has changed so that there cannot be copies of itself and can thus trigger no infections in humans."</seg>
<seg id="1644">"Advance would have been injected directly into the tumors, enabling the cancer cells to form the normal p53 protein again."</seg>
<seg id="1645">The p53 protein that is formed from which not defective in the human body existing p53 gene is usually contributes to the restoration of corrupt DNA and to the death of cells when the DNA cannot be recovered.</seg>
<seg id="1646">"at Li-Fraumeni-Cancer, where the p53 gene is defective, the p53 protein is not working properly, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"the company laid data from a study with a patient prior to the Li-Fraumeni cancer in the area of the undermining, in the bones and in the brain."</seg>
<seg id="1648">"after the CHMP had the answers of the company to the questions asked questions, there were still some questions unsolved."</seg>
<seg id="1649">"based on the review of the submitted documents, the CHMP mark on day 120 a list of questions that will be sent to the company."</seg>
<seg id="1650">After the CHMP opinion has not been sufficiently proven that the injection of Advance in Li-Fraumeni-tumore offers benefits for the patient.</seg>
<seg id="1651">"the committee also had concerns regarding the processing of the medication by means of the body, the type of administration and the safety of the drug."</seg>
<seg id="1652">"in addition, the company had not proven sufficient that Advance can be established in a reliable way and that it is neither for the environment nor for people who come in close contact with the patient."</seg>
<seg id="1653">"the company was not aware of the CHMP, whether the withdrawal of consequences for patients who currently participate in clinical trials or" compilation "Use" programs with Advance. "</seg>
<seg id="1654">"changed active ingredient, means that the tablets are so collapsed that one of the effective ingredients is immediately unreleased and the other slowly over a few hours."</seg>
<seg id="1655">Aerinaze is used to treat the symptoms of seasonal allergic rhinitis (hay-plate) used by a allergy against pollen in patients with Rhinoplasty (hidden nose).</seg>
<seg id="1656">For adults and adolescents from 12 years the recommended dose of Aerinaze is to be taken every day a tablet which should be taken up with a glass of water with or without food.</seg>
<seg id="1657">"the duration of the treatment should be as short as possible and ended as soon as the symptoms, especially the swelling of the nasal mucosa."</seg>
<seg id="1658">A treatment duration of more than 10 days is not recommended because the effects of the drug can imitate upon the constipation of the nose.</seg>
<seg id="1659">"the main active dimensions were the changes in the heaving of hay symptoms, which were reported by patients before the beginning of the treatment and during the 15-day treatment."</seg>
<seg id="1660">"during the study the patients suffered their symptoms every 12 hours in a diary, and evaluated with a standard scala, how heavy the symptoms in the last 12 hours were."</seg>
<seg id="1661">"considering all the hay symptom symptoms except the constipation of the nose reported the patients who took the aerosze, over a decrease of symptoms around 46.0%, compared to 35.9% in patients, the pseudoephedrine alone."</seg>
<seg id="1662">"if only the swelling of the nasal mucosa was considered, the patients among Aerators showed a reduction of symptoms around 37,4% compared to 26.7% in patients, the Desloratadin alone."</seg>
<seg id="1663">"the most common side effects of aerosze (observed during 1 to 10 of 100 patients) are tachykarst (carditis), glucgilitis (repetitive), clorexy, fatigue, insomnia (sleeplessness), somnolence (sleeplessness), insomnia and nervousness."</seg>
<seg id="1664">"Aeromze may not be used in patients who may possibly be vulnerable (allergic) against Desloratadin, pseudoephedrine or one of the other components, against epinepintoxins or Loratadin (another medicine for the treatment of allergies) are not used."</seg>
<seg id="1665">"Aeromze may also not be used in patients who suffer from a bottangle glaucoma (increased water pressure), cardiac disease (hypertension), hypertension (hypertension), hypertension (hypertension) or a hemian stroke (through a brain-hemian stroke) or have a risk to an hemorrhoid stroke."</seg>
<seg id="1666">"on 30 July 2007, the European Commission announced the European Commission of SP Europe a permit for the discharge of aeromze throughout the European Union."</seg>
<seg id="1667">"the tablet can be taken with a glass of water, however, is in whole to swallow (i.e. without them break, break or slice)."</seg>
<seg id="1668">Aerosze should not be applied due to the misconception of data to immortality and effectiveness (see Section 5.1) in children under 12 years of age.</seg>
<seg id="1669">The duration of the application is as short as possible and should not be continued after disappearance the symptoms.</seg>
<seg id="1670">"it is recommended to limit the use of use at 10 days, as in long-term use the activity of pseudoephedrine with time can decrease."</seg>
<seg id="1671">The decrease in the swelling of the mucous cells in the upper respiration can be continued when needed with Desloratadin as Monotherapy.</seg>
<seg id="1672">"since Aerky pseudoephedrine contains, the medicine is also contraindicated in patients suffering from with a monounding oxidase (MAO) -Hemmer or within 2 weeks after the termination of such therapy."</seg>
<seg id="1673">"this is due to alphamimetical activity in combined use of pseudoephedrine, pergolid, vinegolin, rahydrogeotamine, phenylephrolamine, phenylephrine, ephedrephrine, alhazolin etc.)."</seg>
<seg id="1674">Security and the effectiveness of this combination therapy were not checked for this patient therapy and the data are not enough to trigger corresponding recommendations to dosage.</seg>
<seg id="1675">Security and effectiveness of aerosze were not tested in patients with kidney or liver disturbance and the data are not enough to trigger corresponding recommendations to dosage.</seg>
<seg id="1676">"patients must be informed about the treatment at the appearance of a hypertension or tachykarate or tachyles, cardiac disease, nausea or etwaigen other neurological symptoms (such as headache or a strengthening of the headache)."</seg>
<seg id="1677">"in the treatment of the following patient groups, the patients with cardiac arrhythms • patients with hypertension in patients with hypertension • patients with a myocardinary in the Anamnese, diabetes mellitus, bladder neck or bronchospasmus in the Anamnese."</seg>
<seg id="1678">"Aerinaze is estimated at least 48 hours before carrying dermatological tests, since antihistamine otherwise prevent positive reactions to indicators for concise transactions or reduce in their scale."</seg>
<seg id="1679">"as part of clinical tests with Desloratadin, where Erythromycin or Ketoconazol have additionally been administered, however, were not observed any clinically relevant interactions or changes in the plasma concentration of Desloratadin."</seg>
<seg id="1680">In the results of the psychic tests could not be significant differences between the Desloratadin and those with placebo treated patients regardless of whether Desloratadin was taken alone or with alcohol.</seg>
<seg id="1681">That for the metabolic ism of Desloratadin responsible enzymes was not yet identified so that interactions with other medicines cannot be excluded completely.</seg>
<seg id="1682">"Desloratadin is not inhibited in-vivo CYP3A4, and in-vitro studies have shown that the drug CYP2D6 is not inhibited and neither a substrate nor an inhibitor of the P-glycoprotone."</seg>
<seg id="1683">The immortality of the use of Aerinaze during pregnancy is not secured to experience experience from a large number of affected pregnancies but does not increase the frequency of abnormalities compared to the incidence of normal population.</seg>
<seg id="1684">"as reproduction studies of animals are not always transferred to human beings, and on the basis of vasoonstriktorical properties of pseudoephedrine should not be applied in pregnancy."</seg>
<seg id="1685">"however, patients should be clarified in a very rare cases to a lightheadedness, which can lead to an impairment of traffic noise or the ability to serve machines."</seg>
<seg id="1686">"symptoms can vary between a ZNS Depression (Sedation, Appee, decreased mental attention, cyanose, comma, heart cycle collaps) and a ZNS stimulation (sleeplessness, staircase, convulsions) with possible lettuals."</seg>
<seg id="1687">"headache, anxiety, shredness micronmental, redness, arousal disorders, melancholy, irritation, nautical, nausea, tanness, tapes, tapes, tendemic, tapes, and hypertension or mortgage."</seg>
<seg id="1688">"a zNS stimulation is particularly probably, as also as atropine-typical symptoms (mouth drying, pupwaist and - dilatation, concession, hyperthermia and gastrointestinal symptoms)."</seg>
<seg id="1689">"these include both the inhibition of the release of the inflammatory cytocine like IL-4, IL-6, IL-8 and IL-13 from human MastCs / Basophiles one as well as the inhibition of the expression of the Adhemsionsmolecüls P-Selective cells."</seg>
<seg id="1690">"when a single dose study with adults showed Desloratadin 5 mg no influence on standard measurement sizes including the strengthening of subjective hose, or the tasks that are connected to the finger."</seg>
<seg id="1691">In controlled clinical trials was no increased intake of 5 mg every day in comparison to placebo.</seg>
<seg id="1692">"the oral application of pseudoephedrine in the recommended dosage can produce further sympathomimetical effects, such as an increase in blood pressure, a tachykarate or manifestations of a ZNS arousal."</seg>
<seg id="1693">"1,248 patients aged between 12 and 78 years were attended with seasonal allergic rhinitis, with 414 patients Aerinaze tablets."</seg>
<seg id="1694">"in both studies the histaminantagonistic effectiveness of aeromze tablets, determined by the total core for the symptom (except nasal skin swelling), significantly higher than under a monotherapy with pseudoephedrine about the 2-week period."</seg>
<seg id="1695">The effectiveness of aeromze tablets with regard to the diminishing effect is determined higher than under a monotherapy with Desloratadin on the 2-week treatment period.</seg>
<seg id="1696">The effectiveness of Aerinaze tablets showed no significant differences in terms of gender, age or ethnic affiliation defined patient groups. "</seg>
<seg id="1697">As part of a single dose study for Pharmakokinetics of Aerinaze is Desloratadin within 30 minutes after administration in plasma.</seg>
<seg id="1698">After the peroral application of Aeromze at healthy eating over 14 days the flow-weight of Desloratadin has reached 3-Hydroxydesloratadin and pseudoephedrine in day 10.</seg>
<seg id="1699">"within the framework of a pharmacoinetic multi-dosing, which has been carried out with the formulation as a tablet to healthy grown proportions, was established that four Probanden Desloratadin are poorly dependent."</seg>
<seg id="1700">A component-level study indicates that the Exposure (Cmax and AUC) of Pseudoephedrine after alsome gift of pseudoephedrine bioequivalence was to Exposure of a aeromiso tablet.</seg>
<seg id="1701">"based on conventional studies on safety spharmacology, for toxicity in repeatable gift, to the genotoxicity and for reproductive-toxicity, the preclinical data with Desloratadin will not recognise any special hazards for the people."</seg>
<seg id="1702">The combination had no greater toxicity than its individual components and the observed effects were generally associated with the ingredient pseudoephedrine.</seg>
<seg id="1703">In reproductive-reproductive studies the combination of Loratadin / Pseudoephedrine at the oral Gabe in a dosage of up to 150 mg / kg / day and in rabbits in a dosage of up to 120 mg / kg / day not teratogenic.</seg>
<seg id="1704">March 2007 and in Modul 1.8.1 of the application-driven pharmaceutical vigilance system is established and works before and while the product is on the market.</seg>
<seg id="1705">"anti-histamine contribute to the alleviation of the allergic symptoms by preventing the histamine, a physical substance, its effect can be unfold."</seg>
<seg id="1706">"Aerinaze tablets lindern symptoms, which occur in connection with seasonal allergic rhinitis (hay-carp), such as Niesen, current or jucking nose and trash or jucking eyes with the constipation of the nose."</seg>
<seg id="1707">"20 In certain circumstances, you can be particularly sensitive to the mucosa sultry drug pseudoephedrine, which is included in this medicine."</seg>
<seg id="1708">"(sugar disease), a stenositive handfuller (floor door), a clasp of the stomach or the esophagus (intestinal muscles), a clasp of the stomach-muscles (intestinal muscles), a clasp and problems with the liver, the kidneys or problems with the liver, the kidneys, or the bladder."</seg>
<seg id="1709">"inform your doctor if you can occur or diagnosed with you under the application of Aerinaze the following symptoms or diseases: • Bluthochpressure • heart rate, cardiac and headaches or a reinforcement of existing headache."</seg>
<seg id="1710">"intake of aeromze with other medicines, please inform your doctor or a pharmacist if you have taken other medicines or have recently taken away, even if it is not prescription drugs."</seg>
<seg id="1711">Transportation and storage of machinery for use in recommended dosage is not to reckon that Aeromze leads to lightheadedness or bring attention to the attention.</seg>
<seg id="1712">If you have taken a larger amount of aeromze as you should check immediately your doctor or pharmacist if you have taken a larger amount of aeromze than you should.</seg>
<seg id="1713">"if you have forgotten the intake of aerosze If you have forgotten to take a dose of time, pick up the application as soon as possible and turn the next dose at the scheduled time."</seg>
<seg id="1714">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="1715">"cardiac, implessness with multi-multi-physical activity, mouth drying, shrinkyness, appetite, sugar in the urine, increased blood sugar, thirst, fatigue, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nerv</seg>
<seg id="1716">"heart-carp, or cardiac arrhythms, carelessness, confusion, muscular eyes, nasal headaches, redness, redness, redness, redness, shrinkage, shrinkage, shrinkage, shalleviation of the scuchoneness, striking liver limelting, anxiety, anxiety and irritability."</seg>
<seg id="1717">"after the launch of Desloratadin has been very rare in cases of severe allergic reactions (breathing, pivotal, itch, boiler and swelling) or skin acts."</seg>
<seg id="1718">"cases of cardiac, heart-headaches, nausea, nausea, pertiness, diarrhoea, sleeurial, irritation, crampoutrageous activity, cases of liver inflammation and cases of conspicuous liver values were also very rare reported."</seg>
<seg id="1719">"it is available as a 5 mg tablet, 5 mg- Lyophilisat for inserting (soluble tablet), 2.5 mg- and 5 mg-melting tablets (tablets that arise in the mouth), 0.5 mg / ml-syup and than 0.5 mg / ml solution."</seg>
<seg id="1720">"for children aged one to five years the dose of 1,25 mg once daily, which is in the form of 2.5 ml syrup."</seg>
<seg id="1721">"for children aged six to eleven years the dose is 2.5 mg once daily, either in the form of 5 ml syrup."</seg>
<seg id="1722">Aerius was examined in eight studies with about 4 800 adults and young people with allergic rhinitis (including four studies in seasonal allergic rhinitis and two studies on patients who also had asthma).</seg>
<seg id="1723">"the effectiveness was measured by changing the symptoms of symptoms (itch, number and size of the squares, impairment of sleep and performance on the day) before and after six-week treatment."</seg>
<seg id="1724">"there were further studies presented to prove that the body use the syrup, the solution to the inserting and melting tablets in the same way, as the tablets and the application in children is harmless."</seg>
<seg id="1725">"in allergic rhinitis triggered when the results of all studies were taken together, the two-week treatment with 5 mg Aerius to an average decrease of symptom (symptom) by 25 to 32% in comparison to the decrease of 12 to 26% in patients who received a placebo."</seg>
<seg id="1726">"in the two studies at Urtikaria, the decrease of the symptomless treatment was compared with Aerius 58 and 67%, compared to 40 and 33% in those with placebo treated patients."</seg>
<seg id="1727">Aerius must not be used in patients who may possibly be vulnerable (allergic) against Desloratadin, Loratadin or one of the other components. "</seg>
<seg id="1728">January 2001 the European Commission published the European Commission of SP Europe adopts a permit for the transport of Aerius in the entire European Union.</seg>
<seg id="1729">"one tablet once daily, with one or without a meal, to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1)."</seg>
<seg id="1730">There are limited experience from clinical studies on the effectiveness in applying Desloratadin for young people from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of intermittent allergic rhinitis (occurrence of symptoms for less than 4 days a week or less than 4 weeks) should be performed according to the previous illness and may end after the disappearance of symptoms and can be resumed at its re-occur.</seg>
<seg id="1732">The persensitive Rhinitis (occurrence of symptoms at 4 or more days a week and over 4 weeks) can be recommended to patients during the allergy time a continuous treatment.</seg>
<seg id="1733">Clinically relevant interactions have not been tested in the context of clinician studies with Desloratadin tablets were not listed in which erythromycin or ketoconazol have additionally been administered (see under section 5.1).</seg>
<seg id="1734">In a clinical-pharmacological study was not reinforced by Aerius and alcohol the performance of alcohol abuse (see under section 5.1).</seg>
<seg id="1735">"however, patients should be clarified in a very rare cases of benefits, which can lead to impairment of traffic noise or the ability to serve machines."</seg>
<seg id="1736">"clinical trials in different indications, including allergic rhinitis and chronically idiopathic Urtikaria, were reported in the recommended dose of 5 mg daily 3% more side effects in patients with Aerius, considered in patients who were treated with placebo."</seg>
<seg id="1737">"the most common side effects, about which was more common than in placebo were tiredness (1.2%), mouthdryness (0,8%) and headaches (0,6%)."</seg>
<seg id="1738">"in a clinical study with 578 youthful patients from 12 to 17 years, the most common side effect headaches was treated at 5.5% of patients who were treated with Desloratadin and around 6.7% of patients who were treated with placebo."</seg>
<seg id="1739">"in a multi-dose study, where up to 45 mg of Desloratadin (ninth clinical dose) were administered, no clinically relevant effects were observed."</seg>
<seg id="1740">"this includes both the inhibition of the release of proinflammatory cytocines like IL-4, IL-6, IL-8 and IL-13 from human MastCs / Basophiles one as well as the inhibition of the expression of the Adhemsionsmolecüls P-Selektin on Endothelialcells."</seg>
<seg id="1741">"as part of a clinical study with multifactions, in the Desloratadin was administered in a dosage of up to 20 mg every day over 14 days, has not been statistically significant or clinically relevant cardiovascular effect."</seg>
<seg id="1742">"in a clinical-pharmacological study, in the Desloratadin in a dosage of 45 mg daily (the Neunners of the clinical dose) was administered over ten days, no extension of the QTc intervals."</seg>
<seg id="1743">"for a single dosing study with adults showed Desloratadin 5 mg no influence on standard measurement sizes including the strengthening of subjective hose, or the tasks that are connected to the finger."</seg>
<seg id="1744">"in patients with allergic rhinitis, Aerius was effective in the alleviation of symptoms such as Niesen, Nasensecretion and Juckreiz the nose, itch and redness of the eyes and itch on the palate."</seg>
<seg id="1745">In addition to the established classification in saisonal and perennial, can allergic rhinitis in dependence on the duration of symptoms even in intermittent allergic rhinitis and persistiing allergic rhinitis. "</seg>
<seg id="1746">Intermittent allergic rhinitis is defined as a occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persensitive Rhinitis is defined as a occurrence of symptoms at 4 or more days a week and over 4 weeks.</seg>
<seg id="1748">How with the overall volume of the questionnaires in the quality of life in Rhino gentivitis has been shown diminished Aerius effectively emerges by seasonal allergic rhinitis.</seg>
<seg id="1749">The chronically idiopathic Urtikaria has deputy investigating for other forms of the Urtikaria as the underlying pathphysiological geology has been similar to the modelling in different forms and can be easier prospectated patients easier.</seg>
<seg id="1750">"since the histamine is a common factor in all urban diseases, is expected that Desloratadin is expected to improve the symptoms in other forms of urine. this is confirmed by the recommendations of the clinical guidelines."</seg>
<seg id="1751">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urtikaria, Aerius was effective in improving Pruritus and the reduction of size and number of squares at the end of the first dosage interval."</seg>
<seg id="1752">"as in other studies with Antihistamine in chronic idiopathic Urtikaria, the minority of patients, which is not excluded in antihistamine, from the study."</seg>
<seg id="1753">An improvement of the itch by more than 50% was observed at 55% of patients with Desloratadin patients compared to 19% of the patients treated with placebo.</seg>
<seg id="1754">"the treatment with Aerius reduced the disorder of sleep and guard, as measured by a 4-point scale to evaluate these variables."</seg>
<seg id="1755">"in an Pharmacoinetics study, which were comparable to the patients" demographic rendemic rhinitis population, was achieved with 4% of patients a higher concentration of Desloratadin. "</seg>
<seg id="1756">There are no clue for a clinically relevant culation after once daily use of Desloratadin (5- 20 mg) over 14 days before.</seg>
<seg id="1757">"however, for the metabolic ism of Desloratadin responsible enzymes yet not yet identified, so interactions with other medicines will not be excluded completely excluded."</seg>
<seg id="1758">Desloratadin inhibit in-vivo not CYP3A4 and in-vitro studies have shown that the drug CYP2D6 is not inhibited and neither a substrate nor an inhibitor of the P glycoprotone.</seg>
<seg id="1759">In a single dosisle with Desloratadin in a dosage of 7.5 mg real meals (fatty breakfast) does not cover the availability of Desloratadin.</seg>
<seg id="1760">The clinical trials conducted with Desloratadin and Loratadin shown in a comparable degree of exposure of Desloratadin, not qualitative or quantitative differences regarding the toxicity of Desloratadin and by Loratadin. "</seg>
<seg id="1761">"based on conventional studies on safety spharmacology, toxicity in repeatable gift, comotoxicity and for reproductionalism, the preclinical data with Desloratadin do not recognize any special hazards for the people."</seg>
<seg id="1762">"colour film (includes Lactose-monohydrat, Hypromess, titanium dioxide, Macrogol 400, Indigocarmin (E 132)), Colony film (includes Hypromess, Macrogol 400), Carnautical wax."</seg>
<seg id="1763">Aerius can be taken independent of meals to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1).</seg>
<seg id="1764">The descriptive doctor should be aware that most cases of Rhinitis in children under 2 years can be caused by infection (see under Section 4.4) and that no data are available to support a treatment of infectious Rhinitis with Aerius.</seg>
<seg id="1765">"in addition to the exclusion of upper respiratory infections or anatomical anomalies should be played in the diagnosis the Anamnese, physical investigations and appropriate laboratory and skin investigations."</seg>
<seg id="1766">Approximately 6% of adults and children between 2 and 11 years are metabolize Desloratadin and experience higher substantive load (see under section 5.2).</seg>
<seg id="1767">"the safety of Aerius Sirups in children between 2 and 11 years, the restricted metallization, is identical with the children that are normal metabolize."</seg>
<seg id="1768">"this drug includes Saccharose and Sorbitol, therefore patients with inherited problems of a fructose intolerance, glucose-gomosis or a Saccharase-Isomaltas- insufficiency of this medicine is not taking."</seg>
<seg id="1769">"clinically relevant interactions have not been established within the framework of clinical trials with Aerius tablets, where Erythromycin or Ketoconazol have additionally been administered (see under section 5.1)."</seg>
<seg id="1770">In a clinical-pharmacological study was not amplified by Aerius tablets and alcohol the performance effects of alcohol (see under section 5.1).</seg>
<seg id="1771">The totality of side effects in children between 2 and 11 years was similar to the Aerius Sirup group as in the placebo group.</seg>
<seg id="1772">"clinical trials with adults and young people in different indications, including allergic rhinitis and chronically idiopathic Urtikaria, were reported in the recommended dose 3% more side effects in patients with Aerius, considered in patients who were treated with placebo."</seg>
<seg id="1773">"in a multi-dose study on adults and adolescents, where up to 45 mg of Desloratadin (ninth clinical dose) were applied, no clinically relevant effects have been observed."</seg>
<seg id="1774">Children aged between 1 and 11 years have come to an anti-histamine therapy received by 1,25 mg (at the age between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years).</seg>
<seg id="1775">Because the course of allergic rhinitis / chronically idiopathic Urtikaria and the profile of Desloratadin in adults and children can be similar to the drug data of Desloratadin in adults on the children's population.</seg>
<seg id="1776">"as part of a clinical study with multiple sclerosis and adolescents, in the Desloratadin was applied in a dosage of up to 20 mg every day over 14 days, has not been statistically significant or clinically relevant cardiovascular effect."</seg>
<seg id="1777">"in a clinical-pharmacological study on adults and adolescents, in the Desloratadin was applied in a dosage of 45 mg daily (the Neunner of the clinical dose) over ten days in adults was no extension of the QTc intervals."</seg>
<seg id="1778">In controlled clinical trials was noted during the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of redness compared to placebo.</seg>
<seg id="1779">In a single-day dose of 7.5 mg held Aerius tablets for adults and young people in clinical trials at no impairment of the psychotor.</seg>
<seg id="1780">"in clinical-pharmacological studies in adults, it came up with the simultaneous intake of alcohol neither to reinforcement of alcohol induced performance nor to increase the sleepiness."</seg>
<seg id="1781">"in adult and adolescent patients with allergic rhinitis, Aerius tablets are effective in the alleviation of symptoms such as Niesen, Nasensecretion and Juckreiz the nose, itch and redness of the eyes and itch on the palate."</seg>
<seg id="1782">How with the overall volume of the questionnaires in the quality of life in Rhino gentivitis was shown to diminished Aerius tablets effectively die by seasonal allergic rhinitis.</seg>
<seg id="1783">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urtikaria, Aerius was effective in improving Pruritus and the reduction of size and number of squares at the end of the first dosage interval."</seg>
<seg id="1784">"the spread of this restricted metabolized phenomenon was comparable to adults (6%) and children aged 2 to 11 years (6% adults, 16% children) than in Caucaasies (2% adults, 3% children)."</seg>
<seg id="1785">"similar pharmacopoinetic parameters were observed in a pharmacoinetic multispecialist study with the syruformulsion of children between 2 and 11 years with allergic rhinitis, observed in the restricted metabolic disorders."</seg>
<seg id="1786">The load (AUC) through Desloratadin was after 3 to 6 hours approximately 6times higher and the Cmax is about 3 to 4mal higher with a temporal half value of approximately 120 hours.</seg>
<seg id="1787">There are no clue for a clinically relevant ingredient gulation after once daily use of Desloratadin (5- 20 mg) over 14 days in adults and adolescents.</seg>
<seg id="1788">"12 In various single dose studies showed that AUC- and Cmax values of Desloratadin showed themselves to the recommended doses with those of adults, the Desloratadin-syup in a dosage of 5 mg."</seg>
<seg id="1789">"however, the enzymes of Desloratadin responsible for the metabolic enzyme is not yet identified, so that interactions with other medicines cannot be excluded completely."</seg>
<seg id="1790">"Aerius Sirup is offered in type-III-brown glass bottles with a child-safe polypropylene flap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with a rigid, oversighted polystyrene measurement, calibrated with 2.5 ml and 5 ml or with a application splash for preparation with scaling of 2.5 ml and 5 ml (only for the 150 ml bottle)."</seg>
<seg id="1792">A dose of Aerius Lyophilate to take once a day in the mouth to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1).</seg>
<seg id="1793">"immediately prior to the application the blister has to be carefully opened and the dose of the lyophilation should be taken from, without damage."</seg>
<seg id="1794">Clinically relevant interactions have not been established within the framework of clinical studies with Aerius tablets in addition to the erythromycin or Ketoconazol (see under section 5.1).</seg>
<seg id="1795">"clinical trials in different indications, including allergic rhinitis and chronically idiopathic Urtikaria, were reported in the recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets, than in patients who were treated with placebo."</seg>
<seg id="1796">"in a multi-dose study, where up to 45 mg of Desloratadin (ninth clinical dose) were applied, no clinically relevant effects were observed."</seg>
<seg id="1797">"in two single dose studies, Aerius Lyophilisat was well tolerated; this was documented by clinical laboratory results, medical studies, vitality and ECG interpersonal data."</seg>
<seg id="1798">"as part of a clinical study with multifactions, in the Desloratadin was applied to a dosage of up to 20 mg every day over 14 days, has not been statistically significant or clinically relevant cardiovascular effect."</seg>
<seg id="1799">"in a clinical-pharmacological study, in the Desloratadin in a dosage of 45 mg daily (the neo-fold of the clinical dose) over ten days was applied, no extension of the QTc intervals."</seg>
<seg id="1800">In controlled clinical trials was no increased intake of 5 mg every day in comparison to placebo.</seg>
<seg id="1801">"for a 17 single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes including the strengthening of subjective hose, or the tasks that are connected to the finger."</seg>
<seg id="1802">"in patients with allergic rhinitis, Aerius tablets are effective in the alleviation of symptoms such as Niesen, Nasensecretion and Juckreiz the nose, itch and redness of the eyes and itch on the palate."</seg>
<seg id="1803">How with the overall volume of the questionnaires in the quality of life in Rhino gentivitis has been shown diminished Aerius effectively emerges by seasonal allergic rhinitis.</seg>
<seg id="1804">"18 In an Pharmacoinetics study, which were comparable to the patients" demographic rendemic rhinitis population, was achieved with 4% of patients a higher concentration of Desloratadin. "</seg>
<seg id="1805">Food does not have significant influence on AUC and Cmax of Aerius Lyophilisat as food Tmax from Desloratadin of 2.5 to 4 hours and Tmax of 3-OH-Desloratadin of 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol Aspartame (E 951) Polacrilin-calium Colour (III) oxide (E 172) and Hypromites (E 464)) Aroma Tutti-Frutti water-free citronensäure</seg>
<seg id="1807">An Aerius 2.5 mg melt once daily in the mouth to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1).</seg>
<seg id="1808">Two Aerius 2.5 mg melt tablets once daily in the mouth to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1).</seg>
<seg id="1809">There are limited experience from clinical studies on the effectiveness in applying Desloratadin for young people from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately prior to the application the blister has to be carefully opened and the dose of melting zenge are taken from, without damage to damage."</seg>
<seg id="1811">The effectiveness and immortality of Aerius 2.5 mg of melting tablets during the treatment of children under 6 years have not been proven.</seg>
<seg id="1812">The totality of side effects between the Desloratadine Sirup- and the placebo group was the same and turned not significantly from those presented in adult patients.</seg>
<seg id="1813">In the recommended dose the Aerius melt as an bioequivalent to the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg Lyophilisat for the invitations of Desloratadin.</seg>
<seg id="1814">"as part of a clinical study with multifunctional, in the Desloratadin was applied to a dosage of up to 20 mg daily over 14 days, was not statistically significant or clinically significant."</seg>
<seg id="1815">"when a single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes including the strengthening of subjective hose, or the tasks that are connected to the finger."</seg>
<seg id="1816">"the spread of this bad metabolic phenomenon was comparable to adult (6%) and paediatric patients aged 2 to 11 years (6%), and under Black (adults 18%, children 16%), the safety profile of these patients was not deviating from the general population."</seg>
<seg id="1817">In single dose-crossover studies of Aerius melting-tray with Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat for intake were the formulations of bioequivalence.</seg>
<seg id="1818">Aerius 2.5 mg tablets were not examined by pediatric patients in conjunction with the dosisfinite studies in children however support the use of 2.5 mg dosage for children from 6 to 11 years.</seg>
<seg id="1819">Food does not have significant influence on AUC and Cmax of Aerius Aerius Lyophilisat as food Tmax from Desloratadin of 2.5 to 4 hours and Tmax of 3-OH- Desloratadin of 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of the preclinical and clinical polation tests for melting zenge yielded that this wording constitutes an unprobable risk for local irritation in clinical use.</seg>
<seg id="1821">Micro-crystalline cellulose prediluted strength Carboxymethylmethylmethylmethylmethacrylate-Copolymer (ph.Eur.) Crownvidon Natrium hydrochlorine siciumses Siciol Aspartame (E951) Aroma Tutti Frutti</seg>
<seg id="1822">The coldforming merging is made of polyvinylchlorid (PVC) curative on a steamer (Opa) film made entirely laminated on a polyvinylchlorid (PVC) film.</seg>
<seg id="1823">An Aerius 5 mg melt tablets once daily in the mouth to alleviate the symptoms in allergic rhinitis (including intermittent and persistian allergic rhinitis) and Urtikaria (see Section 5.1).</seg>
<seg id="1824">In the recommended dose of Aerius 5 mg of melting tablets as an bioequivalent to the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg Lyophilisat for the invitations of Desloratadin.</seg>
<seg id="1825">"as part of a clinical study with multifactions, in the Desloratadin was applied to a dosage of up to 20 mg every day over 14 days, has not been statistically significant or clinically relevant cardiovascular effect."</seg>
<seg id="1826">"for a 30 single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes including the strengthening of subjective hose, or the tasks that are connected to the finger."</seg>
<seg id="1827">"in patients with allergic rhinitis, Aerius tablets are effective in the alleviation of symptoms such as Niesen, Nasensecretion and Juckreiz the nose, itch and redness of the eyes and itch on the palate."</seg>
<seg id="1828">In single dose-cross-crossover studies of Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat for intake were the formulations of bioequivalence.</seg>
<seg id="1829">The overall analysis of the preclinical and clinical polation tests for melting zenge yielded that this wording constitutes an unprobable risk for local irritation in clinical use.</seg>
<seg id="1830">"the security of Desloratadin in children between 2 and 11 years, the restricted metabolizes, is identical with the children that are normal metabolize."</seg>
<seg id="1831">"this drug contains Sorbitol, therefore patients with inherited problems of a Fructose- intolerance, glucose-gomosis or a Saccharase-Isomaltase-insufficiency of this medicine is not taking."</seg>
<seg id="1832">The totality of side effects in children between 2 and 11 years was similar to the Desloratadin group as much as the placebo group.</seg>
<seg id="1833">"with small children between 6 and 23 months were the most common side-side effects, reported on the more common than in placebo (3.7%), fever (2,3%) and sleeplessness (2.3%)."</seg>
<seg id="1834">In an additional study were observed in a single dose of 2.5 mg of Desloratadin solution for taking no side-effects in patients aged between 6 and 11 years.</seg>
<seg id="1835">The recommended doses were the Plasmakoncentrations of Desloratadin (see below section 5.2) in the children's and adult population.</seg>
<seg id="1836">In controlled clinical trials was noted during the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of redness compared to placebo.</seg>
<seg id="1837">In addition to the established classification in saisonal and perennial, can allergic rhinitis in dependence on the duration of symptoms even in intermittent allergic rhinitis and</seg>
<seg id="1838">How with the overall volume of the questionnaires in the quality of life in Rhino gentivitis was shown to diminished Aerius tablets effectively die by seasonal allergic rhinitis.</seg>
<seg id="1839">"the spread of this restricted metabolized phenomenon was comparable to adults (6%) and children aged 2 to 11 years (6% adults, 16% children) than in Caucaasies (2% adults, 3% children)."</seg>
<seg id="1840">Since Aerius solution to invoke the same concentration of Desloratadin there was no bioequivalence study and it is expected that they are equivalent to the syrup and the tablets.</seg>
<seg id="1841">In various single dose studies showed that AUC- and Cmax values of Desloratadin were comparable with the recommended doses with those of adults who were desloratadin-syup in a dosage of 5 mg.</seg>
<seg id="1842">"Sorbitol, Propylenglycol, Sucralose E 2910, Natriumcitrate 2 H2O, natural and artificial flavors (Bubble-Gum), water-free Citronensacid, sodium water."</seg>
<seg id="1843">"Aerius solution for inserting will be offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III Braunglass flasks with a simple secure polyethylene dipped application."</seg>
<seg id="1844">All packaging sizes except the 150 ml package size are offered with a measuring spoon with markings for dosages of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml package size is a measurement spaspoon or a application splash for preparation with scaling of 2.5 ml and 5 ml are attached.</seg>
<seg id="1846">"subsequently, for the extension of the approval of the approval, the filing has updated regularly updated reports of the immortality of a drug by all two years, unless there is something else from CHMP."</seg>
<seg id="1847">1 film-tablette 2 film-coated 5 film-coated 5 Filmtray for 15 film-coated 15 film-coated 20 film-coated 200 film-coated 90 film-coated 100 film-coated</seg>
<seg id="1848">1 film-tablette 2 film-coated 5 film-coated 5 Filmtray for 15 film-coated 15 film-coated 20 film-coated 200 film-coated 90 film-coated 100 film-coated</seg>
<seg id="1849">Sirup 30 ml with 1 measuring spoon 50 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spaspoon</seg>
<seg id="1850">30 ml with 1 measuring spoon 50 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spaspoon</seg>
<seg id="1851">1 doses Lyophilate for inserting 3 cans of Lyophilisat for intake 10 cans of Lyophilisat for intake 30 cans of Lyophilisat for intake 50 cans of Lyophilate to the intake 100 cans of Lyophilate to the intake 100 cans of Lyophilate to the intake 100 cans of Lyophilate to the intake 100 cans of Lyophilate to inhaling</seg>
<seg id="1852">5 melting tablets 6 melting tabletting 10 melting tabletting 20 melting tabletting 20 melting tabletting 30 melting tabletting 60 melting tabletting 60 melting tablets 100 melting tablets</seg>
<seg id="1853">Solution for inserting 30 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spaspoon</seg>
<seg id="1854">Pregnancy and downtime ask questions during pregnancy and lactation before taking all drugs to your doctor or a pharmacist to advice.</seg>
<seg id="1855">Transportation and storage of machinery for use in recommended dosage is not to reckon that Aerius leads to lightheadedness or bring attention to the attention.</seg>
<seg id="1856">"if you have said by your doctor, you have a intolerance on certain sugar, ask your doctor before you take this medicine."</seg>
<seg id="1857">"concerning the treatment of treatment, your doctor will determine the type of allergic rhinitis, under which you suffer and will determine how long you should take aserius."</seg>
<seg id="1858">If your allergic rhinitis interruptions is (the symptoms more rare than 4 days per week occur or less than 4 weeks last) your doctor will recommend you a treatment scheme that depends on your previous disease.</seg>
<seg id="1859">If your allergic rhinitis persist (the symptoms at 4 or more days per week occur and more than 4 weeks) can your doctor recommend you a longer digestible treatment.</seg>
<seg id="1860">"if you have forgotten the intake of aserius If you have forgotten your dose to take in time, take it as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1861">"71 After market launch of Aerius has been very rare in cases of severe allergic reactions (difficulties in breathing, pipes, kidney, kidney, and swelling) and rash."</seg>
<seg id="1862">"cases of cardiac, cardiac, nausea, vomiting, diarrhea, diarrhoea, sleeplessness, burns, misery, decency, misery, misinflammation and unusual physical activity was also very rare reported."</seg>
<seg id="1863">"tray suit consists of coloured film (contains Lactose- Monohydrat, Hypromess, titanium, Macrogol 400, Indigocarmin (E 132)), colorful film (contains hymflawless, Macrogol 400), Carnautical wax."</seg>
<seg id="1864">"Aerius 5 mg Filmtablets are individually packed in blister packs with 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90, 90 or 100 tablets."</seg>
<seg id="1865">"Aerius Sirup is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older people included."</seg>
<seg id="1866">Important information on certain other components of Aerius you should not take Aerius syup when you are allergic to the dye E 110.</seg>
<seg id="1867">"if your doctor has informed that you own an incompatibility with some sweets, please contact your doctor before you take this medicine."</seg>
<seg id="1868">"if there is syrup a application spelling, feed for insertions with Skalloys, you can use this alternatively to take the appropriate amount of syrup."</seg>
<seg id="1869">"concerning the treatment of treatment, your doctor will determine the type of allergic rhinitis, under which you suffer and will determine how long you are taking Aerius Sirups."</seg>
<seg id="1870">"however, with children under 2 years of diarrhea, fever and sleeplessness frequent side effects, while in adults fatigue, mouthfulness and headaches were reported than with placebo."</seg>
<seg id="1871">"after the launch of Aerius has been very rare in cases of severe allergic reactions (difficulties in breathing, piping of breathing, jucks, kidney failure and swelling) and rash."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with child-safe wear folder with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">Aerius Lyophilisat for inscription improves the symptoms in allergic rhinitis (through an allergy-inflammation of the nasal sounds, for example hay-carp or house-milk allergy). "</seg>
<seg id="1874">"at intake of Aerius Lyophilisat to take in along with foods and beverages Aerius Lyophilisat, do not need to be taken with water or any other fluid."</seg>
<seg id="1875">"concerning the treatment of treatment, your doctor will determine the type of allergic rhinitis, under which you suffer and will determine how long you should take Aerius Lyophilisat."</seg>
<seg id="1876">"81 If you forget the intake of Aerius Lyophilisat, If you have forgotten your dose to take in time, take them as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1877">"after the launch of Aerius has been very rare in cases of severe allergic reactions (difficulties in breathing, piping of breathing, jucks, kidney failure and swelling) and rash."</seg>
<seg id="1878">"Aerius Lyophilisat for intake is individually in blister packs with 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 or 100 cans of the Lyophilisats to take."</seg>
<seg id="1879">Aerius melting graves improves the symptoms in allergic rhinitis (through an allergy-inflated inflammation of the nasal sounds, for example hay-carp or household milk - allergy). "</seg>
<seg id="1880">"at intake of aserius melting, together with food and drinks Aerius melting-tray does not need to be taken with water or any other fluid."</seg>
<seg id="1881">"concerning the treatment of treatment, your doctor will determine the type of allergic rhinitis, under which you suffer and will determine how long you may take aserius melt tablets."</seg>
<seg id="1882">"86 If you have forgotten the intake of aserius melting, If you have forgotten your dose to take in time, take it as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1883">"Aerius melting-tray is individually packed in blister packs of 5, 6, 10, 12, 15, 18, 20, 60, 50, 60, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90,</seg>
<seg id="1884">"at intake of aserius melting, together with food and drinks Aerius melting-tray does not need to be taken with water or any other fluid."</seg>
<seg id="1885">"if you forget the intake of aserius melting tray, If you have forgotten your dose to take in time, take it as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1886">"after the launch of Aerius has been very rare in cases of severe allergic reactions (difficulties in breathing, piping of breathing, jucks, kidney failure and swelling) and rash."</seg>
<seg id="1887">"Aerius solution for entry is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older persons included."</seg>
<seg id="1888">"if the solution to the insertion of application for preparations for preparation with scaling is attached, you can use this alternatively to take the appropriate amount of solution to take."</seg>
<seg id="1889">"concerning the treatment of treatment, your doctor will determine the type of allergic rhinitis, under which you suffer and will determine how long you should take aserius solution to inhalation."</seg>
<seg id="1890">"however, with children under 2 years of diarrhea, fever and sleeplessness frequent side effects during adults fatigue, mouthdryness and headaches were reported than with placebo."</seg>
<seg id="1891">"97 Aerius solution for insertion is available in bottles with child-safe wear folder with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml package size is a measuring spaspoon or a application spective for feed with scaling of 2.5 ml- and 5 ml cans.</seg>
<seg id="1893">June 2008 Novartis Vaccines and Diagnostics S.r.l. to the Committee for Humanarztend (CHMP) officially approved that the company takes its application for approval by Aflunov to prevent the aviary H5N1-influenza in adults and elderly people.</seg>
<seg id="1894">"Aflunov should be applied to adults and older people to protect the flu, which will be applied by the tribe (type) H5N1 of the influenza A virus."</seg>
<seg id="1895">"this is a special type of vaccine that could cause a future pandemic, which is intended to protect a future pandemic."</seg>
<seg id="1896">"a Grippepandemie breaks out, when a new tribe of the Grippevirus emerges to spread easily from humans, because people still have no immunity (no protection) against it."</seg>
<seg id="1897">"after administration of the vaccine the immune system detects the immune system the parts of the Grippevirus as" "physical" "and forms antibodies against it."</seg>
<seg id="1898">Thus the immune system later is able to form in contact with a Grippevirus this pedigree faster siRNA.</seg>
<seg id="1899">"subsequently the membranes of the virus with the" "surface antigens" "(proteins on the membrane surface which recognizes the human body as body-alien) and used as a component of the vaccine."</seg>
<seg id="1900">"an inspection of some of the study centres showed that the study was not conducted in accordance with the" "Good clinical practice" "(GCP)."</seg>
<seg id="1901">Thus the scale of the clinical data base for evaluating the safety of the vaccine would not consist in order to meet the requirements of the EMEA's guidelines for premandemic vaccines.</seg>
<seg id="1902">"should you take part in a clinical trial and need further information on your treatment, please feel free to contact your doctor."</seg>
<seg id="1903">"if you want more information about the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"it is being applied in combination with other antiviral medicines for the treatment of adults and children over four years, which is caused by human immunity virus from type 1 (HIV-1) which are the acquired quired Immune Deficiency (AIDS)."</seg>
<seg id="1905">"for patients who can not swallow the capsules, stands also as a solution for insertion, but these can not be taken together with Ritonavir because the safety of this combination was not examined."</seg>
<seg id="1906">"Agenerase should only be prisoned when the doctor has tested, which anti-viral medicines of the patient has previously taken, and the likelihood judged that the virus is to speak to the medicine."</seg>
<seg id="1907">The recommended dose for patients over twelve years amounts to 600 mg twice daily which can be taken together with twice daily 100 mg ritonavir and with other antiviral medicines.</seg>
<seg id="1908">For children between four and twelve years and in patients with a body weight of less than 50 kg the recommended dose of Agenerase is governed by body weight.</seg>
<seg id="1909">Agenerasis decreases with intake in combination with other antiviral drugs the HIV-quantity in the blood and keeps them at a low level.</seg>
<seg id="1910">"AIDS not to heal, however, the damage of the immune system and thus the development of AIDS related infections and diseases delay."</seg>
<seg id="1911">"Agenerase has been studied in combination with other antiviral medicines, but without ritonavir, were examined in two main studies with 736 HIV-infected adults, which had previously been treated with protesters."</seg>
<seg id="1912">This with low dosified Ritonavir increased medicine Agenerase was compared with 206 adults who had formerly been used to be used by other proteins.</seg>
<seg id="1913">Main Indicator for the effectiveness was the proportion of patients with non-verifiable concentrations of HIV in the blood (Viruslast) or the change in the viral last after the treatment.</seg>
<seg id="1914">"in the studies with patients who had previously taken no prototype, after 48 weeks under Agenerase, more patients had a Viruslast less than 400 copies / ml than in placebo, but Agenerase was less effective than indinavir."</seg>
<seg id="1915">"in children decreased aromaase also reduced the viral load, although some of the children had been treated earlier with protesters, only very few on the treatment languages."</seg>
<seg id="1916">"in the study with adults, which had been treated earlier with protonavir enhanced medicine Agenerase the Viruslast after 16-week treatment as effective as other proteins:"</seg>
<seg id="1917">"in patients with HIV, which was against four other proteins resistant to four weeks, it came under Agenerase together with Ritonavir to a stronger waste from Viruslast after four weeks as with the patients who took their previous prototype:"</seg>
<seg id="1918">"the most common side effects of Agenerase (observed in more than 1 of 10 patients) are headaches, diarrhoea (diarrhea), nausea (nausea), vomiting, rash and Illnesses (fatigue)."</seg>
<seg id="1919">2 / 3 Agenerase may not be used in patients who may possibly be vulnerable (allergic) against amoavir or one of the other components.</seg>
<seg id="1920">"Ageneric may also not be used in patients with currants (a herbal supplement to treat depression) or drugs, which are just as aromase, and are in high concentrations in the blood of health harmful."</seg>
<seg id="1921">"as in other medicines for HIV, the Ageneric drugs have to take the risk of lipodystrophy (changes in the distribution of body fat), an Osteonekrose (symptoms of an infection which will be caused by the increased immune system)."</seg>
<seg id="1922">The committee for human medicines (CHMP) came to the conclusion that the benefits of Ageneric drugs used in combination with other antiretroviral medicines to treat HIV-1-infected adults and children over four years compared to the risks.</seg>
<seg id="1923">"Agenerase is usually taken together with the pharmacoinetic amplifier ritonavir, but the committee presented that the use of Agenerase in combination with Ritonavir in patients who had previously taken no prototype, not proven."</seg>
<seg id="1924">"Agenerase was originally approved under" extraordinary circumstances, as at the time of approval for scientific reasons only limited information. "</seg>
<seg id="1925">October 2000 the European Commission announced the European Commission of Glaxo Group Limited approval for the consumption of Agenerase in the entire European Union.</seg>
<seg id="1926">Agenerase is shown in combination with other antiretroviral drugs for the treatment of HIV-1- infected versions (PI) pre-treated adults and children from 4 years onwards.</seg>
<seg id="1927">"for usually, Agenerase capsules are to be administered to the pharmacoinetic boosting by Ambelavir, along with low doses of Ritonavir (see sections 4.2 and 4.5)."</seg>
<seg id="1928">The use of amoavir should be carried out in consideration of the individual viral resistance-pattern and the treatment of the patient (see section 5.1).</seg>
<seg id="1929">"the bioavailability of amoavir as a solution to the entry is 14% lower than by Amperavir as capsule; hence, Agenerase capsules and solution for insertion on a milligram per milligram base is not interchangeable (see Section 5.2)."</seg>
<seg id="1930">The recommended dose for Agenerase capsules is 600 mg of ampouflr twice a day together with 100 mg ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="1931">"2 If Agenerase capsules are applied without the amplify additive of Ritonavir (Boostery), must be applied higher doses of Agenerase (1200 mg twice daily)."</seg>
<seg id="1932">The recommended dose for Agenerase capsules is 20 mg of amoavir / kg body weight twice daily in combination with other antiretroviral drugs up to a daily dose of 2400 mg of Aminnavir that should not be exceeded (see Section 5.1).</seg>
<seg id="1933">"Pharmakokinetics, effectiveness and safety of Agenerase in combination with low doses from Ritonavir or other proteins were not examined in children."</seg>
<seg id="1934">"Agenerase is not recommended for use in children under 4 years, due to the failure of data to immortality and effectiveness (see Section 5.2)."</seg>
<seg id="1935">"based on pharmacopoeia, the dose of Agenerase capsules in adult patients should be reduced to 450 mg twice daily and in patients with severe liver dysfunctions to 300 mg twice daily."</seg>
<seg id="1936">"the simultaneous application is to be done in patients with mild or moderate hepatitis, in case of patients with severe hepatic disorder, it is contraindicated (see Section 4.3)."</seg>
<seg id="1937">Agenerase may not be given at the same time with medicines that have a small therapeutic width and also a substrate of the Cytochrom P450-Isoenzymms 3A4 (CYP3A4).</seg>
<seg id="1938">Herbal supplements containing currants (hypericum perforatum) contain, may not be applied due to the risk reduction of reduced plasma centriations and a diminished therapeutic effect of Aminnavir during the intake of Aminnavir (see Section 4.5).</seg>
<seg id="1939">Patients should be advised that Agenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunist infections or other complications of an HIV infection.</seg>
<seg id="1940">The current antiretroviral therapy including treatment with Agenerase does not prevent the risk of transmission of HIV to others through sexual contact or contamination with blood.</seg>
<seg id="1941">For usually Agenerase capsules are supposed to be applied with low doses of Ritonavir and in combination with other antiretroviral medicines (see Section 4.2).</seg>
<seg id="1942">Patients suffering from chronic hepatitis B or C and with an antiretroviral combination therapy did have a increased risk for heavy liver impacts with potentially deadly disease.</seg>
<seg id="1943">"for the event of simultaneous antiviral treatment of hepatitis B or C, please read the specialized information of these medicines."</seg>
<seg id="1944">Patients with pre-existing liver function including a chronic hepatitis are an increased incidence of liver dysfunctions under an antiretroviral combination therapy and should be monitored according to the clinical practice.</seg>
<seg id="1945">"the simultaneous application of Agenerase and Ritonavir with Fluticason or other gluctionists, which will be confused via CYP3A4, is not recommended that the potential benefits of treating the risk of systemic corrosive effects including Morbus Cusdepended and Suppression of the adrenaline function (see Section 4.5)."</seg>
<seg id="1946">Since the metering of the HMG-CoA-Reduktase-Hemmer Lovematin and Similatin is strongly dependent on CYP3A4 is an simultaneous administration of Agenerase with Lovastatin and Simultatin is not recommended because of the increased risk of myopathies including Rhabdomyolysen.</seg>
<seg id="1947">"4 For some medicines which can cause serious or life-threatening side effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and Warfarin (under surveillance of the International Standardisation ratio), are methods for determination of the active concentration."</seg>
<seg id="1948">"in case of patients who take these medicines at the same time, Agenerase may be less effective due to reduced Plastimpiegel of Aminnavir. (see Section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic interactions with Ambelavir, the effectiveness of hormonal contrast can be changed, however the information is not sufficient to estimate the type of interactions."</seg>
<seg id="1950">"when methadone is given at the same time with Ambelavir, patients therefore should be monitored on opiatentance symptom symptoms, especially if there are also low doses of Ritonavir administered."</seg>
<seg id="1951">"due to the possible risk of toxicity, due to the high propylenglycolousealts of the Agenerase solution to invitations, this formulation is contraindicated with children under an age of four years and should be applied with caution in certain other patient groups."</seg>
<seg id="1952">Agenerase should be divided into duration 5 if a rash is accompanied by systemic or allergic symptoms or the veils are involved (see Section 4.8).</seg>
<seg id="1953">"in case of patients who were an antiretroviral therapy including protector inhibitors, was reported on the appearance of diabetes mellitus, hyperglycaemia or an exactionation of an existing diabetes mellitus."</seg>
<seg id="1954">Many of the patients had different diseases related to their treatment drugs that were associated with the development of a diabetes mellitus or hyperglycaemia.</seg>
<seg id="1955">"B. higher age, and with drug-dependent factors, such as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="1956">"for domestic aid patients (type A and B), which were treated with protesters, reports of an increase in bleeding including spontaneous kutaner hematoms and hemorthrosen."</seg>
<seg id="1957">In HIV-infected patients with severe immunity can develop an inflammatory response to asymptomatic or residuous opportunist infections that leads to heavy clinical conditions or deterioration of symptoms.</seg>
<seg id="1958">"although a multifactorial ether is accepted (including application of corticosteroids, alcohol intake, heavy immunosuppression, higher Body-Mass-Index), were reported cases of Osteonekrose especially in patients with advanced HIV disease and / or long-term use of antiretroviral combination therapy (ART)."</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width Agenerase may not be given at the same time with medicines that have a small therapeutic width and also a substrate of the Cytochrom P450-Isoenzymms 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with lower therapeutic width Agenerase with Ritonavir may not be changed together with pharmaceuticals whose ingredients are primarily associated with CYP2D6 and for the increased plasma cutting with heavier and / or life-threatening side effects.</seg>
<seg id="1961">"it has been shown that Rifampicin a 82% reduction in AUC by Aminnavir causes, which can lead to an virology failure and lead to an resistance development."</seg>
<seg id="1962">"at the trial, the lowest Plastimpiegel is observed by a dosage of other protein inhibitors in combination with Ritonavir, were very frequently unwanted effects on the liver."</seg>
<seg id="1963">Johanniskraut (Hypericum perforatum) The Serumber of Ambelavir can be slower by the simultaneous application of herbal preparations (hypericum perforatum).</seg>
<seg id="1964">"when a patient is already crowned by Johanniskraut, the Ambelavirspiegel and, if possible, the viral load to review and the Johanniskraut."</seg>
<seg id="1965">A dosage adjustment for one of the medicine is not required when Nelfinavir is administered together with Aminnavir (see also Efavirenz below).</seg>
<seg id="1966">"508% increases, for Cmax on the other by 30% lower, if Ritonavir (100 mg twice daily) in combination with Amperavir capsules (600 mg twice daily) was administered."</seg>
<seg id="1967">"in clinical trials, Dosieves were applied twice daily and ritonavir 100 mg twice daily, applying the effectiveness and immortality of this treatment schemas."</seg>
<seg id="1968">52% lower if Aminnavir (750 mg twice daily) in combination with Kaletra (400 mg Lopinavir + 100 mg Ritonavir twice a daily).</seg>
<seg id="1969">"the Cmin values of Aminnavir in plasma, which were obtained during the combination of Amperra (600 mg twice daily) with Kaletra (400 mg Loponavir + 100 mg ritonavir twice a day) in combination with 100 mg Ritonavir twice a daily basis."</seg>
<seg id="1970">"a dosage intake for the simultaneous administration of amoavir and Kaletra can not be given, however, there will be a narrow surveillance, since the effectiveness and immortality of this combination is not known."</seg>
<seg id="1971">"there was no pharmacoinetic study conducted in combination with Didanosin, however, due to the antacid component of didanosin is recommended that the revenue of didanosin and Agenerase are at least one hour apart. (see Antazida below)."</seg>
<seg id="1972">Therefore in combination of Efavirenz in combination with Amperavir (600 mg twice daily) and Ritonavir (100 mg twice daily) no dosage adjustment required.</seg>
<seg id="1973">The treatment with Efavirence in combination with amoavir and Saquinavir is not recommended as the exposure of both protesters would be low.</seg>
<seg id="1974">The effect of Nevirapin to other types of protein and existing limited data are suspected that Nevirapinto the serverkonzentration of Aminnavir may sensed.</seg>
<seg id="1975">"if these drugs should be used simultaneously, caution is advisable, since Delavirdin because of the reduced or perhaps subtherapeutic plastic mask could be less effective."</seg>
<seg id="1976">"if these drugs are used together, caution is advisable; a thorough analysis of clinical and virological monitoring should be made, as a precise predicting of the effect of combining amoavir and Ritonavir is difficult to Delavirdin."</seg>
<seg id="1977">The simultaneous gripping of amoavir and Rifabutin led to a rise in plasma concentration (AUC) of Rifabutin by 193% and thus to a rise in with rifabutin side effects.</seg>
<seg id="1978">"if it is required for clinical reasons, rifabutin together with Agenerasis will be administered to a reduction in dosage of rifabutin at least half of the recommended dose, though no clinical data are available."</seg>
<seg id="1979">"Pharmakokinetic studies with Agenerase in combination with erythromycin have not been carried out, however, the Plastimpiegel of both medicines could be increased in the case of simultaneous administration."</seg>
<seg id="1980">The simultaneous application of twice daily 700 mg Fosamprenavir and 100 mg of ketoconazol once daily led to an increase in the Cmax of Ketoconazol in plasma by 25% and the AUC (0-pin) compared to the value that has been observed after 200 mg Ketoconazol once daily without simultaneous application of Fosamprenavir with Ritonavir.</seg>
<seg id="1981">"other medicines which are listed below, including substrates, inhibitor or induction of CYP3A4, if they are used together with Agenerase, possibly to interactions."</seg>
<seg id="1982">"patients should therefore be connected to toxic reactions, which are associated with these drugs, in combination with Agenerase."</seg>
<seg id="1983">"based on the data of other proteins, it is advisable that Antazida cannot be taken at the same time as Agenerase, as it can be resoratory disorders."</seg>
<seg id="1984">"the simultaneous application of anticonvulva, which are known as enzyminduktors (phenytoin, phenobarbital, Carbamazepin), with Ambelavir can lead to a degradation of the plasma seal of Ambelavir."</seg>
<seg id="1985">"the Serum concentrations of calcium block such as Amlodipin, Diltiazem, roodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine,</seg>
<seg id="1986">"the simultaneous intake with Ageneric may increase their plasma centric levels, and reinforce with PDE5-inhibitors in connection with PDE5-inhibitors, including hypotting, tendure and priapism (see Section 4.4)."</seg>
<seg id="1987">"in a clinical study, in the Ritonavir 100 mg capsules twice daily along with 50 µg fluticasonpropionat-Plasmaspiegel, while the endogenous cortisol rose by approximately 86% (90% reduction of 82 to 89%)."</seg>
<seg id="1988">"consequently, the simultaneous Got of Agenerase is not recommended with Ritonavir along with these gluctionists who is not recommended that the potential benefits of treating the risk of systemic corrosive effects (see Section 4.4)."</seg>
<seg id="1989">At HMG-CoA-Reduktase-Hemmics such as Lovematin and Similatin that is strongly dependent on CYP3A4, are pronounced enhancements of Plastimpiegel in simultaneous administration of Agenerase. "</seg>
<seg id="1990">"since Plasmaspiegelincreases with this HMG-CoA reduction of myopathy, including Rhabdomyolyse, the combined application of these medicines will not be recommended using Aminnavir."</seg>
<seg id="1991">"it will be a prevalent monitoring of the therapeutic concentrations up to stabilisation of the mirror, since the plasma concentration of cyclosporin, Rapamycin and Tacticlim can be increased (see Section 4.4)."</seg>
<seg id="1992">"therefore, Ageneric may not be used together with oral ingested Midazolam (see Section 4.3) while being offered with paraxial Midazolam caution."</seg>
<seg id="1993">Data for the simultaneous application of parenteral Midazolam with other protein release notes on a possible increase in plasma seal from Midazolam to 3-fold.</seg>
<seg id="1994">"when methadone is administered together with Amflavir, patients therefore should therefore be monitored on opiatentance symptom symptoms, especially if there are also low doses of Ritonavir administered."</seg>
<seg id="1995">"due to the lower negligence of historical comparisons, there is currently no recommendation to be given as the amoavir- dose, if Aminnavir is administered simultaneously with methadon at the same time."</seg>
<seg id="1996">"with simultaneous gripping of Warfarin or other orial antibodies together with Agenerase, a strengthened control of INR (International normals Ratio) is recommended because of the possibility of a weakening or strengthening of anti-thrombal effect (see Section 4.4)."</seg>
<seg id="1997">The effect of an additional administration of Ritonavir on hormonal contraceptive is not predictable so alternative methods for conception is recommended.</seg>
<seg id="1998">A careful monitoring of the therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended by both Aesipramine and Nortryptilin) (see Section 4.4).</seg>
<seg id="1999">This drug may only be applied after pregnancy only after careful inspection of the possible farm for the mother compared to the potential risks for fetus.</seg>
<seg id="2000">"in the milk latile rats, amoavir-related substances were proven, but it is not known whether Aminnavir passes to men into the mother's milk."</seg>
<seg id="2001">A re-production of impairments which was administered by the embedding in the uterus up to the end of the stagnation of Ambelavir during the lactation period showed a diminished increase in the 12 body weight during pregnancy.</seg>
<seg id="2002">The further development of accountability including fertilisation and reproduction capacity was not affected by the administration of amoavir to the womb.</seg>
<seg id="2003">The immortality of Agenerase was examined in adults and children from 4 years in controlled clinical studies in combination with various other antiretroviral medicines.</seg>
<seg id="2004">"most of the side effects associated with the Agenerase treatment side effects were slightly up to moderate, they entered early and led rarely to treatment."</seg>
<seg id="2005">"with many of these events is not clarified whether they are related to the intake of Agenerase or another at the same time for HIV treatment, or if they are a result of atrocities."</seg>
<seg id="2006">"most of the side-mentioned side effects come from two clinical studies (PROAB3001, PROAB3006) in which with protector number, patients 1200 mg of Agenerase occurred twice a day."</seg>
<seg id="2007">"events (degrees 2 to 4), which were employed by the investigators as in connection with the study media, and at more than 1% of patients were performed, and under the treatment of elaborate laboratory changes (degrees 3 to 4) are listed."</seg>
<seg id="2008">"the antiretroviral Combination therapy has been associated with an redistribution of the body fat (Lipodystrophy) in HIV-patients, including loss of peripheral and visceral fat tissues, hypertrophic of the breasts and dorsocervical liposing."</seg>
<seg id="2009">Under 113 antiretroviral do not pre-treated people who were treated with amoavir in combination with Lamivudine / Zidovudine about a medium duration of 36 weeks was only observed (&lt; 1%).</seg>
<seg id="2010">"in the study PROAB 3006, at 245 NRTI- treated patients under ampouavir 7 cases (3%) compared to 27 cases (11%) in 241 patients under Indinavir, in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0,001)."</seg>
<seg id="2011">"rashes were normally slightly up to moderate, erythemed or maculopapulously nature, with or without itch and disappeared spontaneously during the second treatment week and disappeared spontaneously within two weeks, without that the treatment had to be abandoned with amoavir."</seg>
<seg id="2012">"cases of osteonekrose have been reported in particular in patients with general known risk factors, advanced HIV disease or long-term use of an antiretroviral combination therapy (ART)."</seg>
<seg id="2013">In HIV-infected patients with severe immunity can be developed at the time of an antiretroviral combination therapy (ART) a inflammatory response to asymptomatic or residuous opportunistic infections (see Section 4.4).</seg>
<seg id="2014">"treated with PI-treated patients, the 600 mg of Agenerase twice daily along with low dosified Ritonavir (degrees 2 to 4) and laboratory changes (degrees 3 and 4) which were observed in patients with low-generic Ritonavir, very frequently applied."</seg>
<seg id="2015">"in case of overdosage, the patient is based on signs of an intoxication (see section 4.8) if required, necessary support measures are necessary."</seg>
<seg id="2016">"Ambelavir binds to the active centre of HIV-1-protease, and thereby prevents the procedures of viral gag- and gag-pol- Polyprotrudes with the consequence of an education unripe, not infectious virus infection."</seg>
<seg id="2017">The antiviral activity of Aminnavir in vitro against HIV-1 IIIB was examined both in acut and chronic infallitic cellular lines (MT-4, CEM-CCRF, H9) as well as on peripheral blood vessels. "</seg>
<seg id="2018">The 50% of Hemmkonzentration (IC50) of Amperavir lies in the range of 0.012 to 0.08 µm in acut infected cells and amounts to three µm in chronic cells.</seg>
<seg id="2019">The connection between the activity of amoavir against HIV-1 in vitro and the inhibition of the HIV-1 replication on people is not yet defined.</seg>
<seg id="2020">"during the treatment of antiretroviral, patients with the currently approved fosamprenavir / Ritonavir-dosages were used - like with other ritonavir-oosterols - the mutations used only rarely observed."</seg>
<seg id="2021">"in sixteen of 434 antiretroviral do not pre-treated patients, the 700mg Fosamprenavir with 100mg ritonavir came twice daily in the study ESS100732 occurred twice daily in the study ESS100732."</seg>
<seg id="2022">"an initial analysis of the insulin analysis of 13 of 14 children, where a virology failure did not appear in the 59 included, with protesters did not pre-treated patients, showed resistance muster that were similar to those with adults."</seg>
<seg id="2023">"L10F / I / V, V11I, I80I, I2I, I48I, I71V, I71V, I71V, V8A / I, I85V, I85V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V and I93L / M."</seg>
<seg id="2024">In the study APV30003 and its extension APV30005 (700 mg Fosamprenavir / 100 mg Ritonavir twice a day: N = 107) in patients with virology failure above 96 weeks, the following protector-mutations on: "</seg>
<seg id="2025">Evaluation-based analyses Genotypic interpretations systems can be applied to devaluation of the activity of amoavir / Ritonavir or Fosamprenavir / Ritonavir for patients with protector-resistant isolation.</seg>
<seg id="2026">"current (July 2006) ANRS-AC-11-algorithm for Fosamprenavir / Ritonavir / V, or I50V, I8A / C / F / F / F / F / F / F / F / G, I84V and L90M, with Ritonavir, with Ritonavir and a decreased likelihood of an virology response (resistance)."</seg>
<seg id="2027">The conclusions regarding the relevance of certain mutations or mutations are subject to change due to additional data and it is advised to move up the current interpretations systems to analyse the results of resistance tests.</seg>
<seg id="2028">Based on photypic resistance of clinical analysis systems can be used in combination with the genotypic data for estimation of the activity of amoavir / Ritonavir / Ritonavir / Ritonavir for patients with protector-resistant isolation.</seg>
<seg id="2029">Companies that distribute diagnostic resistance tests have developed clinically-phenomenal cut-offs (divider) for FPV / RTV that can be applied to the interpretation of outcomes of an resistance tests.</seg>
<seg id="2030">"each of these four with reduced sensitivity to Aminnavir Associated genetic model creates a certain Crusher against Ritonavir, the sensitivity against Indinavir, Nelfinavir and Saquinavir, but generally preserved."</seg>
<seg id="2031">"there is currently data to cross-resistant between amoavir and other protein numbers for all 4 Fosamprenavir resistance, either alone or in combination with other mutations."</seg>
<seg id="2032">"on the basis of five andtwenty antiretroviral, non-treated patients in which a Fosamprenavir / Ritonavir (three of 25 isolation), Indinavir / Ritonavir (three of 24 insulin), inquinavir / Ritonavir (three of 24 insulates), Saquinavir / Ritonavir (four of 24 insulates) and Tipranavir / Ritonavir (four of 24 insulates)."</seg>
<seg id="2033">"conversely, amoavir retains its activity against some other protein-resistant isolation in the preservation of this activity seems to be dependent on the number and the type of resistance-mutations in the isolation."</seg>
<seg id="2034">"the early disruption of a reconciling therapy is recommended to hold the accumulation of a variety of mutations in borders, which can affect the following treatment."</seg>
<seg id="2035">"the cover of the effectiveness of Agenerase in combination with Ritonavir 100 mg twice daily based on the study PRO30017, a randomized open trial (Viruslast ≥ 1000 copies twice daily) and Nukleosidanaloga (NTTI) or a standard therapy (standard of care, SoC) with a PI, primarily with a lower ritual" "oostert". ""</seg>
<seg id="2036">"sixty-three-sixty-three (n = 163) patients with a proven virus-sensitivity to Agenerase, at least another PI and at least one NRTI were included in the part study A of PRO30017."</seg>
<seg id="2037">The primary analysis presented the non-subjection of APV / Ritonavir in comparison to the SoC-PI Group in the connection to the time-violence (AAUCMB) in the plasma after 16 weeks in a non-subject area of 0.4 logten copies / ml.</seg>
<seg id="2038">The cover of the effectiveness of imbroosterous Agenerase is based on two uncontrolled studies with a total of 288 HIV-infected children aged 2 to 18 years of which 152 were treated with PI.</seg>
<seg id="2039">"in the studies, Agenerase solution for taking and capsules in dosages of 15 mg / kg three times daily, 20 mg / kg twice daily and 22.5 mg / kg twice daily, whereby the majority of patients receive 20 mg / kg twice a day."</seg>
<seg id="2040">"it was given no low dosified Ritonavir at the same time; the majority of patients with PI-treated patients had previously received at least one (78%) or two (42%) of the patients together with Agenerase, NRTIs."</seg>
<seg id="2041">After 48 weeks approximately 25% of the patients included a Plasma HIV-1-RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml with an median increase in CD4 cell count from 26 cells / mm ³ (n = 74) compared to the starting value. "</seg>
<seg id="2042">19 Basics to this data should be considered with PI-optimised children of the expected benefits of "unsastoostertem" Agenerase. "</seg>
<seg id="2043">After oral administration the average duration (tmax) up to maximum Serum concentration of amoavir approximately 1 to 2 hours for the capsule and approximately 0.5 to 1 hour for the solution.</seg>
<seg id="2044">"508% increases, for Cmax. at about 30% reduced, if Ritonavir (100 mg twice daily) together with Amperavir (600 mg twice daily) was administered."</seg>
<seg id="2045">Administration of Aminnavir with a meal leads to a 25% of the AUC but has no effect on the concentration of amoavir 12 hours after dosage (C12).</seg>
<seg id="2046">"therefore the minimum concentration in the Steady-State (Cmin, ss) remained uninfluenced by food intake, although the simultaneous food intake and the rate of the resorption remained."</seg>
<seg id="2047">The seeming volume capacity is approximately 430 l (6 l / kg at a body weight of 70 kg) and is adjustable to a large distribution volume and an enormous penetration of amoavir from the bloodstream into the tissue.</seg>
<seg id="2048">"this change leads to a decrease in the total concentration of the drug in the plasma, with the amount of unoccupied Ambelavir, which represents the active part, probably remains unchanged."</seg>
<seg id="2049">"during the absolute concentration of unbent ammatavir constant, the percentage of the free active component in the steelation period in the steady state over the range of Cmax, ss up to Cmin, ss."</seg>
<seg id="2050">"therefore medicines must induce drug or inhibits or a substrate of CYP3A4, with caution when they are given at the same time with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Agenerase capsules, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily amoavir-exposure such as adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">Aminnavir is from the solution 14% less bioverable than from the capsules; therefore Agenerase solution and Agenerase capsules are not interchangeable on a milligrammar basis.</seg>
<seg id="2053">"also, the renal clearance of Ritonavir neglected, therefore the effect of a kidney function is likely to be low to the elimination of amoavir and Ritonavir."</seg>
<seg id="2054">These treatment units lead to amoavir-Plasmaspiegulas comparable those that can be obtained from healthy proportionally after a dose of 1200 mg of Aminnavir twice daily without simultaneous administration of Ritonavir.</seg>
<seg id="2055">"in long-term studies on cancery with amoavir an mice and rats stood at doses of male animals, hepatea hepatropes in dosages (mice) or 3,8- triple (rat) of exposure to people, after twice daily gift of 1200 mg of Ambelavir, entspils."</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of hepatcell adenoma and Karzinome has not yet been clarified and the relevance of these observed effects for man is unclear.</seg>
<seg id="2057">"however, resulting from clinical studies as well as from therapeutical application, however, however little notes for the adoption of a clinical relevance of these findings."</seg>
<seg id="2058">"in a standard battery of in-vivo- and In-vitro-Genotoxicity tests, the bacterial-lymphoma testing (ames test), mouse-lymphom test, microsctest of rats and chromosensuprey-legged, was amassavir neither mutagen nor genotoxious."</seg>
<seg id="2059">These liver toxicity can be monitored and proven in clinical daily life by measurement of AST, ALT and the activity of alkaline phosphate ase. "</seg>
<seg id="2060">"so far in clinical studies have not observed yet significant liver toxicity in patients, neither during the administration of aromases nor after the end of the treatment."</seg>
<seg id="2061">Studies on toxicity in juveniles who were treated at an age of 4 days both at the checkers and with the Ambelavir-treated animals a high mortality.</seg>
<seg id="2062">"in a systemic plasma exposure, the significant under (rabbits) or not significantly higher (rats) than the expected exposition under therapeutic dosage, however, were observed a number of minor changes including Thymuselongation and lower skeleton changes that refer to a hesitated development."</seg>
<seg id="2063">"24 If Agenerase capsules are applied without the amplify additive of Ritonavir (Boostery), must be applied higher doses of Agenerase (1200 mg twice daily)."</seg>
<seg id="2064">The recommended dose for Agenerase capsules is 20 mg of amoavir / kg body weight twice daily in combination with other antiretroviral drugs up to a daily dose of 2400 mg of Aminnavir that should not be exceeded (see Section 5.1).</seg>
<seg id="2065">The simultaneous application is intended to be treated in patients with watchful or lighter hepatitis with caution in case of patients with severe liver malfunctions it is contraindicated (see Section 4.3).</seg>
<seg id="2066">"26 For some medicinal drugs can cause serious or life-threatening side effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and Warfarin (under surveillance of the International Standardisation ratio), are methods for determination of the active concentration."</seg>
<seg id="2067">Agenerase should be set on length 27 if a rash is accompanied by systemic or allergic symptoms or the veiling are involved (see Section 4.8).</seg>
<seg id="2068">"increased risk for a Lipodystrophy was associated with individual factors, such as higher age, and with drug-dependent factors, such as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2069">"it has been shown that Rifampicin a 82% reduction in AUC by Aminnavir causes, which can lead to an virology failure and lead to an resistance development."</seg>
<seg id="2070">"508% increases, for Cmax on the other by 30% lower, if Ritonavir (100 mg twice daily) in combination with Amperavir capsules (600 mg twice daily) was administered."</seg>
<seg id="2071">"the Cmin values of Aminnavir in plasma, which were obtained during the combination of Amperra (600 mg twice daily) with Kaletra (400 mg Loponavir + 100 mg ritonavir twice a day) in combination with 100 mg Ritonavir twice a daily basis."</seg>
<seg id="2072">"a dosage intake for the simultaneous administration of amoavir and Kaletra can not be given, however, there will be a narrow surveillance, since the effectiveness and immortality of this combination is not known."</seg>
<seg id="2073">The treatment with Efavirence in combination with amoavir and Saquinavir is not recommended as the exposure of both protesters would be low.</seg>
<seg id="2074">"if these drugs are used together, caution is advisable; a thorough analysis of clinical and virological monitoring should be made, as a precise predicting of the effect of combining amoavir and Ritonavir is difficult to Delavirdin."</seg>
<seg id="2075">"if it is required for clinical reasons, rifabutin together with Agenerasis will be administered to a reduction in dosage of rifabutin at least half of the recommended dose 31, although there is no clinical data."</seg>
<seg id="2076">"the Serum concentrations of calcium block such as Amlodipin, Diltiazem, roodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nimodipine, Nim</seg>
<seg id="2077">"in a clinical study, in the Ritonavir 100 mg capsules twice daily along with 50 µg fluticasonpropionat-Plasmaspiegel, while the endogenous cortisol rose by approximately 86% (90% reduction of 82 to 89%)."</seg>
<seg id="2078">"with simultaneous gripping of Warfarin or other orial antibodies together with Agenerase, a strengthened control of INR (International normals Ratio) is recommended because of the possibility of a weakening or strengthening of anti-thrombal effect (see Section 4.4)."</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg Ethinylestradiol plus 1.0 mg Norethindron) led to a decrease in AUC and Cmin by Amperavir by 22% bzw.</seg>
<seg id="2080">This drug may only be applied after pregnancy only after careful inspection of the possible farm for the mother compared to the potential risks for the fetus.</seg>
<seg id="2081">A re-production of impairments which was administered by the embedding in the uterus until the end of the stagnation of Ambelavir during the lactation period showed a diminished increase in mind.</seg>
<seg id="2082">The immortality of Agenerase was examined in adults and children from 4 years in controlled clinical studies in combination with various other antiretroviral medicines.</seg>
<seg id="2083">"in case of overdosage, the patient is based on signs of an intoxication (see section 4.8) if required, necessary support measures are necessary."</seg>
<seg id="2084">The antiviral activity of Aminnavir in vitro against HIV-1 IIIB was examined both in acut and chronic infallitic cell lines (MT-4, CEM-CCRF, H9) as well as peripheral bloodymphocytes. "</seg>
<seg id="2085">The 50% of Hemmkonzentration (IC50) of Amperavir lies in the range of 0.012 to 0.08 µm in acut infected cells and amounts to three µm in chronic cells (1 µm = 0,50 µg / ml).</seg>
<seg id="2086">"conversely, amoavir retains its activity against some other protein-resistant isolation in the preservation of this activity seems to be dependent on the number and the type of resistance-mutations in the isolation."</seg>
<seg id="2087">"based on these data, the treatment should be considered with PI pre-treated children to the expected benefits of" "unbent" "vase."</seg>
<seg id="2088">"during the absolute concentration of unbent ammatavir constant, the percentage of the free active component in the steelation period in the steady state over the range of Cmax, ss up to Cmin, ss.."</seg>
<seg id="2089">"therefore medicines must induce drug or inhibits or a substrate of CYP3A4, with caution when they are given at the same time with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">Also the renal clearance of Ritonavir neglected; therefore the effect of a kidney function is likely to be low on the elimination of amoavir and Ritonavir.</seg>
<seg id="2091">"in long-term studies on the cancery with amoavir an mice and rats stood in doses of male animals, hepatoms hepatular adenoma for dosages (mice) or 3,8- triple (rat) of exposure to man after twice daily gift of 1200 mg of Ambelavir."</seg>
<seg id="2092">The underlying mechanism for the origin of hepatzelulary adenoma and Karzinome has not yet been clarified and the relevance of these observed effects for man is unclear.</seg>
<seg id="2093">"however, resulting from clinical studies as well as from therapeutical application, however little notes for the adoption of a clinical relevance of these findings."</seg>
<seg id="2094">"in a standard battery of in-vivo- and In-vitro-Genotoxicity tests, the bacterial-lymphoma testing (ames test), mouse-lymphom test, microsctest of rats and chromosencropped-legged, was amassavir or sotoxious."</seg>
<seg id="2095">Studies on toxicity in juveniles who were treated at an age of 4 days both at the checkers and with the Ambelavir-treated animals a high mortality.</seg>
<seg id="2096">"these results can conclude that in juveniles the metabolic systems are not fully mature, so Aminnavir or other critical components of the formulation (z)."</seg>
<seg id="2097">Agenerase solution to the insertion is shown in combination with other antiretroviral medicines to treat HIV-1-infected versions (PI) pre-treated adults and children from 4 years onwards.</seg>
<seg id="2098">The use of Ritonavir "astoosterter" Agenerase solution to the entry was neither taken with PI pretreated patients nor with PI-treated patients.</seg>
<seg id="2099">"the bioavailability of amoavir as a solution to the entry is 14% lower than by Amperavir as capsule; hence, Agenerase capsules and solution for insertion on a milligram per milligram base is not interchangeable (see Section 5.2)."</seg>
<seg id="2100">Patients should be as soon as they are able to swallow the capsules with the intake of the solution to the inserting (see Section 4.4).</seg>
<seg id="2101">The recommended dose for Agenerase solution amounts to 17 mg (1.1 ml) Aminnavir / kg body weight three times daily in combination with other antiretroviral medicinal drugs up to a daily dose of 2800 mg Aminnavir that should not be exceeded (see Section 5.1).</seg>
<seg id="2102">"additionally, since no dosage intake for the simultaneous application of Agenerase solution to take and low dosified Ritonavir can be avoided to avoid this combination with these patients."</seg>
<seg id="2103">"although a dosage adjustment for amoavir is not necessary for use, is an application of Agenerase solution for taking patients with kidney failure (see Section 4.3)."</seg>
<seg id="2104">"due to the potential risk of a toxic reaction as a result of high propylenglycolgehalts, Ageneric solution for invitations in toddlers and children under 4 years, in pregnant women, with patients with reduced liver function or liver blends and in patients with kidney failure."</seg>
<seg id="2105">The simultaneous administration may lead to a competitive inhibition of the metabolic ization of these medicines and potentially cause serious and / or life-threatening side effects such as cardiac arrhythmia (z).</seg>
<seg id="2106">Patients should be advised that Agenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunist infections or other complications of an HIV infection.</seg>
<seg id="2107">The current antiretroviral therapy including treatment with Agenerase does not prevent the risk of 47 a transmission of HIV to others through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that can cause serious or life-threatening side effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and Warfarin (under surveillance of the International Standardisation ratio), are methods for determination of the active concentration."</seg>
<seg id="2109">Agenerase should be adjusted to long when a rash is accompanied by systemic or allergic symptoms or the veils are involved (see Section 4.8).</seg>
<seg id="2110">"increased risk for a Lipodystrophy was associated with individual factors, such as higher age, and with drug-dependent factors, such as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2111">"for domestic aid patients (type A and B), which were treated with protesters, reports of an increase in bleeding including spontaneous kutaner hematoms and hemorthrosen."</seg>
<seg id="2112">"it has been shown that Rifampicin a 82% reduction in AUC by Aminnavir causes, which can lead to an virology failure and lead to an resistance development."</seg>
<seg id="2113">"508% increases, for Cmax on the other by 30% lower, if Ritonavir (100 mg twice daily) in combination with Amperavir capsules (600 mg twice daily) was administered."</seg>
<seg id="2114">"the simultaneous intake with Ageneric may increase their plasma centric levels, and lead to PDE5-inhibitors in connection with PDE5-inhibitors, including hypotting, tendings and priapism (see Section 4.4)."</seg>
<seg id="2115">On the basis of data on 54 other CYP3A4-inhibitors are expected to be significant by Midazolam significantly higher plasma concentration by Midazolam.</seg>
<seg id="2116">"the potential risk for the human being is not known, Ageneric solution to inhalation may not be applied due to possible toxic reactions of fetus to the enthused propylene glycol during pregnancy."</seg>
<seg id="2117">"in the milk latile rats, amoavir-related substances were proven, but it is not known whether Aminnavir passes to men into the mother's milk."</seg>
<seg id="2118">A re-production of impairments which has been administered by the embedding in the uterus up to the end of the lacing time Ambelavir during the lactation a decreased increase in the 55 body weight at night's departure.</seg>
<seg id="2119">The immortality of Agenerase was examined in adults and children from 4 years in controlled clinical studies in combination with various other antiretroviral medicines.</seg>
<seg id="2120">"with many of these events is not clarified whether they are related to the intake of Agenerase or another at the same time for HIV treatment, or if they are a result of atrocities."</seg>
<seg id="2121">"during the treatment of antiretroviral, patients with the currently approved fosamprenavir / Ritonavir-dosages were used - like with other ritonavir-oosterols - the mutations used only rarely observed."</seg>
<seg id="2122">The early disruption of a miserable 60 therapy is recommended to hold the accumulation of a variety of mutations in borders that can affect the following treatment.</seg>
<seg id="2123">62 Basics on this data should be considered with PI-optimised children of the expected benefits of "unbent" Agenerase. "</seg>
<seg id="2124">The seeming volume capacity is approximately 430 l (6 l / kg at a body weight of 70 kg) and is adjustable to a large Veteilvolumenical and an enormous penetration of amoavir from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the origin of hepatcellular adenoma and Karzinome has not yet been clarified and the relevance of these observed effects for man is unclear.</seg>
<seg id="2126">"in a systemic plasma exposure, the significant under (rabbits) or not significantly higher (rats) than the expected exposition under therapeutic dosage, however, were observed a number of minor changes including Thymuselongation and lower skeleton changes that refer to a hesitated development."</seg>
<seg id="2127">Perhaps you would like to read this later. − If you have any further questions please contact your doctor or a pharmacist. − This medicine was personally prescribed for you.</seg>
<seg id="2128">"it can harm other people, even if they have the same complaints like you. − If any of the above side effects you have significantly impairs or you may notice the side effects that are not specified in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2129">Your doctor will normally apply Agenerase capsules along with low doses ritonavir to strengthen the effect of Agenerase.</seg>
<seg id="2130">The use of Agenerase is based on your doctor for you the individual viral resistance of treatment and of your treatment prescribed.</seg>
<seg id="2131">"inform your doctor, if you suffer from one of the above conditions or take any of the above medicines."</seg>
<seg id="2132">"if your doctor is recommended that you have Agenerase capsules along with low doses from Ritonavir to gain the effect (boosting), make sure you have carefully read before starting the usage information on Ritonavir."</seg>
<seg id="2133">"likewise, there are no adequate information to be recommended to use Agenerase capsules, together with Ritonavir for the efficiency of children aged 4 to 12 years or in general in patients under 50 kg of body weight."</seg>
<seg id="2134">"therefore, it is important that you can read the section" "If intake of Agenerase with other medicines," before you begin with the intake of Agenerase. "</seg>
<seg id="2135">"possibly you need additional factor VIII to control the blood circulation. − For patients who receive an antiretroviral combination therapy, a redistribution, accumulation, or loss of body fat."</seg>
<seg id="2136">"if you can lead to serious side effects, such as Carbamazepin, phenobarbital, phenytoin, phenamycin, tricyclic antidepressants, rapamycin, tricyclic antidepressants, will perform your doctor maybe additional blood tests to minimize possible security issues."</seg>
<seg id="2137">It is recommended that HIV-positive women should not breastfeeding their children under no circumstances to avoid a transfer of HIV.</seg>
<seg id="2138">Transportation and storage of machines There were no studies on the influence of aromatics on driving resistance or the ability to serve machines.</seg>
<seg id="2139">"please take this medicine only after consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="2140">"Didanosin) take it, it is advisable that you take this more than an hour before or after a generase, otherwise the effects of Agenerase can be diminished."</seg>
<seg id="2141">Dose of Agenerase capsules is 600 mg twice daily along with 100 mg ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="2142">"if your doctor decides that the intake of Ritonavir is not suitable for you, you will have to take higher doses (1200 mg Ambelavir twice daily)."</seg>
<seg id="2143">"85 Damit Agenerase delivers as much as possible as possible, it is very important that you have prescribed the whole day dose which you have prescribed for you."</seg>
<seg id="2144">"if you have taken a larger amount of Agenerase, when you should have taken over the prescribed dose of Agenerase, you should immediately contact your doctor or a pharmacist."</seg>
<seg id="2145">"if you forget the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think, and then put the intake as before."</seg>
<seg id="2146">"in the treatment of a HIV infection, it is not always possible to tell if emerging-effects caused by Agenerase, by other medicines that may be taken at the same time, or by the HIV disease itself."</seg>
<seg id="2147">"headache, rubbing-feeling, disease, break-esteem, break-break (redness, blowing or itch) - occasionally can the rash may be severe in-in-law nature and you can force the break of taking this medication by means of force."</seg>
<seg id="2148">"refinement, depression, sleeping troubles, appetite loss of cribbles in the lips and in the mouth, uncontrolled movements pain, insocontrolled or obese, the transamos are called, increase of a enzymes of pancreas called Amylase"</seg>
<seg id="2149">Increased blood levels for sugar or cholesterol (a certain blood fat) Heightened blood levels of a substance called Bilirubin swelling of the faces, the lips and the tongue (angioödem bzw. "</seg>
<seg id="2150">"this can make fat loss of legs, poor and in face, a fetus at the stomach and in other internal organs, breast enlargement and obesity in the neck."</seg>
<seg id="2151">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="2152">"therefore, it is important that you can read the section" "If intake of Agenerase with other medicines," before you begin with the intake of Agenerase. "</seg>
<seg id="2153">"in some patients who receive an antiretroviral combined treatment, one can develop as Osteonekrose (dying of bone tissues as a result of insufficient demand of bone disease)."</seg>
<seg id="2154">"Didanosin) take it, it is advisable that you take this more than an hour before or after a generase, otherwise the effects of Agenerase can be diminished."</seg>
<seg id="2155">"94 Damit Agenerase delivers as much as possible as possible, it is very important that you have prescribed the whole day dose which you have prescribed for you."</seg>
<seg id="2156">"if you forget the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think, and then put it the ingesting as before."</seg>
<seg id="2157">"headache, rubbing-feeling, disease, break-esteem, break-break (redness, blowing or itch) - occasionally can the rash may be severe in-in-law nature and you can force the break of taking this medication by means of force."</seg>
<seg id="2158">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="2159">Dose of Agenerase capsules is 600 mg twice daily along with 100 mg ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="2160">"with this Agenerase takes as much as possible as possible, it is very important that you have prescribed the whole day dose which you have prescribed for you."</seg>
<seg id="2161">"if you have taken greater quantities of Agenerase, when you should have taken over the prescribed dose of Agenerase, you should immediately contact your doctor or a pharmacist."</seg>
<seg id="2162">The benefits of Ritonavir "astoosterter" Agenerase solution to the entry was neither used with protector-treated patients nor with protector-treated patients.</seg>
<seg id="2163">"for the application lower doses of Ritonavir (usually applied to reinforcement of the effect [boosting] of Agenerase capsules) together with Agenerase solution, can be given no dosing recommendations."</seg>
<seg id="2164">"Ritonavir solution to invitations), or in addition propylenglycol during the intake of Agenerase solution (see also Agenerase may not be taken)."</seg>
<seg id="2165">"your doctor will possibly have you on side effects which can be associated with the propylenglycolcontent of the Agenerase solution for insertion in connection, especially if you have a kidney or liver disease."</seg>
<seg id="2166">"111 If you can lead to severe-in-law side effects, such as Carbamazepin, phenobarbital, phenytoin, maramycin, tricyclic antidepressants, rapamycin, tricyclic antidepressants, will perform your doctor maybe additional blood tests to minimize possible security issues."</seg>
<seg id="2167">Ritonavir solution to invitations) or an additional propylenglycol may not be taken during the intake of Agenerase (see Agenerase may not be taken).</seg>
<seg id="2168">Important information on certain other components of the Agenerase solution for inserting the solution includes propylenglycol which can lead in high doses of side effects.</seg>
<seg id="2169">"Propylenglycol can cause a number of side-effects including Krampfanatic, cardiopsy, cardiac disease and the reduction of the red blood cells (see also Agenerase may not be taken; special caution when intake of Agenerase is required precautions)."</seg>
<seg id="2170">"if you forget the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think, and then put the intake as before."</seg>
<seg id="2171">"headache, rubbing-feeling, disease, break-esteem, break-break (redness, blowing or itch) - occasionally can the rash may be severe in-in-law nature and you can force the break of taking this medication by means of force."</seg>
<seg id="2172">"this can make fat loss of legs, poor and in face, a fetus at the stomach and in other internal organs, breast enlargement and obesity in the neck."</seg>
<seg id="2173">"other components are propylenglycol, Macrogol 400 (Polyethylenglycol 400), Accurferchlorid, artificial chewinoxen, Levomenthol, Citominol, Citronensol, ratriumcitrate-dihydrate, rounded water."</seg>
<seg id="2174">"the applicdity and the duration of the treatment with Aldara depend on the disease to be borne by the disease in the genital area, Aldara is a week to wear for a maximum of 16 weeks. • In case of small basal cancer cycles, it is possible during one or two four-week treatment cycles, with four weeks pause between treatment cycles, three times weekly."</seg>
<seg id="2175">"the cream is dilated in front of sleep-layered to the affected skin areas so that they have enough for a long time (about eight hours) on the skin, before it is washed."</seg>
<seg id="2176">"in all studies, Aldara was compared to a placebo (the same creams but without the active ingredients). • Aldara was tested in four main studies at 923 patients with warts in the genital area at 16 weeks."</seg>
<seg id="2177">The main indicator of the efficacy was the number of patients with complete cooling of the patients. • Aldara was also studied at 724 patients with small basal cell carcinoma in two studies where patients were treated for six weeks and Aldara or the placebo either daily or five times weekly.</seg>
<seg id="2178">The main indicator of the efficacy was the number of patients with complete cooling of tumors after twelve weeks. • Aldara was also tested in two studies in a total of 505 patients with aktinic notation.</seg>
<seg id="2179">"in all studies, Aldara was more effective than placebo. • For the treatment of warts in the genital area, the total gap between 66% to 80% in those with the patients treated patients. • The results of the two studies carried out in basal cancer patients compared to 0% to 3% in the placebo group."</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the use of the cream (pains or itch).</seg>
<seg id="2181">"clinically typical, not hypertension, nonhypertrophic keratants (AKS) in the face or on the scalp on immunomant adults, if the size or the number of lesions limit the effectiveness and / or the acceptance of a crotherapy, and other topical treatment options contraindicated or less suitable."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before entering and leave 6 to 10 hours on the skin."</seg>
<seg id="2183">Treatment with imiodine creme is as long as to continue until all the visible pareigts in the genital or Perianalies have disappeared or up to a maximum of 16 weeks per treatment period.</seg>
<seg id="2184">Any interruption in the above treatment process should be erated when intensive local inflammation transactions occur (see Section 4.4) or when in the treatment range an infection is observed.</seg>
<seg id="2185">"when follow the follow-up examination 4 to 8 weeks after the second treatment period the patients treated only discompletely cured, a different therapy should be started (see Section 4.4)."</seg>
<seg id="2186">"when a dose was omitted, the patient commits the cream as soon as he / she noticed this and then continue with the usual therapeutic plan."</seg>
<seg id="2187">"imiiodine creme is in a thin layer to carry and cast into the geres, with feigwarts of infected skin area, until the cream is completely retired."</seg>
<seg id="2188">"it should take place in these patients, between the benefits of a treatment with Imiiodine and the risk associated with a possible worsening of their autoimmune disease."</seg>
<seg id="2189">"it should take place in these patients, between the benefits of a treatment with Imiquimod and the associated with a possible organist or GRAFT-versus-host- reaction."</seg>
<seg id="2190">"in other studies, in which no daily pre-authyism has been carried out, two cases of severe phimosis and a case with one of circumcision's leading strides were observed."</seg>
<seg id="2191">"in case of an application of imiiodine creams in higher than the recommended doses, there is increased risk for heavy local skin irritation (see section 4.2.) In rare cases were also observed under case of severe local skin irritation which made a treatment needed and / or to a temporary physical impairment."</seg>
<seg id="2192">"in cases where such reactions at the outcome of the urethra came up, some women had trouble passing urine, which made a pouts and treatment of the affected area."</seg>
<seg id="2193">The use of imiiodine creme immediately following a treatment with other cutaneous funds for the treatment of external auction in the genital and Perianalies are so far no clinical experiences.</seg>
<seg id="2194">Limited data refers to an increased rate of moisture reduction in HIV-positive patients; Imiquimod cream in this patient group has shown a lower effectiveness in this patient group.</seg>
<seg id="2195">"the treatment of the basic cell carcinoma with imiquimod within 1 cm to the eyelids, the nose, the lips, or the hairline has not been studied."</seg>
<seg id="2196">Local sports actions are common but the intensity of these reactions increases in general during therapy or the reactions form after completion of the treatment with Imiquimod cream.</seg>
<seg id="2197">"if possible due to the complaints of the patient or due to the severity of the local left transactions, a treatment plan can be made of several days."</seg>
<seg id="2198">The clinical result of therapy can be assessed after the regeneration of the treated skin around 12 weeks after the end of treatment.</seg>
<seg id="2199">"there is currently no data on long-term healing rates of more than 36 months after the treatment, should be considered to be supervised by other suitable therapy forms."</seg>
<seg id="2200">"in patients with recurrent and treated BCCs do not lie in clinical experiences, therefore the application is not recommended in the tumors."</seg>
<seg id="2201">Data from an open clinical trial suggest that at large tumors (&gt; 7.25 cm2) a lower likelihood of response to the imitic therapy.</seg>
<seg id="2202">"ibiiodine was not examined for the treatment of acoustical keratants on eyelids, inside the nose or the ears or on the lips area inside the lips."</seg>
<seg id="2203">There are only very limited data on the application of imiquimod for the treatment of acoustical keratants to anatomical bodies outside the face and the scalp.</seg>
<seg id="2204">"the data on acoustical keratose of the underpoor and hands will not support the effectiveness in this application, therefore a kind of application is not recommended."</seg>
<seg id="2205">Local sports actions frequently occur but these reactions usually take over the therapy of intensity or go back after lowering the therapy with Imiquimod cream.</seg>
<seg id="2206">"if the local carbances can cause serious discomfort or very strong, the treatment may be exposed for a few days."</seg>
<seg id="2207">"from the data of an open clinical trial, patients with more than 8 AK- Läsions reported a lower full healing rate than patients with less than 8 lesions."</seg>
<seg id="2208">"due to the immutable properties, imiiodine creme should be used with caution in patients who receive an immunosuppressive treatment (see 4.4)."</seg>
<seg id="2209">"from animal studies do not pass direct or indirect harmful effects on the pregnancy, the embryonic / fetal development, the debinding or postnatal development (see 5.3)."</seg>
<seg id="2210">"although neither for one-time still has been achieved, quantifiable application quantifiable Serumber (&gt; 5ng / ml) can no recommendation be given during the lactation period."</seg>
<seg id="2211">The most frequently shared referenced and as likely or possibly using the application of Imiquimod creme in connection with three times weekly treatment were local reactions in the treatment of the fetters (33,7% of the patients treated with Imiiodine-treated patients).</seg>
<seg id="2212">Among the most frequently reported and considered probably or possibly with the application of Imiquimod creme in connection with side effects belong to the applicationslocation with an incidence of 28.1%.</seg>
<seg id="2213">The patients treated by 185 with Imiquimod-Creme-treated Basaliom patients from a placebo-controlled clinical study of phase III reported side effects are shown below.</seg>
<seg id="2214">The most common ones as likely or possibly with the application of Imiiodine creme in connection with effect were in these studies a reaction at the applicationslocation (22% of the patients with Imiiodine-treated patients).</seg>
<seg id="2215">The side effects that were listed by 252 in placebokontrolded clinical studies of phase III with imiquimod-Creams treated patients with actinic notation are listed below.</seg>
<seg id="2216">"according to the clinical signs proposed by the clinical signs indicates that it is often shown in these placebo-controlled clinical trials with three times week-controlled treatment with beyiodine-cream (30%), Erosion (30%), excitation / descents (23%) and Ödem (14%) (see Section 4.4)."</seg>
<seg id="2217">"according to the clinical signs proposed by the clinical signs clearly shows that in these studies with five times of weekly treatment with Imiiodine creme very often to serious Eryorum (31%), severe erosions (13%), and to severe harness (19%)."</seg>
<seg id="2218">"in clinical studies on the examination of the application of imiiodine for the treatment of actincal keratose, Alopezie was established with a frequency of 0.4% (5 / 1214) at the treatment location or in the surrounding area."</seg>
<seg id="2219">"the weekly unique orale intake of 200 mg Imiquimod, which corresponds to the content of about 16 bags, could nausea, vomiting, headaches, myalgies and fever."</seg>
<seg id="2220">"the clinical-law-in-law-law-effect, which entered into several orals doses of &gt; 200 mg, consisted in hypotonia, which is dedicated to orinal or intravenous hydration."</seg>
<seg id="2221">In a pharmacoinetic examination have been proven according to the topical application of imiquimod increasing systemic concentrations of the alphainterferons and other cytokine.</seg>
<seg id="2222">In 3 non-assuring the relevant phase 3 efficacy studies could be shown that the effectiveness in relation to a complete cooling of the fetters in an imiodine treatment over 16 weeks of placebo treatment is clearly superior.</seg>
<seg id="2223">"at 60% of the total of 119 with Imiquimod, patients incurred completely off; this was at 20% of the 105 with placebo therapy in the case (95% CI):"</seg>
<seg id="2224">A complete cooling could be achieved at 23% of 157 with Imiquimod-treated male patients compared to 5% of 161 with placebo treated male patients (95% CI):</seg>
<seg id="2225">The effectiveness of imiiodine for five-time use per week over 6 weeks was examined in two double-flacons, placebo-controlled clinical studies. "</seg>
<seg id="2226">The target-tumors were histological confirmed individual primary superfluous basal cell carcinoma with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"those from an open, uncontrolled-long-term study after four years of this data show that about 79.3% [95% CI (73.7%, 84.9%)] all treated patients were clinically cured and this was also 48 months long."</seg>
<seg id="2228">"the effectiveness of imiodine at three times weekly application in one or two treatment periods of 4 weeks, interrupted by a four-week, treatment period, was examined in two double-blinked, placebokontrolfiled clinical studies."</seg>
<seg id="2229">"the patients had clinically typical, visible, discrete, not hypertrophic, not hypertrophic AK- lesions within a separate 25 cm2 large treatment areals on the unhairy pillows or on the face."</seg>
<seg id="2230">The single-year data from two combined obstructions studies show patients with clining cooling down after one or two treatment periods a reaction rate of 27% (35 / 128 patients).</seg>
<seg id="2231">"the approved indications of external feigts, actinic keratose and superfiziic Basalcellom occur in paediatric patients usually not up and were therefore not examined."</seg>
<seg id="2232">"Aldara Creme was examined in four randomized, double-based placebo-controlled studies on children aged 2 to 15 years with Molluscum Contagiosum (Imiquimod n = 576, placebo n = 313)."</seg>
<seg id="2233">The effectiveness of Imiquimod could not be shown in these studies where dosages were not shown (3x / week for a period of ≤ 16 weeks).</seg>
<seg id="2234">A minimal systemic recording of the 5% hemiodine creams by the skin of 58 patients with acoustic keratose was observed during three weeks of weekly application during 16 weeks.</seg>
<seg id="2235">"the highest number of pharmaceuticals in serum at the end of the week 16 were observed between 9 and 12 hours and be observed 0.1, 0.2 and 1,6 ng / ml of application in the face (12.5 mg, 1 bag) and on the hands / poor (75 mg, 6 bags)."</seg>
<seg id="2236">The calculated-obvious half-day period was approximately 10times higher than the 2th half-value after subcutaneous application in a previous study; that points to a prolonged retention of the medication by means of the skin.</seg>
<seg id="2237">The data for systemic exposure shown that the resorption of imiiodine intended for topical application of patients aged 6 - 12 years was low and comparable with healthy adults and adults with an acoustic keratose or superfizial basal cell carcinoma.</seg>
<seg id="2238">"in a four month study on the paint toxicity in the rat led doses from 0,5 up to 2.5 mg / kg KG to significant weight-weight and increased malt-weight; a also four months long-performed study on the paint application yielded with the mouse no similar effects."</seg>
<seg id="2239">A two-year trial for carcinogenicity in mice at three days per week induced no tumors at the use point.</seg>
<seg id="2240">"the corresponding mechanism is not known, but since Imiquimod is only a low systematic absorption from the human skin and is not mutation, is a risk to man due to the systemic exposition as very low."</seg>
<seg id="2241">The tumors appeared in the group of mice who was treated with the real-free creams, formerly and in larger numbers in the control group with low UVR. "</seg>
<seg id="2242">"there can other people harm, even though these same symptoms have you like you. − If any of the above side effects you have significantly impaired or you may notice that not in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2243">● Feigwarts (Condylomata acuminata) have formed on the skin in the area of genitals (Geschlechtsorgane) and Anus (After) ● the superficial Basalcelloma this is a frequent rewarding, slowly growing form of skin creatic with very low probability of spreading to other parts of the body. "</seg>
<seg id="2244">"if it remains uncovered, it can lead to resolutions, especially in the face - hence, is an early detection and treatment."</seg>
<seg id="2245">"Aktinic keratants are smoking areas of skin, which occur in humans, which were exposed during their previous life much of sunlight."</seg>
<seg id="2246">"Aldara should only be applied with flat actinic notation in the face and on the scalp in patients with a healthy immune system, where your doctor decided that Aldara is the most suitable treatment."</seg>
<seg id="2247">"Aldara Creams supports your body's own immune system in the production of natural substances, which help your body to fight the superficial coriodine, or to fight for the infection with neigwarts."</seg>
<seg id="2248">"O If you already have used earlier once Aldara Cream or other, similar supplements please inform your doctor if you begin with your immune system. o informing your doctor if you treat problems with your immune system. o avoid the contact with eyes, lips and nasal mucosa."</seg>
<seg id="2249">"in case of accidental contact the cream with water away. o Wend you disseminate the cream than your doctor. o If reactions to the expulose of Aldara Cream does not occur with a association or plaster creams, which will give you strong inconvenience, wash the cream with a mild soap and water."</seg>
<seg id="2250">"once the reactions are flaws, you can continue treatment. o check your doctor if they have no normal blood-image"</seg>
<seg id="2251">"if this daily cleaning is not carried out under the foreskin, can be attributed to increased occurrence of pre-skin swelling, thin, the skin or trouble passing the foreskin."</seg>
<seg id="2252">"use Aldara Cream not in the Urethra (urethra), in the vagina (Scheide), the cervix (cervix) or within the Anus (After)."</seg>
<seg id="2253">"taking other medicines serious problems with your immune system, you should use this medication for no more than a treatment cycle."</seg>
<seg id="2254">If you have sexual intercourse during the infection with ruction in the genital area is the treatment with Aldara Creme after intercourse (not previously) perform.</seg>
<seg id="2255">"please inform your doctor or a pharmacist if you apply other medicines or have recently applied, even if it is not prescription drugs."</seg>
<seg id="2256">Breastfeeding your infants during the treatment with Aldara Cream not because Imiquimod came into the mother's milk.</seg>
<seg id="2257">The frequency and duration of the treatment are different at Feigwarts, Basalcellular and acoustic keratose (see specific instructions for every application area). "</seg>
<seg id="2258">"wear a thin layer of Aldara Cream on the clean, dry skin place with the Feigwarts and prohibit the cream cautious on the skin as far as the cream."</seg>
<seg id="2259">Men with feigts under the foreskin must wash the foreskin every day and wash the skin area beneath them (see Section 2 "What you need to consider before the use of Aldara Cream?).</seg>
<seg id="2260">Please talk to your doctor or a pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">"6 weeks each week, 5 days a week in order to carry a sufficient amount of Aldara Creams to cover the affected area and 1 cm around this area."</seg>
<seg id="2262">Very common side effects (with more than 1 of 10 patients expected) Frequent Side Effects (in less than 1 of 10 patients to expect) selective side effects (when less than 1 of 10 patients) Very rare side effects (if less than 1 of 10,000 patients expected) "</seg>
<seg id="2263">Inform your doctor / your doctor or your pharmacist / your pharmacist immediately when you don't feel at ease during the use of Aldara Cream.</seg>
<seg id="2264">"if your skin reacts too strong to the treatment with Aldara Creme, you should not use the cream, wash the affected skin area with water and a mild soap, wash your doctor or your pharmacist."</seg>
<seg id="2265">A reduced number of blood cells may make you accumulate for infections; it can make effect that you get faster a blue stain from you or she can emerge.</seg>
<seg id="2266">"inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects which are not specified in this usage information."</seg>
<seg id="2267">"in addition, you can feel Juckreiz (32% of patients), burning (26% of patients) or pain in the fields, to which you have applied Aldara Creams (8% of patients)."</seg>
<seg id="2268">Mostly it deals with easier conceptions which can end within approximately 2 weeks after finishing the treatment again.</seg>
<seg id="2269">"occasionally, some patients notice changes in the applicationslocation (Wundsecret, swelling, floral deformation, bubbles, bubbles) or irritability, nausea, dry mouth, grievous symptoms and fatigue."</seg>
<seg id="2270">"occasionally, some patients suffer from changes at the applicationsort (Bluten, inflammation, swelling, swinging or grieving, diarrhea, diarrhoea, reddish, reddish, redness, limbs, fences, fences, fences, fever, weakness or shakes."</seg>
<seg id="2271">"Althirazyme is used for the enzymes therapy in patients with secured diagnosis of a Mukopolysaccharides I (MPS I; α-L-Iduronidase deficiency) to deal with brain or nerves in connection)."</seg>
<seg id="2272">"this means that certain substances (glycosaminoglycaane, gags) are not to be reconstructed and thus in most organs in the body blammers and these compensate."</seg>
<seg id="2273">"following not neurological symptoms of MPS I can occur: enlarged liver, stiff joints, the movements are scared, diminished lung volumes, cardiac disease, cardiac disease."</seg>
<seg id="2274">The treatment with Althirazyme should be monitored by a doctor who has experience in the treatment of patients with MPS I or other hereditary metabolic disorders.</seg>
<seg id="2275">"administration of Althirazyme should take place in a hospital or clinic with reconditioning devices, and patients need under circumstances prior to administration of appropriate medicine to prevent an allergic reaction."</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.</seg>
<seg id="2277">"in the study, mainly the safety of the drug has been tested, however, it was also measured by its effectiveness (by pursuing its effect with regard to reducing the GAG concentrations in the urine and in terms of the size of the liver)."</seg>
<seg id="2278">In children under five years Althirazyme the GAG concentrations in the urine around 60% and half of the treated children pointed out a normal great liver at the end of the study.</seg>
<seg id="2279">"the most common side effects of Althirazyme at patients aged over 5 years (be observed if more than 1 of 10 patients) are headaches, skin headaches, skin pain, pain relief, pain in the limbs (in hands and feet), Hitzegezer, fever and reactions to the infusion place."</seg>
<seg id="2280">"very common side effects in patients under five years are increased blood pressure, reduced oxygen saturation (a measuring size of the pulmonary function), tachykarst (accelerated heart rate), fever and shakes."</seg>
<seg id="2281">"Althirazyme may not be applied in patients, which may possibly be highly vulnerable (allergic) to Laronidase or one of the other components (anaphylactic reaction), not applied."</seg>
<seg id="2282">"the European Drug Agency (EMEA) will be announced every year all new information that may be known, review and update this summary."</seg>
<seg id="2283">"the manufacturers of Althirazyme will receive patients, the althirazyme, as regards the reactions to the infusion and the development of antibodies."</seg>
<seg id="2284">June 2003 the European Commission announced the European Commission of Genzyme Europe BV.</seg>
<seg id="2285">Laronidase is a recombinant form of human α-L-Iduronidase and is produced by recombinant DNA technology using Cho-mammal-cell culture (Chinese Hamster Ovary, Eierstock of the Chinese Hamsters). "</seg>
<seg id="2286">"Althirazyme is for long-term enzymes in patients with secured diagnosis of a Mukopolysaccharides I (MPS I, α -L-Iduronidase deficiency) indexed to treat the non-neurological manifestations of the disease (see Section 5.1)."</seg>
<seg id="2287">The treatment with Althirazyme should take place by a doctor who owns experience in the treatment of patients with MPS I or other hereditary metabolic disorders.</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can if the patient can tolerate this every 15 minutes in single steps on a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">"the safety and effectiveness of Althirazyme for adults over 65 years has not been determined, and for these patients cannot be recommended any dosing scheme."</seg>
<seg id="2290">"the safety and effectiveness of Althirazyme should not be determined in patients with kidney or liver insufficiency, and for these patients may not be recommended any dosing scheme."</seg>
<seg id="2291">"with Althirazyme patients may develop infusion conditional reactions, which are defined as any related side effect that occurs during infusion or until the end of infusion (see section 4.8)."</seg>
<seg id="2292">"for this reason, these patients should continue to be monitored closer to these patients, and the infusion of althirazyme should only be made available in an appropriate clinical environment, in the revitalization equipment for medical emergencies."</seg>
<seg id="2293">"due to the clinical phase 3 study, it is expected that nearly all patients form IgG antibodies against Laronidase, usually within 3 months from treatment."</seg>
<seg id="2294">"patients, the antibodies or symptoms of a infusion conditional reaction must be treated with caution (see sections 4.3 and 4.8)."</seg>
<seg id="2295">"as little experience regarding the resumption of treatment after a longer break, must be cautious due to the theoretically increased risk-reaction after an interruption of treatment."</seg>
<seg id="2296">60 minutes before the start of infusion with medication (antihistamine and / or antipyretica) to treat the potential appearance-related reactions.</seg>
<seg id="2297">"in case of an easy or moderate-related reaction, the treatment should be associated with anti-histamine and paracetamol / Ibuprofen and / or a reduction in infusion rate at half of the infusion rate in which the reaction occurred."</seg>
<seg id="2298">"in case of single, heavy infusion conditional reaction must be stopped until the symptoms are brought into decline, treatment with anti-histamine and paracetamol / Ibuprofen is to consider."</seg>
<seg id="2299">"infusion can be recorded with a reduction in infusion rate on 1 / 2 - 1 / 4 of infusion rate, when the reaction occurred, will be resumed again."</seg>
<seg id="2300">3 are used (antihistamine and paretamol / Ibuprofen and / or Corticosteroids) as well as a reduction in infusion rate on 1 / 2 - 1 / 4 of infusion rate in which the presenters reaction is performed.</seg>
<seg id="2301">"Althirazyme should not be applied at the same time with chloroquin or Procain, because a potential risk of interference with the intrinsiellular recording of Laronidase."</seg>
<seg id="2302">"veterinary studies do not leave a direct or indirect impact on the pregnancy, the embryonic development, birth and postnatal development (see Section 5.3)."</seg>
<seg id="2303">"since no data on newborns were expelled from Laronidase over the mother's milk, is recommended, during the treatment with Althirazyme not to breastfeeding."</seg>
<seg id="2304">Side effects in clinical trials were arranged primarily as infusion conditional reactions that were observed at 53% of patients in phase 3-study (treatment duration up to 4 years) and 35% of patients in the study with participants under 5 years (treatment duration up to 1 year).</seg>
<seg id="2305">Unwanted drug transactions associated with Althirazyme who were observed during phase-3 study or older at a total duration of 45 patients aged 5 years or older at a treatment of treatment: very often (≥ 1 / 10); frequently (≥ 1 / 100 to &lt; 1 / 10).</seg>
<seg id="2306">"in some patients with severe MPS-I-conditional participation of the upper respiratory and lungs in the history, in addition, severe reactions to, including bronchospasm, breathing, and face-face (see Section 4.4)."</seg>
<seg id="2307">"children unsolicitation effects in connection with Althirazyme, which were reported during a phas- 2 study involving 20 patients aged under 5 years, with predominantly heavy duty form and treatment duration up to 12 months, reported are listed in the table."</seg>
<seg id="2308">"100 E / kg intravenously once weekly (recommended dose), 200 E / kg intravenous once weekly, 200 E / kg intravenous every 2 weeks or 300 e / kg intravenous every 2 weeks."</seg>
<seg id="2309">"most patients came to a serokonversion within 3 months after the start of treatment, whereby at the age of 5 with a heavier break-shape usually within one month to a serokonversion (average of 26 days over 45 days in patients at the age of 5 years and older)."</seg>
<seg id="2310">"until the end of the phase 3 study (or up to a premature excretion from the study) occur at 13 / 45 patients none by radiosophilation (rip) Assay discreputable antibodies, among which 3 patients who have never came to serokonversion."</seg>
<seg id="2311">"patients with failure to lower antibodies to a robust reduction in the GAG mirror in Harn, while in patients with high antibodies to determine a variable reduction of GAG in the harn."</seg>
<seg id="2312">Four patients (three in phase 3 study and one in the phase 2 study) showed a marginale until low-neutral inhibital effect on enzymatic Laronidase- activity in vitro which seemed to not affect the clinical effectiveness and / or reducing GAG in the harn.</seg>
<seg id="2313">"the presence of antibodies did not seem to stand in connection with the incidence of unwanted drug transactions, even if the occurrence of unwanted drug actions typically coincided with the formation of IgG antibodies."</seg>
<seg id="2314">The grounds for the enzymes is located in one of the hydrolysis of the accumulated substrate and the prevention of a further accumulation of sufficient restoration of enzymes.</seg>
<seg id="2315">"after intravenous infusion, Laronidase is rapidly taken out of the circulation and cells into the lysosomes, most likely about Mannose-6-phosphate receptors."</seg>
<seg id="2316">"the safety and effectiveness of Althirazyme have been tested in randomized, double-blinked, placebokontrolaved phase-3 study at 45 patients aged 6 to 43 years."</seg>
<seg id="2317">"although patients were recruited for the study, the entire disease spectrum was reported, the majority of patients were seen from the middle phenomenon and only one patient proved to be the heavy balance."</seg>
<seg id="2318">Patients were curated if they had a forcated expiratory volume (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">The primary endpoints for the effectiveness were the percentage change to be expected to be expected to be expected in the 6-minuten-.</seg>
<seg id="2320">All patients were subsequently curated for an open label extension where they received another 3.5 years (182 weeks) each week 100 E / kg Althirazyme.</seg>
<seg id="2321">"after 26 weeks of therapy the patients treated with Althirazyme treated patients compared to the placebo group, an improvement in the pulmonary function and the enviability that is shown in the following table."</seg>
<seg id="2322">The open extension study showed an improvement and / or maintaining this effects of up to 208 weeks in the Althirazyme / Althirazyme-group and from 182 weeks in placebo / Althirazyme group as from the following table.</seg>
<seg id="2323">The decrease of the expected percentage FEV is not significant over this period of clinically not significant and the absolute pulmony-volume increases further proportional to the height of growing children.</seg>
<seg id="2324">"from 26 patients with a Hepatomegaly treatment, 22 (85%) until the end of the study had a normal liver size."</seg>
<seg id="2325">Within the first 4 weeks a clear waste of the GAG mirror in the Harn (µg / mg Kreatinin) was established until the end of the course was constant.</seg>
<seg id="2326">"in regard to the heterogeneous illness of illness between patients, characterized by using a combined endpoint variable, the clinically significant changes in the 6-minute walk, movement of the school-span AHI and Sehsharfe), was generally an improvement in 26 patients (58%), no change in 10 patients (22%) and a deterioration of 9 patients (20%)."</seg>
<seg id="2327">"it was carried out a one-year open phase 2 study conducted in which primarily the security and Pharmakokinetics of Althirazyme were examined in 20 patients who were at the time of their recording to study under 5 years old (16 patients with severe debit form and 4 with middle circulation)."</seg>
<seg id="2328">In four patients the dosage was increased due to increased gAG- mirror in the harn in week 22 in the last 26 weeks to 200 E / kg.</seg>
<seg id="2329">In several patients a size growth (n = 7) and a weight increase (n = 3) has been determined after the Z-Score for these age group The younger patients with heavy wear-form (&lt; 2.5 years) and all 4 patients with heavy duty cycle form a normal spiritual evolving form (&lt; 2.5 years) and all 4 patients with heavy wear-shape are limited limited or even no progress in cognitive development.</seg>
<seg id="2330">"in a phase-4 study, studies on pharmacodynamic impacts of different althirazyme-Dosation schemata were conducted at the GAG mirror in the harn, the liver volume and the 6-minute walk."</seg>
<seg id="2331">"100 E / kg intravenously once weekly (recommended dose), 200 E / kg intravenous once weekly, 200 E / kg intravenous every 2 weeks or 300 e / kg intravenous every 2 weeks."</seg>
<seg id="2332">"the dosage scheme with 200 E / kg intravenous every 2 weeks can be with patients, the difficulties with weekly information; however, is not proven that the long-term clinical effectiveness of these two doses are equal."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will evaluate each new information, which will be available annually, and if required, the summary of the characteristics of the drug will be updated."</seg>
<seg id="2334">The therapeutic profile in patients at the age of 5 were similar to older and less affected patients.</seg>
<seg id="2335">"based on conventional studies on safety spharmacology, toxicity in exceptional gases, toxicity in repeatable gift and reproductionist, the preclinical data do not have any special hazards for the people."</seg>
<seg id="2336">"as no compatibility studies were carried out, this medicine may not be mixed with other medicines, except with those under 6.6 listed."</seg>
<seg id="2337">"if the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution under controlled and validated aseptic conditions were carried out."</seg>
<seg id="2338">5 ml of concentarte for the production of a solution in flow-bottle (typ- I-glass) with Stoples (silicone-chlorbutyl-rubber) and sealing (aluminium) with cracker (polypropylene).</seg>
<seg id="2339">10 preparation of the althirazyme infusion (by means of aseptic technique) • Je according to body weight of the individual patient first determine the number of dilution bottles.</seg>
<seg id="2340">"the owner of the permit has to complete the following study programme within the given time, whose results are the basis for the annual evaluation report on the benefit-risk ratio."</seg>
<seg id="2341">"this register will include longer-term security and efficacy information to patients who were treated with Althirazyme, as well as data for the natural Progredience of the disease in patients without this treatment."</seg>
<seg id="2342">"in case of patients suffering from MPS I, a enzyme called α-L-Iduronidase, which divides specific substances in the body (Glycosaminoglycaane), either in small amount before or this enzyme is missing."</seg>
<seg id="2343">If you are allergic to one of the components of Althirazyme or if you have an severe allergic reaction to Laronidase.</seg>
<seg id="2344">"infusion conditional reaction is any side effect that occurs during infusion or until the end of infusion (see section 4" "Which side effects are possible"). "</seg>
<seg id="2345">"when using Althirazyme with other medicines, please inform your doctor if you take drugs, the chloroquin or Procain, because a possible risk of a diminish effect of althirazyme."</seg>
<seg id="2346">"please inform your doctor or a pharmacist if you have no other medicines or have recently taken, including prescription drugs."</seg>
<seg id="2347">References for handling - dilution and application The concentrates for the production of an infusion solution must be diluted before the application and is intended for intravenous application (see information for doctors or medical professionals).</seg>
<seg id="2348">The initial infusion rate of 2 E / kg / h can if the patient can tolerate this every 15 minutes gradually increased to a maximum dose of 43 E / kg / h.</seg>
<seg id="2349">"in some patients with severe MPS-I- conditional participation of the upper airways and lungs in the history, however occurred severe reactions to, including bronchospasm, breathing, fire and face."</seg>
<seg id="2350">"very common (appearance at more than 1 of 10 patients): • headaches • Cornish diseases • rash, pain adaches, pain adaches, pain, pain, poor and legs • flake • Hypertone • slightly oxygen in the blood • reaction to the infusion place"</seg>
<seg id="2351">"the European Drug Agency (EMEA) will be released every new information, which will be available annually, and if required, the packers will be updated."</seg>
<seg id="2352">"if the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution under controlled and validated aseptic conditions were carried out."</seg>
<seg id="2353">Preparing the althirazyme infusion (by means of aseptic technology) • Je according to body weight of the individual patient first determine the number of bottles consumed.</seg>
<seg id="2354">Alimta is used together with cisplatin (another medicine against cancer) if cancer is not resezable (caused by surgery alone or spread themselves slightly to other parts of the body). • advanced or metastatic "non-clauses" lung cancer which is not the sheet cells.</seg>
<seg id="2355">"Alimta is used in patients who had previously been treated yet, in combination with cisplatin and with patients who have previously used other chemotherapies than usual therapy."</seg>
<seg id="2356">"to reduce side effects, patients should take care of vitamin B12 patients during treatment with Alimta and folic acid (a vitamin) and injections of vitamin B12."</seg>
<seg id="2357">"when Alimta is administered with cisplatin, should be used before or after the gift of cisplatin in addition an" antiemetic "(medicines for fatigue) and liquids (to bend a liquid-gel)."</seg>
<seg id="2358">"in patients whose blood-image changes or when certain other side effects occur, the treatment should be raised, disset or the dose decreases."</seg>
<seg id="2359">The active form of Pemetrexed thus demanded the formation of DNA and RNA and prevent the cells to share.</seg>
<seg id="2360">The transformation of Pemetrexed into its active form goes easier in cancer cells than in healthy cells, which leads to higher concentrations of the active form of medication by means of a longer active period of cancer cells. "</seg>
<seg id="2361">Alimta was examined for the treatment of malignant Plothelioms Alimta studied in a main study of 456 patients who had previously received any chemotherapy against their disease.</seg>
<seg id="2362">"in the treatment of non-national lung cancer, the effects of Alimta were compared to 571 patients with local advanced or metastatic disease which had previously been treated with chemotherapy, with the effects of docetaxel (other medicines for cancer)."</seg>
<seg id="2363">Alimta was also compared with gemcitabine (another medicine against cancer) and both in combination with cisplatin in a study on 1 725 patients who had previously received no chemotherapy for lung cancer.</seg>
<seg id="2364">"patients who were treated with Alimta and cisplatin were treated at an average of 12,1 month, compared to 9,3 months in general administration of cisplatin."</seg>
<seg id="2365">"in patients who had previously received an chemotherapy, was the average survival time with Alimta 8,3 months, compared to 7,9 months at Docetaxel."</seg>
<seg id="2366">"however, in both studies there are patients suffering in which cancer is not the turnable cells. in the administration of Alimta longer survival times than with the comparative medicine."</seg>
<seg id="2367">September 2004 the European Commission of the company Eli Lilly Nederland B.V. has been approached by Alimta throughout the European Union.</seg>
<seg id="2368">Every diarrhea bottle has to be reactivated with 4.2 ml 0.9% low sodium solution (9 mg / ml) which results in a solution of 25 mg / ml.</seg>
<seg id="2369">The corresponding volume of the necessary Do- SIS is taken from the flow bottle and with 0.7% natural sodium solution (9 mg / ml) to 100 ml further diluted (see Section 6.6).</seg>
<seg id="2370">ALIMTA is shown in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic bronchialkarmic histology (see Section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is shown for the treatment in second-line treatment of patients with lo- Kal advanced or metastatic non-claws bronchialkarmic histology (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface (KOF) extends as intravenous infusion over a period of 10 minutes on the first day every 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of cisplatin is 75 mg / m ² KOF as infusion for a period of 2 hours about 30 minutes after completion of the Pemetrexed- Infusion on the first day every 21-day treatment cycle.</seg>
<seg id="2374">In case of patients with non-single bronchialkarzinom the recommended dose of ALIMTA 500 mg / m ² KOF extends as intravenous infusion over a period of 10 minutes on the first day every 21-day treatment cycle.</seg>
<seg id="2375">"the reduction of the frequency and severity of doorstep must be given on the day before and on the day of Pemetrexed-Gabe, as well as on the day after the treatment a cortiosteroid."</seg>
<seg id="2376">"during the seven days before the first dose of Pemetrexed must be taken at least 5 cans of folic acid, and the intake must be continued during the entire therapy of therapy and for another 21 days after the last Pemetrexed- dose."</seg>
<seg id="2377">Patients must also get an intra-muscular injection of vitamin B12 (1000 mcg) during the week before the first Pemetrexed dose as well as after every third party cycle.</seg>
<seg id="2378">"in case of patients, the Pemetrexed Set, should be created before every gift of a complete blood-image, including a differentiation of the leucocytes and a romatic cylinders."</seg>
<seg id="2379">The alkaline phosphatase (AP), asparting transaminase (AST or SGOT) and Alanin-Transaminase (ALT or SGPT) should be ≤ 3-fold of the upper limits. "</seg>
<seg id="2380">At the beginning of a new treatment cycle a dosage is necessary to take place under Berrecess of blood cells or the maximum non-hematological toxicity of the predictive therapy cycles.</seg>
<seg id="2381">"after recovery, patients must be treated according to references in tables 1, 2 and 3, suitable for ALIMTA than Monotherapy or in combination with cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degrees 2 blocking.</seg>
<seg id="2383">"should patients non-domestic toxicity decreased by degree 3 (except neurotoxicity), the therapy with ALIMTA must be interrupted until the patient is worth the value before the treatment"</seg>
<seg id="2384">"the treatment with ALIMTA must be abandoned, if in case of patients after 2 dosiscent toxicity or non-hematological toxicity degree 3 or 4 appearance or so- continue at the appearance of degrees 3 or 4 neurotoxicity."</seg>
<seg id="2385">Clinical studies had no indication that in patients at the age of 65 but compared to patients at the age of 65 is a increased by-effective epithus- ko.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under the age of 18 due to non-sufficient data for immortality and effectiveness.</seg>
<seg id="2387">Clinical trials were incompatible with patients with a creatinin-Clearance of ≥ 45 ml / min no dosage adaptations that go beyond for all patients recommended Dosissions.</seg>
<seg id="2388">The data base for patients with a creatinin-Clearance of under 45 ml / min was not sufficient; therefore the application is not recommended (see Section 4.4).</seg>
<seg id="2389">"however, patients with a liver functioning of the upper Bilirubin- Limit and / or transcendental value of &gt; the 3,0-digit of the upper limit value (in the presence of liver metastatic) or &gt; 5,0-in of the upper limits (in the presence of liver metastatic), not specifically studied in studies."</seg>
<seg id="2390">Patients must be monitored with regard to bone mineral soup and Pemetrexed must not be administered to patients before their absolute neutropite will again have a value of ≥ 1500 cells / mm ³ and the romatic cytes can be reached a value of ≥ 100.000 cells / mm ³.</seg>
<seg id="2391">"a dosage reduction for further cycles is based on the Nadir of the absolute neutropite number, thrombozytenants and maximum non-hemological toxicity, as they were observed in the preceding treatment cycles - (see Section 4.2)."</seg>
<seg id="2392">A lower toxicity and a reduction of degrees 3 / 4 hematological and nonthesmatological toxicity such as Neutropenie and infection with degrees 3 / 4 neutropenie has been beamed if a pre-treatment with folc acid and vitamin B12 had taken place.</seg>
<seg id="2393">"therefore, all patients need to be relied with Pemetrexed patients, folic acid and vitamin B12 as a prophesied measure for reduction-related toxicity (see Section 4.2)."</seg>
<seg id="2394">Patients with mild to medium-insufficiency (Kreatinin-Clearance 45 to 79 ml / min) need to avoid the simultaneous insteroidal antiphlogistika (NSAIDs) for at least 2 days before the therapy, on the day of therapy and mindset (see Section 4.5). "</seg>
<seg id="2395">"all patients, provided for therapy with Pemetrexed, must avoid taking NSAIDs with long semi-value for at least 5 days before therapy, at the day of therapy and at least 2 days after therapy with Pemetrexed (see Section 4.5)."</seg>
<seg id="2396">"many patients in which these events appeared, appropriate risk factors for the appearance of renal events, including dehydration, pre-existence hypertension or Diabetes."</seg>
<seg id="2397">Therefore in patients with clinically significant fluid - accumulation in the transcellular space a drain in the transcellular space will be erated in front of the Pemetrexed treatment.</seg>
<seg id="2398">"5 serious cardiovascular events, including myocardinary, and cerebrovascular events were reported in clinical studies with Pemetrexed occasionally, if this drug is usually administered in combination with another cytotoxical active ingredient."</seg>
<seg id="2399">"for this reason, the simultaneous application of attenusted life-vaccines (except vbfever, this vaccination is contraindicated) not recommended (see Section 4.3 and 4.5)."</seg>
<seg id="2400">"because the possibility of irreversible cranial adjustment of reproductive-ability by Pemetrexed, men should be noted above the treatment of treatment, advice regarding the sperm conservation."</seg>
<seg id="2401">In patients with normal kidney function (Creatinin-Clearance ≥ 80 ml / min) can lead high doses non-steroidal Antiphlogistika (NSAIDs) such as Ibuproms &gt; 1600 mg / day) and acetylsalicylic acid in high dosage (≥ 1,3 g daily) to a reduced Pemetrexed excretion with the result of a multiplication of side effects. "</seg>
<seg id="2402">Therefore caution is advisable when in patients with normal kidney function (Creatinin-Clearance ≥ 80 ml / min) high doses from NSAIDs or Ace- tylsalicylic acid in high dosage.</seg>
<seg id="2403">"Ibuprofen) or acetylsalicyl- acid in high dosage for at least 2 days before the therapy, on the day of therapy and mindset - TENS 2 days after therapy with Pemetrexed (see Section 4.4)."</seg>
<seg id="2404">"since there is no data in terms of interaction potential than Piro- xicam or Rofecoxb, the simultaneous application must be avoided by Pemetrexed for at least 5 days before therapy, on the day of therapy and at least 2 days after therapy with Pemetre- xed"</seg>
<seg id="2405">The large intra-individual variability of the gerinnacle status during the disease and the possibility of interactions between orinal anticoagulants and antineoplasty chemotherapy requires increased monitoring frequency of INR (International Standardisation ratio) when the decision was made to treat the patients with oral anticoagulants.</seg>
<seg id="2406">"there are no data for the use of Pemetrexed in pregnant women, but as at ande- ren antimetolites are expected to be expected in pregnant heavy goods."</seg>
<seg id="2407">"Pemetrexed must not be used during pregnancy, except if absolutely extraordinary and after careful handling of the farm for the mother and risk for the fetus (see Section 4.4)."</seg>
<seg id="2408">"because the possibility of irreversible cranial of reproductive-ability by Pemetrexed, men should be advised before the treatment of treatment, advice regarding the sperm vieto."</seg>
<seg id="2409">"it is not known whether pemetrexed into the mother's milk and unwanted effects in the distilled infward cannot be excluded."</seg>
<seg id="2410">The following table shows the frequency and severity unwanted effects that were reported in &gt; 5% of 168 patients with Mesotheliom and the randomized cisplatin and Pemetrexed Er- stopped as well as 163 patients with Mesotheliom that were randomized cisplatin as monotherapy.</seg>
<seg id="2411">"side effects: very common (≥ 1 / 10, often (≥ 1 / 100 and &lt; 1 / 10), occasionally (≥ 1 / 1,000 and &lt; 1 / 1,000), very rare (&lt; 1 / 10,000) and not known (on the basis of available data of spontandisreporting)."</seg>
<seg id="2412">"* reference to National Cancer Institute CTC Version 2 for any toxicity, the event" Creatinin-Clearance "* * * referred to at National Cancer Institute CTC (v2.0; NCI 1998) shall be made of taste and hair loss only as degrees 1 or 2."</seg>
<seg id="2413">"for this table a threshold of 5% specified regarding the recording of all events, in which the doctor reported a connection with Pemetrexed and cisplatin for possible."</seg>
<seg id="2414">"clinically relevant CTC toxicity, reported at &lt; 1% (occasionally) the patients were reported that randomized cisplatin and Pemetrexed received, fists arrhythmia and motoric neuropathy."</seg>
<seg id="2415">"the following table shows the frequency and severity of unwanted effects that were reported by &gt; 5% of 265 patients who were randomized Pemetrexed as monotherapy with gifts of folklore and vitamin B12 as well as 276 patients, the randomized docetaxel as monotherapy."</seg>
<seg id="2416">* Move to National Cancer Institute CTC Version 2 for any toxicity. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as degrees 1 or 2.</seg>
<seg id="2417">"for this table, a threshold of 5% specified regarding the inclusion of all events in which the doctor was held a connection with Pemetrexed for possible."</seg>
<seg id="2418">"clinically relevant CTC Toxicarities, which were reported at &lt; 1% (occasionally) the patients were reported the randomized Pemetrexed received, embraced supraventricular arrhythmia."</seg>
<seg id="2419">"the clinically relevant laboratory toxicity level 3 and 4 was compared with the generalized results of three single Pemetrexed-Monotherapiestudes, except Neutropenie (12.8% compared to 5,3%) and an increase in Alanintransaminase (15.2% compared to 1.9%)."</seg>
<seg id="2420">These under- differences are likely to result in differences in the patient's population as the Pha- se 2 studies both chemonaive and well-treated breast cancer patients with existing hepatitis and / or abnormalities of the liver functional tests.</seg>
<seg id="2421">"the following table shows the frequency and severity of unwanted effects, which could be possible by &gt; 5% of 839 patients who were randomized with NSCLC, the randomized cisplatin and Pemetrexed received and 830 patients with NSCLC, the randomized cisplatin and gemcitabine received."</seg>
<seg id="2422">11 * P values &lt; 0.05 comparison of Pemetrexed / cisplatin and gemcitabine / cisplatin. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) shall be made of taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2423">"for this table, for the inclusion of all events in which the doctor was held a connection with Pemetrexed and Cisplatin for possible, a threshold of 5%."</seg>
<seg id="2424">"clinical relevant toxicity that were reported by ≥ 1% and ≤ 5% (common) of patients were reported, the randomized Cisplatin and Pemetrexed received, fists:"</seg>
<seg id="2425">"clinical relevant toxicity that were reported at &lt; 1% (occasionally) of patients were reported, the ran- domized Cisplatin and Pemetrexed received, covered:"</seg>
<seg id="2426">"serious cardiovascular and cerebrovascular events, including myocardines, Angina pectoris, cerebrovasculosis and transitorical attacks were administered in combination with a different cytotoxical drug, occasionally."</seg>
<seg id="2427">"clinical trials were reported in patients with Pemetrexed treatment occasionally cases of colitis (including intestinal and rektale bleeding, sometimes fatal delay, intestinal Perfo- ration, intestinal nekrose and typhlitis)."</seg>
<seg id="2428">From clinical trials were reported in patients with Pemetrexed treatment occasionally cases of sometimes fatal interstitial Pneumonitis with respiratory insufficiency.</seg>
<seg id="2429">It has been reported about cases of acutant kidney failure at Pemetrexed Monotherapy or in combination with other chemotherapeutics (see Section 4.4).</seg>
<seg id="2430">They reported cases of radiation pneumatitis in patients who reported before or after their Pemetrexed therapy (see Section 4.4).</seg>
<seg id="2431">ALIMTA (Pemetrexed) is an antineoplasty Antitrust that breaks its effect by turning it into force-dependent metabolic processes that are necessary for the cellreplication.</seg>
<seg id="2432">In vitro studies showed that Pemetrexed it works as antifolate with several attacks by the Thymidylatbladder (DHFR) and glycinamdribonucleotidfor- myltransferase (GARFT) blocked, the folatdependence of the de Novo Biosynthesis of Thymier and Purinnucleotides are. "</seg>
<seg id="2433">"EMPHACIS, a multicentric, randomized, simple-blind Phase 3 study of ALIMTA plus cisplatin treated patients a clinically significant advantage of a median 2.7-month prolonged survival compared to such patients who were just troubled with cisplatin."</seg>
<seg id="2434">Primary analysis of this study was carried out in the population of all patients who were received in the treatment of treatment (randomized and treated).</seg>
<seg id="2435">A statistically significant improvement in the clinically relevant symptoms (pains and dyspnoe) in connection with the malignant Pleuramesotheliom was shown in the application of the Lunches-cancer symptomatic arms in the ALIMTA / cisplatin-arm (218 patients) compared to the allsome cispla- tin arms (218 patients).</seg>
<seg id="2436">The differences between the two treatment parameters were characterized by an improvement of the pulmonary parameters in the ALIMTA / cisplatin-arm and a perseverance of the pulmonary function over time in the control unit.</seg>
<seg id="2437">"a multicentric, randomized, open phase III study with ALIMTA against docetaxel in patients with locally advanced or metastatic NSCLC after previous chemotherapy (Intent to treat Population n = 283) and from 7,9 months at with docetaxel-treated patients (ITT n = 288)."</seg>
<seg id="2438">"an analysis of the influence of histology on the overall survival fell to favor of ALIMTA with patients with NSCLC (n = 399, 6.6% CI = 0.61-1,00, p = 0,61-1,00 (n = 0.6%, customized HR = 1,56; 95% CI = On-Day, p = 0,018)."</seg>
<seg id="2439">"limited data of a separately randomized, controlled phase 3 study demonstrate that drug data (survival and progressing free survival) for pemetrexed between patients with (n = 41) and without (n = 540) pre-treatment by docetaxel are similar."</seg>
<seg id="2440">The drug analysis of the PQ Population are consistent with the analyses of ITT populations and support the non-submission of the ALIMTA Cisplatin combination compared to the gemcitabin Cisplatin combination.</seg>
<seg id="2441">"medium PFS was 4,8 months for the combination of ALIMTA Cisplatin compared to 5.1 month for combining the MTA Cisplatin compared to 28,2% (95% CI = 25,0 - 31.4) for the combination of gemcitabin Cisplatin."</seg>
<seg id="2442">"the analysis of the flow of the NSCLC histology on the survival showed clinically relevant sub-differences according to histology, see below the table below."</seg>
<seg id="2443">CI = Konfidenzinterval; ITT = free-to-treat; N = size of the overall population a statistically legible for non-subjectivity, with a total confeeder interval of 1,17645 (p &lt; 0.001). "</seg>
<seg id="2444">"patients who were treated with ALIMTA and cisplatin (16,4% versus 28.9%, p &lt; 0.001), erythrocytlenmergers (1.8% versus 4,5%, p = 0,002)."</seg>
<seg id="2445">"in addition the patients required the gift of erythropoetin / Darbopoetin (10,4% versus 18.5%, p &lt; 0.001), G-CSF / GM-CSF (4.3% versus 7.0%, p = 0,021)."</seg>
<seg id="2446">The pharmacoinetic properties of Pemetrexed to Gabe as monotherapeutic have been examined at 426 cancer patients with various solid tumors in doses from 0,2 to 838 mg / m ² in Infusio over a period of 10 minutes. "</seg>
<seg id="2447">Pemetrexed is mainly left unchanged in the urine and 70% to 90% of the administered dose are found unchanged within 24 hours of application unchanged in the urine.</seg>
<seg id="2448">Pemetrexed has a total amount of 91.8 ml / min and the half-value in the plasma is 3.5 hours in patients with normal kidney sound (Creatinin-Clearance 90 ml / min).</seg>
<seg id="2449">In a study with Beagle dogs that had received for 9 months intravenous Bolus injections have been observed testified changes (Degene- ration / Nekrose of the seminiferen epithelanebes).</seg>
<seg id="2450">"unless otherwise uttered, the storage periods and conditions after preparation in the responsibility of the user and should normally not overlap 24 hours at 2 to 8 ° C, unless the preparation / dilution has taken place under controlled and validated aseptic conditions."</seg>
<seg id="2451">"redeem the content of 100 mg-flow bottles with 4,2 ml 0,9% injections (9 mg / ml) without preserves, resulting a solution with a concentration of approximately 25 mg / ml Pemetrexed results."</seg>
<seg id="2452">The essential solution is clear and the coloring ranges from colourless to yellow or green yellow without that the product quality is affected.</seg>
<seg id="2453">Each diarrhod bottle has to be reactivated with 20 ml 0.9% injecting lymph injection solution (9 mg / ml) - what a solution is 25 mg / ml.</seg>
<seg id="2454">"23 serious cardiovascular events, including myocardinary, and cerebrovascular events were reported in clinical studies with Pemetrexed occasionally, if this drug is usually administered in combination with another cytotoxical active ingredient."</seg>
<seg id="2455">"* regards the National Cancer Institute CTC Version 2 for any toxicity, the event" Creatinin-Clearance "* * * referred to at National Cancer Institute CTC (v2.0; NCI 1998) shall be made of taste and hair loss only as degrees 1 or 2."</seg>
<seg id="2456">For this table you have been fixed a threshold of 5% regarding the recording of all events where the beroking doctor held a connection with Pemetrexed and cisplatin for possible.</seg>
<seg id="2457">* Move to National Cancer Institute CTC Version 2 for any toxicity. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as degrees 1 or 2.</seg>
<seg id="2458">29 * P values &lt; 0.05 comparison of Pemetrexed / cisplatin and gemcitabine / cisplatin. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) shall be made of taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2459">"clinical relevant toxicity that were reported at &lt; 1% (occasionally) of patients were reported, the ran- domized Cisplatin and Pemetrexed received, covered:"</seg>
<seg id="2460">"an analysis of the influence of histology on the overall survival fell to favor of ALIMTA with patients with NSCLC (n = 399, 6.6% CI = 0.61-1,00, p = 0,61-1,00 (n = 0.6%, customized HR = 1,56; 95% CI = On-Day, p = 0,018)."</seg>
<seg id="2461">"redeem the content of the 500 mg supplement bottles with 20 ml 0,9% injecting solution (9 mg / ml) without preserves, resulting a solution with a concentration of approximately 25 mg / ml Pemetrexed results."</seg>
<seg id="2462">The essential solution is clear and the sharpening ranges from colourless to yellow or green yellow without that the product quality is affected.</seg>
<seg id="2463">"Pharmakovigilance System The owner of the permit for authorisation has to worry that the pharmaceutical covigilance system, as described in Version 2.0, is ready and ready to market as soon as the product is placed in the market and while the product is in the market."</seg>
<seg id="2464">Risk Management plan The owner of the approval for the permit has pledged to the studies and the re- Pharmakovigilance Plan on how agreed in version 1.2 of the Risk Management Plan (RMP) presented in modules 1.8.2. of approval for sale and all the following updates of the RMP that were decided by CHMP.</seg>
<seg id="2465">"according to" CHMP guideline on Risk Management Systems for Medicinal products for human use "needs to be submitted an updated RMP with the next" Periodic Safety Update Report "(PSUR)."</seg>
<seg id="2466">"in addition, a updated event must be submitted • If new information has to be submitted, which could have an effect on the current security specs, the pharmaceutical vigilance plan or risk management activities • within 60 days after reaching an important (pharmaceutical vigilance or risk) milestones • On request by the EMEA"</seg>
<seg id="2467">ALIMTA 100 mg powder mixer for the production of an infusion - ERALMTA 500 mg powder for the production of a conusion to the production of an infusion</seg>
<seg id="2468">"ALIMTA is used for patients who have received no previous chemotherapy, used for the assignment of malignant Pleuramesothelioms (malicious illness of the Rippenfells) in combination with cisplatin, another medicine used to treat cancer."</seg>
<seg id="2469">"if you have a kidney suffering or earlier one, please discuss this with your doctor or hospital reporting, as you may not get ALIMTA."</seg>
<seg id="2470">"with you will be done before any infusion blood tests, it is checked whether your kidney and liver feature is sufficient and whether you have enough blood cells to get ALIMTA to 49."</seg>
<seg id="2471">Your doctor will possibly change the dose or break the treatment if it requires your general condition and when your blood values are too low.</seg>
<seg id="2472">"if you also obtain cisplatin, your doctor will ensure sufficient water and you get the notable medicines to avoid the break before and after the cisplatin grid."</seg>
<seg id="2473">"if you have a LPG collection around the lungs, your doctor will be able to eliminate these fluid before you get ALIMTA."</seg>
<seg id="2474">"if you wish to make a child during the treatment or during the first 6 months after the treatment, please talk to your doctor or a pharmacist."</seg>
<seg id="2475">"interactions with other medicines please tell your doctor if you are medicines for pain or inflammation (gellun- gen), such as such drugs, the" non-steroidal antiphlogistika "(NSAIDs), including medicines that are not prescription-in (like Ibuprofen)."</seg>
<seg id="2476">"depending on the planned daunces of your ALIMTA infusion and / or the extent of your kidney function your doctor will tell you what other medicines you can take, and when."</seg>
<seg id="2477">Please inform your doctor or a pharmacist if you have no other medicines or have recently taken it even if it is not prescription drugs.</seg>
<seg id="2478">A hospital pharmacists who nursing staff or a doctor will mix the ALIMTA powder with steriler 0,9% injections (9 mg / ml) before it is used by you. "</seg>
<seg id="2479">Your doctor will merge you cortison tablets (according to 4 mg Dexametha- son two times daily) that you have to take on the day during and on the day after the application of ALIMTA.</seg>
<seg id="2480">"your doctor will take you folic acid (a vitamin) for taking or multivitamins, the folic acid contain (350 to 1000 mcg), which will have to take part during the use of ALIMTA."</seg>
<seg id="2481">A week before the application of ALIMTA and approximately every 9 weeks (according to 3 cycles of treatment with ALIMTA) you will also receive an injection of Vi- tamine B12 (1000 mcg).</seg>
<seg id="2482">"in this usage information a side effect is described as" very often, "this means that it was reported by at least 1 of 10 patients."</seg>
<seg id="2483">"if a side effect is described as" frequently, "this means that it was reported by at least 1 of 100 patients but was reported less than 1 out of 10 patients."</seg>
<seg id="2484">"if a side effect is described as" "occasionally", "this indicates that they reported by at least 1 of 1,000 but less than 1 of 100 patients - de.A side effect as a" rare, "means that it has been reported by at least 1 of 10,000 but less than 1 of 1,000 patients."</seg>
<seg id="2485">Fever or infection (common): if you have a body temperature of 38 ° C or above that have sweating or other signs of an infection (because you may have less white blood cells than normal what is very common).</seg>
<seg id="2486">If you feel tired or weak to look rapidly in breathing or blass (because you possibly have less hemoglobin than normal what is very frequent).</seg>
<seg id="2487">"if you find a blood of the gum, the nose or the mouth, or another blood, which does not come to a standstill, or a reddish or russet blood (because you may have less blood cell than normal, which is very common)."</seg>
<seg id="2488">"occasionally (in case of at least 1 of 1,000 patients) increased powder rate Colitis (inflammation of the inner lining of the colorectal) Interstitielle pneumatic, Ödeme (leaving the pulmonary) odeme (leaving the water into the body tissue, which leads to swelling)."</seg>
<seg id="2489">"rare (occurs with more than 1 of 10,000 patients on, but less than 1 of 1,000 patients)" Radiation Recall "(a rash similar to a serious sunburn), appearing on the skin, which was previously exposed (several days to years) of a radiation therapy."</seg>
<seg id="2490">"occasionally joined patients, the ALIMTA, commonly used in combination with other cancer."</seg>
<seg id="2491">"in case of patients who received before, during or after their ALIMTA treatment also a radiation-treatment, can occur through radiation caused by radiation of pulmonary (narrowing of the pulmonary, which is associated with the radiotherapy in connection)."</seg>
<seg id="2492">"52 Informing your doctor or pharmacist, if any of the listed side effects you can impairs or if you notice side effects, which are not performed in this package."</seg>
<seg id="2493">"if applicable as prescribed, the chemical and physical stability of the diluted and infusion solution in keeping in the fridge or at 25 ° C for a period of 24 hours."</seg>
<seg id="2494">"Tél / Tel: + 32- (0) 2 548 84 84 Бълиария. + 359 2 491 41 40 č-ká Republika Elly č R, s.r.o."</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Elly Danmark A / S Tlf: + 45 45 26 6100 Germany Lilly Germany GmbH phone. + 49- (0) 6172 Eesti Eli Holly Limited Eesti filiaal: + 3726441100 203dpi Accept.</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) 1 661 4377 Ísland Icepharma HF.</seg>
<seg id="2497">Phone: + 39- 055 42571 Catering Ls Phadisco Ltd as well as λ: + 357 22 715000 Latly Holly Limited Eetuva Eli Holly Limited atstovybology phone. + 370 (5) 2649600</seg>
<seg id="2498">Phone: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 România Eli Lilly România S.R.L. "</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland From Puh / Tel: + 358- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Redeem the content of the 100 mg supplement bottles with 4.2 ml 0,9% injections (9 mg / ml) without preservative solution that gives a solution with a concept of approximately 25 mg / ml Pemetrexed. "</seg>
<seg id="2501">Redeem the content of the 500 mg supplement bottles with 20 ml 0.9% injections (9 mg / ml) without preservative solution that gives a solution with a concept of approximately 25 mg / ml Pemetrexed.</seg>
<seg id="2502">The unstable solution is clear and the coloring ranges from colourless to yellow or green yellow without that the probable quality is affected.</seg>
<seg id="2503">"it is used in overweight adults with a mass index (Body Mass Index - BMI) of ≥ 28 kg per square meter in connection with a calorie poor, fatty nutrition."</seg>
<seg id="2504">Patients who take up Alli and take no weight after 12 weeks should contact their doctor or pharmacist.</seg>
<seg id="2505">"will this enzymes inhibited, they can not build some fats into food, causing about a quarter of with the food-guided naturette ingested the intestine happened."</seg>
<seg id="2506">"in a third study Alli was compared to 391-made patients with a BMI between 25 and 28 kg / m2 with placebo."</seg>
<seg id="2507">"in the two studies in patients with a BMI of ≥ 28 kg / m2 had patients, the Alli 60 mg, after a year to record an average weight loss of 4,8 kg, compared to 2.7 kg at taking placebo."</seg>
<seg id="2508">"in the study with Alli in patients with a BMI between 25 and 28 kg / m2, no one could be observed for patients-relevant weight loss."</seg>
<seg id="2509">"the most common side effects of Alli (observed in more than 1 of 10 patients) are diligent stains at After, Flatus (Winde) with fahling, marital / öliger chair, flatulence (wind), flatulence (wind) and soft chairs."</seg>
<seg id="2510">It must not be used in patients who are treated with Ciclosporin (to prevent the organ removal during transplanchment) or with medicines such as Warfarin to prevent bleeding.</seg>
<seg id="2511">"it may not be used in case of patients suffering from the digestive syndicate (in which not enough nutrients are taken out of the digestive tract) or in Cholestase (a liver disease), and in pregnant or breastfeeding mothers."</seg>
<seg id="2512">July 2007 the European Commission announced the European Commission of Glaxo Group Limited for approval by Orlistat GSK in the entire European Union.</seg>
<seg id="2513">Alli is for weight reduction of adults with overweight (Body-Mass-Index BMI ≥ 28 kg / m2) indices and should be applied in conjunction with an easily hypokaline fetal nutrition.</seg>
<seg id="2514">"alli shall not be applied to children and young people under 18, as not enough data for effectiveness and safety."</seg>
<seg id="2515">"however, Orlistat is only minimal resorted, is made with elder and with patients with reduced liver and / or kidney function, no adjustment of dosage is necessary."</seg>
<seg id="2516">• hypersensitivity to the active ingredient or any of the other components • simultaneous treatment with Ciclosporin (see Section 4.6) • Limitation (see Section 4.6) • parallel treatment with warning or other ornamental anticoagulants (see sections 4.5 and 4.8)</seg>
<seg id="2517">The likelihood of occurrence gastrointestinal symptoms (see section 4.8) may increase if alli is taken together with a fat-time or fat diet.</seg>
<seg id="2518">"as the weight reduction in diabetes can be associated with an improved metabolic control, patients who consult a medicine against diabetes before starting a therapy with alli a doctor or a pharmacist, because the dosage of antidiabetics must be adjusted accordingly."</seg>
<seg id="2519">"patients, the alli as well as medicines for hypertension or an increased cholesterol levels should take their physician or pharmacists, if the dosage of these medicines must be adjusted."</seg>
<seg id="2520">"it is recommended to meet additional sultry measures, in order to bow in the case of severe diarding possible observing the oral contrasts (see Section 4.5)."</seg>
<seg id="2521">Both in a study on interactions of pharmaceuticals as well as in several cases with simultaneous application of Orlistat and Ciclosporin was observed a divergence of the Ciclosporin plasma seal.</seg>
<seg id="2522">"in combination with Warfarin or other orthodontics in combination with Orlistat, the Quick values (internationally normals Ratio, INR) can be influenced (see Section 4.8)."</seg>
<seg id="2523">"most patients who were treated in clinical studies up to 4 full years with Orlistat, the concentrations of vitamins A, D, E and K and the beta carotins at the standardization sector."</seg>
<seg id="2524">"however, the patients should be recommended to take a complementary multivitamin supplement to ensure sufficient showering (see Section 4.4)."</seg>
<seg id="2525">"after the gift of a single dose Amiodaron was observed in a limited number of healthy volunteers, which at the same time Orlistat was observed, a slight decrease of the Amiodaron plasma concentration."</seg>
<seg id="2526">"veterinary studies showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see Section 5.3)."</seg>
<seg id="2527">The side effects of Orlistat are mainly gastrointestinal nature and hang together with the pharyngeological effect of the drug by means of absorption of biased fat.</seg>
<seg id="2528">Gastrointestinal side effects were obtained from clinical studies with Orlistat 60 mg over a period of 18 months to 2 years and were generally light and temporary.</seg>
<seg id="2529">"the cottage are defined as follows: very often (≥ 1 / 10), often (≥ 1 / 1,000, &lt; 1 / 100), rare (≥ 1 / 10,000, &lt; 1 / 1,000) and very rare (&lt; 1 / 10,000), not known (frequency on the basis of available data non-estimated)."</seg>
<seg id="2530">"the frequency of what side effects, which were established after the launch of Orlistat, is not known as these events were voluntarily reported by a population imcertain size."</seg>
<seg id="2531">† It is plausible that treatment with alli can lead to clamps with regard to possible or actual gastrointestinal side effects.</seg>
<seg id="2532">Single pants of 800 mg of orlistat and multi-width of up to 400 mg three times a day were administered over a period of 15 days at normalgeimportant and overweight probanden without that significant clinical evidence appeared.</seg>
<seg id="2533">In the majority of the cases reported by Orlistat-Overdosage either have no side effects or similar side effects as with the recommended dose of Orlistat.</seg>
<seg id="2534">"based on investigations on man and animal can be attributed by a fast reformation of systemic effects, which are due to the livable properties of Orlistat."</seg>
<seg id="2535">The therapeutic effect sets in the lumens of the stomach and the upper dune by koventente to the active Serin-rest of the gastric and pancreatic lips.</seg>
<seg id="2536">"clinical trials has been derived, that 60 mg of Orlistat, blocks daily, the absorption of approximately 25% of food fat."</seg>
<seg id="2537">"two double blind, randomized, placebokontrolfiled Studies at adults with a BMI ≥ 28 kg / m2, the effectiveness of 60 mg of Orlistat, was taken three times a day in combination with a hypokaline, fetal nutrition."</seg>
<seg id="2538">"primary parameters, the change of body weight opposite the output value (at the time of Randomisation), was assessed as follows: as a change in the body weighting in study (Table 1) and as a share of that study participants, who lost more than 5% or more than 10% of their output weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction has been observed over 12 months, the greatest weight loss entered into the first 6 months."</seg>
<seg id="2540">The average change in the overall cholesterin was with Orlistat 60 mg -2.9% (starting value 5.20 mmol / l) and with placebo + 2.8% (starting value 5.26 mmol / l).</seg>
<seg id="2541">The average change of the LDL cholesterol was rated with Orlistat 60 mg -3.5% (output value in mmol / l) and with placebo + 3.8% (starting value 3.41 mmol / l).</seg>
<seg id="2542">"the waist circumference, the average change -4.5 cm with orlistat 60 mg (starting value 103,7 cm) and with placebo -3.6 cm (output value 103,5 cm)."</seg>
<seg id="2543">Plasmakoncentrations from not metabolized orlistat were 8 hours after the oral Gabe of 360 mg of Orlistat not measurable (&lt; 5 ng / ml).</seg>
<seg id="2544">"7 In general, a metabolic orations could not only be sporadically in the plasma, and in extremely low concentrations (&lt; 10 ng / ml or 0,02 µmol) and without signs of a gulation."</seg>
<seg id="2545">"in a study with adipous patients who was minimal systemic resorate dose, could be identified two main metaboliite, namely M1 (in position 4 hydrolysized Lactoring) and M3 (M1 after fixing the N-form Leucine-group), the approximate 42% of the total plasma concentration."</seg>
<seg id="2546">"based on conventional studies on safety spharmacology, toxicity in repeatable gift, genotoxicity, cancery potential and reproductive material, the preclinical data cannot be recognized any particular danger to the people."</seg>
<seg id="2547">"Pharmakovigilanzsystem The owner of the permit has to ensure that the pharmaceutical vigilance system, is described in accordance with the version of July 2007 as in module 1.8.1. the authorisation is applied, and works before and while the product is available on the market."</seg>
<seg id="2548">"risk management, the holder of the approval of the permit is obliged to perform the studies and additional pharmacovigilanzplan (RMP), as well as in the Pharmacovigilanzplan (RMP) of October 2008 as well as all other updates of the RMPs, which will be agreed with the Committee of Humanarztend (CHMP)."</seg>
<seg id="2549">"according to the CHMP guidelines on risk management systems for human cells, the updated project must be submitted at the same time with the next PSUR (Periodic Safety Update Report)."</seg>
<seg id="2550">"furthermore, a updated event should be submitted: • when new information is available, the current security guidelines, the pharmaceutical vigilance or risk-inimitation - within 60 days of enriching an important, the Pharmakovigilance or Risikominimitation segment • On request of the European Medicines Agency (EMEA)."</seg>
<seg id="2551">"12 PSURs The holder of approval for sale will be included in the first year after the Commission decision on expanding the alli 60 mg cemented PSURs every 6 months, then for two years annual and then every three years."</seg>
<seg id="2552">"do not use if you are under 18 are, • If you are pregnant or breastfeeding, • if you are pregnant at Orlistat or one of the other components, • if you suffer from Cholestase (disease of the liver, in which the gallbladder neck), • if you have problems with food intake (chronic painters syndrom)."</seg>
<seg id="2553">"take three times a day with every captain time, the fat contains, one capsule with water. • You should take once daily, before bedtime, a multivitamintablace (with the vitamins A, D, E and K). • You should not apply alli longer than six months."</seg>
<seg id="2554">"application: • take three times a day with every captain time the fat contains, one capsule with water. • You should take once daily, before bedtime a multivitamintentiette (with the vitamins A, D, E and K). • You should not apply alli longer than six months."</seg>
<seg id="2555">Perhaps you would like to read this later. • If you need more information or a pharmacist if you have further information or advice. • If you have any further information or advice. • If you have no weight reduction after 12 weeks after alli do not ask a doctor or a pharmacist to advice.</seg>
<seg id="2556">"possibly you have to finish the intake of alli. • If any of the above side effects you have significantly impaired or you may notice the side effects, please inform your doctor or a pharmacist."</seg>
<seg id="2557">What do you need to be considered before intake of alli? • alli may not be applied • Special caution at intake of alli is required • At intake of alli with other medicines • At intake of alli together with food and drink • gestation and fuel-time • traffic noise and serving machines 3.</seg>
<seg id="2558">How is alli going to take? • How do you take your weight-up? O Choose your start-time frame - How long should you take you? O adults from 18 years o How long should I do alli? O If you have alli forgotten in large quantities o If you have forgotten the intake of alli 4.</seg>
<seg id="2559">Which side effects are possible? • severe side effects • Very common side effects • Frequent side effects • effects on blood examinations • How can you check-related monitoring?</seg>
<seg id="2560">Further information • What alli contains • How the alli looks and content of the package • pharmaceutical entrepreneurs and manufacturers • other helpful information</seg>
<seg id="2561">The weight reduction and is used in overweight adults from 18 years with an Body-Mass-Index (BMI) of 28 or above. alli should be applied in conjunction with a fat and low-calorie diet.</seg>
<seg id="2562">BMI will help you determine whether you have a normal weight in the relationship with your height.</seg>
<seg id="2563">"even if these diseases do not cause you to feel uncomfortable, you should nevertheless ask your doctor for controlling."</seg>
<seg id="2564">"for each 2 kg body weight, which you lose in the frame of a diet, you can lose using alli an extra kilograms."</seg>
<seg id="2565">"please inform your doctor or a pharmacist, if you have taken other medicines or have been recently taken, even if it is not prescription drugs."</seg>
<seg id="2566">Ciclosporin is used for organtransplants in severe rheumatoid arthritis and certain heavy artery disease. • Warfarin or other medicines that have a bleeding effect.</seg>
<seg id="2567">"oral contraception and alli • The effect of oral inconsequential resources for pregnancy loss (pill) will be deed or eliminated, if you have strong Diarrhö (diarrhea)."</seg>
<seg id="2568">Please contact your doctor or a pharmacist if you are taking: • Amiodaron to treat cardiac arrhythmia. • Acarbose for the treatment of diabetes.</seg>
<seg id="2569">"ask your doctor or pharmacist if you use alli and if you take drugs against hypertension, since maybe the dosage needs to be adapted to high cholesterol levels, since maybe the dosage needs to be adjusted."</seg>
<seg id="2570">How to set up your calory goals and Fetting limits you can learn under further useful information on the blue pages in Section 6.</seg>
<seg id="2571">"if you leave a meal or a meal no fat, take no capsule. alli can only act if food fat contains."</seg>
<seg id="2572">"if you take the capsule in conjunction with a meal, which contains too much fat, risk-conditioned related condomes (see Section 4)."</seg>
<seg id="2573">"to get used to your body to the new eating habits, start before the first capsule with a calorie and fetal diet."</seg>
<seg id="2574">"nutritional books are effective, since you can retire at any time you eat how much you eat and it will probably be easier to change your dietary habits."</seg>
<seg id="2575">"to achieve your target weight, you should set in advance two daily goals: one for calories and one for fat."</seg>
<seg id="2576">"• feed yourself fatty, in order to reduce the probability for nourishing-conditional companions (see Section 4). • Try to move more before you begin with the intake of the capsules."</seg>
<seg id="2577">"remember in advance your doctor, if you are not used physical activity during taking and after ending the intake of alli physically active."</seg>
<seg id="2578">"• alli must not be taken longer than 6 months. • If you can notice after twelve weeks use of alli no reduction of your weight, please ask your doctor or a pharmacist to advice."</seg>
<seg id="2579">"in circumstances, you need to finish the intake of alli. • At a successful weight acceptance it is not about to change the diet and then return to the old habits."</seg>
<seg id="2580">"• If less than one hour has passed since the last meal, take the intake of the capsule. • If more than one hour has passed since the last meal, take no capsule."</seg>
<seg id="2581">Bubbles with and without oligaments, sudden or more multiplasted jumped and weigh chair) are due to the host mechanism (see Section 1). "</seg>
<seg id="2582">"heavy allergic reactions • severity allergic reactions recognize the following changes: heavy respiratory, welding outbreaks, mattresses, itch, swelling in the face, cardiac, circulation systems."</seg>
<seg id="2583">"29 Very common side effects These can occur at more than 1 of 10 people, the alli, occur. • Blestivities (Flatulence) with and without oligous chair • weigh chair informing your doctor or pharmacist when one of these side effects is amplified or you considerably impaired."</seg>
<seg id="2584">"frequent Side Effects These may take in 1 of 10 people, the alli originals. • Magnet (abs) - aqueous chair • playful chair • Beads informing your doctor or pharmacist when one of these side effects is amplified or you considerably impaired."</seg>
<seg id="2585">Effects on blood examinations It is not known as often these effects occur. • increase of particular liver intoxicity • effects on blood circulation in patients suffering the warning or other bleeding (antics) medicine.</seg>
<seg id="2586">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="2587">The most common side effects depend on the mode of the capsules working together and thereby arise that it is eliminated fat from the body.</seg>
<seg id="2588">"these side effects usually occur within the first weeks after treatment of treatment, as you might not have consistently reduced the fat content in the diet."</seg>
<seg id="2589">"with the following basic rules you can learn to minimize the nutritionable escents: • Beginside you already few days, or better a week, before the first intake of your favorite diet. • learn more about the usual fat content of your favorite food and about the size of the portions that you normally take to take."</seg>
<seg id="2590">"if you know exactly how much you eat, sinks the likelihood that you don't exceed your fat. • Connect your recommended fat evenly on the daily meals."</seg>
<seg id="2591">"save the amount of calories and fat, which you must take for each meal, not to take them in the form of a fettling main court or any of an old postpity, how you may have to control them with other programs for weight reduction. • Most of the people in which these companions occur, they learn to control the time through adapting their diet."</seg>
<seg id="2592">• Possible medicines for children unaccessible. • You may not apply alli after checking the expiration date no longer apply. • The bottle contains two white versed container with Silicagel that serve to keep the capsules dry.</seg>
<seg id="2593">Swallow this in no case. • You can run your daily dose alli in the blue transport box (shuttle) with you that this pack is enclosed.</seg>
<seg id="2594">"FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">"overweight has an impact on your health and increases the risk for the emergence of various heavier diseases such as: • Blutholic pressures, diabetes • disease cases • Osteoarthritis speaking with your doctor about your risk to these diseases."</seg>
<seg id="2596">"a lasting weight loss, for example by improving the diet and more exercise, the abnormative disorders can preventative and has a positive influence on your health."</seg>
<seg id="2597">"choose meals that include a wide range of nutrients, and learn to live permanently healthy."</seg>
<seg id="2598">Energy is also measured in Kilojoule which you can also find as specification of the packaging of foods. • The recommended calorie intake gives you how many calories you should take a maximum of each day.</seg>
<seg id="2599">Refer to the table below in this section tables. • The recommended fat cells in grams is the maximum amount of fat that you should take with each meal.</seg>
<seg id="2600">"what quantity is suitable for you, see the information below, which is the number of calories created for you. • Background of the mode of operation of the capsule is the compliance with recommended fat cells."</seg>
<seg id="2601">"if you take the same amount of fat how far, this may mean that your body can not process this amount of fat."</seg>
<seg id="2602">"by adherence to recommended fat, you can maximize the weight and at the same time reduce the likelihood of nutritional deficiencies. • You should try to gradually increase steadily."</seg>
<seg id="2603">"34 This decreasing calorie intake should allow you to be gradual and continuously losing approximately 0.5 kg per week, without fruity and disappointments."</seg>
<seg id="2604">"the more active you are, the higher your recommended calorie intake is here that you can burn daily or at all, stairs, in the garden work or other physical activity. •" medium-physical activity "means that you can work by moving daily 150 kcal, for example by moving daily 150 kcal, 30- to 45-minute garden work or 2 km running in 15 minutes."</seg>
<seg id="2605">• For permanent weights it is necessary to put on realistic calorie and obesity. • useful is a nutritional content with details of calorie and fat content of your meals. • Try to move more before you begin taking the intake of alli.</seg>
<seg id="2606">"the alli program for supporting weight capture combines the capsules with an diet plan and a large number of further information material that can help you to feed calorie and fatty acids, to feed physically active."</seg>
<seg id="2607">"in conjunction with one to your type cropped program for supporting the weight acceptance, this information can help you to develop a healthier lifestyle and to achieve your target weight."</seg>
<seg id="2608">"Aloxi is applied in chemotherapies, the strong trigger for nausea and omiting are (such as cisplatin), as well as in chemotherapies, which are moderate trigger for nausea and omiting are (like Cyclophosphamide, Doxorubicin or Carboplatin)."</seg>
<seg id="2609">The effectiveness of Aloxi can be used by the additional gift of a Corticosteroids (a medicine that can be used as antiemetics).</seg>
<seg id="2610">The use in patients under 18 years of age is not recommended as the effects in this age group is not enough information.</seg>
<seg id="2611">"this means that the effectiveness of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as serotonin), to the receptors in the intestines."</seg>
<seg id="2612">"Aloxi was examined in three main studies at 1 842 adults, the chemical therapy received, which are strong or moderate trigger for nausea and vomiting."</seg>
<seg id="2613">"in chemotherapies, the strong trigger for nausea and vomiting are, 59% of patients, which were treated with aloxi, in the 24 hours after chemotherapy (132 of 223), compared to 57% of the patients with Ondansetron for patients (126 of 221)."</seg>
<seg id="2614">"in chemotherapies, the moderate trigger for nausea and vomiting are, shown 81% of patients, which were treated with Aloxi in 24 hours after chemotherapy (153 of 189), compared to 69% of the patients treated with Ondansetron for patients (127 of 185)."</seg>
<seg id="2615">When compared with Dolasetron these values are 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">March 2005 the European Commission announced the company of Helsinki Birex Pharmaceuticals Ltd.</seg>
<seg id="2617">Aloxi is indices: to prevent malnourishment and vomiting chemotherapy due to cancer disease and to the prevention of nausea and vetogenic chemotherapy due to cancer disease.</seg>
<seg id="2618">"the effectiveness of Aloxi regarding the prevention of nausea and vomiting, which is induced by a strongly emetogenic chemotherapy, can be enhanced by adding one before chemotherapy given by chemotherapy."</seg>
<seg id="2619">Since Palonosetron can extend the Dickdarmpassage, patients should be monitored with anamnestial Obstipation or signs of a subcontractor Ileus after the injection-maShip. "</seg>
<seg id="2620">"however, as with other 5HT3 antagonists, however, caution is advisable to extend the QT-Intervall or for patients in which the Qt- interval is prolonged or which tend to be an extension."</seg>
<seg id="2621">"except related to another chemotherapeutics gift, Aloxi should neither be used in the days after chemotherapy or to treat nausea and vomiting."</seg>
<seg id="2622">"in clinical trials inhibited Palonosetron against tumors the activity of the five studied chemotherapeutic does not (Cisplatin, Cyclophosphamid, Cycliabin, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">"in a clinical study, no significant pharmacopoinetic interaction between a unique intravenous dose Palonosetron and a Steady-state- concentration ornamental Metoclopramids, one CYP2D6-Inhibitors."</seg>
<seg id="2624">"in one of a population-based pharmacopoinetic analysis was shown that the simultaneous gripping of CYP2D6-Induktoros (Amiodaron, Sanoxidol, oxicetin, ritonavir, ritonavir, sertrinated and terbinafine) had no significant effect on the clearance of Palonosetron."</seg>
<seg id="2625">"experience for the use of Palonosetron for human pregnancies are not before, therefore Palonosetron should not be used in pregnant women, unless it is necessary from the patient doctor as necessary."</seg>
<seg id="2626">"clinical trials were the most common in a dose of 250 micrograms to observant side effects (total 633 patients), which were at least possibly with Aloxi related to Aloxi (9%) and Obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10,000) of oversensitivity reactions and reactions on administration (burning, failure, complaints and pains) were stated in post-marketing experience."</seg>
<seg id="2628">In the group with the highest dosage demonstrated similar prevalence of unwanted events like in other doses; there were no dose-efficacy relations.</seg>
<seg id="2629">"there were no dialysis studies performed, due to the great distribution volumes, however, a dialysis is probably no effective therapy in an alxirs."</seg>
<seg id="2630">"in two randomized dual-blind studies were given a total of 1,132 patients who received a moderated chemotherapy with ≤ 50 mg / m2 Cyclophosphid (half value of 4 hours) or 100 mg Dolasetron (half-value 7,3 hours), which was given to day 1 without dexamethason intravenous."</seg>
<seg id="2631">"in a randomized twin-foals of 667 patients were given a strongly emetogenic chemotherapy with ≥ 60 mg / m2 Cyclophosphamide and Dacarbazin, as well as 250 or 750 microgram Palonosetron, with patients compared to the 32 mg of onsetron that were given to day 1 intravenous."</seg>
<seg id="2632">The results of the studies with moderemetoer chemotherapy and the study with strongly emetoer chemotherapy are summarized in the following tables.</seg>
<seg id="2633">In clinical studies for the indications of chemotherapy-induced nausea and vomiting (CINV) were the effects of Palonosetron on blood pressure, heart rate and ECG parameters including the QTc intervalls with the corresponding effects of ondansetron and Dolasetron. "</seg>
<seg id="2634">"according to the pre-clinical studies, Palonosetron possesses the ability to blocking on the ventricular De- and repolarization of participating iterations and to extend the duration of the potential potential."</seg>
<seg id="2635">"the aim of the study carried out by 221 healthy masculinity, the assessment of the ECG-effects of i.v. administered Palonosetron in single dosis of 0.25, 0.75 and 2.25 mg."</seg>
<seg id="2636">Resorption After intravenöser Gabe follows an initial acceptance of the plasma centriations a slow elimination of the body with an average terminalen half-value of approximately 40 hours.</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the area under the concentration time curve (AUC0-) are generally in the whole dosage range of 0.3- 90 μ g / kg at gestures and cancer patients.</seg>
<seg id="2638">After intravenous Gabe of Palonosetron 25 mg every second day for a total of 3 doses was the average of 11 Hodenkarst medium (± SD) rise in Palonosetron-Plasmakoncentation at 42 ± 34%.</seg>
<seg id="2639">From pharmacoinetic simulations emerges that at once daily intravenous Gabe of 0.25 mg Palonosetron of 3 consecutive days reached total amount of 0.75 mg; however, the Cmax was higher after the sale of 0.75 mg higher. "</seg>
<seg id="2640">"about 40% will be eliminated about the kidneys, and some more 50% will be converted into two primary metals, which compared to Palonosetron over less than 1% of the antagonistic effect on 5HT3 receptors."</seg>
<seg id="2641">"in-vitro studies for Metabolisation have shown that CYP2D6 and, in the lower dimensions, the Isoenzme CYP3A4 and CYP1A2 at the Metabolism of Palonosetron are involved."</seg>
<seg id="2642">"Elimination After an intravenous single dose of 10 Microgram / kg [14C] -Palonosetron were found approximately 80% of the dose within 144 hours in the urine, Palonosetron of approximately 40% of the given dose."</seg>
<seg id="2643">After a unique intravenous Bolusininjection in gesounds the total body of 173 ± 73 ml / min and the renal clearance 53 ± 29 ml / min.</seg>
<seg id="2644">"although patients with severe liver functionally increases the terminale elimination of elimination with Palonosetron, a reduction in dose is not justified."</seg>
<seg id="2645">"in clinical trials, effects were observed only by expositions which are considered adequate above the maximum human therapeutic exposure, which indicates a low relevance for the clinical use."</seg>
<seg id="2646">10 of preclinical trials examine that Palonosetron can only block that Palonosetron can only be involved in very high concentrations of iterations and repression in the ventricular De- and repolarisation.</seg>
<seg id="2647">"high doses Palonosetron (each dose corresponded over two years ago, led to a multi-prolonged frequency of liver limbs, endophysise, pancreas, pancreas, persuerenmark) and skin-tumors, but not in mice."</seg>
<seg id="2648">"the underlying mechanisms are not fully known, but due to the used high doses and since Aloxi is intended for a unique application, the relevance of these results is low."</seg>
<seg id="2649">The owners of this permit has to inform the European Commission on plans for the transport of goods within the framework of this decision-approved drug.</seg>
<seg id="2650">"• If any of the above-side effects you have considerably impaired, or you may notice the side effects which are not specified in this usage information, please inform your doctor."</seg>
<seg id="2651">"• Aloxi is a clear, color injecting solution to injection in a vene. • The substance (Palonosetron) belongs to a group of drugs used as Serotonin (5HT3) antagonists. • Aloxi will be used to prevent nausea and vomiting resulting in connection with chemotherapy for cancer."</seg>
<seg id="2652">"21 For application of Aloxi with other medicines, please inform your doctor if you have to take other medicines / apply or applied recently, even if it is not prescription drugs."</seg>
<seg id="2653">"pregnancy If you are pregnant or believe, pregnant, your doctor will not give you Aloxi unless, unless it is clear."</seg>
<seg id="2654">"ask before taking any medicines to your doctor or a pharmacist to advice, if you are pregnant or believe, pregnant."</seg>
<seg id="2655">"in some very rare cases, it came to allergic reactions to Aloxi or burning or pain at the embedding."</seg>
<seg id="2656">Like Aloxi looks and content of the package Aloxi injection solution is a clear blue color solution and is available in a package containing 1 bucket bottle available that contains 5 ml of solution.</seg>
<seg id="2657">Белария срматрматреторедыоредыоредыоредыоредыоредыоредыоредыреторедыоредыоредыреторедыоредыоредыреторедыоредыоредыреторедыоредыреторедыоредыоредыреторедыоредыреторедыоредыредыоредыредыредыредыреторедыоредыреторедыоредыоредыреторедыоредыоредыреторедыоредыоредыредыретор</seg>
<seg id="2658">"Latvija pharmaceutical Swiss Latvia SIA 54-5, ertrū of Street Riga, LV-1011 Tel: + 37167502185 Lietuva UAB pharmaceutical Swiss Addimyniš kidist."</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK phone: + 44 1244 625 152</seg>
<seg id="2660">June 2006 adopted the committee for human medicines (CHMP) has been a negative expertise in which the approval of authorisation for the handling of hepatitis C aged by Alpheon 6 million IE / ml injections recommended.</seg>
<seg id="2661">"this means that Alpheon is a biological drug called Roferon-A with the same cells as an effective component, which is already approved in the EU (also" "reference medicines" ")."</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long anhalatory) hepatitis C (one caused by a virus infection).</seg>
<seg id="2663">"in a microscopic investigation, the liver tissue damage, the values of the liver enzymms Alanin- Aminotransferase (ALT) increased in the blood standard."</seg>
<seg id="2664">It is produced by a yeast into which a gene (DNA) was brought to the formation of the active ingredients.</seg>
<seg id="2665">"the makers of Alpheon put data in front of the comparison of Alpheon with Roferon-A (active ingredients, composition and purity of the drug, mode, safety and effectiveness in hepatitis C)."</seg>
<seg id="2666">"in the study on patients with hepatitis C, the effectiveness of Alpheon was compared to 455 patients."</seg>
<seg id="2667">"in the study was measured, how many patients were after 12 from a total of 48 treatment weeks as well as 6 months after setting the treatment to the medication (i.e., no signs of the virus in the blood)."</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.eme</seg>
<seg id="2669">"furthermore, concerns have been expressed concerns that the data for the stability of the drug and the market-marketable drug has not been sufficient."</seg>
<seg id="2670">"the number of patients with hepatitis C, which resulted in the treatment with Alpheon and Roferon-A, was similar in clinical study."</seg>
<seg id="2671">After setting the treatment with Alpheon flammers the disease in more patients more than at the reference cells. moreover Alpheon had more side effects.</seg>
<seg id="2672">"apart from that, the test has been inserted in the study for examining the question, indefinitely the drug forms an immune response (i.e. the body forms antibody - special proteins - against the medicine), not adequately validated."</seg>
<seg id="2673">"it can be applied to the treatment of Impetigo (one with cruising awareness) and small inverted launderations (cracking, or cutting-wounds), creases and sewn wounds."</seg>
<seg id="2674">Altargo is not supposed to be used for the treatment of infections that were verifiable or probably caused by methicized resistant Staphylococcus aureus (MRSA) because Alargo against this sort of infections could not affect.</seg>
<seg id="2675">"Altargo can be used in patients from the age of nine months, but patients under the age of 18 may not be more than 2% of the body surface."</seg>
<seg id="2676">"if the patient speaks for two or three days not on the treatment, the physician should examine the patient again and consider alternative treatments."</seg>
<seg id="2677">It works by blockade of bacterial ribosomes (the parts of the bacterial cells in which proteins are produced) and inhibits the growth of bacteria.</seg>
<seg id="2678">Main Indicator of the efficacy was in all five studies of the percentage of patients whose infection declined after the end of treatment.</seg>
<seg id="2679">119 (85.6%) 139 patients under Altargo and 37 (52.1%) of the 71 patients under placebo spoke on the treatment.</seg>
<seg id="2680">"in the treatment of infected parts, Altargo and Cefalexin similar to rates: if the results of both studies have been considered in front-parts, they spoke about 90% of the patients of both groups in the treatment."</seg>
<seg id="2681">"however, in these two studies, however, was noted that Altargo has been caused in the treatment of abyss (the filling hollowed in the body tissue) or of infections that were subsequently caused by MRSA, not effective enough."</seg>
<seg id="2682">The most common side effect with Altargo (which was observed during 1 to 10 of 100 patients) is a maturity in the order.</seg>
<seg id="2683">"the committee for human cells (CHMP) came to the conclusion that the benefits of Altargo in the spa-treatment of the following superficial skin infections towards the risks overbalance: • Impetigo, • infected small Lazerations, sayes or gendared wounds."</seg>
<seg id="2684">"May 2007, the European Commission announced the European Commission of Glaxo Group Ltd. a permit for the transport of Altargo throughout the European Union."</seg>
<seg id="2685">Patients in which two or three days are not likely to be examined once more and an alternative therapy is to be considered (see Section 4.4).</seg>
<seg id="2686">"in the event of raising awareness or serious local irritation by applying retapamulin salads, the treatment should be cancelled carefully and an adequate alternative therapy for infection."</seg>
<seg id="2687">"Retapamulin should not be used to treat infections, where MRSA is known as Erreger or suspected (see Section 5.1)."</seg>
<seg id="2688">"in clinical studies with secondary-infected wound, the effectiveness of retapamulin in patients with infections caused by a methicillin-resistant Staphylococcus aureus (MRSA) were insufficient."</seg>
<seg id="2689">An alternative therapy is to be considered if after a 2- to 3-day treatment no recovery or deterioration of the infected place occurs.</seg>
<seg id="2690">The effect of simultaneous application of Retapamulin and other topical means on the same skin surface is not examined and the simultaneous application of other topical medicines is not recommended.</seg>
<seg id="2691">"due to the small plastic centrations, which were achieved by humans according to topical use on the diced skin or infected superficial wounds, is a clinically relevant inhibiting in vivo not to expect (see Section 5.2)."</seg>
<seg id="2692">3 After simultaneous gripping of 2-times 200 mg Ketoconazol increased the middle Retapamulin salads on the diced skin of healthy grown men by 81%.</seg>
<seg id="2693">"due to the low system exposure to topical applications in patients will not be held dosissions not required, if topical retapor is used during a systemic treatment with CYP3A4 Inhibitors."</seg>
<seg id="2694">Animal studies have shown a reproduction shock according to orinal intake and are inadequate in regards to a statement on the birth and the fetal / postnatal development (see Section 5.3).</seg>
<seg id="2695">"Retapamulin Salbe should only be used during pregnancy, if a topical antibacterial therapy is clearly indexed and the application of retapamulin the gift of a systemic antibiotic."</seg>
<seg id="2696">"when deciding whether the breastfeeding continues / ended or therapy with Altargo, should be terminated between the benefit of breastfeeding for the baby and the benefit of the Altargo therapy for women."</seg>
<seg id="2697">"clinical studies at 2150 patients with superficial skin infections, the Altargo was used, the most frequently reported tributary irritation at the appointment of about 1% of patients concerned."</seg>
<seg id="2698">"mode Retapamulin is a semi-synthetic derivatives of Pleuromutilin, a substance that is insulated by fermentation from Clitopilus passeckerianus (formerly Pleurotus passeckerianus)."</seg>
<seg id="2699">The Anti-Mechanism of Retapamulin is based on selective inhibital protein synthesis by interaction at a particular bond of the bacterial cells of the bacterial ribosomal interacting of antibacterial substances.</seg>
<seg id="2700">Data point out that the bonds of the ribosomales protein L3 involved and is located in the region of the ribosomental P bonds and the Peptidyltransferasecentre.</seg>
<seg id="2701">"by binding on this connectedness hemuromutiline the Peptidyltransfer, block partial P bonds and prevent normal formation of active 50s ribosomaler sub-units."</seg>
<seg id="2702">"should be based on the basis of local prevalence of resistance to the application of retapamulin, at least some Infection forms, a consultation should be targeted by experts."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of retapamulin compared to S.aureus, regardless of whether the insulin or resistant to methicillin were."</seg>
<seg id="2704">"in case of failure to treat S.aureus, the presence of tribes should be considered with additional virus factors (such as PVL = Panton-Valentine Leucocidin)."</seg>
<seg id="2705">Resorption In a study with healthy adults was brought 1% Retapamulin salads daily under Occlusion on intact and shielding skin for up to 7 days.</seg>
<seg id="2706">"by 516 patients (adults and children), the 1% Retapamulin salbe received twice a day for 5 days to topical treatment of secondary traumatist wounds, individual plastic maprobes were obtained."</seg>
<seg id="2707">The sampling took place at the days 3 or 4 in adult patients in front of the medication and in the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual systemic reception of the people after topical use of 1% of Salbe on 200 cm2 (Cmax = 22 ng / ml; AUC (0-24) = 238 ng · h / ml) 660-times lower than the retapamulin IC50 for the PGP inhibition."</seg>
<seg id="2709">Metabolism The in vitro oxidative Metabolism in humanic liver microsomen was primored by CYP3A4, among low participation of CYP2C8 and CYP2D6 (see Section 4.5). "</seg>
<seg id="2710">"in studies on oral toxicity to rats (50, 150 or 450 mg / kg) which have been carried out over 14 days, there were signs of adaptive liver and thyroid."</seg>
<seg id="2711">In-vitro-review on commutation and / or chromosomale effects in the mouse-Lymphoma test and in cultures of human peripheral blood vessels and in the rats-microkernel to the-vivo-investigation chromosomaler effects.</seg>
<seg id="2712">"there was neither male nor female signs of reduced fertilisation at orchards dosages of 50, 150 or 450 mg / kg / day, thus making up to 5 times higher exposure was achieved than the highest estimated exposure to people (topical application to 200 cm2 of diced skin:"</seg>
<seg id="2713">In an embryootoxicity study on rats were established at oral dosages of ≥ 150 mg / kg / day (according to the ≥ 3-digit of the estimated human exposure (see above)), development of the fetus (see above) and maternal toxicity. "</seg>
<seg id="2714">"the holder of approval for the permit has to ensure that an Pharmacovigilanzsystem is present, as in the module 1.8.1 of the authorisation application (version 6.1) and works before the product is marketed and as long as the product will be applied."</seg>
<seg id="2715">"the owner of the permit is obliged to perform detailed studies and additional pharmacovigilanzplan, as described in the Version 1 of the Risk Management Plan (RMP), as well as any additional updates of the application that will be agreed with the CHMP."</seg>
<seg id="2716">"as described in the CHMP" "guideline on Risk Management Systems for Medicinal products for human use," the updated target will be submitted at the same time with the next Periodic Safety Update Report. "</seg>
<seg id="2717">"to show irritation or other signs and symptoms at the top, you should end the application of Altargo and speak with your doctor."</seg>
<seg id="2718">"do not turn any other salts, creams or lotions on the surface which is treated with Altargo if it was not expressly authorized by your doctor."</seg>
<seg id="2719">"it may not be applied in the eyes, at the mouth or on the lips, in the nose or in the female genital area."</seg>
<seg id="2720">"when the salads look out to one of these areas, wash the place with water and ask your doctor for advice if discomfort occur."</seg>
<seg id="2721">"after wearing the Salbe, you can cover the affected area with a sterile association or a Gazing band, unless your doctor did not get to cover the surface."</seg>
<seg id="2722">"it is offered in a aluminum tube with a plastic fastener, which contains 5, 10 or 15 gram of Salbe, or in a aluminium bag, the 0.5 g Salbe."</seg>
<seg id="2723">Ambirix is used for protection against hepatitis A and hepatitis B (diseases that apply the liver) with children aged between one and 15 years that have not been immune to these two diseases.</seg>
<seg id="2724">Ambirix is used as part of one of two doses existing vaccines whereby one protection against hepatitis B may only be achieved after administration of the second dose.</seg>
<seg id="2725">"for this reason, Ambirix may only be used when immunization is a low risk of hepatitis B infection and is ensured that the vaccination can be held at the end of two doses."</seg>
<seg id="2726">If a refresher dose against hepatitis A or B is desired can Ambirix or another hepatitis or -B vaccine.</seg>
<seg id="2727">Vaccines have to act by raising the immune system (the natural defence of the body) as it can be against a disease.</seg>
<seg id="2728">"after a child has received the vaccine, the immune system detects the viruses and surface antigens than" strangers "and generates antibodies against it."</seg>
<seg id="2729">Ambirix contains the same components such as the vaccine Twinrix adults and the vaccine has been approved since 1997.</seg>
<seg id="2730">"the three vaccines are applied to protect the same diseases, however Twinrix adults and Twinrix children are administered within a three doses of existing vaccines."</seg>
<seg id="2731">"because Ambirix and Twinrix adults identical ingredients, some of the data that supports the application of Twinrix adults, even as a cover for the application of Ambirix."</seg>
<seg id="2732">"the main indicator of the efficacy was the proportion of vaccinated children, who had developed a month after the last injection of antibodies."</seg>
<seg id="2733">In an additional study with 208 children the effectiveness of the vaccine has been compared to an sixteen-month and a 12-month gap between the two injections.</seg>
<seg id="2734">Ambirix led children between 98 and 100% of the vaccinated children one month after the last injection of antibodies against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection of Ambirix was similar between injections and a 12-month gap between injections.</seg>
<seg id="2736">"the most common side effects of Ambirix (observed during more than 1 of 10 vaccines) are headache, appetite lack, pain at the injecting place, redness, Matity (fatigue) as well as maturity."</seg>
<seg id="2737">Ambirix may not be resensitive (allergic) to the active ingredients to form one of the other components or Neomycin (an antibiotic).</seg>
<seg id="2738">August 2002 announced the European Commission to the company GlaxoSmithKline Biologicals s.a. a permit for the sale of ambitions in the whole</seg>
<seg id="2739">The standardisation plan for the Primers with Ambirix consists of two vaccinations; the first dose at the time of choice and the second dose is administered between six and twelve months after the first dose.</seg>
<seg id="2740">"if a refresher is required both for hepatitis A and hepatitis B, can vaccinated with the corresponding monovalous vaccines or with a Combination of combination."</seg>
<seg id="2741">The anti-hepatitis with the Combination-coated anti-hepatitis (anti-HBsAg) - and Anti-Hepatitis A virus (anti-HAV) -antibodies are in the same sizes as according to vaccination with the respective monovalies vaccines.</seg>
<seg id="2742">"it is not completely secured, whether immunoeing expert persons who have addressed to a hepatitis C, a refresher cannot be protected as protection, since they are also protected by immunological memory."</seg>
<seg id="2743">3 How in all injections should be available for the rare case of an anaphylactic reaction after the gift of the vaccine corresponding options for medical treatment and monitoring always available immediately.</seg>
<seg id="2744">"if a fast protection against hepatitis B is required, the standardisation period is recommended with the Comational units, the 360 ELISA units formated hepatitis A virus and 10 µg recombinant hepatitis B surface."</seg>
<seg id="2745">At hematalysis and persons with disturbances of the immune system may not be achieved after the Primary anti-HAV- and anti-hbs-antibodies so that in these cases the gift of another vaccines can be required.</seg>
<seg id="2746">Since an intradermal injection or intra-muscular administration in the gluteal muscle could lead to a subtle impending success, these injections should be avoided. "</seg>
<seg id="2747">"with Thrombozytopenie or bloodine disruptions, Ambirix may be subcutaneous in such cases, since it can occur in these cases after intramuscular gift of blood."</seg>
<seg id="2748">If Ambirix was administered in the second year in the form of a separate injector, Tetanus-, inforcing polomyelitisement and Haemophilus comenzae type b-rons (DTPa-IPV / Hib) or with a combined masonry vaccine has been administered, the immune response to all antigens was sufficient (see section 5.1). "</seg>
<seg id="2749">"in patients with immunosuppressive therapy, or in patients with immune defective must be out of that, possibly no adequate immune response is achieved."</seg>
<seg id="2750">"in a clinical trial which has been conducted with 3 vaccinations of this formulation in adults, the frequency of pain, redness, swelling, gastroenteritis, headaches and fever comparable with the frequency which was observed in the former Thiomersal- and preservatives vaccines."</seg>
<seg id="2751">Clinical trials were attributable to a total of 1027 vaccines at the age of 1 to 15 years.</seg>
<seg id="2752">"in a study with 300 participants aged 12 to 15, including 15 years, the compatibility of Ambirix was compared with the 3-doses combined."</seg>
<seg id="2753">Only exceptions were the higher prevalence of pain and mity based on a computed base per vaccination Ambirix not on a calculation base per person.</seg>
<seg id="2754">Pain was observed after the gift of Ambirix at 50,7% of the proportions compared to 39.1% in the probable after the gift of the 3-doses of combination. "</seg>
<seg id="2755">"after the complete vaccine cycle 66,4% of the Probanden, the Ambirix had administered over pain, compared to 63.8% in the proportions which were vaccinated with the 3-dosage of Combination."</seg>
<seg id="2756">"however, the frequency of Maty was compared high (i.e. about the entire vacccycle at 39,6% of the Probanden, the Ambirix received, compared with 36,2% in the proportions which received the 3-doses of Combination)."</seg>
<seg id="2757">The frequency of distinctive pains and mity was low and comparable to the submission of the Combination of Commodelling with the 3-cap vaccination was observed.</seg>
<seg id="2758">"in a comparative study with 1- 11-year-year-vaccinated, the occurrence of locomotive actions and general actions in the Ambirixgroup was comparable with the 3-doses combined with 360 ELISA units of hepatitis C virus and 10 µg recombinable hepatitis B surface."</seg>
<seg id="2759">"however, at the 6- until 11- year-old, however, after vaccination by Ambirix was a frequent appearance of pain (at the injection point) per dose, not per proband."</seg>
<seg id="2760">"the share of Immediingen, which reported on serious side effects during the 2-cans vaccines with Ambirix or during the 3-doses vaccines with 360 ELISA- units forminforated Hepatitis A virus and 10 µg recombinable hepatitis, was statistically not different."</seg>
<seg id="2761">"in clinical studies, which have been carried out in clinical studies at the age of 1 to 15, including 15-HAV 99,1% a month after the first dose and 100% a month after the second, to month 6 administered dose (d. h. in month 7)."</seg>
<seg id="2762">The servings rates for anti-hbs were 74.7% a month after the first dose and 100% a month after the second one to the month 6 administered dose (i.e. in month 7).</seg>
<seg id="2763">"7 In a comparative study conducted at 12- until including 15-year-olds, 142 two doses Ambirix and 147 the standard combinations of three doses."</seg>
<seg id="2764">"for the 289 people whose immunogenicity was valuable, the Seroprotective rates (SP in the table below) against hepatitis B in the month 2 and 6 after Gabe of the 3 dosage is significantly higher than with Ambirix."</seg>
<seg id="2765">"the immunity that were achieved in a clinical trial for 1- 11-year-olds, one month after the completion of the full vaccine (i.e. in month 7), are listed in the following table."</seg>
<seg id="2766">In both studies the impregnate is either a 2-cans-vaccination with Ambirix or a 3-cans vaccination with a combined hepatitis with 360 ELISA units-inforated hepatitis A virus and 10µg recombinable hepatitis B surface.</seg>
<seg id="2767">"with persons who were at the time of the Grundimmunisation between 12 and 15 years old, the persistence of anti-HAV- and anti-hbs antibodies could be proven over at least 24 months after the immunization with Ambirix in the 0-6-months vaccination scheme."</seg>
<seg id="2768">The immune action against both antigens were comparable to that which after vaccination were compared to vaccination of 3 doses with a combined hepatitis - A virus and 10 µg recombinable hepatitis B cooling volume of 0.5 ml.</seg>
<seg id="2769">In a clinical study at 12- and including 15-year-olds could be shown that the persistence of anti-HAV- and anti-hbs antibodies 24 months after immunization in the 0-6- months-vaccination is comparable to that in the 0-12 months inoctrap scheme.</seg>
<seg id="2770">If the first dose ambitions in the second year at the same time with the refresher of a combined diphther-, Tetanussia (DTPa-IPV / Hib) or with the first dose of a combined mask-vaccine vaccine has been administered, the immune response to all antigens was adequate. "</seg>
<seg id="2771">"a clinical trial, which was conducted with 3 doses of the present formulation in adults, showed similar to current seroprotective and serokonary rates as for the former formulation."</seg>
<seg id="2772">The vaccine is both before and after resignant to examine the partikel and / or physiological visible changes.</seg>
<seg id="2773">"pursuant to Article 114 of the Directive 2001 / 83 / EC amended version, the state charcoal has been made by an state laboratory or any authorized laboratory for this purpose."</seg>
<seg id="2774">14 data AUF THE MOTIGSPRITZE OHNE needle 1 FERTIGSPRIER 10 FERTIGSPRIER 10 FERTIGSPRIER 50 FERTIGSPRITZEN OHNE needles</seg>
<seg id="2775">Suspension to injection 1 finished splash with needle 10 finished splash with needle 10 manufacturing splash with needles 50 predrums without needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 Completching without needle EU / 1 / 02 / 224 / 003 10 ready-splash with needle EU / 1 / 02 / 224 / 005 50 Completching without needles</seg>
<seg id="2777">"the Hepatitis A virus is usually transmitted by viral foods and drinks, but can also be transmitted by other ways, such as bathing in through drained waters, etc."</seg>
<seg id="2778">"you can feel very tired, have a dark urine, a blending face, yellow skin and / or eyes (yelid) and other symptoms that may possibly make a stationary treatment necessary."</seg>
<seg id="2779">As with all vaccines Ambirix not completely protect against an infection with hepatitis Aor hepatitis B) even if the complete vaccine has been completed with 2 cans.</seg>
<seg id="2780">If you are already infected / your child prior to administration of both vaccinated Ambirix / is (although you / your child does not feel uncomfortable or sick / feels) a vaccination may not prevent a disease.</seg>
<seg id="2781">An protection against other infections that cause the liver damaging or symptoms which are similar to those of a hepatitis or hepatitis B infection cannot be conveyed.</seg>
<seg id="2782">• If you have already shown an allergic reaction to Ambirix or any part of this vaccine including Neomycin (an antibiotic).</seg>
<seg id="2783">An allergic reaction can occur through juckskin rash, breathing difficulties or tongue. • If with you / your child has already occurred an allergic reaction to a former vaccination against hepatitis A or hepatitis B. • If you have a severe infection with fever. "</seg>
<seg id="2784">• If you want to have a protection against hepatitis B quickly (i.e. within 6 months and prior to the commonly used administration of the second vaccine dose).</seg>
<seg id="2785">In any possible risk of infection with hepatitis B between the first and second vaccination the doctor will advise you / your child from a vaccination with Ambirix.</seg>
<seg id="2786">Instead he will recommend you / your child 3 injections of a combined hepatitis C vaccine with a reduced salary to effective components per vaccination (360 ELISA units of an forminal hepatitis B-virus and 10 microgram of a recombinant hepatitis B cooling).</seg>
<seg id="2787">The second vaccination of this vaccine with reduced salary to efficient components is usually administered a month after the first dose and is likely to give you a vaccination before finishing the vaccine.</seg>
<seg id="2788">"sometimes Ambirix will suffer from people who injected in serious blood disorders, under the skin and not in the muscle tissue. • If you are weakened by your child due to illness or treatment in your body's own defence, or if you fall / your child to a hematalysis."</seg>
<seg id="2789">Ambirix may be given in these cases but the immune response of these people on vaccination can not be sufficiently so that a blood test can be required to see how strongly the reaction to vaccination is.</seg>
<seg id="2790">"21 If you have your doctor, if you can take your child further medicines, including those who can get without prescription, or if you have not been vaccinated without prescription (antibodies) or if you have administered / or immunoglobulins (antibodies) / has or this is planned in the near future."</seg>
<seg id="2791">But it may be that in this case the immune response on the vaccine is not sufficient and the person is not protected against one or both hepatitis A and B viruses.</seg>
<seg id="2792">"if another vaccine has to be given at the same time with Ambirix, should be vaccinated on separate bodies and as possible different limbs at the same time."</seg>
<seg id="2793">"if Ambirix will be administered at the same time or just before or after an injection of immunoglobulins, it is likely that the reaction to the vaccine will nevertheless be adequate."</seg>
<seg id="2794">"commonly, Ambirix will not be administered, except it is urgent that they can be vaccinated against hepatitis A and hepatitis B."</seg>
<seg id="2795">Important information on certain other components of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"if you miss the agreed appointment for the second vaccination, talk to your doctor and make an appointment as soon as possible."</seg>
<seg id="2797">♦ very often (more than 1 case per 10 decimal cans): • pain or discomfort at the insertion or redness • irritability • heaters • appetite - appetite</seg>
<seg id="2798">♦ commonly (up to 1 case per 10 contaminated doses): • swelling at the injection point • fever (over 38 ° C) • Benefit • gastrointestine discomplaints</seg>
<seg id="2799">"further side effects, the days or weeks after vaccination can be reported with comparative combination of hepatitis A and hepatitis B very rarely (less than 1 case for 10.000 desimp cans), are:"</seg>
<seg id="2800">"these include a limited-limited or vast envelopes, the jucks can be or bluish-shaped, swelling of the eye-partitions and the face, scrutiny atmen or flakes, sudden blood pressure-resistant and consciousness."</seg>
<seg id="2801">"flu-like complaints, including shakes, mussels, mussels, disruptions such as tingling and" ants ", multiple sclerosis, diseases of the visual nerves, loss of sensation or lack of movement, strong headaches and rigidity of the neck, interruption normal brain functions"</seg>
<seg id="2802">"impotence of inflammation odine blood vessels, diarrhea, diarrhea, diarrhea, diarrhea, diarrhea, diarrhoea, diarrhoea and blood cells (blue spots) caused by waste of the blood pressure."</seg>
<seg id="2803">"23 Informing your doctor or pharmacist, if any of the listed side effects you / your child impaired considerably, or you may notice the side effects that are not specified in this package."</seg>
<seg id="2804">Ambirix is available in packs of 1 and 10 with or without needles and in packs of 50 without needles.</seg>
<seg id="2805">"on the basis of data, which has become known since the issuance of the first approval for the discharge, the CHMP opinion that remains positive that the benefit-risk ratio for Ambirix remains positive."</seg>
<seg id="2806">"Ambirix was only used in a Member State (in the Netherlands since May 2003), the available security data for this medicine was limited due to the low patient exposure."</seg>
<seg id="2807">Ammonite can also be used in patients at the age of over a month with invaluable Enzymdefective or with hyperammonium bovine spongiform encephalopathy (deer) in the history of history.</seg>
<seg id="2808">Ammonaps will - split up to several individuals with meals - swallowed under the food or through a Gastroome iescheme (through the abdomes in the stomach of leading hose) and administered by the nose in the stomach-leading hose).</seg>
<seg id="2809">"it was not a comparative study, as Ammonite did not compare with another treatment or with placebo (a pseudrug drug, i.e. without any active ingredient)."</seg>
<seg id="2810">"Ammonite can also cause appetite acidity in the blood, depression, irritation, hydration, fladache, redness, redness, exiting, redness, rash, unpleasing body or weight increase."</seg>
<seg id="2811">The committee for human cells (CHMP) came to the conclusion that Ammonaps in patients with disorders of the urinary cycle to high ammonium values are effectively prevented.</seg>
<seg id="2812">Ammonaps was approved under "extraordinary circumstances, as due to the rarity of the disease at the time of approval only limited information on this medicine."</seg>
<seg id="2813">"the use is indices in all patients, where a complete Enzymology already has already manifested in the newborn old (within the first 28 days)."</seg>
<seg id="2814">"in case of patients with a late-manifold form (incomplete Enzymdefective, which exists after the first life-smonat), then there is an indication of use when in the anamnese is a hyperopic acid."</seg>
<seg id="2815">"for infants, for children who are not able to swallow tablets or for patients with difficulty, AMMONAPS is also available in granite form."</seg>
<seg id="2816">The daily dose is individually calculated considering the protein-tolerant and for the growth and development of the daily intake of the patient.</seg>
<seg id="2817">According to previous clinical experiences the normal daily dose of sodium polyyrate: • 450 - 600 mg / kg / day with children with a body weight of less than 20 kg • 9,0 g / m ² / day with children with a body weight of 20 kg and in growing and adults.</seg>
<seg id="2818">In case of patients who suffer from an early manipulator or ornithintranscarbamates is the substitution of Citrullin or Arginine in a dosage of 0.17 g / kg / day or 3,8 g / m ² / day required.</seg>
<seg id="2819">Patients with an argininosuccinatsynthetase deficiency must be arginine in a dosage of 0.4 - 0.7 g / kg / day or 8,8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"AMMONAPS tablets must not be administered by patients with snibances, as a risk for the emergence of Ösophagusulzera, if the tablets are not immediately going to get into the stomach."</seg>
<seg id="2821">"each tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, according to 2,5 g (108 mmol) sodium, which corresponds to the maximum daily dose."</seg>
<seg id="2822">AMMONAPS should therefore be used in patients with congestive heart failure or severe kidney failure as well as with sodium and eco-building clinical states only with caution.</seg>
<seg id="2823">Since Metabolisation and excretion of natriumphenylbutyrate on the liver and the kidneys will take place AMMONAPS should only be applied with patients with liver or kidney failure.</seg>
<seg id="2824">The meaning of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contraindicated (see 4.3).</seg>
<seg id="2825">"in subcutaneous gift of phenylacetate on young rats in high dosage (190 - 474 mg / kg) it came to a slowing of neuronal expiration and increased loss of neurons."</seg>
<seg id="2826">There were also a hesitation of cerebral synapses and a diminishing number of working nerve cells in the brain and thus a disability of brain growth.</seg>
<seg id="2827">"it could not be noticed whether phenyletate is retired of man into the mother's milk, and for this reason the use of AMMONAPS during the lacing time is contraindicated (see 4.3)."</seg>
<seg id="2828">"in clinical trials, with AMMONAPS entered at 56% of patients at least an unwanted event (AE) and at 78% of these undesirable events that they were not associated with AMMONAPS."</seg>
<seg id="2829">"frequency is defined as follows: very often (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a probable toxic response to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorekite patients, which developed a metabolic inopathy in conjunction with Laktatazide, Panzytopenie, periphergeothermal neuropathy and pancreatitis."</seg>
<seg id="2831">A case of overdosage occurred at a 5 month old small child with a versed single dose of 10 g (1370 mg / kg).</seg>
<seg id="2832">These symptoms go with the accumulation of phenylacetate which showed at a intravenous administration of doses up to 400 mg / kg / day a dosistical neurotoxicity.</seg>
<seg id="2833">Phenylacetate is a metabolic active connection that is conjured by acetylation with glutamine with phenylacetylglutamine that is retired over the kidneys.</seg>
<seg id="2834">Stöchiometrically seen is phenylacetylglutamine with urea comparable (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore suitable as alternate carrier for excretion of excess nitrogen nitrogen.</seg>
<seg id="2835">5 patients with disorders of the urethane cycle may be accepted that for every gram biased sodium butyrate between 0.7 and 0.15 g phenylacetylglutamine nitrogen.</seg>
<seg id="2836">It is of importance that the diagnosis was early early and the treatment is immediately begun to improve the survival chances and the clinical result.</seg>
<seg id="2837">"prognosis of the early manifold form of the disease with the appearance of the first symptoms in the newborn was almost always infalliist, and the disease led itself in the treatment with peritonealdialysis and essential amino acids or with the stuffed-free analoga within the first year of life."</seg>
<seg id="2838">"by hematalysis, the utilization of alternative ways of nitrogen lamination, sodium and sodium-acid-Acetate), protested rust and possibly substitution of essential amino acids, it was possible to increase the survival rate of newborn diseases to 80% within the first life of life)."</seg>
<seg id="2839">"in patients whose disease was diagnosed in the course of pregnancy, the survival rate was 100%, but even with these patients there was time with many to spiritual disabilities or other neurological deficits."</seg>
<seg id="2840">"in patients with a late-manifold form of the disease (including feminine patients with the heterogeneous form of ornithdscarbamylase-defect) that were treated by a hyithinkylbutyrate and a protested diet, the survival rate was 98%."</seg>
<seg id="2841">Already existing neurological deficits are hardly reversible and in some patients can occur a further deterioration of neurological condition.</seg>
<seg id="2842">"it is known that phenylbutyrate is oxidized to phenylacetate oxidized in liver and kidney enzymatic with glutamine, where phenylacetylglutamine arises."</seg>
<seg id="2843">The concentrations of phenylbutyrat and its metabolic rate of 5 g sodium polycarbonate and patients with disorders of the urethane-cycle, of hemorglobalism and with liver liars made by up to 20 g / day (non-controlled studies). "</seg>
<seg id="2844">The behaviour of phenylbutyrat and its metabolic rate was also examined in cancer patients after intravenous hub of sodium polyyrate (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">After a orinal dose of 5 g sodium polyyrate in tablet form were found 15 minutes after taking immeasurable Plasmakoncentrations of phenylbutyrate.</seg>
<seg id="2846">In the majority of patients with urinary cylinders or hemoglobinopathies was after different doses phenylbutyrate (300-650 mg / kg / day up to 20 g / day) at the next morning after nightly Fasts no phenylacetate in plasma.</seg>
<seg id="2847">"in three of six patients with liver cirrhosis, which were repeated with sodium-phenylbutyrate (20 g / day orally in three single dosis), the middle of phenylacetatkonzentrations in Plastimpiegel on the third day five times higher than after the first gifts."</seg>
<seg id="2848">Retirement The drug will be avoided within 24 hours to about 80 - 100% in the form of conjugiated product phenylacetylglutamine via the kidneys.</seg>
<seg id="2849">After the results of the Micronucleus tests had Natriumphenylbutyrat with with toxic and non-toxic cans of treated rats no clamed effects (examination 24 and 48 h after oral administration of a single dose of 878 to 2800 mg / kg).</seg>
<seg id="2850">"AMMONAPS Granules will be taken either oral (infants and children, who can still swallow any tablets, or patients with slightning disorders) or through a host-roastern."</seg>
<seg id="2851">"according to recent clinical experiences the normal daily dose of sodium polyyrate: • 450 - 600 mg / kg / day at newborns, infants and children with a body weight of less than 20 kg • 9,0 g / m ² / day with children with a body weight of 20 kg and in growing and adults."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (especially branched-chain amino acids), Carnitin and serumprotein in plasma should be kept inside the Normal area."</seg>
<seg id="2853">In case of patients who suffer from an early manipulator or ornithintranscarbamates is the substitution of Citrullin or Arginine in a dosage of 0.17 g / kg / day or 3,8 g / m ² / day required.</seg>
<seg id="2854">"AMMONAPS Granules contains 124 mg (5,4 mmol) sodium, according to 2,5 g (108 mmol) sodium, which corresponds to the maximum daily dose."</seg>
<seg id="2855">If Rattenforders were exposed before the birth of phenylacetate (active metabolit by phenylbutyrate) came to lesions in the pyramids cells of the deer.</seg>
<seg id="2856">"a probable toxic response to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorekite patients, which developed a metabolic inopathy in conjunction with Laktatazide, Panzytopenie, periphergeothermal neuropathy and pancreatitis."</seg>
<seg id="2857">Stöchiometrically seen is phenylacetylglutamine with urea comparable (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore suitable as alternate carrier for excretion of excess</seg>
<seg id="2858">On the basis of investigations on the retirement of phenylacetylglutamine in patients with disorders of the urinary cycle may be accepted that for any grammar butyrate between 0.7 and 0.15 g phenylacetylglutamine nitrogen.</seg>
<seg id="2859">"already existing neurological deficits are hardly reversible, and in some patients can occur a further deterioration of neurological condition."</seg>
<seg id="2860">After a orinal dose of 5 g sodium polyyrate in granite form 15 minutes after taking immeasurable Plasmakoncentrations of phenylbutyrat.</seg>
<seg id="2861">"during the duration of the durability, the patient can preserve the finished product once for a period of 3 months at a temperature of over 25 ° C."</seg>
<seg id="2862">With this action the small measurement spoon consists of the medium measuring ranspoons 2,9 g and the big messlons 8,6 g sodium polyphenylbutyrate. "</seg>
<seg id="2863">If a patient has to get the medication about an probe may be dissolved AMMONAPS before use also in water (the solubility of sodium butyrate is up to 5 g in 10 ml of water).</seg>
<seg id="2864">"in patients with these rare diseases, certain liver enzymes lacks certain liver enzymes, so that they can accumulate the stuffed waste products that can cause proteins in the body after consumption of proteins in the body."</seg>
<seg id="2865">"if you have to be done with you laboratories, you must inform the doctor that you may take from AMMONAPS, as sodium phenylbutyrate can affect the results of certain laboratory investigations."</seg>
<seg id="2866">"intake of AMMONAPS with other medicines, please inform your doctor or pharmacist if you have to take other medicines or have recently taken it, even if it is not prescription drugs."</seg>
<seg id="2867">"during the lactation period you may not take AMMONAPS, since the drug could move into the mother's milk and harm your baby."</seg>
<seg id="2868">"in rare cases also confess, headaches, tastes, flavours, disrupting, disorientation, memory-disorders and a deterioration of existing neurological conditions."</seg>
<seg id="2869">"if you find one of these symptoms, you immediately contact your doctor or with the emergency service of your hospital stay for an appropriate treatment."</seg>
<seg id="2870">If you have forgotten the intake of AMMONAPS take the corresponding dose as soon as possible with the next meal.</seg>
<seg id="2871">"blood flow (red blood cells, white blood cells, thinkytes, depression, irritation, crabs, crabs, disruption, infestation, infestation, infomiting, kidney failure, weight increase and anomic labs."</seg>
<seg id="2872">"please inform your doctor or a pharmacist, if any of the listed side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="2873">You may not use AMMONAPS after checking on the carton and refrigeration after "Verdelectable" up to the given expiration date.</seg>
<seg id="2874">"as AMMONAPS looks and contents of AMMONAPS tablets are of white color and oval shape, and they are equipped with the stamping" UCY 500 "." "</seg>
<seg id="2875">"30 If you are done with you laboratories, you must inform the doctor that you may take from AMMONAPS, as sodium phenylbutyrate can affect the results of certain laboratory investigations."</seg>
<seg id="2876">"intake of AMMONAPS with other medicines, please inform your doctor or pharmacist if you have to take other medicines or have recently taken it, even if it is not prescription drugs."</seg>
<seg id="2877">"you should take AMMONAPS distributed on the same single dless orally or through a Magenfistel (hose, which runs through the abdominal wall directly into the stomach) or a Nasensonde (hose, which led by the nose into the stomach)."</seg>
<seg id="2878">"31 • take out of the tank a leak fair granules. • Storing a straight edge, for example a knife on the edge of the measurement, to overhaul Granules left corresponds to a messenger. •, take a look at the recommended number of spoon granules out of the container."</seg>
<seg id="2879">"angiox is used for the treatment of adult patients with" acute coronarsyndromes "(ACS, decreased blood flow to the heart), for example in instabiler Angina (a form of pain in chest with different strength) or myocardinary (heart attack) without" ST- Heber "(an anomnial measurement at the electrokarogram or ECG)."</seg>
<seg id="2880">"Angiox to prevent blood clauses on patients applied to one PCI, a higher dose is administered and the infusion can be continued up to four hours after the procedure."</seg>
<seg id="2881">This can contribute in patients with Angina or cardiopause to maintain blood flow to the heart and increase the effectiveness of one PCI.</seg>
<seg id="2882">"nearly 14 000 patients attended the main study about the treatment of ACS, in which the effect of angioxen-IIb / IIIa-inhibitor (GPI, a different drug to prevent bleeding) with the conventional comforting treatment with Heparin (another anti-agulant) and a GPI."</seg>
<seg id="2883">"during the PCI the patient is often a clent (a short tube that remains in the artery in order to prevent a clasp), and they also received other medicines to prevent blood clauses, such as Abciximab and aspirin."</seg>
<seg id="2884">"at the treatment of ACS, Angiox - with or without hub of GPI - in preventing new events (deaths, cardiac accidents or revasculzation) after 30 days or one year as well as conventional treatment."</seg>
<seg id="2885">"in case of patients suffering from one PCI, angioox regarding all indicators was just as effective as Heparin, except in severe blood circulation, in which it was significantly more effective than hepatarin."</seg>
<seg id="2886">"angiox may not be used in patients who may possibly be vulnerable (allergic) against bivalirudine, other studine or one of the other components."</seg>
<seg id="2887">"it may also not be used in patients who had recently awarded a blood, as well as people with high blood pressure or severe kidney problems or cardiac infection."</seg>
<seg id="2888">The committee for human medicines (CHMP) came to the conclusion that angiox in the treatment of ACS and during an PCI a acceptable replacement for Heparin is.</seg>
<seg id="2889">September 2004 the European Commission gave the Company The Medicines Company UK Ltd a permit for the sale of Angiox in the entire European Union.</seg>
<seg id="2890">For the treatment of adult patients with acute coronarsyndromes (instabile Angina / non-ST-lever) in case of emergency grip or when an early intervention is planned.</seg>
<seg id="2891">The recommended Initial dose of Angiox in patients with ACS is an intravenous bolt of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if the patient is performed in another episode a PCI, an additional bolt of 0.5 mg / kg should be increased and the infusion for the duration of the operation on 1,75 mg / kg / h."</seg>
<seg id="2893">After the PCI required according to clinical requirements the reduced infusion dose of 0.25 mg / kg / h for 4 to 12 hours.</seg>
<seg id="2894">"directly in front of the procedure, a bolting of 0.5 mg / kg will be administered, followed by an infusion of 1,75 mg / kg / h for the duration of the Rhinoplasty."</seg>
<seg id="2895">The recommended dosage of angiox in patients with a PCI card consists of an initials intravenous Bolusation of 0.75 mg / kg body weight and an immediate subsequent intravenous infusion with a dose of 1,75 mg / kg body weight / h at least for the duration of the operation.</seg>
<seg id="2896">"the safety and effectiveness of a few Bolus-Gabe of Angiox was not examined and is not recommended, even if a short PCI procedure is planned."</seg>
<seg id="2897">This value is shortened (ACT after 5 minutes) to less than 225 seconds should be a second bolt of 0.7 mg / kg / body weight.</seg>
<seg id="2898">"in order to reduce the occurrence of lower ACT values, the reconstitutional and diluted medicines must be carefully mixed and administered Bolusdosis rapidly intravenous."</seg>
<seg id="2899">"once the ACT amounts to more than 225 seconds, a further monitoring is no longer required, provided the 1,75 mg / kg infusion dose is administered properly."</seg>
<seg id="2900">"in case of patients with moderate kidney function (GFR 30-59 ml / min), treated one PCI (whether with bivalirudine against ACS or not), should be used a lower infusion rate of 1,4 mg / kg / h."</seg>
<seg id="2901">"lies the ACT-value below 225 seconds, is a second Bolusddose of 0,3 mg / kg to be administered and the ACT 5 minutes after the second Bolusdosis again."</seg>
<seg id="2902">"in case of patients with moderate kidney damage, which were included in phase III- PCI study (replace-2) which were included for approval, was the ACT value 5 minutes after gift of bivalirudin-Bolus without dosage adjustment at an average 366 ± 89 seconds."</seg>
<seg id="2903">3 When patients with severe kidney damage (GFR &lt; 30 ml / min) and also for dialyseated patients is angiox contraindicated (see under Section 4.3).</seg>
<seg id="2904">The treatment with angiox can be initiated 30 minutes after the termination of the intravenous gift of unfractional hepatitis or 8 hours following the termination of subcutaneous ferous hepatitis.</seg>
<seg id="2905">• Comwell-known hypersensitivity to the active ingredient or other components or against Hirudine • active blood vessels or increased blood-risk due to a disturbance of hemogasesystems and / or irreversive bacterial endemic. • severe kidney damage (GFR &lt; 30 ml / min) and for dialysis patients</seg>
<seg id="2906">Patients are carefully monitored during the treatment with regard to symptoms and signs of a blood of blood especially when Bivalirudine is administered in combination with another anti-agulant (see Section 4.5).</seg>
<seg id="2907">"even if you can occur in PCI-patients under bivalirudinto most bloodings in arterial points, can occur in patients suffering from a perkutaneous coronary interventions (PCI) during the treatment in principle all bleeding."</seg>
<seg id="2908">"in patients who are treated Warfarin and treated with Bivalirudin, should ensure a monitoring of the INR Werts (International Standardisation ratio), in order to ensure that the value after lowering the treatment with bivalirudinto again, achieved before the treatment existing level."</seg>
<seg id="2909">"based on the knowledge of the Anti-Mechanism of anticoagulants (Heparin, Warmbin, Thrombolytika or Thrombozytenaggregationshemmer) can be assumed that these ingredients increase the blood vessels."</seg>
<seg id="2910">In the combination of bivalirudin with Thrombozytencing aggregations or anticoagulants are the clinical and biological hermostepic parameters in any case regularly.</seg>
<seg id="2911">"the animal studies are related to the effects on pregnancy, the embryonic / fetal development, unbinding or the postnatal development inadequate (see under section 5.3)."</seg>
<seg id="2912">4612 were randomized to Bivalirudin alone; 4604 were randomized to Bivalirudin plus GPIIb / IIIa Inhibitor and 4603 were randomized to either unfractional Heparin or Enoxaparin plus GPIIb / IIIa Inhibitor.</seg>
<seg id="2913">Both in the Bivalirudine-group as well as in hepatals treated as well as in patients with hepatitis, it was more common in women and patients over 65 years of more undesirable events than in male or younger patients. "</seg>
<seg id="2914">Serious blood-ups were defined according to the ACUITY and Timi measures for heavy blood lines as specified in the table of table 2.</seg>
<seg id="2915">Both light and heavy blood flow occurred in alone less frequently than in the groups with Heparin plus GPIIb / IIIa-Inhibitor and Bivalidrudin plus GPIIb / IIIa- Inhibitor (see table 2).</seg>
<seg id="2916">"a ACUITY serious blood-blood has been defined as one of the following events: incontracts, hemperitoneale, intraocular blood flow of ≥ 4 g / dl with well-obvious blood flow, reduction of hemoglobinels of ≥ 3 g / dl with known blood flow, reoperation due to a bleeding, application of blood products for transfusion."</seg>
<seg id="2917">"more, less frequently observed blood-localizations that occurred at more than 0.1% (occasionally) were" other "points, retroperitoneal, gastrointestinal, ear, nose or neck."</seg>
<seg id="2918">The following information on side effects are based on the data of a clinical trial with Bivalirudin at 6000 patients involving one PCI.</seg>
<seg id="2919">"both in the Bivalirudin group as well as in hepatitis, it was more common in women as well as in patients over 65 years of more undesirable events than for male or younger patients."</seg>
<seg id="2920">Both light and heavy blood flow occurred under Bivalirudin significantly less frequently than in the compares group under Heparin plus GPIIb / IIIa-Inhibitor.</seg>
<seg id="2921">"the following side effects, which are not listed above, were reported after comprehensive application in practice and are arranged according to system organclasses in table 6."</seg>
<seg id="2922">In case of overdosage the treatment with bivalirudine is immediately devoting and to monitor the patient with regard to signs of a bleeding.</seg>
<seg id="2923">"Angiox contains Bivalirudin, a direct and specific Thrombininhibitor, which binds both at the catalytic centre as well as at the Anibal-binding region of Thrombin, regardless of whether Thrombin in the liquid phase or in Gerinnsel."</seg>
<seg id="2924">"the binding of Bivalirudine to Thrombin, and with it its effect, is reversible because Thrombin turn on the bond of bivalirudine-Arg3-Pro4 slowly regenerate the function of the active centre of Thrombin regenerated."</seg>
<seg id="2925">"moreover, by Bivalirudine with Serum of patients in which it was come to hepatic induced Thrombozytopenie / hepatinduced Thrombosis syndrome (HIT / HITTS), no thrombozych aggregation induce."</seg>
<seg id="2926">"in healthy food and in patients Bivalirudine shows Bivalirudinto a dosis- and concentric-based effect that is occupied by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if the patient was carried out in the following, an additional bolt of 0.5mg / kg Bivalirudine and the infusion should be increased for the duration of the operation on 1.75mg / kg / h."</seg>
<seg id="2928">In the arm A of the ACUITY study was unfractionated hepatitis or Enoxaparin according to relevant guidelines for the treatment of akutem coronary coronary (ACS) in patients with instabiler Angina / non-ST-Heber (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to receive a GPIIb / IIIa Inhibitor either before the beginning of angiography (at the time of Randomisation) or with the PCI.</seg>
<seg id="2930">"in the ACUITY study, the characteristics of high-risk factors, which required an angiography within 72 hours, evenly distributed over the 3 treatment stations."</seg>
<seg id="2931">"approximately 77% of patients had a recurring subsidiary, 70% had dynamic EKG- changes or increased cardiac biomarker, 28% had diabetes and approximately 99% of all patients suffering from 72 hours of an angiography."</seg>
<seg id="2932">Primary analysis and the results of the ACUITY study for the 30-tage- and the 1- annual point for the overall population (ITT) and for patients who received aspirin and Clopidogrel according to protocol (before the angiography or prior to the PCI) are presented in tables 7 and 8.</seg>
<seg id="2933">ACUITY study; 30 days and 1 year risk difference for the combined-comic endpoint and its components for patients who received aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients who received aspirin and Clopidogrel according to protocol received arm A arm B arm C UFH / Enox Bival B- A C- A Bival + GPIIb / IIIa risk Diff.</seg>
<seg id="2935">"the incidence of blood cuts both in ACUITY- and Timi-scale up to day 30 for the overall population (ITT) and for patients, the aspirin and Clopidogrel according to protocol is presented in table 9."</seg>
<seg id="2936">Patients who received aspirin and Clopidogrel total population (ITT) according to protocol UFH / Enox Bival / IIIa GPIIb / IIIa (N = 4603) (N = 4604) (N = 2842)%%%%</seg>
<seg id="2937">"* Clopidogrel before angiography or prior to PCI 1 A ACUITY, hematoma with diameter ≥ 5 cm at the point of point, reduction of hemoglobinical blood flow of ≥ 3 g / dl with known blood flow, reoperation due to a bleeding, application of blood products for transfusion."</seg>
<seg id="2938">"the 30 days of results, based on quadruped and triple-end-points of a randomized twin-blind study with more than 6,000 patients who moved one PCI (replace-2), are shown in table 10."</seg>
<seg id="2939">Clinical studies with a small number of patients provided limited information about using angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharynokinetic properties of Bivalirudin were evaluated with patients being evaluated by a perkutaneous coronary interventions (PCI) and in patients with ACS.</seg>
<seg id="2941">It is expected that Bivalirudin as Peptid a catabolic ism takes into its amino acids in its amino acids with subsequent recycling of the amino acids in the body pool.</seg>
<seg id="2942">The primary metabolit which results from the split of the Arg3-Pro4 bonds of the N-terminology sequence is due to the loss of its affinity to the catalytic centre of Thrombin.</seg>
<seg id="2943">The elimination takes place in patients with normal kidney function after a process first order with a temporal half-value of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on safety spharmacology, toxicity in repeatable gift, comotoxicity or reproductionalism, the preclinical data have no special hazards for the people."</seg>
<seg id="2945">The toxicity in animals at repetitive or continuous exposure (1 day to 4 weeks at an exposure to 10-fold of clinical Steady-state plasma plasma) limited by pharyngeological effects.</seg>
<seg id="2946">Side effects due to a longer-term physiological burden than reaction to a non-homecstatic coagulation with short-term exposure comparable to those during the clinical use, even with much higher dosage, not observed. "</seg>
<seg id="2947">"if the manufacture of ready-to-use solution is 17 not under controlled and validated aseptic conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox is an freezed powder mixers made of type-1-glass to 10 ml which is locked with a butyl gummistress locked and a cap made of pressed aluminium sealed.</seg>
<seg id="2949">5 ml of sterile water for injection molds are given in a diarrhea bottle and slightly sainted to itself everything completely dissolved and the solution is clear.</seg>
<seg id="2950">5 ml are taken from the flow-bottle and further diluted with 5% of gluten solution to injection or with 9 mg / ml (0.9%) Natriumchloridsolution for injection in a total volume of 50 ml to obtain a final concentration of 5mg / ml bivalirudin.</seg>
<seg id="2951">"the owner of the permit is given to the permit, the studies and Pharmakovigilance Plan listed in Version 4 of the risk Management Plan (RMP) agreed and illustrated in module 1.8.2 of approval for the discharge, and any subsequent changes in the RMP, which was agreed by the CHMP."</seg>
<seg id="2952">"according to CHMP guideline to risk management systems for human medicines, the revised RMP will be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast cancer prevention due to a heart disease (acute coronarians - ACS) • patients who are operated for the treatment of closures in the blood vessels (Angioplasty and / or perkutane Koronarangioplasty - PCI).</seg>
<seg id="2954">"• You are pregnant or suspect that you might be pregnant, you intend to get pregnant • you are currently breastfeeding."</seg>
<seg id="2955">"there were no investigation of the effects on traffic noise, and the ability to serve machines, but one knows that the effects of this medication are only in short notice."</seg>
<seg id="2956">"should an hemorrhage occur, treatment with angioox. • At the beginning of injection or infusion, you will inform your doctor about the possible character of an allergic reaction."</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 of 1000 treated patients). • A particularly careful surveillance is performed when you supply a radiation therapy for the vessels which will depend on your body or gamma-Brachytherapy). • The dose which you will receive from your body weight and depend on the type of therapy you get.</seg>
<seg id="2958">• 0.1 mg / kg body weight than injecting followed by an infusion (tropical solution) with 0.25 mg / kg body weight per hour (0.1 mg / kg body weight; 1 mg / kg body weight per hour means a quarter of a milligrams of medication by means of any kilograms of body weight per hour).</seg>
<seg id="2959">Probable if angiox is administered in combination with other germalline or antithrombal medication (see Section 2 "For application of angiox with other medicines.).</seg>
<seg id="2960">"these are occasional side effects (if less than 1 of 100 treated patients). • Thrombosis (blood-blood), which could lead to heavier complications like a heart attack."</seg>
<seg id="2961">"this is a occasional tributary (if less than 1 of 100 treated patients). • Pain, blood-blood and blood-cast in the point of point (according to a PCI treatment)."</seg>
<seg id="2962">"please inform your doctor, if any of the above side effects you have significantly impaired or you may notice the side effects that are not specified in this usage information."</seg>
<seg id="2963">Angiox may be no longer applied to the expiration date on the label and the carton after the expiration date.</seg>
<seg id="2964">Polska The Medicines Company UK Ltd Phone: + 800 843 633 26 lub + 41 61 564 1320 free of λ: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"Apidra is used to treat adults, young people and children from six years with diabetes which require treatment with insulin."</seg>
<seg id="2966">"Apidra is subcutted (under the skin) into the abdomes, the thigh or the upper arm injizo, or as continuous infusion with an insulin pump."</seg>
<seg id="2967">Diabetes is a disease in which the body does not produce enough insulin for the regulation of gluctpiegels (sugar) produced in the blood or the insulin cannot be effected.</seg>
<seg id="2968">"Insulinglulisin differs very slightly from humaninsulin, and the change means that it works faster and a shorter period of activity has as a short-effective humaninsulin."</seg>
<seg id="2969">"Apidra has been studied in combination with a long-effective insulin for patients with type-1 diabetes, in which the body could not produce insulin in two studies with a total of 1 549 adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">"with type-2 diabetes, in which the body insulin cannot be effected effective, Apidra was studied in a study with 878 adults."</seg>
<seg id="2971">"the main indicator of the efficacy was the change of concentration of the substance glycosylized Hemmoglobin (HbA1c) in the blood, which indicates how well the blood sugar is set."</seg>
<seg id="2972">"in the first study with adults with type-1 diabetes, after six months a reduction of 0.14% (7,60% to 7,46%) compared to a reduction of 0.14% at Insulinlisper."</seg>
<seg id="2973">In adults with type-2 diabetes the reduction of the HbA1c concentration 50% after six months with Apidra in comparison to 10.9% at human Normalinsulin.</seg>
<seg id="2974">"Apidra may not be used in patients who may possibly be vulnerable (allergic) against insulin lulisin or one of the other components, or in patients who already suffer from a hypoglycaemia."</seg>
<seg id="2975">The doses of Apidra may possibly be adjusted when it is administered with a number of other medicines that can affect the blood of gluelectal seals.</seg>
<seg id="2976">September 2004 the European Commission of Sanofi-Aventis Deutschland GmbH distributed a permit for the transport of Apidra in the entire European Union.</seg>
<seg id="2977">Apidra is referred to as subcutaneous injection either in the field of the abdominal ceiling or delicials or subcutaneous by continuous infusion into the area of the abdomes.</seg>
<seg id="2978">"due to the reduced gleogenesis capacity and the diminishing insulin, the insulin can be enforced in patients with a limitation of liver function."</seg>
<seg id="2979">"any change of the efficacy, the brand (Her- co-operation), the Insulchyps (normal, NPH, galvanized, etc.), the type of insulus (animal insulin) and / or the manufacturing method may draw a change in the insulin demand."</seg>
<seg id="2980">"3 A inadequate dosage or the interruption of a treatment, in particular in patients with a insulin-based diabetes, can lead to a hyperglycaemia and a diabetic Ketoazier; these states are potentially life-threatening."</seg>
<seg id="2981">The changeover from one patient to another insulin type or insulin a different vendor should be under strict medical supervision and can make a change of dosage required.</seg>
<seg id="2982">The time of occurrence of a hypoglycaemia depends on the drug profile of the used insulin and can therefore be changed at the conversion of the treatment schemas.</seg>
<seg id="2983">"among the substances, which can increase the bleeding activity and increase the inclination to hypoglycaemic, Fibrate, anti-oxetric Oxidase (MAO) -Hemmer, anti-oxy Oxidase, Propoxyphs, Salizylates and Sulfonamid-antibiotics."</seg>
<seg id="2984">"in addition, under the effect of sympathizolytika such as Betablockers, Clonidin, Guanethidin and reserves the symptoms of inephraggen alleviate or are missing."</seg>
<seg id="2985">"Animal Experimental studies on reproductive-toxicity revealed no differences between Insu- linglulisin and Humaninsulin in terms of pregnancy, the embryonic / fetal development, the birth or the postnatal development (see Section 5.3)."</seg>
<seg id="2986">"it is not known whether insulinglulisine into the human mother's milk-milk, but generally occurs insulin neither in the mother's milk, nor will it resorated after orical use."</seg>
<seg id="2987">"below are the clinical studies known from clinical studies (very often: ≥ 1 / 100, &lt; 1 / 10; occasionally: ≥ 1 / 1,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000); not known (frequency on availability of availability)."</seg>
<seg id="2988">"cold-speaking, cold, bliss, nervousness, nervousness, nervousness, nervousness, anxiety, nervousness or weakness, anxiety, unusual creation or weakness, confusion, concentration, concentredness, headaches, nausea, nausea and cardiac."</seg>
<seg id="2989">"Lipodystrophy Wird fails to switch the injection point within the injecting range, can occur in the result of a Lipodystrophy at the injection point."</seg>
<seg id="2990">Heavy hypoglycaemic with consciousness can be given by an intra-muscular or subcutaneous injection of Glukagon (0.5 to 1 mg) that will be treated by one accordingly trained person or by intravenous goabe of glucose by a doctor.</seg>
<seg id="2991">After a gluctonal jection the patient should be monitored in a hospital to determine the urine thing for the heavy hypoglycaemia and avoid similar episodes.</seg>
<seg id="2992">Insulin reduces the blood sugar levels by stimulation of the peripheral glucose (especially by skeleton muscles and fat) as well as by the imitation of glucose production in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that at subcutaneous Gather- be carried out by islanders and the efficacy is shorter than with hu- manem Normalinsulin.</seg>
<seg id="2994">"in a study involving 18 male people aged 21 to 50 years with type-1-diabetes, insulinglulisin in the therapeutic relevant dosing effect of 0.075 to 0.15 E / kg or more a disproportionate increase in the gluing effect, just like human insulin."</seg>
<seg id="2995">Insulinglulisin has twice as fast as normal human rights and achieves the complete gluing effect of approximately 2 hours earlier than Humaninsulin.</seg>
<seg id="2996">"the data was clear that during an application of insulin lulisin 2 minutes before meal a comparative postprangeal glycaemic control is achieved, as being given by human normalinsulin, which is 30 minutes before meal."</seg>
<seg id="2997">"Insulinglulisin 2 minutes before meal believed, a better postpranal control was given as with human normalinsulin, which was reached 2 minutes before meal."</seg>
<seg id="2998">"insulinglulisin 15 minutes after the beginning of the meal, a comparable glycaemic control such as humanized Normalinsulin, which is given 2 Mi- nuten before meal (see Figure 1)."</seg>
<seg id="2999">"Insulinglulisin at Gabe 2 minutes (GLULISIN - before) before the beginning of the meal (NORMAL - 30 min.) before the beginning of meal was given (picture 1A), as well as compared to humanem Normalinsulin, which was 2 minutes (NORMAL - previously) before a meal (figure 1B)."</seg>
<seg id="3000">"Insulinglulisin at Gabe 15 minutes (GLULISIN - after the beginning of the meal in comparison to human Normandinsulin, which was 2 minutes (NORMAL - before) before the beginning of the meal (figure 1C)."</seg>
</doc>
</tstset>
